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Abstract
Infliximab, adalimumab and golimumab for treating
moderately to severely active ulcerative colitis after the
failure of conventional therapy (including a review of
TA140 and TA262): clinical effectiveness systematic review
and economic model
Rachel Archer,1* Paul Tappenden,1 Shijie Ren,1
Marrissa Martyn-St James,1 Rebecca Harvey,1 Hasan Basarir,1
John Stevens,1 Christopher Carroll,1 Anna Cantrell,1 Alan Lobo2
and Sami Hoque3
1Health Economics and Decision Science, School of Health and Related Research (ScHARR),
University of Sheffield, Sheffield, UK
2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
3Barts Health NHS Trust, London, UK
*Corresponding author r.archer@sheffield.ac.uk
Background: Ulcerative colitis (UC) is the most common form of inflammatory bowel disease in the UK.
UC can have a considerable impact on patients’ quality of life. The burden for the NHS is substantial.
Objectives: To evaluate the clinical effectiveness and safety of interventions, to evaluate the incremental
cost-effectiveness of all interventions and comparators (including medical and surgical options), to estimate
the expected net budget impact of each intervention, and to identify key research priorities.
Data sources: Peer-reviewed publications, European Public Assessment Reports and manufacturers’
submissions. The following databases were searched from inception to December 2013 for clinical
effectiveness searches and from inception to January 2014 for cost-effectiveness searches for published
and unpublished research evidence: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health
Literature, The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane
Controlled Trials Register, Database of Abstracts of Reviews of Effects, the Health Technology Assessment
database and NHS Economic Evaluation Database; ISI Web of Science, including Science Citation Index,
and the Conference Proceedings Citation Index-Science and Bioscience Information Service Previews.
The US Food and Drug Administration website and the European Medicines Agency website were also
searched, as were research registers, conference proceedings and key journals.
Review methods: A systematic review [including network meta-analysis (NMA)] was conducted to
evaluate the clinical effectiveness and safety of named interventions. The health economic analysis
included a review of published economic evaluations and the development of a de novo model.
Results: Ten randomised controlled trials were included in the systematic review. The trials suggest that
adult patients receiving infliximab (IFX) [Remicade®, Merck Sharp & Dohme Ltd (MSD)], adalimumab (ADA)
(Humira®, AbbVie) or golimumab (GOL) (Simponi®, MSD) were more likely to achieve clinical response and
remission than those receiving placebo (PBO). Hospitalisation data were limited, but suggested more
favourable outcomes for ADA- and IFX-treated patients. Data on the use of surgical intervention were
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sparse, with a potential benefit for intervention-treated patients. Data were available from one trial to
support the use of IFX in paediatric patients. Safety issues identified included serious infections,
malignancies and administration site reactions. Based on the NMA, in the induction phase, all biological
treatments were associated with statistically significant beneficial effects relative to PBO, with the greatest
effect associated with IFX. For patients in response following induction, all treatments except ADA and
GOL 100mg at 32–52 weeks were associated with beneficial effects when compared with PBO, although
these were not significant. The greatest effects at 8–32 and 32–52 weeks were associated with 100mg of
GOL and 5mg/kg of IFX, respectively. For patients in remission following induction, all treatments except
ADA at 8–32 weeks and GOL 50mg at 32–52 weeks were associated with beneficial effects when
compared with PBO, although only the effect of ADA at 32–52 weeks was significant. The greatest effects
were associated with GOL (at 8–32 weeks) and ADA (at 32–52 weeks). The economic analysis suggests
that colectomy is expected to dominate drug therapies, but for some patients, colectomy may not be
considered acceptable. In circumstances in which only drug options are considered, IFX and GOL are
expected to be ruled out because of dominance, while the incremental cost-effectiveness ratio for ADA
versus conventional treatment is approximately £50,300 per QALY gained.
Limitations: The health economic model is subject to several limitations: uncertainty associated with
extrapolating trial data over a lifetime horizon, the model does not consider explicit sequential pathways of
non-biological treatments, and evidence relating to complications of colectomy was identified through
consideration of approaches used within previous models rather than a full systematic review.
Conclusions: Adult patients receiving IFX, ADA or GOL were more likely to achieve clinical response and
remission than those receiving PBO. Further data are required to conclusively demonstrate the effect of
interventions on hospitalisation and surgical outcomes. The economic analysis indicates that colectomy is
expected to dominate medical treatments for moderate to severe UC.
Study registration: This study is registered as PROSPERO CRD42013006883.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
U lcerative colitis (UC) is a form of inflammatory bowel disease. Patients with this disease experiencesymptoms including bloody diarrhoea, abdominal pain, weight loss and tiredness.
We reviewed the evidence for the use of infliximab [Remicade®, Merck Sharp & Dohme Ltd (MSD)],
adalimumab (Humira®, AbbVie) and golimumab (Simponi®, MSD) for the treatment of patients with UC.
The clinical trials included in the review suggested that adult patients receiving these drugs were more
likely to achieve a treatment response than patients receiving placebo. More evidence is needed to
determine whether or not these drugs reduce the need for hospitalisation or surgery in such patients.
We also assessed whether or not these therapies represent good value for money for the NHS. The analysis
suggests that surgery may be more effective and less expensive than medical therapies. For patients that
do not want to, or cannot, undergo surgery, the incremental cost-effectiveness ratios for these therapies
are expected to be greater than £50,300 per quality-adjusted life-year gained.
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Scientific summary
Background
Ulcerative colitis (UC) is recognised as the most common form of inflammatory bowel disease in the UK.
Peak incidence is between 15 and 25 years of age, with a potential second peak between 55 and
65 years. Inflammation in UC typically occurs in the colon and rectum. Symptoms include the development
of bloody diarrhoea with or without mucus, abdominal pain, weight loss, fatigue and an urgent need to
defecate. UC can have a substantial impact on the health-related quality of life (HRQoL) of patients owing
to the young age of disease onset for some patients, the severity of symptoms and the likelihood of
relapse. The burden of UC for the NHS is substantial.
Objectives
The aim of this assessment is to assess the clinical effectiveness and cost-effectiveness of infliximab (IFX)
[Remicade®, Merck Sharp & Dohme Ltd (MSD)], adalimumab (ADA) (Humira®, AbbVie) and golimumab
(GOL) (Simponi®, MSD) for the treatment of patients with moderately to severely active UC after the failure
of conventional therapy.
The objectives of the assessment are:
l to evaluate the clinical effectiveness of each intervention
l to examine the effect of disease duration on the clinical effectiveness of each intervention (subject to
the availability of evidence)
l to evaluate the adverse effect profile of each intervention
l to evaluate the incremental cost-effectiveness of each intervention compared (1) against each other
and (2) against all comparators (including medical and surgical options)
l to estimate the expected net budget impact associated with implementing each intervention
l to identify key areas in which future research may be valuable.
Data sources
The following databases were searched from inception to December 2013 for clinical effectiveness
searches and from inception to January 2014 for cost-effectiveness searches for published and unpublished
research evidence: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, The
Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials
Register, Database of Abstracts of Reviews of Effects, the Health Technology Assessment (HTA) database
and NHS Economic Evaluation Database; ISI Web of Science, including Science Citation Index, and the
Conference Proceedings Citation Index-Science and Bioscience Information Service Previews. The US Food
and Drug Administration website and the European Medicines Agency (EMA) website were also searched
as were research registers, conference proceedings and key journals.
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Methods
A systematic review of the literature including network meta-analyses (NMAs) was conducted in order to
evaluate the clinical effectiveness and safety of IFX, ADA and GOL in the treatment of moderately to
severely active UC after the failure of conventional therapy. The protocol for this review is registered with
PROSPERO (CRD42013006883). A review of the existing cost-effectiveness literature was also undertaken.
A de novo health economic model was constructed by the Assessment Group in order to evaluate the
cost-effectiveness of the interventions under assessment.
Results
Number and quality of studies
A total of 10 randomised controlled trials (RCTs) were identified in the clinical effectiveness systematic
review. Five, three and two RCTs evaluated the use of IFX, ADA and GOL, respectively, in the treatment of
moderately to severely active UC. Nine trials related to adults and one trial was conducted in a paediatric
population. All of the adult RCTs (with the exception of one trial, UC-SUCCESS) were performed against
placebo (PBO). No head-to-head RCTs were identified in which the interventions of interest were assessed
against each other.
The risks of bias associated with included RCTs were assessed using the Cochrane risk-of-bias instrument.
Only three RCTs could be considered as being at overall low risk of bias (as allocation concealment,
blinded outcome assessment and completeness of outcome data were all judged as low risk). It should be
noted that one of the maintenance trials [Program of Ulcerative Colitis Research Studies Utilizing an
Investigational Treatment (PURSUIT)-Maintenance] rerandomised patients who had previously responded to
GOL induction therapy in two previous trials; the extent of this potential bias on patient outcomes is unclear.
Summary of benefits and risks
The outcome measures specified in the final National Institute for Health and Care Excellence (NICE) scope
were all addressed by the included trial evidence, with the exception of rates of relapse. Clinical response
and remission data based on complete Mayo scores were well reported across trials. Evidence was
identified to demonstrate that patients receiving IFX, ADA or GOL were more likely to achieve clinical
response and remission at induction and maintenance time points than patients receiving PBO. Patients in
the UC-SUCCESS trial who received combination treatment with IFX and azathioprine (AZA) experienced
the most favourable rates of steroid-free remission when compared with IFX and AZA treatment groups.
Seven RCTs performed on adult populations contributed data on clinical response and remission at
induction or maintenance time points to NMAs.
Based on the NMA, in the induction phase all treatments were associated with statistically significant
beneficial effects relative to PBO, with the greatest effect being associated with IFX. For patients classified
as responders at the end of the induction phase, treatment effects were not statistically significant,
although the greatest effect at 8–32 weeks was associated with 100mg of GOL. At 32–52 weeks, only IFX
and 50mg of GOL were associated with beneficial effects on clinical response. For patients classified as
being in remission at the end of the induction phase, all treatments except for ADA were associated with
beneficial treatment effects relative to PBO, with the greatest effect being associated with 50mg and
100mg of GOL, although the effects were not statistically significant at 8–32 weeks. At 32–52 weeks, all
treatments except 50mg of GOL were associated with beneficial treatment effects relative to PBO, with
the greatest effect being associated with ADA (the only treatment with statistically significant effect). ADA
was associated with the highest probability of staying in remission and the smallest probability of moving
from remission to response and from remission to no response.
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Sensitivity analyses were conducted to assess the impact of including different studies and subgroups in the
NMA. The sensitivity analyses conducted included replacing Ulcerative colitis Long-Term Remission and
maintenance with ADA treatment of moderate to severe ulcerative colitis (ULTRA2) anti-tumour necrosis
factor alpha (TNF-α)-naive data with ULTRA2 intention-to-treat (ITT) data (sensitivity analysis 1), including
Suzuki et al. (Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson A, et al. Efficacy and safety of ADA
in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology
2014;49:283–94) (sensitivity analysis 2), and replacing ULTRA2 anti-TNF-α-naive data with ULTRA2 ITT data
plus including Suzuki et al. (sensitivity analysis 3).
Available data on hospitalisation outcomes were very limited but suggested that outcomes may be more
favourable for ADA-treated and IFX-treated patients compared with PBO (with no data available from GOL
trials). Data on the use of surgical intervention were also very sparse, with a potential inconclusive benefit
for intervention-treated patients compared with PBO. No trials reported whether or not surgical outcomes
were elective or emergency in nature. However, more data are required to demonstrate the impact of
interventions on hospitalisation and surgical intervention more conclusively. Data were available from a
single trial to support the use of IFX in induction and maintenance treatment in a paediatric population.
The main safety issues highlighted in the RCT evidence appeared to be generally consistent with those
previously discussed in the respective Summary of Product Characteristics (including serious infections,
malignancies and administration site reactions). Deaths occurring during and after the study period were
described in some trials evaluating GOL (PURSUIT-Maintenance) and IFX [Active Ulcerative Colitis Trials (ACTs)]
of which infection or malignancy were most commonly implicated. This underlines the importance of
monitoring and treating serious infections and malignancies in patients receiving immunosuppressive treatment.
Two biosimilars (Remsima®, Celltrion Healthcare, and Inflectra®, Hospira) to Remicade were considered as part
of the evidence base for IFX within this assessment. The sponsor submission received from the manufacturers
of Remsima and the European Public Assessment Reports for Remsima and Inflectra indicated that both
biosimilars were approved by the EMA on the basis of reported similar pharmacokinetic and efficacy profiles
to Remicade (demonstrated in ankylosing spondylitis and rheumatoid arthritis patients). No further trials of
Remsima or Inflectra were identified over the course of this assessment.
Summary of cost-effectiveness evidence
The manufacturers of ADA, IFX and GOL submitted economic models to assess the cost-effectiveness of
biological therapies versus conventional treatment. The MSD IFX submission model indicates that the
estimated incremental cost-effectiveness ratio (ICER) for IFX versus standard non-biological treatment
(colectomy) is £37,682 per quality-adjusted life-year (QALY) gained. The MSD GOL submission reports an
estimated ICER of £27,322 per QALY gained. The AbbVie submission reports a base-case ICER of £34,590
per QALY gained. The Assessment Group identified several problems with these models. In particular,
none of the models included all relevant treatment options specified in the final NICE scope and each
model adopted a short time horizon (10 years). The Assessment Group does not consider that the
cost-effectiveness evidence submitted by either manufacturer represents a sufficient basis for informing
decision-making.
In order to address the problems identified within the manufacturers’ submitted economic models, the
Assessment Group developed a de novo cost-effectiveness model to assess IFX, ADA, GOL, conventional
non-biological treatments and elective surgery within the moderate to severe UC population over a lifetime
horizon. Underpinning the Assessment Group model is a series of NMAs that synthesise all relevant
evidence relating to IFX, ADA, GOL and conventional non-biological therapies [5-aminosalicylates (5-ASAs),
corticosteroids, immunosuppressants and surgery] in the induction and maintenance settings.
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The base-case analysis of the Assessment Group model suggests that colectomy is expected to produce
14.71 QALYs at a cost of approximately £56,300 over the patient’s remaining lifetime. All medical options
are expected to produce substantially fewer QALYs at a greater cost than colectomy; hence, colectomy is
expected to dominate IFX, ADA, GOL and conventional non-biological treatments. For some patients,
elective colectomy may not be considered an acceptable or preferable option. In circumstances whereby
only drug options are considered acceptable, the Assessment Group model suggests that IFX and GOL are
expected to be ruled out because of dominance, while the incremental cost-effectiveness of ADA versus
conventional non-biological treatment is expected to be approximately £50,300 per QALY gained.
A separate economic analysis of IFX, conventional non-biological treatments and colectomy was
undertaken within a paediatric population (mean age of 15 years). When colectomy is an acceptable
treatment option, the economic analysis suggests that this option is expected to dominate IFX and
conventional non-biological treatments. When colectomy is not an acceptable option, the economic
analysis suggests that the incremental cost-effectiveness of IFX versus conventional treatments is
approximately £68,000 per QALY gained. However, this analysis is based on adult efficacy evidence and,
thus, it should be interpreted with some degree of caution.
A number of sensitivity analyses were undertaken using the Assessment Group model. These suggested
that the results of the economic analysis are largely insensitive to changes in the model assumptions,
except for scenarios in which the post-surgery utility value is altered. When utility scores from Swinburn
et al. are used in the model (Swinburn P, Elwick H, Bean K, Curry A, Patel S, Bodger K, et al. The Impact
of Surgery on Health Related Quality of Life in Ulcerative Colitis. Gut Conference: Digestive Disorders
Federation Meeting, Liverpool; 2012) [rather than those reported by Woehl A, Hawthorne A, McEwan P.
The relation between disease activity, quality of life and health utility in patients with ulcerative colitis.
Gut 2008;57(Suppl. 1):A153], colectomy produces the lowest QALY gain and conventional management
and GOL are ruled out as a consequence of extended dominance. Within this scenario, the incremental
cost-effectiveness of ADA versus elective colectomy is estimated to be £79,714 per QALY gained, while
the incremental cost-effectiveness of IFX versus ADA is estimated to be £178,982 per QALY gained.
Although these results are very different from the Assessment Group’s preferred base-case analysis, the
economic conclusions that should be drawn from this sensitivity analysis are not.
Discussion
Strengths, limitations of the analyses and uncertainties
The systematic review was based on rigorous methods, with comprehensive searches for evidence, a good
level of consistency between reviewers in study selection and double-checking of data extraction. Clinical
response and remission data were well reported across included trials and study authors were consistent in
their use of the complete Mayo score, which aided the comparison of trials. NMAs were performed to
permit a comparison of the efficacy of interventions in terms of clinical response and remission.
The Assessment Group’s economic analysis has a number of strengths:
l The treatment pathway represented within the model was based on considerable expert opinion from
several leading UC experts.
l The Assessment Group model is underpinned by a complex NMA across all drug options, thereby
synthesising relevant efficacy outcomes data within a single network of evidence.
l The model generally adheres to the NICE reference case and fully addresses the decision problem set
out in the final NICE scope.
l When appropriate and possible, systematic search methods have been used to identify, select and use
evidence to inform the model’s parameters (efficacy, HRQoL and colectomy rates).
l The Assessment Group has undertaken extensive sensitivity analyses to examine the impact of
alternative assumptions and sources of evidence on the robustness of the results of the model.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxii
The Assessment Group model is also subject to a number of limitations:
l There is considerable uncertainty associated with Assessment Group’s extrapolation of short-term trial
data (maximum 54 weeks) to a lifetime horizon.
l The model does not consider an explicit sequential pathway of non-biological treatments. Instead,
during any cycle, a proportion of patients are assumed to receive 5-ASAs, immunomodulators
and steroids.
l Evidence relating to complications of colectomy was identified through consideration of approaches
used within previous models rather than through a full systematic review; however, these assumptions
were tested within the sensitivity analyses.
Key uncertainties in this assessment include:
l the optimal duration of intervention treatment in responding patients
l the maintenance of efficacy outcomes and safety of interventions beyond the limited study
lengths available
l the maintenance of outcomes in responding patients following cessation of anti-TNF-α treatment.
Generalisability of the findings
The trials included in the clinical effectiveness systematic review typically excluded patients with ulcerative
proctitis, patients with fulminant/acute severe disease, those with a history of or at imminent risk of bowel
surgery, pregnant or lactating women, and patients with diseases of the central nervous system (e.g.
demyelinating disease). Furthermore, patients with history of serious infection and/or immunodeficiency
were also typically excluded, as were individuals with a history of malignancy or signs of dysplasia.
Therefore, the effects of ADA, GOL or IFX in these UC populations have not specifically been investigated.
Study registration
This study is registered as PROSPERO CRD42013006883.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
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Chapter 1 Background
Description of health problem
Ulcerative colitis (UC) is recognised as the most common form of inflammatory bowel disease (IBD) in the
UK. The incidence of UC is approximately 10 per 100,000 population per year, while the prevalence of the
disease is approximately 240 per 100,000 population.1 This is typical for countries with a Westernised
lifestyle.2 Peak incidence is between 15 and 25 years of age, with a potential second peak between 55 and
65 years.1 The majority (approximately 80%) of incident cases are reported to be of mild or moderate
severity. An estimated 132,600 people in England and Wales have been diagnosed with UC,1 which is
distinct from Crohn’s disease (CD) – the other principal form of IBD.2
Ulcerative colitis is a chronic disease of unknown cause. It is understood that pathogenesis may result from
a change in the colonic environment of a genetically susceptible person and the condition is genetically
heterogeneous, having a large number of implicated genes.2,3 Genetic screening is therefore not currently
indicated for UC;2 however, appendectomy and smoking have been linked with a reduced risk and severity
of UC.2
Inflammation in UC typically occurs in the colon and rectum. Disease may be limited to the rectum
(proctitis), may be left sided or distal, or may be extensive (pancolitis).3 Symptoms include the development
of bloody diarrhoea with or without mucus, abdominal pain, weight loss, fatigue and an urgent need to
defecate. Extraintestinal manifestations may occur in 10–30% of patients on the skin, eyes, mouth, joints
or liver.2,4 Symptoms may vary according to the degree and severity of bowel inflammation.1,2 Acute severe
exacerbations of UC are characterised by the development of systemic signs of disease (e.g. high temperature,
tachycardia, anaemia, etc.) and require admission to hospital for urgent monitoring and treatment.3
Diagnosis of UC is made by medical history, endoscopy and biopsy following the exclusion of potential
infectious causes by stool examination.5 These techniques permit the evaluation of relevant histological
features and enable the differentiation of UC from other conditions such as CD.2 For example, inflammation
is characteristically restricted to the mucosal layer of the colon.2 Diagnostic investigations also enable a
determination of disease severity and there is evidence to indicate that severity of disease may be associated
with younger age at diagnosis.6,7 Based on the findings of diagnostic investigations, appropriate treatment can
then be identified.
Colectomy by definition removes the source of inflammation in UC and is therefore associated with the
relief of UC symptoms but is associated with a range of complications.2,8 Pharmacological treatments for
UC do not offer the possibility of cure and the disease course follows a relapsing–remitting pattern.
The aim of clinical management is to induce and maintain disease remission and to avoid potential
complications and the necessity for surgical intervention.9 Selection of the appropriate therapy to induce
remission of UC is determined by a number of factors, including severity and extent of disease. Evidence
on prognosis indicates that, in the first decade, remission occurs in most patients and the rate of colectomy
after diagnosis is low.10 Otherwise, reported rates of colectomy among patients with UC are in the region
of approximately 5% and 20%11,12 however this is an area of considerable uncertainty (some studies in
selected populations have reported markedly higher colectomy rates, e.g. Gustavsson et al.13). A range of
factors have been suggested as potentially influencing the risk of relapse, including age (and age at first
relapse), sex, smoking status and number of previous relapses.12
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Impact of health problem
Significance for patients
Complications of UC, depending on the severity and duration of the disease and age at onset, include
severe bleeding and toxic megacolon, extraintestinal manifestations and osteoporosis.2 Dysplasia and
bowel cancer may also develop. A meta-analysis by Jess et al.14 demonstrated that UC is not associated
with an increase in overall mortality. UC can have a substantial impact on the health-related quality of life
(HRQoL) of patients on account of the young age of disease onset for some patients, the severity of
symptoms and the likelihood of relapse.8,15–17 The risk of relapse and disease flares is increased by poor
adherence to medication regimens.18,19 Relapse and flares can be unpredictable and require further
treatment, thus affecting patients’ HRQoL, their ability to perform daily activities (including work) and lead
to increases in health-care costs.8,19,20
Significance for the NHS
The burden of UC for the NHS is substantial, particularly with respect to those patients who suffer from
poor disease control. A study of the costs of IBD (UC and CD) to the NHS reported in 2004 found that,
compared with quiescent cases of IBD, disease relapse was associated with a two- to threefold increase in
costs for non-hospitalised cases and a 20-fold increase in costs for hospitalised cases.21
Measurement of disease
A range of clinical measures are available for the assessment of disease activity in UC.22 Of most relevance
to this assessment are the modified Truelove and Witts’ criteria,23 the Mayo score24 and the Paediatric
Ulcerative Colitis Activity Index (PUCAI).25
Truelove and Witts’ severity index23
The Truelove and Witts’ severity index describes the frequency of diarrhoea and whether or not systemic
features of illness, such as high temperature, tachycardia and anaemia, are present or absent in patients
(Table 1). When the disease is active, patients are categorised as having mild, moderate or severe disease.
TABLE 1 Features of the Truelove and Witts’ severity index (adapted from Ha26 and Cooney et al.22)
Disease classification Clinical features
Severe disease Diarrhoea frequency > 6 stools per 24 hours with blood
Temperature > 37.5 °C
Tachycardia > 90 b.p.m.
Anaemia (< 75% of normal value)
Erythrocyte sedimentation rate > 30 mm per hour
Moderate disease Values ranging between mild and severe
Mild disease Diarrhoea < 4 stools per 24 hours, intermittently or non-bloody
No fever
No tachycardia
Normal haemoglobin
Erythrocyte sedimentation rate≤ 30 mm per hour
b.p.m., beats per minute.
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Mayo score
The Mayo score assesses patients’ disease in relation to four components: (1) stool frequency; (2) rectal
bleeding; (3) endoscopic findings; and (4) physician’s global assessment24 (Table 2). Full Mayo scores range
from 0 to 12 points, with scoring increasing with disease severity. The partial Mayo score, which comprises
the non-endoscopic elements of the full Mayo score (i.e. stool frequency, rectal bleeding and physician’s
global assessment), has been reported to have reasonable correlation with the full Mayo score (Spearman’s
correlation coefficient ρ= 0.70). Partial Mayo scores range from 0 to 9 points.27
Paediatric Ulcerative Colitis Activity Index
The PUCAI was developed with the aim of providing a non-invasive assessment instrument for use in
paediatric practice and is based on measures of abdominal pain, rectal bleeding, stool consistency, stool
frequency, nocturnal stools and activity level (Table 3). The tool has been described as showing good
correlation with physician’s global assessment (Pearson’s r= 0.91; p< 0.001), full Mayo scores (r= 0.95;
p< 0.001) and endoscopic subscores (r= 0.77; p< 0.001).25
TABLE 2 Features of the Mayo score (adapted from Ha26 and Cooney et al.22)
Mayo score features
Stool frequency
0 Normal stool frequency for patient
1 1–2 stools more than usual
2 3–4 stools more than usual
3 ≥ 5 stools more than usual
Rectal bleeding
0 No blood
1 Streaks of blood < 50% of time with stool
2 Obvious blood most of time with stool
3 Blood alone passed
Endoscopic findingsa
0 Normal/inactive disease
1 Mild disease (erythema, decreased vascular pattern, mild friability)
2 Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)
3 Erosions
Physician’s global assessment
0 Normal
1 Mild
2 Moderate
3 Severe
a Not included in partial Mayo score assessments.
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Current service provision
Clinical guidelines
As outlined in National Institute for Health and Care Excellence (NICE) Clinical Guideline 166,1 conventional
treatment options for moderately to severely active (non-systemic) UC include the use of oral or topical
aminosalicylates, corticosteroids and/or immunosuppressants. Recommended conventional treatment
options can vary according to the extent and location of colitis. Colectomy may be considered in the event
of inadequate control of symptoms and/or poor HRQoL on conventional drug treatment.
Current NICE Technology Appraisal Guidance
Three NICE Technology Appraisals have previously been undertaken.28–30 Infliximab (IFX) [Remicade®, Merck
Sharp & Dohme Ltd (MSD)] was not previously recommended by NICE for the treatment of ‘subacute’
manifestations of moderately to severely active UC (NICE Technology Appraisal Guidance 140).28 NICE
Technology Appraisal 262 was terminated as no evidence submission was provided by the manufacturer.29
NICE Technology Appraisal Guidance 163 recommended the use of IFX as an option for the treatment of
TABLE 3 Features of the PUCAI (adapted from Ha26)
Variable Points scored
Abdominal pain
Absent 0
Able to be ignored 5
Not able to be ignored 10
Rectal bleeding
None 0
Small amount (< 50%) of stools 10
Small amount with most stools 20
Large amount (> 50%) of stools 30
Stool consistency
Formed 0
Partially formed 5
Completely loose 10
Stool frequency (in 24 hours)
0–2 0
3–5 5
6–8 10
≥ 9 15
Nocturnal stools
Absent 0
Present 10
Activity level
No limitations 0
Occasional limitations 5
Severe limitations 10
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acute exacerbations of severely active UC only in patients for whom ciclosporin is contraindicated or
clinically inappropriate.30
Current service cost
Cohen et al.31 reports estimates of the direct and indirect costs of UC within the USA and Europe based on
a systematic review of published cost studies. Cohen reports estimated annual per-patient direct medical
costs of UC of between €8949 and €10,395 in Europe (2008 currency values). The study authors note that
hospitalisations associated with UC accounted for 41–55% of direct medical costs. Indirect costs are also
reported to be substantial, accounting for between 54% and 68% of total costs in Europe. The total
economic burden of UC in Europe was estimated to be in the range of €12.5B to €29.1B.
Variation in services and uncertainty about best practice
The optimal treatment duration using IFX, adalimumab (ADA) (Humira®, AbbVie) and golimumab (GOL;
Simponi®, MSD) is not yet known. The safety and efficacy of the readministration of interventions
following an interruption of treatment has not been fully established. Furthermore, the maintenance of
clinical remission following the withdrawal of biological treatment in responding patients is also unclear.
There is no randomised controlled trial (RCT) evidence for the efficacy and safety of switching to a second
biological intervention in patients who are primary or secondary non-responders, or in patients who are
intolerant to a first biological intervention.
Current treatment pathway
There does not exist a universally agreed pathway for the second-line treatment of patients with
moderate to severe UC. Treatments received by patients may be influenced by the severity of symptoms,
the extent and location of inflammation, clinical advice and individual patient choice. Treatments may
include a combination of aminosalicylates [5-aminosalicylates (5-ASAs) – sulfasalazine, mesalazine/
mesalamine, balsalazide and olsalazine], corticosteroids (beclomethasone, budesonide, hydrocortisone or
prednisolone), and thiopurines [6-mercaptopurine (6-MP) or azathioprine (AZA)], calcineurin inhibitors and
surgical intervention (colectomy). The care of people with UC is usually shared between primary care and
specialist gastroenterology units working in collaboration with specialist colorectal surgical units.1 Figure 1
presents a simplified pathway of the main types of treatments used for the management of patients with
moderately to severely active UC who have had an inadequate response to conventional therapy including
corticosteroids and 6-MP or AZA, or who are intolerant to, or have medical contraindications against,
such therapies.
Induction and maintenance of response
Current medical treatments for UC are principally concerned with treating active disease to address
symptoms of urgency, frequency of defecation and rectal bleeding to improve the patient’s HRQoL and,
thereafter, to maintain remission.1 Treatment usually follows an escalation approach whereby additional
drugs are added in order to induce and subsequently maintain response/remission. Initially, patients would
most likely be treated using oral and topical 5-ASAs to induce a response. Most commonly, oral 5-ASA
treatment involves high-dose oral mesalazine (usually 2.4–4.8 g/day depending on the particular product
used). A dose of up to 2.4 g/day of mesalazine is used for maintenance. It is very likely that topical 5-ASAs
(enemas or suppositories) would also be used during induction; the use of topical 5-ASAs is time-limited
(usually a maximum of 4 weeks) and their efficacy is dependent on the extent of disease and severity
of symptoms. If the patient does not respond or achieves but subsequently loses a response, or is
contraindicated to or unable to tolerate 5-ASAs, treatment is likely to involve the use of oral corticosteroids
and immunomodulators. Oral corticosteroids (most likely prednisolone) would be used as a short-term
therapy with the intention of inducing a response; however, corticosteroids are not used as a maintenance
treatment. Prednisolone is typically given at a dose of 40mg/day, with the aim of the dose being tapered
by 5mg each week (8 weeks of treatment until the dose is zero). Treatment using immunomodulators,
most commonly AZA and less commonly 6-MP, would be started at the same time as oral corticosteroids.
These are indicated for maintenance rather than induction of response; hence patients may receive them
on a long-term basis. Patients would likely remain on oral 5-ASA treatment continuously as they may
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confer other benefits in avoiding cancer, although evidence is conflicting in this respect.32 If the patient
does not respond to corticosteroids, it is likely that the patient would be considered for treatment using
tacrolimus, intravenous (i.v.) steroids or anti-tumour necrosis factor alpha (anti-TNF-α) therapy.
Surgery may be required in emergency scenarios (e.g. in cases of acute severe/fulminant UC) but within
the moderately to severely active population, surgery is most likely to be elected by the individual patient.
Emergency surgery may be required to ameliorate life-threatening complications of UC, such as toxic
megacolon, colonic perforation and massive haemorrhage; it should be noted that surgery might also be
used prophylactically to avoid the onset of these complications. More commonly, surgery is elective and is
undertaken for severe disease characterised by prior treatment failures and/or frequent UC flares. In some
cases, surgery may also be indicated owing to the increased risk of colorectal cancer associated with
long-standing UC and may also be driven by the identification of pre-malignant dysplasia or malignant
neoplasia. Colectomy is associated with post-operative morbidity and a risk of death. Among others,
complications of surgery may include infertility, transient and chronic pouchitis, wound infections, wound
dehiscence and small bowel obstruction.1
Patients with less severe disease may be managed either in primary or secondary care. For patients with
left-sided or extensive UC, follow-up is likely to take place in an outpatient setting, with appointments
every 3–12 months depending on the pattern of flares. Follow-up may be consultant-led or IBD nurse-led,
but will usually involve a combination of both.
Description of technology under assessment
Interventions considered in the scope of this report
Three interventions are considered for the adult population (IFX, ADA and GOL). Only IFX is licensed for
use in children and adolescents. Two biosimilars (Remsima®, Celltrion Healthcare, and Inflectra®, Hospira)
are also considered as part of the evidence base for IFX. Interventions are assessed in line with licensed
indications, as described in the respective Summary of Product Characteristics (SmPCs) for each
intervention.33–35 The interventions under assessment are licensed for the treatment of rheumatoid arthritis
(RA), adult CD (IFX and ADA only), paediatric CD (IFX and ADA only), adult UC, paediatric UC (IFX only),
ankylosing spondylitis (AS), psoriatic arthritis and psoriasis (IFX and ADA only).33–35
Mode of action
Infliximab, ADA and GOL are monoclonal antibodies that inhibit the activity of TNF-α, a key component in
the inflammation process.
Marketing licence and administration method
Infliximab
Infliximab has a UK marketing authorisation for the treatment of moderately to severely active UC in
adults who have had an inadequate response to conventional therapy including corticosteroids and
mercaptopurine or AZA, or who are intolerant to, or have medical contraindications against, such
therapies.33 IFX also has a UK marketing authorisation for the treatment of severely active UC in children
and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy
including corticosteroids and mercaptopurine or AZA, or who are intolerant to or have medical
contraindications against such therapies.33
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Infliximab for the treatment of UC is administered by i.v. infusion at a dosage of 5mg/kg followed by
additional 5-mg/kg infusion doses at 2 and 6 weeks after the initial infusion, then every 8 weeks thereafter.33
The SmPC states that other concomitant therapies (e.g. corticosteroids and immunosuppressants) should be
optimised during IFX therapy.33 IFX is typically administered intravenously over a 2-hour period as an
outpatient or day-case appointment. As IFX treatment is associated with the development of acute infusion
reactions, all patients receiving IFX are required to be observed, in a setting where emergency equipment is
available, during the infusion for 1–2 hours post infusion for safety. Patients may receive pre-infusion
treatment with, for example, an antihistamine, hydrocortisone and/or paracetamol. Contraindications to IFX
treatment include a history of hypersensitivity to IFX or other murine proteins, the presence of tuberculosis (TB)
or other severe infections such as sepsis, abscesses, and opportunistic infections, and moderate or severe
heart failure. Furthermore, women of childbearing potential must use adequate contraception and continue
use for at least 6 months after last receipt of IFX treatment.
Biosimilar versions of IFX (Remsima and Inflectra) are licensed for the same indications as Remicade.
The therapeutic indications (including the wording of the licensed indication), dosage and method of
administration for Remsima and Inflectra are identical to those for IFX (Remicade).
Adalimumab
Adalimumab has a UK marketing authorisation for the treatment of moderately to severely active UC in
adults who have had an inadequate response to conventional therapy including corticosteroids and
mercaptopurine or AZA, or who are intolerant to, or have medical contraindications against, such
therapies.34 ADA for the treatment of UC is administered subcutaneously according to an induction dose
regimen of 160mg at week 0 and 80mg at week 2 followed by a recommended maintenance dosage of
40mg every other week (increased to 40mg every week if clinical response is insufficient).34 Following
physician advice, appropriate training and medical follow-up if required, patients may self-inject with ADA.
The SmPC states that other concomitant therapies (e.g. corticosteroids and immunosuppressants) should
be optimised during ADA therapy.34 Contraindications to ADA treatment include hypersensitivity to the
active substance, the presence of active TB or other severe infections such as sepsis and opportunistic
infections, and moderate to severe heart failure [New York Heart Association (NYHA) class III/IV]. The
administration of ADA during pregnancy is not recommended.
Golimumab
Golimumab has a UK marketing authorisation for the treatment of moderately to severely active UC in adults
who have had an inadequate response to conventional therapy, including corticosteroids and mercaptopurine
or AZA, or who are intolerant to, or have medical contraindications against, such therapies.35
Golimumab for the treatment of UC is administered subcutaneously according to body weight. Patients
with body weight < 80 kg receive an initial dose of 200mg, followed by 100mg at week 2, then 50mg
every 4 weeks thereafter. Patients with body weight ≥ 80 kg receive an initial dose of 200mg, followed by
100mg at week 2, then 100mg every 4 weeks thereafter.35 Following physician advice and adequate
training, patients may self-inject with GOL. Contraindications to GOL include hypersensitivity to the active
substance, the presence of active TB or other severe infections such as sepsis, opportunistic infections, and
moderate or severe heart failure (NYHA class III/IV). The use of GOL during pregnancy is not recommended.
Criteria for continuing treatment
The SmPC for each intervention describes the use of stopping rules for treatment in non-responders.33–35
The SmPC for IFX states that clinical response should typically be achieved within 14 weeks of treatment
(i.e. three doses) and that continued therapy should be carefully reconsidered in patients who show no
evidence of therapeutic benefit within 14 weeks. The SmPC also indicates that, for paediatric patients,
there is no evidence to support the further use of IFX in patients who do not respond within the first
8 weeks of treatment.
BACKGROUND
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For ADA, the SmPC states that clinical response should be reached within 2–8 weeks of treatment and
that treatment should not be continued in patients who fail to respond within this time frame.
The SmPC for GOL states that clinical response is expected to be achieved within 12–14 weeks of
treatment (i.e. after four doses) and that continued therapy should be reconsidered in patients who do not
experience therapeutic benefit within this time period.
The SmPCs for each intervention also refer to the requirement to monitor patients closely for infections
and to discontinue treatment in patients who develop a serious infection or sepsis.
Current usage in the NHS
Infliximab is currently recommended by NICE as an option for the treatment of acute exacerbations of
severely active UC, only in patients in whom ciclosporin is contraindicated or clinically inappropriate. ADA
and GOL do not have recommendations from NICE for use in the treatment of UC. The Assessment Group
has received clinical advice to suggest that IFX, and to a lesser degree ADA, are currently used for the
treatment of moderate to severe UC in some larger centres in England and Wales.
Identification of important subgroups
The only subgroup pre-specified in the final NICE scope36 relates to duration of disease.
Anticipated costs associated with interventions
Table 4 summarises the costs associated with the interventions based on their list prices.37
TABLE 4 Acquisition costs associated with IFX, ADA and GOL
Drug Unit type and dose Price per unit
IFX Powder for reconstitution, 100-mg vial £419.62
ADA 40-mg pre-filled pen or pre-filled syringe, 40-mg/0.8-ml vial £352.14
GOL 50-mg pre-filled pen or pre-filled syringe £762.97
100-mg pre-filled pen £1525.94
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Chapter 2 Definition of the decision problem
Decision problem
The aim of this assessment is to evaluate the clinical effectiveness and cost-effectiveness of IFX, ADA
and GOL for the treatment of patients with moderately to severely active UC after the failure of
conventional therapy.
Interventions
Three interventions are considered within this assessment: IFX (Remicade), ADA (Humira) and GOL (Simponi).
These interventions are described in detail in Chapter 1, Description of technology under assessment.
Biosimilar versions of IFX (Remsima and Inflectra) are also licensed for the same indications and are considered
as part of the evidence base for IFX within this assessment report.
Populations (including subgroups)
The assessment considers the following two populations:
1. Adults aged ≥ 18 years with moderately to severely active UC who have had an inadequate response to
conventional therapy including corticosteroids and mercaptopurine or AZA, or who are intolerant to, or
have medical contraindications against, such therapies.
As referred to in the final NICE scope,36 severity of disease in adults would be defined according to the
modified Truelove and Witts’ severity index (as described in NICE Clinical Guideline 166).1
The following interventions are indicated for use in adults:
i. ADA
ii. IFX
iii. GOL.
2. Children and adolescents aged 6–17 years (inclusive) with severely active UC, who have had an
inadequate response to conventional therapy including corticosteroids and mercaptopurine or AZA,
or who are intolerant to, or have medical contraindications against, such therapies.
As described in NICE Clinical Guideline 166,1 severity of UC in children and adolescents was to be
assessed using the PUCAI.25
The following intervention is indicated for use in children and adolescents:
i. IFX.
The final NICE scope36 highlighted duration of disease as a potential subgroup of interest; this is examined
according to the availability of evidence.
Populations outside of the scope of the appraisal
The following groups were considered to be beyond the scope of the appraisal and, therefore, are not
considered in this assessment report:
l children with mildly or moderately active UC (as defined by the PUCAI measure)
l adults with mildly active UC (as defined by the modified Truelove and Witts’ criteria)
l adults and children with acute severe (systemic) UC.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Relevant comparators
The interventions are compared against each other. Other relevant comparators include standard clinical
management options, which (as described in the final NICE scope36) could include a combination of
aminosalicylates (sulfasalazine, mesalazine, balsalazide or olsalazine), corticosteroids (beclomethasone,
budesonide, hydrocortisone or prednisolone), thiopurines (mercaptopurine or AZA), calcineurin inhibitors or
elective surgical intervention.
Emergency surgical intervention is not considered as a comparator in this assessment as acute severe UC
was stated in the final scope as being beyond the remit of the appraisal.
Outcomes
The outcome measures to be considered included:
l mortality
l measures of disease activity
l rates of and duration of response, relapse and remission
l rates of hospitalisation
l rates of surgical intervention (both elective and emergency)
l time to surgical intervention (both elective and emergency)
l adverse events (AEs) of treatment (including leakage and infections following surgery)
l HRQoL.
Following discussions during the NICE appraisal scoping process, data relating to mucosal healing were not
considered eligible for this assessment.
Overall aims and objectives of assessment
This assessment addresses the question ‘what is the clinical effectiveness and cost-effectiveness of IFX,
ADA and GOL for the treatment of patients with moderately to severely active UC after the failure of
conventional therapy as compared against each other and standard clinical management?’.
More specifically, the objectives of the assessment are:
1. to evaluate the clinical effectiveness of each intervention
2. to examine the effect of disease duration on the clinical effectiveness of each intervention (subject to
the availability of evidence)
3. to evaluate the adverse effect profile of each intervention
4. to evaluate the incremental cost-effectiveness of each intervention compared (1) against each other and
(2) against all comparators (including medical and surgical options)
5. to estimate the expected net budget impact associated with implementing each intervention
6. to identify key areas in which future research may be valuable.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
A systematic review of the literature including network meta-analyses (NMAs) was conducted in order toevaluate the clinical effectiveness and safety of IFX, ADA and GOL in the treatment of moderately to
severely active UC after the failure of conventional therapy.
The systematic review of clinical effectiveness was undertaken in accordance with the general principles
recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.38
Methods for reviewing clinical effectiveness
The protocol for this review is registered with PROSPERO (CRD42013006883).39
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Identification of studies
A comprehensive search was undertaken to systematically identify literature relating to the clinical
effectiveness and safety of IFX, ADA and GOL for treating moderately to severely active UC after the failure
of conventional therapy. The search strategy comprised the following main elements:
l searching of electronic databases
l hand-searching bibliographies of retrieved papers, key journals and conference proceedings
l contact with experts in the field.
The following electronic databases were searched from inception for published trials and
systematic reviews:
l MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations: via Ovid – 1946 to December 2013.
l EMBASE: via Ovid – 1974 to December 2013.
l Cochrane Library: via Wiley Interscience
¢ Cochrane Database of Systematic Reviews (CDSR) – 1996 to December 2013
¢ Database of Abstracts of Reviews of Effects (DARE) – 1995 to December 2013
¢ Cochrane Central Register of Controlled Trials (CCRT) – 1995 to December 2013
¢ Cochrane Methodology Register – 1904 to December 2013
¢ Health Technology Assessment (HTA) database – 1995 to December 2013.
l Cumulative Index to Nursing and Allied Health Literature (CINAHL): via EBSCOhost – 1982 to
December 2013.
l Web of Science Citation Index: via Web of Knowledge – 1900 to December 2013.
l Conference Proceedings Citation Index: via Web of Knowledge – 1990 to December 2013.
l Bioscience Information Service (BIOSIS) Previews: via Web of Knowledge – 1969 to December 2013.
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The MEDLINE search strategy is presented in Appendix 1. The search strategy combined free text and
medical subject headings (MeSHs) or thesaurus terms relating to UC, with free text and MeSHs or
thesaurus terms relating to IFX, ADA or GOL combined with highly sensitive filters to retrieve RCTs and
systematic reviews. Search terms for IFX biosimilars were also included. The search strategy was translated
across all databases. No date or language restrictions were applied. Literature searches were conducted
during December 2013. References were collected in a bibliographic management database and duplicates
were removed.
Searches were undertaken to identify unpublished studies (nearing or at completion) relevant to the
decision problem within the following research registers:
l ClinicalTrials.gov (searched December 2013)
l UK Clinical Research Network Portfolio database (searched December 2013)
l World Health Organization International Clinical Trials Registry Platform (searched March 2014).
Proceedings of the following conferences were searched from 2009 to 2014 (when possible) for
recent research:
l Congress of Crohn’s and Colitis Conference, European Crohn’s and Colitis Organisation (ECCO)
l Digestive Disease Week
l Gut (British Society of Gastroenterology).
Key journals were identified using the PubMed PubReMiner facility and electronic tables of contents were
searched from March 2013 to February 2014 for the following journals:
l Inflammatory Bowel Diseases
l Alimentary Pharmacology & Therapeutics
l Gastroenterology
l Journal of Crohn’s and Colitis
l American Journal of Gastroenterology.
Citation searches were performed on included studies in Web of Science in March 2014.
Manufacturers’ submissions received by NICE, as well as any relevant systematic reviews, were also
hand-searched in order to identify any further potentially relevant clinical trials.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were based on the final NICE scope36 and were applied as described below.
Study selection
The selection of eligible articles was undertaken using a two-stage process. First, in order to assess
agreement in the sifting approach between systematic reviewers, a check for consistency was conducted in
the early stages of the sifting process. The reviewers (RA and MMSJ) double-sifted a total of 940 titles and
abstracts. Kappa statistics of 0.888 and 1.000 were obtained, indicating very high strength of agreement.
All remaining titles and abstracts were examined for inclusion by one reviewer (either RJA or MMSJ sifted
50% of total citations at title and abstract level). Any citations that clearly did not meet the inclusion
criteria (e.g. animal studies, studies unrelated to UC) were excluded. During the second stage of the sifting
process, full-text articles were examined for inclusion by one reviewer (RJA or MMSJ). Any uncertainty in
the eligibility of potentially relevant full-text articles was resolved through discussion. Trials retrieved for
full-paper screening which were subsequently excluded were tabulated (see Appendix 2) together with
justification for their exclusion.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Inclusion criteria
Studies were included in the review if they met the inclusion criteria outlined below.
Interventions
Any of the following interventions were included:
i. For adults (defined by the Assessment Group as aged ≥ 18 years):
l ADA
l IFX
l GOL.
ii. For children and adolescents aged 6–17 years (inclusive):
l IFX.
Biosimilar versions of IFX (Remsima and Inflectra) are also licensed for the same indications as Remicade
and have been considered as part of the evidence base for IFX within this assessment.
Studies in which the interventions were assessed in line with licensed indications were included in the
systematic review.
Populations
i. Adults aged ≥ 18 years with moderately to severely active (non-systemic) UC (defined as patients with
moderately active disease according to the modified Truelove and Witts’ criteria23) whose disease has
responded inadequately to conventional therapy including corticosteroids and mercaptopurine or AZA,
or who are intolerant of, or have medical contraindications to, such therapies.
ii. Children and adolescents aged 6–17 years with severely active (non-systemic) UC (as classified by the
PUCAI measure25) whose disease has responded inadequately to conventional therapy including
corticosteroids and mercaptopurine or AZA, or who are intolerant to, or have medical contraindications
to, such therapies.
Comparators
Relevant comparators included in the final NICE scope were (1) interventions as defined in the protocol for
this assessment (i.e. IFX, ADA or GOL compared with each other) and (2) standard clinical management,
which may include a combination of aminosalicylates (sulfasalazine, mesalazine/mesalamine, balsalazide or
olsalazine), corticosteroids (beclomethasone, budesonide, hydrocortisone or prednisolone), thiopurines
(mercaptopurine or AZA), calcineurin inhibitors or elective surgical intervention.
It should be noted that although calcineurin inhibitors (tacrolimus and ciclosporin) were included as
potential comparators in the final NICE scope, these options were excluded from the assessment for
two reasons:
1. They are treatments typically reserved for patients with acute severe disease. This differs to the
population within the final NICE scope. Studies were specifically excluded if they related to these
patients (see Exclusion criteria).
2. There are no direct data comparing biologicals versus calcineurin inhibitors for the population under
investigation. Altogether, there are very limited data on the efficacy of either ciclosporin or tacrolimus in
this indication.
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Outcomes
Eligible outcomes for consideration were:
l mortality
l measures of disease activity
l rates of and duration of response, relapse and remission
l rates of hospitalisation
l rates of surgical intervention (both elective and emergency)
l time to surgical intervention (both elective and emergency)
l AEs of treatment (including leakage and infections following surgery)
l HRQoL.
Following discussions during the NICE appraisal scoping process, data relating to mucosal healing were not
considered eligible for this assessment.
Study design
Randomised controlled trials were eligible for inclusion in the systematic review of clinical effectiveness.
Long-term extension studies associated with included RCTs were also included in the review.
Studies published as abstracts or conference presentations were eligible for inclusion only if sufficient
details were presented to allow an assessment of the trial methodology and results to be undertaken.
Exclusion criteria
The following types of studies were excluded from the review:
l Studies that included adults with mildly active UC (as defined by the modified Truelove and Witts’
criteria23), for which no separate data were reported for patients with moderate to severe UC.
l Studies that included children with mildly or moderately active UC (as defined by the PUCAI measure25).
l Studies that included adults with (acute) severely active UC as defined by the modified Truelove and Witts’
criteria23 (representing patients who are systemically ill and are, therefore, beyond the remit of this appraisal).
l Studies that included adults, adolescents or children with acute severe UC, whose disease is systemic as
shown by tachycardia, fever, anaemia or a raised erythrocyte sedimentation rate (representing patients
who are excluded as they are outside the remit of this appraisal).
l Studies that included patients with acute severe UC previously hospitalised and treated with i.v. steroids
(representing patients in a potentially life-threatening medical emergency and excluded as they are
outside the remit of this appraisal).
l Studies that included patients with IBD other than UC (e.g. CD) for which data were not reported
separately for UC patients.
l Studies that interventions were not administered in accordance with licensed indications.
l Systematic reviews and clinical guidelines (selected systematic reviews identified by the clinical
effectiveness searches were used as sources of references).
l Studies that were published only in languages other than English.
l Studies based on animal models.
l Pre-clinical and biological studies.
l Narrative reviews, editorials and commentaries.
l Reports published as abstracts or conference presentations only, for which insufficient details were
reported to allow an assessment of study quality or results.
Data abstraction strategy
Data relevant to the decision problem were extracted by one reviewer (RA or MMSJ). Data were extracted
without blinding to authors or journal. A data extraction form was developed and piloted on two included
trials before slight revisions and final use on all included trials. Data relating to study arms in which the
intervention treatments were administered in line with their licensed indications were extracted; data
ASSESSMENT OF CLINICAL EFFECTIVENESS
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relating to the unlicensed use of the interventions were not extracted. All extracted data were double-
checked by a second reviewer (MMSJ or CC). The safety data extracted were informed by the SmPCs for
each product [available from www.medicines.org.uk/emc/ (accessed 26 May 2014)].33–35 The key safety
issues included such items as the number of patients experiencing infections, number of patients
experiencing serious infections, number of patients experiencing malignancy and the occurrences of
infusion-related or injection site reactions (as appropriate to the mode of administration for each
intervention). Study results that were presented only in graphical format were digitised and estimated
using Engauge software version 4.1 [http://sourceforge.net/projects/digitizer/files/Engauge%20Digitizer/
digitizer-4.1/ (accessed April 2014)]. When multiple publications of the same study were identified, data
extraction was undertaken on all relevant associated publications and findings were presented together
with reference to their published source.
Critical appraisal strategy
The methodological quality of each included study was assessed by one reviewer (RJA or MMSJ). The
quality of included studies was assessed using the Cochrane Risk of Bias Tool.40 This tool addresses specific
domains, namely sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data and selective outcome reporting. RCTs were
classified as being at ‘high risk’ of attrition bias where drop-out in any treatment arm was ≥ 10%.41 The
Assessment Group requested the trial protocols for all included trials from the manufacturers of the
products included in this appraisal. These were received for some trials and were used alongside clinical
study reports (CSRs) provided by the manufacturer for some trials and outcomes listed in ClinicalTrials.gov
records in order to inform the selective reporting domain of the Cochrane Risk of Bias Tool. All quality
assessment findings were double-checked by a second reviewer (RJA or MMSJ).
Methods of data synthesis
The extracted data were presented for each study, both in structured tables and as a narrative description.
Methods for the estimation of efficacy using network meta-analysis
Network meta-analysis methods are described in full on page 69.
Supplementary meta-analyses
When considered appropriate, secondary outcomes of interest were analysed using classical meta-analysis
methods. Meta-analysis was undertaken using Cochrane Review Manager software (version 5.2; The
Cochrane Collaboration, Copenhagen, Denmark). Outcomes reported as continuous data were estimated
using a mean difference with 95% confidence intervals (CIs). Dichotomous outcomes were estimated as
risk ratios (RRs) with associated 95% CIs. When RCTs reported AEs in sufficient detail, these were analysed
as dichotomous data. Clinical heterogeneity across RCTs (the degree to which RCTs appear different in
terms of participants, intervention type and duration and outcome type) was considered prior to data
pooling. Random-effects models were applied and effect estimates, estimated in Review Manager as
z-values, were considered statistically significant at a cut-off point of p< 0.05.
Results
Quantity of research available
The searches described in Identification of studies yielded 7774 potentially relevant citations (7602 from
searches of electronic databases after removal of duplicates), three from hand-searching of key journals,
one from sponsor submissions and 168 from trial register searches). Of these records, 7546 were excluded
at the title and abstract stage. Full texts of 228 studies were obtained for scrutiny and of these,
181 citations were excluded (it was not possible to obtain nine studies and hence these were excluded;
see Appendix 2).
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No additional eligible trials that were completed or nearing completion were identified through the trial
register searches. Trial NCT01551290 [a study of IFX vs. placebo (PBO) in Chinese subjects by Xian-Janssen
Pharmaceutical Ltd42] was stated to be ongoing with an estimated completion date of November 2014.
Trial NCT01863771 (a study of GOL maintenance treatment vs. PBO in Japanese patients by Janssen
Pharmaceutical43) was recruiting as of February 2014. As such, neither trial was judged to be completed or
nearing completion.
A total of 47 citations relating to 10 RCTs were included in the review.44–52 The search process is
summarised in the form of a PRISMA diagram in Figure 2.
European Public Assessment Reports (EPARs) were available for all included interventions; however,
associated Food and Drug Administration (FDA) reports for interventions could not be identified from the
FDA website (www.fda.gov/drugs/).
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(n = 172)
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• Trial register searches, n = 168
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(n = 7774)
Records excluded at title/abstract stage
(n = 7546)
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(n = 228)
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Appendix 3)
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FIGURE 2 Flow diagram of study inclusion (adapted from PRISMA).53 a, Not including sponsor submissions and
European Public Assessment Reports.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Summary of study and population characteristics of included trials
Study characteristics
The available comparisons between licensed doses of interventions and PBO are tabulated within the adult
population RCTs in Table 5. The trial design characteristics of the included trials are outlined in Tables 6
and 7. The outcome measures pre-specified in the final NICE scope36 and protocol were all addressed by
the included trial evidence, with the exception of rates of relapse. As stated in Methods for reviewing
clinical effectiveness, data relating to mucosal healing were not eligible for this assessment.
Population: adults aged ≥ 18 years with moderately to severely active ulcerative colitis
who have had an inadequate response to conventional therapy including corticosteroids
and mercaptopurine or azathioprine, or who are intolerant to, or have medical
contraindications against, such therapies
A total of nine relevant RCTs were identified which were performed in adult populations. Four RCTs
evaluated the use of IFX [Active Ulcerative Colitis Trial (ACT)1,49 ACT2,49 Probert et al.50 and UC-SUCCESS51],
three RCTs were of ADA [Ulcerative colitis Long-Term Remission and maintenance with Adalimumab
treatment of moderate to severe ulcerative colitis (ULTRA)1,44 ULTRA2,45 and Suzuki et al., 201446] and two
RCTs were of GOL [Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment
(PURSUIT)-SC,47 PURSUIT-Maintenance48]. Four of these RCTs (ACT1,49 ACT2,49 ULTRA1,44 and ULTRA245)
had long-term open-label extension studies associated with them (ACT1 and ACT2 extension studies,55
ULTRA354) that were also included as part of the evidence for these interventions. All of the included RCTs
for adults were undertaken against a comparator of PBO, with the exception of UC-SUCCESS51 which
assessed the use of IFX against active comparators of AZA and combination IFX/AZA. No head-to-head RCTs
comparing interventions of interest against each other were identified for adults. All RCTs were Phase III (if
stated), with the exception of Suzuki et al.46 (Phase II/III) and PURSUIT-SC47 (Phase II/III). If stated, all included
adult population trials were powered for the primary end points of clinical remission (ULTRA1,44 ULTRA2,45
Probert et al.,50 UC-SUCCESS51) or clinical response (ACT1,49 ACT2,49 PURSUIT-SC,47 PURSUIT-Maintenance48).
Where the geographical location(s) of study sites were reported, all trials were multicentre, international
studies, with the exception of Probert et al.,50 which was performed in the UK and Germany, and Suzuki
et al.,46 which was conducted exclusively in Japan. All trials were at least partly industry funded.
TABLE 5 Licensed dose comparisons for included adult population RCTs
Trial Licensed treatment comparisons
ULTRA144 PBO; 160mg/80mg of ADA (licensed induction dose)
ULTRA245 PBO; 160mg of ADA at week 0, 80mg at week 2 and then 40mg every other week
(licensed maintenance dose) beginning at week 4
Suzuki et al.46 PBO; 160mg/80mg of ADA (licensed induction dose)
PURSUIT-SC47 PBO; 200mg/100mg of GOL (licensed induction dose)
PURSUIT-Maintenance48 PBO; 50mg of GOL; 100mg of GOL (licensed maintenance doses)
ACT149 PBO; 5mg/kg of IFX
ACT249 PBO; 5mg/kg of IFX
Probert et al.50 PBO; 5mg/kg of IFX
UC-SUCCESS51 No PBO; 5mg/kg of IFX; AZA; IFX5mg/kg/AZA
ACT1, Active Ulcerative Colitis Trial 1; ACT2, Active Ulcerative Colitis Trial 2; PURSUIT, Program of Ulcerative Colitis
Research Studies Utilizing an Investigational Treatment; ULTRA, Ulcerative colitis Long-Term Remission and maintenance
with Adalimumab treatment of moderate to severe ulcerative colitis.
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Eight trials included time points for the assessment of the use of interventions in achieving induction of
clinical response or remission, of which four assessed IFX (ACT1,49 ACT2,49 Probert et al.50 and
UC-SUCCESS51), three assessed ADA (ULTRA1,44 ULTRA245 and Suzuki et al.46) and one assessed GOL
(PURSUIT-SC47). Six trials reported outcomes at time points for the evaluation of the use of interventions in
the maintenance of clinical response or remission, consisting of three IFX trials (ACT1,49 ACT249 and
UC-SUCCESS51), two ADA trials (ULTRA245 and Suzuki et al.46) and one GOL trial (PURSUIT-Maintenance48).
None of the included RCTs applied Truelove and Witts’ disease severity criteria23 in their eligibility criteria (as
referred to in the final NICE scope for this appraisal36 and as specified in the protocol). All included trials
applied the Mayo score [except Probert et al.50 for which the score was specified simply as Ulcerative Colitis
Symptom Score (UCSS)] to classify the disease severity of potential participants (note: the UCSS was
confirmed to be equivalent to Mayo score by Professor C Probert, University of Liverpool, 2014, personal
communication). The included trials required a Mayo score of 6–12 points (with evidence of endoscopic
disease) for participant eligibility. Mayo scores of 6–12 points were described in the included trial literature
as moderate to severe disease and were also subsequently confirmed following clinical advice as
representing moderate to severe disease (note: ad-hoc searches were performed to attempt to identify
evidence relating to the relationship between the Truelove and Witts’ and Mayo disease severity indices;
however, no evidence published in full text in English could be identified). Included trials required a varying
range of prior use of conventional therapy for eligibility, as described in Tables 6 and 7. The UC-SUCCESS
trial,51 which specified patients to be either AZA-naive or free from AZA treatment for at least 3 months
before enrolment, was a borderline inclusion in the clinical effectiveness systematic review because the
wording of the population in the scope and the licensed indications required prior use of AZA or 6-MP.
However, as the trial reported the use of a stated (albeit low) proportion of prior immunosuppressant use,
this trial was included in the clinical effectiveness systematic review for completeness. However, this trial
was not eligible for subsequent inclusion in meta-analyses or NMAs. Suzuki et al.46 included Japanese
patients aged ≥ 15 years (ADA is not licensed in the paediatric population), but the mean ages of
participants across treatment arms at baseline was 41.3–42.5 years.
The Core Outcome Measures in Effectiveness Trials (COMET) initiative,56 which promotes the use of core
outcome sets in clinical trials, referenced the work by Cooney et al.22 in classifying the use of outcome
measures in UC clinical trials. Although acknowledging the very broad range of available disease severity/
activity measures available, all adult population trials included in the assessment were consistent in their
utilisation of the Mayo score as a measure of clinical response and/or remission. The included trial by
Probert et al.50 applied the UCSS in the evaluation of clinical remission at induction. This score is equivalent
to the full Mayo score: the components of the UCSS are consistent with the elements assessed within the
Mayo score (i.e. stool frequency, rectal bleeding, sigmoidoscopic appearance and physician’s global
assessment) and also is referenced using the citation quoted for the Mayo score.24 None of the included
studies utilised the modified Truelove and Witts’ criteria23 (as referred to in the NICE appraisal scope36 and
as specified in the assessment protocol) in their outcome assessments.
As recommended in the Committee for Human Medicinal Products (CHMP) guideline57 on the development
of new medicinal products for the treatment of UC patients with confirmed UC were eligible for the
included trials. Severity of disease was defined by clinical and endoscopic evaluation, as recommended in
the CHMP guideline. Although the interventions of interest in this assessment were developed for the
treatment of patients not responding/intolerant to previous immunomodulatory therapy, the Assessment
Group did not consider that adequate definitions of inadequate response/intolerance were included in trials,
as recommended by the CHMP guideline. The guideline recommended that, for refractory populations, a
minimum duration and dose of previous baseline medication should be defined, but this was not the case in
the included trials. In addition, intolerance was not defined by minimum criteria of severity in the trials. In
terms of study duration, it was recommended that induction studies should be 8–12 weeks, but could be
shorter based on the pharmacodynamic properties of the study drug. All induction trials assessed efficacy at
8 weeks, with the exception of the PURSUIT-SC GOL trial,47 which was a 6-week study. All maintenance
studies were at least 1 year in length, as recommended in the CHMP guideline.
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Adalimumab
ULTRA144 was a multicentre Phase III RCT in adults undertaken across the USA, Puerto Rico, Canada,
Western Europe, and Eastern Europe. In the original protocol, 186 participants were randomised and in
the amended protocol 390 were randomised (130 per group including PBO). Length of treatment was
12 weeks in the original protocol and 8 weeks in the amendment, and outcomes were reported at week 8.
ULTRA245 was a multicentre Phase III RCT in adults undertaken across North America, Europe, Australia,
New Zealand and Israel. A total of 518 patients entered the study, of which 258 were randomised to
160mg/80mg/40mg of ADA and 260 were randomised to PBO. Outcomes were reported at week 8 and
week 52. Suzuki et al.46 was a 52-week Phase II/III trial in Japanese adults in which 274 participants were
randomised to three treatment groups, including PBO. Outcomes were reported at 8 weeks and 52 weeks.
The two induction ADA groups (one licenced dose and the other unlicensed) were combined as one active
treatment group for outcomes at 52 weeks. ULTRA354 was the 156-week open-label extension study to
ULTRA144 and ULTRA2.45
Golimumab
PURSUIT-SC47 was a Phase II/III multicentre RCT in adults reporting outcomes at week 6. The trial was
performed across 217 sites (Eastern Europe, 400 patients; North America, 278 patients; Asia Pacific and
South Africa, 204 patients; and Western Europe and Israel, 183 patients). This was a dose-ranging study
with 169 patients randomised to four groups, including PBO. PURSUIT-Maintenance48 was a Phase III RCT
in adults across 251 sites (Eastern Europe, 477 patients; North America, 323 patients; Asia Pacific and
South Africa, 237 patients; and Western Europe and Israel, 191 patients). Out of the 1228 patients who
enrolled in PURSUIT, 464 were randomised to receive PBO (n= 156), 50mg of GOL (n= 154) or 100mg of
GOL (n= 154). A total of 764 patients were not randomised: 129 were PBO non-responders, 230 were
PBO induction non-responders and 405 were GOL induction non-responders.
Infliximab
ACT149 was a multicentre Phase III RCT conducted across 62 sites. A total of 364 adult patients were
randomly assigned to licensed and unlicensed induction doses or PBO. ACT2 was a multicentre Phase III
RCT across 55 sites. A total of 364 adult patients were randomly assigned to licensed and unlicensed
maintenance doses or PBO. Probert et al.50 was a RCT undertaken across four centres in the UK and
Germany; 43 adult participants were randomised to IFX or PBO and outcomes assessed at week 6.
UC-SUCCESS51 was a multicentre RCT undertaken in adults. A total of 239 participants were randomised
to IFX, AZA or combination therapy (with no PBO group included). Outcomes were assessed at weeks
8 and 16.
Population: children and adolescents aged 6–17 years (inclusive) with severely active
ulcerative colitis who have had an inadequate response to conventional therapy
including corticosteroids and mercaptopurine or azathioprine, or who are
intolerant to, or have medical contraindications against, such therapies
A single Phase III open-label RCT was identified for the paediatric population (T7252) which evaluated the
use of IFX in maintenance therapy. All patients received the licensed IFX induction regimen before being
randomised to one of two IFX maintenance regimens. Outcomes were reported at week 30 and week 54.
No PBO-controlled or head-to-head RCTs were identified for children and young people. The absence of a
PBO or non-IFX control group in the included RCT made it difficult to consider the effectiveness of IFX in
paediatric patients compared with conventional UC therapies. This industry-funded trial had the primary
end point of clinical response and was conducted in the USA, the Netherlands, Canada and Belgium.
Eligible patients were 6–17 years of age with moderately to severely active UC and a Mayo score of
6–12 points with endoscopic evidence of disease. Therefore, although IFX is licensed in this age group
with severe disease only (as reflected in the scope population), this trial was included in consideration of
limited paediatric RCT evidence.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Quality of included evidence
All of the included trials were considered to be at low risk of selection bias as all trials reported an
appropriate method for generating the randomisation sequence. Likewise, the majority of trials reported
adequate information that allocation was concealed and were considered to be at low risk of bias for this
domain. This was with the exception of two trials in which there was no information reported to make a
judgement. These trials were therefore classified as being at unclear risk of bias.46,52 Eight out of the
10 trials (see Figure 3) were considered to be at low risk of performance bias because there was reporting
to indicate that participants and personnel were blinded to participants’ treatment allocation. Two trials
were considered at unclear risk of bias for this domain; one because there was no clear statement in the
trial report52 and one because the treatment regimen differed for non-responders at week 8 in AZA arm
which could break the blinding.51 Blinding of the outcome assessment was reported by five trials,44,45,47,48,50
all of which were considered at low risk of bias for this domain. The remaining five trials included no
statement in the trial report and were considered at unclear risk for this domain (ACT1,49 ACT2,49 Hyams
et al.,52 UC-SUCCESS,51 Suzuki et al.46).
All included trials were reported according to the intention-to-treat (ITT) principle. However, for two trials
(ACT149 and ACT249), although ITT was reported, > 50% of patients in the PBO group and > 30% of patients
in IFX groups did not complete the trial. Similarly, in another IFX trial,52 the numbers of patients withdrawing
from the study were unbalanced across groups with > 50% of patients withdrawing from the every 12-week
dose group. In the UC-SUCCESS trial,51 there was also a high level of attrition and an imbalance between
treatment groups (AZA, 34%; IFX, 18%; IFX/AZA, 21%). In one of the ADA trials (ULTRA245), although ITT
analysis was undertaken, there was a high level of attrition and an imbalance between treatment groups
(PBO, 44.2%; ADA, 36.4%). In the GOL maintenance trial (PURSUIT-Maintenance48), withdrawal of > 10%
was evident across all treatment groups. These trials were all considered to be at high risk of bias for this
domain. Of note, the trial of ADA reported by Suzuki et al.46 was considered at low risk of attrition bias for
the induction phase (Figures 3 and 4). A high risk of attrition bias was evident for the maintenance phase
(> 10% withdrawing). The maintenance active treatment group comprised participants receiving both licensed
and unlicensed doses of ADA during induction (data not used in this report). Details of the numbers of
participants withdrawing and reasons for withdrawal by trial are presented in Appendix 3. The extent
of reporting of the reasons for withdrawals was variable between studies.
Selective outcome reporting was assessed based on ClinicalTrials.gov records, trial protocols and CSRs
when provided by the manufacturers. Adequate data were available across ClinicalTrials.gov records
and CSRs (available for some trials only) to compare outcomes with those reported in the associated
peer-review publications for all included trials with the exception of Probert et al.50 Stated primary
outcomes were compared between published reports and trial protocols (for those RCTs for which trial
protocols were provided by manufacturers). With the exception of Probert et al.50 and Suzuki et al.,46
all included RCTs were considered to be of at low risk of bias for this domain. Probert et al.50 and
Suzuki et al.,46 were judged as being at unclear risk of selective reporting bias.
Population characteristics
The baseline characteristics of participants in the included RCTs are presented in Tables 8 and 9. In
addition to comparator arm data, only data relating to licensed doses of interventions are presented.
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FIGURE 3 Risk-of-bias summary: review authors’ judgements about each risk-of-bias item for each included study.
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Population: adults aged ≥ 18 years with moderately to severely active ulcerative
colitis who have had an inadequate response to conventional therapy including
corticosteroids and mercaptopurine or azathioprine, or who are intolerant to,
or have medical contraindications against, such therapies
Mean and median reported ages of participants were considered consistent across included adult
population trials, ranging from 37 to 42.5 years. Mayo scores at baseline were also consistent across trials
and spanned from 8.1 to 8.9. Average proportions of male participants ranged from 41% to 73% and
the majority of included patients (when reported) were Caucasian in ethnicity (79.5–95.9%), with the
exception of the Suzuki et al.46 study, which included exclusively Japanese patients. Mean and median
disease duration of participants ranged from 59 months (4.9 years) to 8.5 years. Conventional UC
medications at baseline were variable between the included trials. In none of the included studies had all
participants previously been trialled on corticosteroids and AZA or 6-MP, as required by the wording used
in the final NICE scope36 population and the wording of the European Medicines Agency (EMA) licensing
for IFX, ADA and GOL. Although it is noted that AZA and 6-MP may be used more typically in clinical
practice as maintenance therapies owing to their longer initiation of effect, it is debatable whether or not
the included trial populations would represent patients who had failed or were intolerant to previous
conventional therapies. All trials related to anti-TNF-α-naive populations, with the exception of ULTRA245
(which permitted the inclusion of anti-TNF-α experienced patients) and PURSUIT-Maintenance48 (in which
patients responding to prior GOL induction therapy were randomised to GOL maintenance regimens or
PBO). Data at induction were reported according to anti-TNF-α experience. Data relating to patients who
were anti-TNF-α-naive for maintenance time points were requested and received from the manufacturer of
ADA (AbbVie). Weight and smoking status were both relatively poorly reported across included studies.
Population: children and adolescents aged 6–17 years (inclusive) with severely active
ulcerative colitis who have had an inadequate response to conventional therapy
including corticosteroids and mercaptopurine or azathioprine, or who are
intolerant to, or have medical contraindications against, such therapies
The included trial population52 averaged 15 years of age in both treatment groups, was 43.5–45.5% male
and mostly Caucasian in ethnic origin (82.6–90.9%) with average disease duration of 1.1–1.8 years.
Patients had a median Mayo score of 7.5 to 8.0 points and a median PUCAI score of 50–57.5 points, for
which a PUCAI of score of ≥ 65 would indicate severe disease (and, therefore, were a mixture of patients
with moderate and severe disease, while IFX is licensed in paediatric patients with severe disease only).
Participants were required to have had prior use of at least one conventional therapy (with 61% to 64%
receiving corticosteroids, 50% to 57% immunosuppressants and 46% to 52% aminosalicylates
at baseline).
Assessment of effectiveness
Population: adults aged ≥ 18 years with moderately to severely active
ulcerative colitis who have had an inadequate response to conventional
therapy including corticosteroids and mercaptopurine or azathioprine,
or who are intolerant to, or have medical contraindications against,
such therapies
Rates of and duration of response, relapse and remission
Clinical response and remission data were well reported across the included trials for the adult population.
It was assumed by the Assessment Group that the numbers of patients who were reported in the trial
publications as being in clinical response also included those patients who were in clinical remission. Data
relating to transitions of patients between no response, response and remission categories at maintenance
time points were requested and received from the manufacturers (MSD and AbbVie). The induction
trial data (as reported in the trial publications) and maintenance transition data (received from the
manufacturers) from eligible trials were analysed using NMA methods (see page 69). Definitions of clinical
response and clinical remission used in the included trials are presented in Table 10.
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TABLE 10 Definitions of clinical response and remission in adult population RCTs included in the clinical
effectiveness systematic review
Trial Definition of clinical response
Definition of clinical
remission Measurement time points
ACT149 Decrease from baseline in total
Mayo score of ≥ 3 points and
≥ 30%, with accompanying
decrease in subscore for rectal
bleeding of ≥ 1 point or absolute
rectal bleeding subscore of 0 or 1
Total Mayo score of ≤ 2 points,
with no individual subscore of
> 1
Clinical response and remission
assessed at weeks 8, 30 and 54
ACT249 As above As above Clinical response and remission
assessed at weeks 8 and 30
Probert et al.,
200350
No definition of response, mean
UC ‘severity score’ and
improvement reported only
UCSS (i.e. Mayo score). Clinical
remission=UCSS ≤ 2
Outcomes reported at week 2
and 6
UC-SUCCESS51 Decrease in total Mayo score of
≥ 3 points and ≥ 30% decrease
from baseline Mayo score
CS-free remission= total Mayo
score of ≤ 2 points, with no
individual subscore of > 1 point
without the use of CSs
Mayo scores assessed at weeks
0, 8 (partial Mayo) and 16
ULTRA144 Decrease in Mayo score of ≥ 3
points and ≥ 30% from baseline
plus decrease in subscore for rectal
bleeding of ≥ 1 point or absolute
rectal bleeding subscore of 0 or 1
Mayo score of ≤ 2 points, with
no individual subscore of > 1
Mayo scores recorded at weeks
0 and 8
ULTRA245 Decrease from baseline in total
Mayo score of ≥ 3 points and
≥ 30% plus decrease in subscore
for rectal bleeding of ≥ 1 point or
absolute rectal bleeding subscore
of 0 or 1
Total Mayo score of ≤ 2 points,
with no individual subscore of
> 1
Clinical response and remission
measured at weeks 8, 32 and
52/early termination
Suzuki et al.,
201446
Decrease from baseline in total
Mayo score of ≥ 3 points and
≥ 30%, with accompanying
decrease in subscore for rectal
bleeding of ≥ 1 point or absolute
rectal bleeding subscore of ≤ 1
Total Mayo score of ≤ 2 points,
with no individual subscore of
> 1
Clinical response and remission
assessed at weeks 8, 32 and 52
PURSUIT-SC47 Decrease from baseline in Mayo
score of ≥ 3 points and ≥ 30%
plus decrease in subscore for rectal
bleeding of ≥ 1 point or absolute
rectal bleeding subscore of 0 or 1
Mayo score of ≤ 2 points, with
no individual subscore of > 1
Mayo scores recorded at weeks
0 and 6
PURSUIT-
Maintenance48
Decrease from baseline value
(observed in preceding induction
study) in Mayo score of ≥ 3 points
and ≥ 30% plus decrease in
subscore for rectal bleeding of ≥ 1
point or absolute rectal bleeding
subscore of 0 or 1
Mayo score of ≤ 2 points, with
no individual subscore of > 1
Mayo scores calculated at
weeks 0, 30 and 54
CS, corticosteroid.
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Adalimumab Four ADA trials presented clinical response and remission data (ULTRA1,44 ULTRA2,45
ULTRA354 and Suzuki et al.46).
At week 8, more patients in the ADA 160mg/80mg induction treatment arm of ULTRA144 achieved
clinical response (54.6% vs. 44.6%; p-value not reported) and twice as many reached clinical remission
(18.5% vs. 9.2%; p= 0.031) than PBO patients.44 Subgroup analyses demonstrated that patients with a
Mayo score of ≥ 10 points at baseline of ULTRA1 were less likely to achieve remission at week 8 than
patients with lower baseline Mayo scores.44 Baseline C-reactive protein (CRP) levels > 10mg/l and baseline
weight of ≥ 82 kg were also linked with lower remission rates in ULTRA1.44 When baseline prior UC
medications were considered, the treatment effect of 160mg/80mg of ADA compared with PBO was
most pronounced in patients who had received immunomodulator treatment (i.e. AZA/6-MP) at baseline
without corticosteroids, and patients who had received no prior aminosalicylates.44 Clinical response rates
at week 8 in the PBO group, when stratified by geographical region, appeared to be higher in Canada
and Eastern Europe (than in USA/Puerto Rico and Western Europe) although reasons for this are unclear.44
In ULTRA2,45 patients in the ADA 160mg/80mg induction group were more likely to achieve clinical
response (50.4% vs. 34.6%; p< 0.005) and clinical remission (16.5% vs. 9.3%; p< 0.05) at week 8 than
in the PBO group.45 Similarly, among patients who had received no prior anti-TNF-α treatment, greater
proportions of patients in the ADA 160mg/80mg induction group reached clinical response (59.3% vs.
38.6%; p< 0.005) and clinical remission (21.3% vs. 11.0%; p< 0.05) at week 8 than PBO-treated
patients.45 Patients receiving ADA as maintenance therapy in ULTRA245 were also more likely at week 52 to
be in clinical response (30.2% vs. 18.3%; p< 0.05) or clinical remission (17.3% vs. 8.5%; p< 0.005)
than subjects in the PBO group.45 Anti-TNF-α-naive ADA-treated patients were also more likely to achieve
clinical response (36.7% vs. 24.1%; p= 0.019) or remission (22.0% vs. 12.4%; p= 0.029) at week 52
than those in the PBO group.45 Patients in the ADA group were more likely to achieve sustained response
(ITT 21.8%, anti-TNF-α-naive 26.7%; both p< 0.05 vs. PBO) and sustained remission (ITT 8.1%,
anti-TNF-α-naive 10.7%; both p< 0.05) than PBO group subjects (sustained response: ITT 11.4%,
anti-TNF-α-naive 16.6%; sustained remission ITT 2.4%, anti-TNF-α-naive 3.4%).58 At week 52 of ULTRA2,
corticosteroid-free remission was achieved by more ADA group patients versus PBO (both p< 0.05).59
A post-hoc analysis of ULTRA245 data at week 52, which included patients from the PBO arm who switched
to ADA, demonstrated that mean days in clinical response (134.58 vs. 94.55; p< 0.001) and mean days in
clinical remission were also greater for ADA-treated patients (85.32 vs. 52.87; p< 0.001).60 For patients
with no prior anti-TNF-α use, stool frequency and rectal bleeding Mayo subscores of ≤ 1 point at week 8
were most likely to be achieved in patients receiving ADA than PBO (both p< 0.05).45 At week 52, the
proportions of patients who had discontinued corticosteroid use and achieved sustained clinical remission
at both weeks 32 and 52 (among patients with baseline corticosteroid use) were 10.0% and 1.2% in the
ADA (no prior anti-TNF-α use) and PBO groups, respectively (p= 0.014).45 At week 52, for patients with no
prior anti-TNF-α use, 20.3% of the ADA group and 6.2% of the PBO group were in corticosteroid-free
clinical remission (p< 0.05).59
The open-label extension study ULTRA354 presented the 4-year efficacy and safety results of 588 patients
from ULTRA144 and ULTRA245 who were followed. Of the 588 patients who entered the ULTRA354
extension study, 52.2% (307/588) were in remission at entry according to partial Mayo scores. Partial
Mayo scores were calculated at each study visit and at week 156, 46.4% (273/588) of patients had
achieved clinical remission.
Patients who received ADA for induction in the Suzuki et al.46 trial were more likely to be in clinical
response (50% vs. 35%; p< 0.05) by week 8 but not in clinical remission (10% vs. 11%; p-value not
reported) than PBO group patients.46 At week 8, a statistically significant greater proportion of patients in
the ADA arm reached a subscore of ≤ 1 for physician’s global assessment domain than in the PBO arm
(p≤ 0.05); differences in the other Mayo subscores were not statistically significant.46 Within the Suzuki
et al.46 trial, greater proportions of ADA maintenance-treated patients were in clinical response than PBO
group patients (31% vs. 18%; p< 0.05) and clinical remission (23% vs. 7%; p< 0.01) through week 52.
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At week 52, a greater proportion of subjects in the ADA group versus PBO experienced subscores of ≤ 1
point for physician’s global assessment and stool frequency subscore (both p≤ 0.05).46 The proportions of
patients in steroid-free clinical remission at week 52 were 14.2% and 6.9% in the ADA and PBO arms,
respectively (p-value not reported).46
Golimumab In the PURSUIT-SC induction trial,47 clinical response and remission data were reported for
both Phase II and Phase III. By week 6, in the Phase II analyses (plus additional Phase II randomised
patients), more patients receiving GOL were in clinical response (46.5% vs. 37.7%; p-value not reported)
and remission (18.3% vs. 10.1%; p-value not reported) than the PBO group. Similarly, more GOL-treated
patients achieved clinical response (51.0% vs. 30.3%; p< 0.0001) and remission (17.8% vs. 6.4%;
p< 0.0001) than PBO-treated patients by week 6 in the Phase III analyses.
In the PURSUIT-Maintenance study,48 proportions of patients maintaining clinical response (47.0% vs.
31.3%; p= 0.010) and in clinical remission [33.1% (50mg of GOL; p= 0.068), 33.8% (100mg of GOL,
p= 0.011) vs. 22.1%] through week 54 were larger for the GOL groups than PBO. PURSUIT-Maintenance
patients who maintained clinical response and were corticosteroid-free among those who receiving
corticosteroids at maintenance baseline were 38.5% in the 50mg of GOL group (p= 0.026), 30.5% in the
100mg of GOL group (p= 0.138) and 20.7% in the PBO group.
Infliximab By week 8 of the ACT1 trial,49 more patients treated with 5mg/kg of IFX were in clinical
response (69.4% vs. 37.2%; p< 0.001) and remission (38.8% vs. 14.9%; p< 0.001) than those who
received PBO. At week 54, more IFX group patients were in clinical response (45.5% vs. 19.8%; p< 0.001)
and remission (34.7% vs. 16.5%; p= 0.001) than PBO-treated subjects.49 Patients who sustained clinical
response at weeks 8, 30 and 54 were 38.8% in the IFX group and 14.0% in the PBO group (p< 0.001).49
Proportions of patients who sustained clinical remission at weeks 8, 30 and 54 were 19.8% and 6.6% in
the IFX and PBO treatment arms, respectively (p= 0.002).49 Of the 5mg/kg of IFX group, 25.7% were in
clinical remission and had discontinued corticosteroids at week 54, compared with 8.9% in the PBO
group (p= 0.006).49
In ACT2,49 more patients in the 5mg/kg of IFX group were in clinical response (64.5% vs. 29.3%;
p< 0.001) and remission (33.9% vs. 5.7%; p< 0.001) at week 8 compared with PBO. By week 30, more
5mg/kg of IFX-treated patients were in clinical response (47.1% vs. 26.0%; p< 0.001) and remission
(25.6% vs. 10.6%; p= 0.003) than PBO.49 The proportions of patients who sustained clinical response
(41.3% vs. 15.4%; p< 0.001) and clinical remission (14.9% vs. 2.4%; p< 0.001) at weeks 8 and 30 were
also higher in the 5mg/kg of IFX group than patients receiving PBO.49
No statistically significant differences were observed between the IFX and PBO treatment groups through
week 6 of the Probert et al.50 trial in terms of clinical remission (as defined by a UCSS of ≤ 2) (39% vs.
30%; p= 0.76). Remission rates among patients receiving AZA were 67% for IFX and 33% for PBO
groups (p= 0.89).50
A greater proportion of patients in the UC-SUCCESS study51 who received combination treatment with IFX
plus AZA were in steroid-free clinical remission at week 16 (39.74%) than in the IFX monotherapy
(22.08%, p vs. IFX= 0.017) and AZA monotherapy (23.68%, p vs. IFX= 0.813; p vs. IFX/AZA= 0.032) groups.51
No included trials reported data on rates or duration of relapse.
Data relating to clinical response and remission are summarised in Table 11.
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TABLE 11 Summarised clinical response and remission data from RCTs in adults
Study name Treatment arm Time point
Rates of and duration of
response
Rates of and duration of
remission
ULTRA144 PBO Week 8 Clinical response: 58/130
(44.6%) (p-value NR)
Clinical remission: ITT-A3
protocol: 12/130 (9.2%)
ULTRA144 160mg/80mg of ADA Week 8 Clinical response: 71/130
(54.6%)
Clinical remission: ITT-A3
protocol: 24/130 (18.5%),
p-value vs. PBO= 0.031
ULTRA245 PBO Week 52 Patients with response:
45/246 (18.3%)
No prior anti-TNF-α: clinical
response 35/145 (24.1%)
Prior anti-TNF-α clinical
response 10/101 (9.9%)
Patients with remission: 21/246
(8.5%)
No prior anti-TNF-α: clinical
remission 18/145 (12.4%)
Prior anti-TNF-α clinical remission
3/101 (3.0%)
ULTRA245 160mg/80mg of ADA Week 52 Patients with response:
75/248 (30.2%)
No prior anti-TNF-α: clinical
response 55/150 (36.7%)
Prior anti-TNF-α clinical
response 20/98 (20.4%)
Patients with remission: 42/248
(17.3%)
No prior anti-TNF-α: clinical
remission 33/150 (22.0%)
prior anti-TNF-α clinical remission
10/98 (10.2%)
Suzuki et al.46 PBO Week 8 Full Mayo score response:
34/96 (35%)
Full Mayo score remission:
11/96 (11%)
Suzuki et al.46 160mg/80mg of ADA Week 8 Full Mayo score response:
45/90 (50%): p-value vs.
PBO ≤ 0.05
Full Mayo score remission:
9/90 (10%)
Suzuki et al.46 PBO Week 52 Full Mayo score response:
17/96 (18%)
Full Mayo score remission:
7/96 (7%)
Suzuki et al.46 ADA 80mg/40mg or
ADA 160mg/80mg to
week 8 then ADA
40mg EOW
Week 52 Full Mayo score response:
55/177 (31%); p-value vs.
PBO, ≤ 0.05
Full Mayo score remission:
41/177 (23%); p-value vs. PBO,
≤ 0.01
PURSUIT-SC47 Phase III PBO Week 6 Phase III. PBO. Proportion
with clinical response:
76/251 (30.3%)
Phase III. Clinical remission:
16/251 (6.4%)
PURSUIT-SC47 Phase III GOL 200mg/
100mg phase III
Week 6 Phase III. GOL 200mg/
100mg. Proportion with
clinical response: 129/253
(51.0%) (p< 0.0001)
Phase III. Clinical remission:
GOL 200/100, 45/253 (17.8)
(p< 0.0001)
PURSUIT-
Maintenance48
PBO Week 54 Proportion of patients
maintaining clinical
response: 31.2%, n= 154
Clinical remission: 34/154
(22.1%)
PURSUIT-
Maintenance48
50mg of GOL Week 54 Proportion of patients
maintaining clinical
response: 47.0%, n= 151
(p= 0.010)
Clinical remission: 50/151
(33.1%) (p= 0.068)
PURSUIT-
Maintenance48
100mg of GOL Week 54 Proportion of patients
maintaining clinical
response: 49.7%, n= 151
(p< 0.001)
Clinical remission: 51/151
(33.8%) (p= 0.011)
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TABLE 11 Summarised clinical response and remission data from RCTs in adults (continued )
Study name Treatment arm Time point
Rates of and duration of
response
Rates of and duration of
remission
UC-SUCCESS51 AZA Week 16 Data not available Patients in steroid-free remission:
18/76 (23.68%); p-value between
IFX, 0.813; IFX/AZA, 0.032
UC-SUCCESS51 IFX 5mg/kg Week 16 Data not available Patients in steroid-free remission
at: 17/77 (22.08%); p-value
between IFX/AZA, 0.017
UC-SUCCESS51 IFX/AZA Week 16 Data not available Patients in steroid-free remission:
31/78 (39.74%)
Probert et al.50 PBO Week 6 Data not available Patients with UCSS of < 2: 6/20
(30%). 95% CI for difference
with IFX –19% to 34%; p= 0.76
When remission rates of patients
with total disease in each of the
two groups were compared, no
significant difference was found
(p= 0.9)
Probert et al.50 5mg/kg of IFX Week 6 Data not available Patients with UCSS of < 2: 9/23
(39%)
ACT149 PBO Week 8 Proportion of patients with
clinical response: 45/121
(37.2%)
Proportion of patients in clinical
remission: 14.9% (18/121)
ACT149 5mg/kg of IFX Week 8 Proportion of patients with
clinical response: 84/121
(69.4%) (p< 0.001)
Proportion of patients in clinical
remission: 38.8% (47/121)
(p< 0.001)
ACT149 PBO Week 54 Proportion of patients with
clinical response: 24/121
(19.8%)
Proportion of patients in clinical
remission: 16.5% (20/121)
ACT149 5mg/kg of IFX Week 54 Proportion of patients with
clinical response: 55/121
(45.5%) (p< 0.001)
Proportion of patients in clinical
remission: 34.7% (42/121)
(p= 0.001)
ACT249 PBO Week 8 Proportion of patients with
clinical response: 36/123
(29.3%)
Proportion of patients in clinical
remission: 5.7% (7/123)
ACT249 5mg/kg of IFX Week 8 Proportion of patients with
clinical response: 78/121
(64.5%) (p< 0.001)
Proportion of patients in clinical
remission: 33.9% (41/121)
(p< 0.001)
ACT249 PBO Week 30 Proportion of patients with
clinical response: 32/123
(26.0%)
Proportion of patients in clinical
remission: 10.6% (13/123)
ACT249 5mg/kg of IFX Week 30 Proportion of patients with
clinical response: 57/121
(47.1%) (p< 0.001)
Proportion of patients in clinical
remission: 25.6% (31/121)
(p= 0.003)
EOW, every other week; ITT-A3, intention to treat-amendment 3.
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Consideration was given to whether or not it would be appropriate to conduct meta-analysis using the
response and remission outcomes within the trials included in the clinical effectiveness review. It was
acknowledged that the ADA trials differed from the IFX and GOL trials in the method of estimation of
Mayo scores, in that the IFX and GOL trials were based on the average Mayo scores over a consecutive
3-day diary period and the ADA trials included scores based on the worst entry over a consecutive 3-day
diary period. However, clinical advisors to the Assessment Group did not expect that this difference would
preclude a synthesis of the evidence. It was further noted by the Assessment Group that there may be
potential issues in the consistency of measurement of Mayo scores and levels of PBO response according
to physician experience and geographical location. The comparability of the trial data set in terms of
prior UC treatment was improved by the requesting and receipt from the manufacturer of ADA of
anti-TNF-α-naive maintenance data from ULTRA2.45 It should also be noted that the PURSUIT-Maintenance
trial48 rerandomised patients who had previously responded to GOL induction therapy in two previous
trials; the extent of this potential bias on patient outcomes is unclear.
Clinical response and remission at induction and maintenance in eligible adult population trials were
analysed using NMAs. The results of these analyses are presented on page 72. For the sake of brevity, all
secondary efficacy and safety outcomes data are presented in Appendices 4 and 5.
Measures of disease activity
Adalimumab At week 8 of the ULTRA1 trial,44 median changes in CRP from baseline were greater in the
ADA 160mg/80mg group than PBO (–0.77mg/l vs.–0.09mg/l). Patients receiving ADA 160mg/80mg in
ULTRA144 were also more likely to achieve scores of ≤ 1 point for the Mayo rectal bleeding (p= 0.038) and
physician global assessment (p= 0.035) subscores.44 Statistically significant changes from baseline in
haemoglobin and red blood cells (both p< 0.001), total protein and albumin levels (both p< 0.01) were
observed in the ADA group versus PBO in ULTRA1.61
In ULTRA2,45 greater proportions of patients receiving ADA achieved Mayo subscores of ≤ 1 point at
week 8 than PBO, although only stool frequency and rectal bleeding were statistically significant at the 5%
level. Significantly more ADA group patients who had not previously received anti-TNF-α treatment
reached a rectal bleeding score of ≤ 1 than PBO (p< 0.001).45
Golimumab At week 6 in the Phase II and Phase III components of PURSUIT-SC,47 mean changes from
baseline in Mayo score were –2.6 [standard deviation (SD) 2.73] points and –1.8 (SD 2.96) points (Phase II;
p= 0.219), followed by –3.1 (SD 2.90) points and –1.6 (SD 2.53) points (Phase III; p< 0.0001) in the GOL
200mg/100mg and PBO arms. Mean changes in CRP concentration (mg/l) at week 6 (Phase III) were
–3.35 (GOL 200mg/100mg) and +1.59 (PBO) (p< 0.0001).
Infliximab In ACT1,49 the proportion of patients at week 8 who were not refractory to corticosteroid
therapy was higher in the IFX group than PBO (66.7 vs. 37.9%; p< 0.001).49 Proportions of patients not
refractory to corticosteroids at week 8 of the ACT2 study49 were 64.8% for 5mg/kg of IFX and 26.4% for
PBO (p< 0.001).49 As of week 152 of the extension studies, 20 patients remained, of whom 18 (90.0%)
had no or mild disease.
Mean improvements in UCSS at week 6 of the Probert et al.50 study were 4 (SD 3) for both PBO and IFX
groups. The mean reduction in daily dose of glucocorticoid was equivalent to 19mg (SD 15mg) and
14mg prednisolone (SD 12mg) in the IFX and PBO groups, respectively (p= 0.037).50 No statistically
significant changes in CRP levels were observed between IFX and PBO arm patients.50
At week 8 of the UC-SUCCESS trial,51 65.79% and 36.84% of the AZA arm, 88.31% and 49.35% of the
IFX arm and 85.90% and 52.56% of the IFX/AZA combination arm achieved partial Mayo score decreases
of ≥ 1 point and ≥ 2 points respectively.51 Week 8 mean changes from baseline in partial Mayo scores
were –2.81 (SD 2.46) points, –3.52 (SD 2.25) points and –4.01 (SD 2.04) points for AZA, IFX and
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combination IFX/AZA.51 Mean changes in total Mayo score from baseline at week 16 were –3.00 (baseline
8.50) points for AZA (p vs. IFX/AZA= 0.001), –4.27 (baseline 8.08) points for IFX (p vs. IFX/AZA= 0.001),
and –5.28 (baseline 8.54) points for combination IFX/AZA.51
Mortality
Reported deaths for the included trials are presented in Appendix 4.
Adalimumab No deaths occurred in the ULTRA144 or ULTRA245 ADA trials. Deaths were not reported in
Suzuki et al.46
Golimumab One death occurred in PURSUIT-SC47 in the unlicensed 400mg/200mg of GOL induction
treatment arm in a patient receiving concomitant 20mg of prednisolone with a case of peritonitis and
sepsis after surgical complications related to an ischiorectal abscess and subsequent bowel perforation after
surgery. In PURSUIT-Maintenance,48 no deaths occurred through week 54 in the PBO arm but one death
(from pneumonia and heart failure) occurred after week 54 in a patient who had received PBO induction
and maintenance. No deaths were observed in the 50mg of GOL group of PURSUIT-Maintenance;
however, one death was reported after week 54 (in a patient who received 100mg/50mg of GOL
induction and 50mg of GOL maintenance) owing to heart dysfunction in the presence of pronounced
atherosclerosis and stenosis affecting the aorta, large arteries and coronary arteries. Three deaths were
reported through week 54 of PURSUIT-Maintenance in the 100mg of GOL treatment arm due to
malnutrition and sepsis (patient receiving 2mg/kg of i.v. GOL induction); cardiac failure with history of
thrombosis (patient receiving 400mg/200mg of GOL, subcutaneous induction); and disseminated TB in
patient who tested positive for latent TB on induction study entry and was receiving isoniazid at time of
event (receiving 200mg/100mg of GOL, subcutaneous induction). Four deaths were reported after week
54 for the 100mg of GOL group in PURSUIT-Maintenance, including one case of myocardial infarction
in a patient with history of myocardial infarction (PBO, subcutaneous induction and 100mg of GOL
maintenance), two deaths due to gallbladder adenocarcinoma with liver metastasis and due to sepsis
(patients receiving 2mg/kg of i.v. GOL induction) and 100mg of GOL maintenance) and one death due to
accidental nitrous oxide overdose (in a patient receiving 200mg/100mg of GOL, subcutaneous induction
and 100mg of GOL maintenance).
Infliximab The only reported deaths in any of the included IFX trials occurred in patients recruited into the
ACT studies.49 No deaths occurred through week 54 in ACT1 and ACT2. After week 54, two patients died
in the PBO arm of ACT1 (due to suicide and cerebrovascular accident). After 54 weeks, four patients died
who received IFX in the ACT studies (no dose information available), histoplasmosis 4 weeks after last
infusion, listeria encephalitis 3 years after last infusion, prostate cancer 3.5 years after last infusion, and
natural causes 10 months after last infusion.
Rates of hospitalisation
A total of four included trials reported hospitalisation data for the adult population (ULTRA144 and
ULTRA245 for ADA, ACT149 and ACT249 for IFX, no trials for GOL).
Adalimumab In ULTRA1,44 all reported hospitalisation outcome measure data were lower in the
160mg/80mg of ADA group than PBO at week 8, indicating more favourable outcomes for the
intervention group, including physician visits (p= 0.559), emergency room visits (p-value not reported),
hospital admissions (p-value not reported) and days in hospital (p= 0.297). None of these differences were
statistically significant.62 Similarly, for the ULTRA2 trial,45 hospitalisation-related outcome data were also
slightly lower for the ADA group than PBO at week 52, although this was only statistically significant for
physician visits (physician visits, p= 0.035; emergency room visit, p= 0.847; hospital admissions, p= 0.418;
and days in hospital, p= 0.467).62 A range of hospitalisation-related measures were also reported for
ULTRA1 and ULTRA2 data combined. The all-cause hospitalisation incidence rate was lower for ADA than
PBO (p= 0.047), as was the UC-related hospitalisation incidence rate (p= 0.002), with a relative risk for
UC-related hospitalisation of 0.48 for ADA versus PBO (p< 0.001).63
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Golimumab No included trials reported hospitalisation data for GOL.
Infliximab In the ACT1 and ACT2 trials,49 hospitalisations through week 54 were reported to be lower for
the 5mg/kg of IFX group than PBO (ACT1, p= 0.061; ACT2, p= 0.009).64
Rates of surgical intervention (both elective and emergency)
Six included trials in the adult population included information on rates of surgical intervention (ULTRA144
and ULTRA245 for ADA, PURSUIT-Maintenance48 for GOL, and ACT1,49 ACT249 and Probert et al.50 for IFX).
No trials reported whether surgical outcomes were elective or emergency in nature.
Adalimumab In ULTRA1,44 colectomies to week 8 were lower in the 160mg/80mg of ADA group than
PBO (1.4% vs. 3.6%; p-value not reported; elective or emergency not reported). Colectomy rates were
very slightly lower through week 52 of ULTRA245 in the ADA group (4%) vs. PBO (4.9%) (p-value not
reported; elective or emergency not reported).63,65
Golimumab Limited data were available for GOL, which indicated that only 2–3% of GOL induction
responders rerandomised to 50mg or 100mg of GOL in PURSUIT-Maintenance48 received colectomy at the
end of maintenance.66
Infliximab Colectomy and ostomy rates through week 54 of ACT149 were both slightly lower in the
5mg/kg of IFX group (5.8% and 2.5%, respectively) than in the PBO group (7.4% and 4.1% respectively)
(p-values not reported).64 One patient in each case from the PBO arm was reported as having the
outcomes of colectomy and an ostomy (0.7% and 0.7%) through week 54 of ACT2, while no patients
in the 5mg/kg IFX group underwent colectomy or ostomy.64 Limited details were available from the
Probert et al.50 trial to the effect that a single patient in the PBO arm received a colectomy during
the intervention period.
Meta-analysis
Colectomy rates during induction were reported by one trial (ULTRA144). The between-group difference
was not statistically significant [RR= 0.63 (random effects), 95% CI 0.21 to 1.86; p= 0.40; Figure 5).
Colectomy rates during maintenance were reported by one trial evaluating the licensed maintenance dose
of ADA comprising a mixed sample of anti-TNF-α exposed and naive participants (ULTRA2,45 517
participants). The between-group difference was not significant [RR= 0.83 (random effects), 95% CI 0.36
to 1.88; p= 0.65). Two trials evaluating the licensed maintenance dose of IFX reported maintenance
outcomes at 30 weeks (ACT249) and 54 weeks (ACT149). The pooled effect across these trials (486
participants) was not significant [RR= 0.73 (random effects), 95% CI 0.29 to 1.81; p= 0.49]. The forest
plot for these analyses (random effects) is presented in Figure 6.
Ostomy rates during maintenance in adults were reported by two trials evaluating the licensed
maintenance dose of IFX at 30 weeks (ACT249) and 54 weeks (ACT149). The pooled effect across these
trials (486 participants) was not significant [RR= 0.55 (random effects), 95% CI 0.15 to 1.98; p= 0.36].
The forest plot for these analyses is presented in Figure 7.
Time to surgical intervention (both elective and emergency)
Very limited data were reported from the included trials in the adult population for the outcome of time to
surgical intervention. Sandborn et al.67 combined data from the ACT1 and ACT2 IFX trials49 and reported
that the cumulative incidence of colectomy through 54 weeks was higher for the PBO group (17%) than
for the combined IFX group (10%) (p= 0.02) and calculated a hazard ratio of 0.59, indicating a 41%
reduction in the risk of colectomy for the combined licensed and unlicensed IFX groups versus PBO.
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Health-related quality of life
Health-related quality-of-life data were available from nine included trials in the adult population
(ULTRA1,44 ULTRA245 and ULTRA3 for ADA, PURSUIT-SC47 and PURSUIT-Maintenance48 for GOL, and
ACT1,49 ACT2,49 UC-SUCCESS51 and Probert et al.50 for IFX, see Appendix 6). Data related to HRQoL were
measured using Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form questionnaire-36 items
(SF-36) and the European Quality of Life-5 Dimensions (EQ-5D) [note: total IBDQ scores can range from
32 (very poor) to 224 (perfect HRQoL)].
Adalimumab
In ULTRA1,44 the changes from baseline scores to week 8 in IBDQ were very similar for the 160mg/80mg
of ADA and PBO groups (153 vs. 152; p-value not reported). Furthermore, the difference between IBDQ
mean responses at week 8 in the 160mg/80mg of ADA and PBO groups was not statistically significant
(70 vs. 75; p= 0.532). Changes from baseline in SF-36 mental and physical component summary scores
were also similar at week 8 in the ADA and PBO group (46 vs. 44). ULTRA245 week 52 IBDQ scores were
higher in the 160mg/80mg of ADA group than PBO, indicating more favourable HRQoL in the ADA group
(27 vs. 19; p< 0.05). A greater proportion of patients experienced an increase in IBDQ of ≥ 16 points from
baseline by week 52 in the ADA group than PBO (26.2% vs. 16.3%; p< 0.05).
Golimumab
In both Phase II and Phase III of the PURSUIT-SC47 GOL trial, patients in the 200mg/100mg of GOL
induction arms reported a greater change in IBDQ from baseline to week 6 than the patients of PBO
groups [Phase II, mean 24.9 vs. 14.8 (p-value NS); Phase III mean 27.0 vs. 14.8; p< 0.0001]. Greater
proportions of patients in each GOL group were also described as achieving ‘any improvement’ to
‘clinically meaningful improvement’ in IBDQ (51.1% vs. 35.2%; p< 0.001), physical component summary
(41.0% vs. 31.6%; p= 0.01) and mental component summary scores (42.7% vs. 28.5%; p< 0.001) at
week 6.
Infliximab
In the ACT1 trial,49 changes from baseline in SF-36 physical and mental component summary scores to
week 8 were larger for the 5mg/kg of IFX group than the PBO group (both p< 0.05). Statistically
significant improvements in IBDQ and SF-36 components were evident in the 5mg/kg of IFX treatment
arm compared with PBO to week 8 for ACT1 and ACT2 trials combined. The greatest changes from
baseline to week 16 in both IBDQ and SF-36 physical function were observed in the IFX/AZA combination
treatment arm (p< 0.05 vs. AZA, p< 0.05 vs. IFX for both outcomes). Improvements in IBDQ and EQ-5D
from baseline to week 6 in Probert et al.50 were larger in the IFX group than PBO (p-value not reported).
Adverse events of treatment (including leakage and infections following surgery)
The included trials report data relating to AEs associated with the interventions under assessment only
(i.e. IFX, ADA and GOL) and do not report safety outcomes (e.g. leakage and infections) post surgery.
However, although the clinical effectiveness systematic review does not take these factors into account,
these factors are relevant to the economic analysis (see Chapter 4). p-values are provided when available;
however, the statistical significance of observed differences in safety outcomes was poorly reported across
the included trials.
Discontinuations due to adverse events
Adalimumab
Discontinuations due to AEs at week 8 in ULTRA144 were 5.4% in both 160mg/80mg of ADA and PBO
groups.44 Withdrawals due to AEs were slightly lower for ADA than PBO by week 52 of ULTRA2,45 at
23 out of 257 (8.9%) for 160mg/80mg of ADA and 34 out of 260 (13.1%) for PBO.45 More AEs leading
to discontinuation occurred in the Suzuki et al.46 trial in the 40mg of ADA every other week group versus
PBO [n= 22 vs. n= 6; 22.4/100 patient-years (PYs) vs. 13.4/100 PYs].
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Golimumab
Numbers of patients who discontinued study agent through week 6 because of at least one AE were
relatively low across both 200mg/100mg of GOL induction (1/331, 0.3%) and PBO (3/330, 0.9%) groups
for PURSUIT-SC.47 Through week 54 of PURSUIT-Maintenance,48 8/154 (5.2%) of the 50mg of GOL,
14/154 (9.1%) of the 100mg of GOL and 10/156 (6.4%) of the PBO groups had discontinued study agent
owing to at least one AE.48
Infliximab
Through week 54 of ACT149 the number of patients with AEs leading to study drug discontinuation was
10 out of 121 (8.3%) and 11 out of 121 (9.1%) for the 5mg/kg of IFX and PBO groups, respectively.
Through week 30 of ACT2,49 discontinuations due to AEs occurred in 2 out of 121 (1.7%) and 12 out of
123 (9.8%) for 5mg/kg of IFX and PBO arm patients, respectively. Through week 8 of UC-SUCCESS51 AEs
leading to discontinuation were highest for AZA (6/79, 8%), compared with 2/78 (3%) for IFX and 3/80
(4%) for combination IFX and AZA.51
Number of patients experiencing one or more adverse event
Adalimumab
In ULTRA1,44 patients reporting at least one treatment emergent AE were 112 out of 223 (50.2%) and
108 out of 223 (48.4%) for the 160mg/80mg of ADA induction and PBO groups, respectively.44 At week
52 of ULTRA2,44 the proportions of patients reporting any AE were similar between groups; 213 out of
257 (82.9%) for the 160mg/80mg of ADA arm and 218 out of 260 (83.8%) of the PBO arm. At week 52
in the Suzuki et al.46 study, fewer AEs occurred (in terms of events per 100 PYs) in the 40mg of ADA every
other week group than in the PBO group (547.9/100 PYs vs. 609.4/100 PYs).
Golimumab
By week 6 of PURSUIT-SC,47 the proportions of patients with at least one AE were similar for 200mg/100mg
of GOL induction (124/331, 37.5%) and PBO (126/330, 38.2%).46 Patients reporting one or more AEs
through week 54 of PURSUIT-Maintenance48 were 112 out of 154 (72.7%) in the 50mg of GOL arm,
113 out of 154 (73.4%) in the 100mg of GOL arm and 103 out of 156 (66.0%) in the PBO treatment arm.
Infliximab
The proportions of patients through week 54 of ACT149 reporting at least one AE were 106 out of 121
(87.6%) and 103 out of 121 (85.1%) for 5mg/kg of IFX and PBO respectively. At week 30 of ACT2,49
these values were 99 out of 121 (81.8%) and 90 out of 123 (73.2%) for 5 mg/kg of IFX and PBO,
respectively. Through week 8 of UC-SUCCESS,51 patients reporting one or more AE were higher in the
AZA group (41/79, 52%) than IFX (26/78, 33%) or combination IFX/AZA (30/80, 38%).
Number of patients experiencing one or more serious adverse event
Definitions of serious adverse events (SAEs) were poorly reported across included RCTs.
Adalimumab
At week 8 in ULTRA1,44 the proportions of patients reporting one or more SAEs were exactly equivalent, at
5.4% (12/223) in the 160mg/80mg of ADA group and 5.4% (12/223) in the PBO group.44 Proportions of
ULTRA245 patients reporting any SAEs were also roughly equivalent, with 12.1% (31/257) and 12.3%
(32/260) in the 160mg/80mg of ADA and PBO groups, respectively.45 At week 52 of the Suzuki et al.46
study, a similar number of events per 100 PYs were classed as serious in the 40mg of ADA every other
week group than in the PBO group (33.6/100 PYs vs. 31.3/100 PYs).46
Golimumab
By week 6 of PURSUIT-SC,47 the proportion of patients reporting at least one SAE was lower in the
200mg/100mg of GOL treatment arm (9/331, 2.7%) than the PBO group (20/330, 6.1%).47 More patients
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in the 100mg of GOL group reported one or more SAE (22/154, 14.3%) than patients in the 50mg of
GOL (13/154, 8.4%) or PBO (12/156, 7.7%) groups by week 54 of PURSUIT-Maintenance.48
Infliximab
Proportions of patients through week 54 of ACT149 who reported SAEs were similar for 5mg/kg of IFX
(26/121, 21.5%) and PBO (31/121, 25.6%) groups.49 At week 30 of ACT2,49 slightly fewer patients
reported SAEs in the 5mg/kg of IFX group [13/121 (10.7%)] than the PBO group [24/123 (19.5%)].49 SAEs
were more frequently reported by week 8 of UC-SUCCESS51 among patients receiving AZA (6/79, 8%)
than IFX (0/78) or combination IFX and AZA (3/80, 4%).
Infections
Adalimumab
The occurrence of infections at week 8 of ULTRA144 was very similar for the 160mg/80mg of ADA group
(32/223, 14.3%) and the PBO group (35/223, 15.7%).44 This was also the case at week 52 of ULTRA2,45
with 45.1% (116/257) and 39.6% (103/260) of patients reporting infections within the 160mg/80mg of
ADA and PBO groups, respectively.45 At week 8 of Suzuki et al.,46 infections occurred in 18.9% (17/90)
and 15.6% (15/96) of the 160mg/80mg of ADA and PBO groups.46
Golimumab
At week 6 of PURSUIT-SC,47 12.1% (40/330) of PBO group patients reported at least one infection, of
which 7.0% required treatment (23/330); these values were similar to those in the 200mg/100mg of GOL
induction group (39/331, 11.8%; 15/331, 4.5%).47 Infections at week 54 of PURSUIT-Maintenance48 were
more common in the 50mg of GOL (60/154, 39.0%; requiring treatment 39/154, 25.3%) and 100mg of
GOL (60/154, 39.0%; requiring treatment 44/154, 28.6%) maintenance groups than PBO (44/156, 28.2%;
requiring treatment 24/156, 15.4%).47
Infliximab
Through week 54 of ACT1,49 infections were slightly more common among patients receiving 5mg/kg of
IFX (53/121, 43.8%; requiring treatment 39/121, 32.2%) than PBO (47/121, 38.8%; requiring treatment
25/121, 20.7%).49 At week 30 of ACT2,49 infections had occurred in 18 out of 121 (14.9%, requiring
treatment 17/121, 14.2%) and 29 out of 123 (23.6%; requiring treatment 15/123, 12.2%) of patients
receiving IFX and PBO respectively.49 Through week 54 of the ACT1 and ACT2 extension studies, infections
occurred in 94 out of 242 (39%) of 5mg/kg IFX and 80 out of 244 (33%) of PBO group patients.67
Serious infections
Adalimumab
Reported serious infections were low through week 8 of ULTRA144 in both PBO (3/223, 1.3%, one
pneumonia, one sepsis, one staphylococcal wound infection) and 160mg/80mg of ADA treatment arms
(0/223), and remained similarly comparable between treatment arms through week 52 of ULTRA245
(160mg/80mg of ADA 4/257, 1.6% vs. PBO 5/260, 1.9%). Serious infections were reported at week 52
of ULTRA3 at a rate of 3.4 events per 100 PYs for patients receiving ADA.62 No serious infections were
reported at week 8 of the Suzuki et al.46 trial in the PBO arm, while three cases occurred by week 8 in the
160mg/80mg of ADA group (3/90, 3.3%).
Golimumab
The proportion of patients reporting one or more serious infections were slightly higher at week 6 of
PURSUIT-SC47 in the PBO treatment arm (6/330, 1.8%) than 200mg/100mg of GOL induction (1/331,
0.3%, one pneumonia).47 By week 54 of PURSUIT-Maintenance,48 the occurrence of serious infections was
marginally higher in the 50mg of GOL (5/154, 3.2%) and 100mg of GOL (5/154, 3.2%) maintenance
groups than PBO (3/156, 1.9%).
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Infliximab
The proportion of patients with serious infections through week 54 of the ACT149 trial was similar
between treatment arms (5mg/kg of IFX 3/121, 2.5%; PBO 5/121, 4.1%). Numbers of patients with
serious infections through week 30 of ACT249 were similar for 5mg/kg of IFX (2/121, 1.7%) and PBO
(1/123, 0.8%).49 Through week 54 of the ACT1 and ACT2 extension studies, serious infections occurred in
7/242 (2.89%) of 5mg/kg of IFX and 6/244 (2.46%) of PBO group patients.67
Serious infections occurred in very low numbers through week 8 of the UC-SUCCESS51 trial (AZA 1/79,
1%; IFX 1/78, 1%; combination IFX/AZA 0/80, 0%).
Meta-analysis
Serious infections associated with the licensed induction dose of ADA in were reported by two trials, one
in Western populations (ULTRA1,44 446 participants) and one in Japanese populations (Suzuki et al.,46
186 participants). The between-group difference in both trials was not significant [RR= 0.14 (random effects)
95% CI 0.01 to 2.75; p= 0.20; RR= 7.46 (random effects) 95% CI 0.39 to 142.47; p= 0.18 respectively].
The forest plot for this analysis (random effects) is presented in Figure 8. Serious infections associated with
the licensed induction of GOL in adults were reported by one trial (PURSUIT-SC,47 661 participants). The
between-group difference was not significant [RR= 0.17 (random effects), 95% CI 0.02 to 1.37; p= 0.10].
Serious infections associated with the licensed maintenance dose of ADA were reported by one trial
comprising a mixed sample of anti-TNF-α exposed and naive participants (ULTRA2,45 517 participants). The
between-group difference was not significant [RR= 0.81 (random effects) 95% CI 0.22 to 2.98; p= 0.75].
Serious infections associated with maintenance dose of 50mg or 100mg of GOL in adults were reported
by one trial (PURSUIT-Maintenance48). The between-group difference for 50mg of GOL compared with
PBO (312 participants) was not significant [RR= 1.67 (random effects) 95% CI 0.41 to 6.85; p= 0.48].
The between-group difference for 100mg of GOL compared with PBO (310 participants) was also not
significant [RR= 1.69 (random effects) 95% CI 0.41 to 6.94; p= 0.47]. Two trials evaluating the licensed
maintenance dose of IFX reported maintenance outcomes at 30 weeks (ACT249) and 54 weeks (ACT149).
The pooled effect across these trials (486 participants) was not significant [RR= 0.82 (random effects)
95% CI 0.24 to 2.77; p= 0.77]. The forest plot for these analyses is presented in Figure 9.
Reactivation of tuberculosis
Adalimumab
No data relating to the reactivation of TB were reported for ULTRA144 or ULTRA2.45 Reactivation of TB
occurred in a single patient (equating to < 0.1 events/100 PYs) by week 52 of ULTRA3.62 No events
occurred in the PBO arm of the Suzuki et al.46 study through week 8, while for the 40mg of ADA every
other week group, a single event of reactivation of TB was described (1.0 events/100 PYs).46
Golimumab
No cases of reactivation of TB were reported in the PURSUIT-SC trial.47 In the PBO maintenance group of
PURSUIT-Maintenance,48 one event of reactivation occurred (in a patient who had received unlicensed
4mg/kg of GOL i.v. induction).47 No cases were reported for patients receiving 50mg of GOL maintenance
treatment. However, three cases occurred in the 100mg of GOL maintenance group (one patient each had
received induction regimens of 400mg/200mg of GOL, subcutaneous; 4mg/kg i.v.; or 200mg/100mg
subcutaneous) (including one fatal case: 200mg/100mg of GOL, subcutaneous).47
Infliximab
No cases of reactivation of TB were reported in the ACT1,49 ACT2,49 Probert et al.50 or UC-SUCCESS51 studies.
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Reactivation of hepatitis B
Adalimumab
No incidents of reactivation of hepatitis B were reported in any of the included ADA trials.
Golimumab
No cases were described in the included GOL studies.
Infliximab
No events were reported in the included IFX studies.
Administration reactions (injection site reactions/infusion reactions/serious
allergic reactions)
Injection site reactions
Adalimumab
Injection site reactions were slightly more frequent at week 8 of ULTRA144 among patients receiving
160mg/80mg of ADA (13/223, 5.8%) than PBO (7/223, 3.1%).44 Injection site reactions were also more
frequent in the 160mg/80mg of ADA group at week 52 of ULTRA245 (31/257, 12.1%) than for PBO
(10/260, 3.8%).45 Patients receiving ADA through week 52 of ULTRA3 experienced injection site reactions
at a rate of 10.5 per 100 PYs.62 Injection site reactions were more frequent through week 8 of the Suzuki
et al.46 trial in the 160mg/80mg of ADA group (7/90, 7.8%) than for PBO (2/96, 2.1%).46
No serious allergic reactions were described as having occurred in the included ADA trials.
Golimumab
At week 6 of the PURSUIT-SC47 trial, injection site reactions were more common in patients receiving
200/100mg of GOL induction (11/331, 3.3%) than PBO (5/330, 1.5%).47 The number of patients reporting one
or more injection site reactions through week 54 of PURSUIT-Maintenance48 was higher in the 100mg of GOL
maintenance treatment arm (11/154, 7.1%) than 50mg of GOL (3/154, 1.9%) and PBO (3/156, 1.9%).47,48
No serious allergic reactions were reported.
Meta-analysis
Injection site reactions associated with the licensed induction dose of ADA in were reported by two trials,
one in Western populations (ULTRA1,44 446 participants) and one in Japanese populations (Suzuki et al.,46
186 participants). The between-group difference in both trials was not significant [RR= 1.86 (random
effects), 95% CI 0.76 to 4.57; p= 0.18; RR= 3.73 (random effects) 95% CI 0.80 to 17.50; p= 0.09
respectively]. The forest plot for this analysis (random effects) is presented in Figure 10. Injection site
reactions associated with the licensed induction dose of GOL in adults were reported by one trial
(PURSUIT-SC,47 661 participants). The between-group difference was not significant [RR= 2.19 (random
effects), 95% CI 0.77 to 6.24; p= 0.14].
Injection site reactions associated with maintenance doses of ADA were reported by one trial comprising a
mixed sample of anti-TNF-α-exposed and -naive participants (ULTRA2,45 517 participants). The between-group
difference was significant in favour of PBO (fewer events) [RR= 3.14 (random effects) 95% CI 1.57 to 6.26;
p= 0.001]. The forest plot for this analysis is presented in Figure 11. Injection site reactions associated with
maintenance dose of 50mg or 100mg of GOL in adults were reported by one trial (PURSUIT-Maintenance48).
The between-group difference for 50mg of GOL compared with PBO (312 participants) was not significant
[RR= 1.00 (random effects), 95% CI 0.20 to 4.88; p= 1.00]. The between-group difference for 100mg of
GOL compared with PBO (310 participants) was significant in favour of PBO (fewer events) [RR= 3.71
(random effects), 95% CI 1.06 to 13.06; p= 0.04].
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Infusion reactions
Infliximab
Acute infusion reactions occurred in similar numbers of patients in both treatment arms through week 54
of ACT149 (5 mg/kg of IFX 12/121, 9.9%; PBO 13/121, 10.7%).49 Infusion reactions were slightly higher
in ACT249 patients receiving 5mg/kg of IFX (14/121, 11.6%) than PBO (10/123, 8.1%).49
Infusion reactions were rare through week 8 of UC-SUCCESS (AZA 1/79, 1%; IFX 0/78, 0%; combination
IFX/AZA 0/80, 0%).51 Possible delayed hypersensitivity reactions occurred in 2/242 (1%) of the 5mg/kg of
IFX group and 2/242 (1%) of the PBO group through week 54 of the ACT1 and ACT2 extension studies.67
No serious allergic reactions were reported.
Heart failure
Adalimumab
Heart failure did not occur in any patients in either 160mg/80mg of ADA induction or PBO arms by
week 8 of ULTRA1.44 Only one case of heart failure was reported through week 52 of ULTRA2,45 which
was in a patient receiving 160mg/80mg of ADA for induction (1/257, 0.4%).45 Heart failure was reported
at a rate of 0.2 events per 100 PYs for 40mg of ADA every other week/every week at week 52 of
ULTRA3.62 Through week 8 of the Suzuki et al.46 trial, no cases of heart failure were reported.
Golimumab
No cases of heart failure were reported for either the 200mg/100mg of GOL induction or PBO treatment arms
through week 6 of PURSUIT-SC47 or for the GOL maintenance or PBO groups in PURSUIT-Maintenance.47,48
Infliximab
No cases of heart failure were reported in the ACT1,49 ACT249 and ACT2 extension studies, Probert et al.50
and UC-SUCCESS51 trials.
Malignancies and lymphoproliferative disorders
Adalimumab
Malignancies were reported at low levels through week 8 of ULTRA1,44 with 2 out of 223 events (0.9%,
one basal cell carcinoma, one breast cancer) in the PBO group and no cases in the 160mg/80mg of ADA
group.44 Two cases of malignancy were reported through week 52 of ULTRA2,45 both of which were in
patients receiving 160mg/80mg of ADA.45 Through week 52 of ULTRA3, events (excluding lymphoma)
occurred in the 40mg of ADA maintenance arm at a rate of 1.0 events per 100 PYs and at a rate of
230.1 events per 100 PYs for lymphoma.62 One case of malignancy (1/90, 1.1%) was described in the
160mg/80mg of ADA group at week 8 of the Suzuki et al.46 trial.
Golimumab
No cases of malignancy were reported for either the 200mg/100mg of GOL induction or PBO treatment
arms through week 6 of PURSUIT-SC.47 Although one malignancy (1/156, 0.6%) was described by week 54
of PURSUIT-Maintenance48 in the PBO arm, four cases each were observed in the 50mg of GOL (4/154, 2.6%)
and 100mg of GOL (4/154, 2.6%) maintenance groups.47,48
Infliximab
Two cases of malignancy were reported through week 54 of ACT149 in patients receiving 5mg/kg of IFX.67
One case of basal cell carcinoma was reported in the PBO arm and one case of rectal adenocarcinoma was
described in the 5mg/kg of IFX arm of ACT249 through week 30. No malignancies were described in the
UC-SUCCESS trial.51
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Hepatobiliary events/liver enzyme changes
Adalimumab
No cases were described in ULTRA144 or ULTRA2.45 Hepatobiliary events were reported at a rate of 0.5
events per 100 PYs in the 40mg of ADA maintenance arm through week 52 of ULTRA2.62 By week 8 of
the Suzuki et al.46 trial, events occurred in 1 out of 90 (1.1%) of 160mg/80mg of ADA and 1 out of
96 (1.0%) of PBO group patients.46
Golimumab
No cases were reported for either the 200mg/100mg of GOL induction or PBO treatment arms through
week 6 of PURSUIT-SC47 or the GOL maintenance or PBO groups of PURSUIT-Maintenance.47,48
Infliximab
No cases of hepatobiliary events were reported in the ACT1 and ACT2 trials.49 The occurrence of
hepatobiliary events was higher in the AZA treatment arm (13/79, 16%) than the IFX (3/78, 4%) and
combination IFX/AZA (5/80, 6%) treatment groups through week 8 of UC-SUCCESS.51
Autoimmune processes (e.g. lupus-like syndrome)
Adalimumab
It was stated that no events of lupus-like syndrome occurred in the 160mg/80mg of ADA or PBO
treatment arms by week 8 of ULTRA1.44 One case of lupus-like syndrome (1/257, 0.4%) was reported in a
patient receiving 160mg/80mg of ADA through week 52 of ULTRA2.45 No cases were reported through
week 8 of the Suzuki et al.46 trial.
Golimumab
No cases of autoimmune processes were reported for either the 200mg/100mg of GOL induction or
PBO treatment arms through week 6 of PURSUIT-SC47 or the GOL maintenance or PBO groups of
PURSUIT-Maintenance.47,48
Infliximab
One patient receiving 5mg/kg of IFX reported experiencing a lupus-like reaction by week 30 of ACT2.49
No cases of autoimmune processes were described in the UC-SUCCESS trial.51
Neurological events
Adalimumab
No cases of demyelinating disease occurred in the 160mg/80mg of ADA or PBO treatment arms by
week 8 of ULTRA144 or by week 52 of ULTRA2.45 No cases of neurological events were reported through
week 8 of the Suzuki et al.46 trial.
Golimumab
No cases were reported for either the 200mg/100mg of GOL induction or PBO treatment arms through
week 6 of PURSUIT-SC47 or the GOL maintenance or PBO groups of PURSUIT-Maintenance.48
Infliximab
One patient receiving 5mg/kg of IFX reported having optic neuritis through week 54 of ACT1. One patient
receiving 5mg/kg of IFX also experienced optic neuritis by week 30 of ACT2.49,67 No neurological events
were described in the UC-SUCCESS trial.51
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Haematological reactions
Adalimumab
No haematological reactions were described in ULTRA1.44 One haematological reaction was reported in
5 out of 257 (1.9%) patients receiving 160mg/80mg of ADA by week 52 of ULTRA2.45 Haematological
reactions occurred in 1 out of 90 (1.1%) and 1 out of 96 (1.0%) patients receiving 160mg/80mg of ADA
and PBO, respectively, by week 8 of the Suzuki et al.46 study.
Golimumab
No haematological reactions were reported for either the 200mg/100mg of GOL induction or PBO treatment
arms through week 6 of PURSUIT-SC47 or the GOL maintenance or PBO groups of PURSUIT-Maintenance.47,48
Infliximab
No haematological reactions were described in ACT1,49 ACT2,49 Probert et al.50 or UC-SUCCESS.51
Population: children and adolescents aged 6–17 years (inclusive) with
severely active ulcerative colitis who have had an inadequate response to
conventional therapy including corticosteroids and mercaptopurine or
azathioprine, or who are intolerant to, or have medical contraindications
against, such therapies
Rates of and duration of response, relapse and remission
Table 12 presents the definitions of clinical response and remission in the included paediatric population RCT.
All enrolled patients received induction therapy with 5mg/kg of IFX. At week 8, clinical response was
reached by 44 out of 60 patients (73.3%), while 24 out of 60 (40.0%) of patients achieved
clinical remission.
The PUCAI remission rates were evaluated at weeks 30 and 54. A greater proportion of patients in the
5mg/kg of IFX every 8 weeks treatment group achieved PUCAI remission at week 30 (40.0% vs. 19.0%;
p-values not reported) and week 54 (38.1% vs. 18.2%, p-values not reported) than the 5mg/kg of IFX
every 12 weeks group. At week 54, PUCAI remission without the use of corticosteroids was reported for
38.5% of the every 8 weeks group and 0% of the every 12 weeks group.52
The absence of a PBO or non-IFX control group limits the comparative evaluation of the efficacy of IFX in
induction and maintenance of clinical response and remission in paediatric patients. A briefing document68
by Centocor Ltd to the FDA Gastrointestinal Drugs Committee was produced in June 2011 and considered
the evidence available from the Hyams et al. 2012/T72 study52 and compared this with the ACT1 and
ACT2 trials49 of IFX previously conducted in the adult UC population. The briefing document considered
efficacy to be similar between T72 and the ACT1 and ACT2 studies during (1) induction (with clinical
response and Mayo remission at week 8 induced in 73.3% and 40.0% of paediatric patients and 66.9%
and 36.4% of pooled 5mg/kg adult patients from ACT1 and ACT2, respectively) and (2) maintenance
(with PUCAI remission at week 54 in 38.1% of paediatric subjects in the every 8 weeks group and 34.7% at
week 54 of ACT1) (with reported good correlation of 0.75–0.88 between PUCAI and Mayo scores described
at baseline and week 8).
TABLE 12 Definitions of clinical response and remission in included paediatric population RCT
Trial Definition of clinical response Definition of clinical remission Measurement time points
Hyams et al.,
201252
Decrease in Mayo score of ≥ 3 points
and ≥ 30%, with accompanying
decrease in subscore for rectal
bleeding of ≥ 1 point or absolute
rectal bleeding subscore of 0 or 1
Mayo score of ≤ 2 points, with
no individual subscore of > 1.
PUCAI clinical remission= score
of < 10
Mayo scores assessed at
weeks 0, 8 and 54.
Endoscopy at week 54
optional
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Measures of disease activity
At week 8 of the Hyams et al.52 study, the median reductions in partial Mayo scores were 4 points for both
the 5mg/kg of IFX every 8 weeks group and 5mg/kg of IFX every 12 weeks group.52 By week 30, the
median reduction in partial Mayo score was approximately 3 points for the every 8 weeks group and
1 point for the every 12 weeks group.52
Mortality
No deaths were reported in the Hyams et al.52 trial.
Rates of hospitalisation
No hospitalisation-related outcome data were reported in Hyams et al.52
Rates of surgical intervention (both elective and emergency)
One of 22 patients (4.5%) in the 5mg/kg of IFX every 8 weeks group required colectomy through
week 54 in the Hyams et al.52 trial as compared with 2 out of 23 (8.7%) patients in the 5mg/kg of IFX
every 12 weeks treatment arm.
Colectomy rates during maintenance in children were reported by one trial evaluating the licensed dose of
IFX every 8 weeks or every 12 weeks (Hyams et al.,52 45 participants). The between-group at week 54 was
not significant [RR= 0.52 (random effects), 95% CI 0.05 to 5.36; p= 0.59; Figure 12].
Time to surgical intervention (both elective and emergency)
No data were reported in the paediatric population for the outcome of time to surgical intervention.
Health-related quality of life
No HRQoL data were included in the Hyams et al.52 trial.
Adverse events of treatment (including leakage and infections following surgery)
Discontinuations due to adverse events Through week 54 of the Hyams et al.52 trial, discontinuations
due to at least one AE were higher in the 5mg/kg of IFX every 12 weeks group than the every 8 weeks
frequency group (6/23, 26.1% vs. 3/22, 13.6%).52
Number of patients experiencing one or more adverse event All patients in both treatment arms of
the Hyams et al.52 study reported at least one AE (22/22, 100% vs. 23/23, 100%).52
Number of patients experiencing one or more serious adverse event The numbers of patients
reporting at least one SAE were similar between the 5mg/kg of IFX every 12 weeks (5/23, 21.7%) and
every 8 weeks (4/22, 18.2%) treatment arms.52
Infections The occurrence of infections was comparable between 5mg/kg of IFX every 8 weeks (13/22,
59.1%) and every 12 weeks (14/23, 60.9%) treatment groups.52
Serious infections No cases of serious infection were reported in the Hyams et al.52 trial.
Reactivation of tuberculosis No cases were reported.
Reactivation of hepatitis B No cases were reported.
Administration reactions (injection site reactions/infusion reactions/serious allergic reactions) The
number of patients experiencing infusion reactions were similar between treatment groups in the Hyams
et al.52 study (4/22, 18.2% vs. 3/23, 13.0%).
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Subgroups
As stated in the assessment protocol, the only pre-specified subgroup of interest was duration of disease.
However, clinical data reported according to disease duration were very limited. The only studies to
evaluate the effect of disease duration on outcomes were ULTRA245 and PURSUIT-Maintenance.47,48
For ULTRA2,45 the odds ratios (ORs) for the proportion of patients in clinical remission at week 8 for ADA
versus PBO were very similar for patients with disease duration of ≤ 2 years (OR 1.91, 95% CI 0.4 to 8.8;
p= 0.40) and those with disease duration of > 2 years (OR 1.92, 95% CI 1.1 to 3.4; p= 0.03). However, at
week 52, the OR for clinical remission was considerably higher for patients with disease duration > 2 years
(OR 3.59, 95% CI 1.9 to 6.9; p< 0.001) than for patients with a shorter disease duration of ≤ 2 years
(OR 0.22, 95% CI 0.04 to 1.1; p= 0.05).
PURSUIT-Maintenance48 reported the ORs for comparing the proportion of patients in clinical response in
the GOL maintenance group versus the PBO group for GOL-induction responders. The OR for proportion
of patients in clinical response through week 54 for 50mg of GOL versus PBO treatment arms was slightly
higher among patients with longer disease duration (> 5 to ≤ 15 years; OR 2.3, 95% CI 1.0 to 5.4;
p= 0.056) than those with shorter duration of disease (≤ 5 years; OR 1.4, 95% CI 0.9 to 2.7; p= 0.533).
Similarly, OR for 100mg of GOL versus PBO groups was also reported to be greater among those with a
disease duration of > 5 to ≤ 15 years (OR 2.2, 95% CI 1.0 to 4.9; p= 0.068) than for patients with disease
duration of ≤ 5 years (OR 1.6, 95% CI 0.8 to 3.1; p= 0.128). However, it was noted that the 95% CIs for
these observations overlapped between estimates.
Methods for network meta-analysis
The trials identified in the systematic review formed a connected network such that each trial had at least
one treatment in common with at least one other trial. Treatment effects were estimated using NMAs of
clinical response and remission as defined by the complete Mayo score.
Selection of evidence contributing to the network meta-analysis
For RCTs to be eligible for inclusion in the NMA they were required to have information about clinical
response and/or clinical remission data for either an induction (6–8 weeks) or maintenance (approximately
30 weeks or 52–54 weeks) time point. It should be noted that two adult population RCTs evaluating the
use of IFX as an induction treatment (Probert et al.,50 and UC-SUCCESS51) were excluded from the adult
population NMA. These studies were excluded for other reasons, as described in the table of trial
characteristics (see Table 6). The base-case analyses utilised data from the anti-TNF-α-naive population
rather than the ITT population in ULTRA245 in order to increase comparability of the dataset. The induction
base case also incorporated both Phase II (plus additional analysed patients from Phase II) and Phase III
data from PURSUIT-SC.47 The effect of using the ITT (mixed anti-TNF-α experienced) population from
ULTRA245 was explored in a sensitivity analysis. As the Suzuki et al.46 trial was conducted in exclusively
Japanese patients, this trial was not included in the base case; however, the addition of this trial to the
network was explored in a sensitivity analysis. Therefore, three sensitivity analyses were performed for both
induction and maintenance phases to assess the robustness of replacing ULTRA2 anti-TNF-α-naive data
with ULTRA2 ITT data (sensitivity analysis 1), including Suzuki et al.46 (sensitivity analysis 2), and replacing
ULTRA2 anti-TNF-α-naive data with ULTRA2 ITT data plus including Suzuki et al.46 (sensitivity analysis 3).
Clinical response and remission data were defined as outlined in Table 10 and were taken from two
different sources. First, data relating to clinical response and remission for the use of interventions as
induction treatment were extracted directly from the published RCT reports. Second, data relating to
clinical response and remission for the use of interventions as maintenance treatments conditional on
outcomes at previous timepoints were requested and received from the manufacturers of the products
under assessment (MSD and AbbVie).
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Statistical model for the network meta-analysis
Clinical response/remission can be considered as ordered categorical data with three mutually exclusive
categories: (1) no response; (2) response; and (3) remission. The model for the data assumed that the
treatment effect was the same irrespective of the category. Data available at 6 weeks and 8 weeks were
combined, as were data available at 30 weeks and 32 weeks, and 52 weeks and 54 weeks. The likelihood
function for the data is described as follows. Let rikj represent the number of patients in arm k of trial i in
the mutually exclusive category j= 1, 2, . . . J. The responses rikj will follow a multinomial distribution
such that:
rik j = 1, :::, J∼Multinomial(pik j = 1, :::, J, nik), ∑
J
j = 1
pik j=1, :::, J = 1. (1)
The parameters in the model are the probabilities, pikj, that a patient in arm k of trial i has a response
equivalent to category j.
We used a probit link function to map the probabilities, pikj, onto the real line such that:
θik j =Φ−1(pik j) = µi j + δi, bkIk ≠ 1 (2)
so that:
pik j =Φ(µi j + δi, bkIk≠1). (3)
In this model, the effect of treatment was to change the probit score of the control arm by δi,bk SDs.
The study-specific treatment effects, δi,bkIk≠1, were assumed to arise from a common population distribution
with mean treatment effect relative to the reference treatment, which in this analysis was PBO, such that:
δi, 1k ∼ N(dti1,tik , τ2). (4)
We further assumed that there is an underlying continuous latent variable that has been categorised by
specifying cut-off points zij, which corresponds to the point at which an individual moves from one
category to the next in trial i. The model is rewritten as:
pik j =Φ(µi + zi j + δi, bkIk≠1). (5)
The zij can be treated as fixed, which would assume that these points are the same in each trial and each
treatment. Alternatively, they can be treated as random in which they are assumed to vary according to
the trial but that within a trial they are the same such that:
zic∼N(νc, σ2z ). (6)
We used a model in which the zij were treated as being random because this resulted in a much better fit
of the model to the data. Further details of the model are presented in Dias et al.69
The model was completed by giving the parameters prior distributions. When there are sufficient sample
data, we can use conventional reference prior distributions and these will have little influence on the
posterior results.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
The reference prior distributions used in the analyses were:
l trial-specific baselines, µi∼N(0, 1000)
l treatment effects relative to reference treatment, d1t∼N(0, 1000)
l between-study SD of treatment effects, τ∼U(0,2)
l population cut-off points, υc j = υc j−1 + υ’c, υ’c∼U(0,5)
l between-study SD of cut-off points, σ2z∼U(0,2).
In both the induction and maintenance phases, there were relatively few studies to allow Bayesian
updating of the implausibly vague prior distribution for the between-study SD. Without Bayesian updating,
a reference prior distribution that does not represent genuine prior belief will have a significant impact on
the results and give posterior distributions that are unlikely to represent genuine posterior beliefs. To allow
for this, we used a weakly informative prior distribution (a half-normal distribution) for the between study
SD such that τ∼HN (0,0.322).
To estimate the absolute probabilities of being in each category for each treatment, we combined the
treatment effects with an estimate of the PBO ‘No response’ category (baseline model). We used a
Binomial likelihood function for the number of patients, rik1 in each study who were classified as having ‘no
response’ when treated with PBO for the baseline model such that:
rik1∼ Binomial(nik, pik1). (7)
We used a probit link function such that:
Φ−1(pik1) = µ’i . (8)
We assumed that the study-specific baselines arose from population of effects such that:
µ’i∼N(µb, τ
2
b). (9)
The model was completed by giving the parameters prior distributions such that:
l population baseline effect, µb∼N(0, 1000)
l between-study SD of the baseline effects, τb∼U(0, 2).
Again, in both the induction and maintenance phase there were relatively few studies providing data so a
weakly informative prior distribution was used for the between-study SD such that:
τ∼HN(0, 0:322). (10)
All analyses were conducted in the freely available software package OpenBUGS version 3.2.3.69,70 For the
baseline and relative treatment effects models, we used a burn-in of 50,000 iterations of the Markov chain
and retained a further 10,000 iterations to estimate parameters. In addition, the NMAs exhibited moderate
correlation between successive iterations of the Markov chains so the chains were thinned by retaining
every tenth sample.
The total residual deviance was used to formally assess whether or not the statistical model provided a
reasonable representation of the sample data. The total residual deviance is the mean of the deviance
under the current model minus the deviance for the saturated model, so that each data point should
contribute about one to the deviance.
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Results of network meta-analyses
A summary of the data used in the NMA is provided in Appendix 7. As described earlier, three sensitivity
analyses were undertaken to assess the robustness of replacing ULTRA245 anti-TNF-α-naive data with
ULTRA245 ITT data (sensitivity analysis 1), including Suzuki et al.46 (sensitivity analysis 2), and replacing
ULTRA2 anti-TNF-α-naive data with ULTRA245 ITT data and including Suzuki et al.46 (sensitivity analysis 3).
The results presented in Base case: induction phase to Sensitivity analysis 3: maintenance phase
32–52 weeks were derived using weakly informative prior distributions (a half-normal distribution) for the
between-study SD such that τ∼HN(0, 0.322). Results using vague reference prior distributions [τ∼U(0,2)]
are presented in Appendix 8.
Base case: induction phase
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
induction phase. Data were available from five studies comparing two treatments.44,45,47,49 Figure 13
presents the network of evidence for the base-case induction phase.
Figure 14 presents the effects of each treatment relative to PBO on the probit scale for the base-case
induction phase. Figure 15 presents the probabilities of treatment rankings for this analysis. The model fitted
the data reasonably well, with the total residual deviance, 18.16, being close to the total number of data
points included in the analysis, 20. The between-study SD was estimated to be 0.12 [95% credible interval
(CrI) 0.01 to 0.50], which implies mild to moderate heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with IFX. All treatment effects were statistically significant at a conventional 5% level. IFX
was associated with the greatest effect –0.92 (95% CrI –1.27 to –0.56) and was most likely to be the most
effective treatment (probability of being the best= 0.93).
Table 13 presents the probabilities of achieving each of the following categories: no response, response
and remission for the base-case induction phase. IFX was associated with the highest probability of moving
from no response to response and no response to remission respectively. The effects of ADA and GOL on
each transition probability were comparable.
GOL
PBO
IFX
ADA
FIGURE 13 Base case: network of evidence for the induction phase. Note: solid line indicates a two-arm trial.
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vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.40 (– 0.76 to – 0.04)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 0.97 to – 0.01)
– 0.92 (– 1.27 to – 0.56)
– 0.10 (– 0.69 to  0.50)
– 0.52 (– 1.03 to 0.00)
– 0.42 (– 1.00 to 0.17)
– 2 – 1 0 1 2
FIGURE 14 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the induction
phase [SD∼HN(0,0.322)].
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FIGURE 15 Base case: ranking probability histograms for the induction phase.
TABLE 13 Base case: probabilities of being in each category for the induction phase
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.640 0.641 0.568 to 0.706 0.260 0.260 0.214 to 0.308 0.099 0.097 0.062 to 0.147
ADA 0.485 0.485 0.330 to 0.642 0.324 0.327 0.247 to 0.385 0.190 0.185 0.092 to 0.322
GOL 0.448 0.447 0.262 to 0.645 0.333 0.337 0.244 to 0.393 0.219 0.212 0.094 to 0.390
IFX 0.292 0.289 0.170 to 0.438 0.351 0.353 0.280 to 0.412 0.356 0.352 0.209 to 0.523
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Base case: maintenance phase 8–32 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase at 8–32 weeks for patients starting in response. Data
were available from four studies comparing two or three treatments.45,48,49 Figure 16 presents the network
of evidence for the base-case maintenance phase at 8–32 weeks for patients starting in response.
Figure 17 presents the effects of each treatment relative to PBO on the probit scale for the base-case
maintenance phase at 8–32 weeks for patients starting in response. Figure 18 presents the probabilities of
treatment rankings for this analysis. There was some suggestion that the model did not represent the data
well with the total residual deviance, 11.73, being smaller than would be expected given the total number
of data points included in the analysis, 18. The probability of observing a value < 11.73 was 0.139, which
means that it could be a chance event. All four studies had smaller residual deviances than expected
(ULTRA2: deviance 3.0 compared with four data points;45 ACT1: deviance 2.1 compared with four data
points;49 ACT2: deviance 2.66 compared with four data points;49 and PURSUIT: deviance 4.0 compared
with six data points).48 The between-study SD was estimated to be 0.17 (95% CrI 0.01 to 0.61), which
implies mild to moderate heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with 100mg of GOL. However, none of the treatment effects were statistically significant
at a conventional 5% level. 100mg of GOL was associated with the greatest effect –0.42 (95% CrI –0.78
to 0.29) and was most likely to be the most effective treatment (probability of being the best= 0.47).
Table 14 presents the probabilities of achieving each of the following categories: no response, response
and remission for the base-case maintenance phase at 8–32 weeks for patients starting in response.
100mg of GOL was associated with the highest probability of moving from response to remission and
staying in the response state at 8–32 weeks. It was also associated with the smallest probability of moving
from response to no response. The probabilities of staying in response were comparable among all
treatments at 8–32 weeks.
50 mg of GOL
100 mg of GOL
PBO
IFX
ADA
FIGURE 16 Base case: network of evidence for the maintenance phase at 8–32 weeks for patients starting in
response. Note: solid line indicates a two-arm trial and dashed line indicates a three-arm study.
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.03 (– 0.76 to 0.68)
– 0.31 (– 0.97 to 0.30)
– 0.42 (– 1.06 to 0.21)
– 0.24 (– 0.78 to 0.29)
– 0.38 (– 1.36 to 0.59)
– 0.29 (– 1.24 to 0.67)
– 0.20 (– 1.09 to 0.69)
– 0.10 (– 0.72 to 0.55)
0.07 (– 0.75 to 0.91)
0.18 (– 0.68 to 1.01)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 17 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 8–32 weeks for patients starting in response [SD∼HN(0,0.322)].
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50 mg 
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100 mg 
of GOL
Best worst Best worst
FIGURE 18 Base case: ranking probability histograms for the maintenance phase at 8–32 weeks for patients
starting in response. Note: the horizontal axis represents the rank of each treatment, i.e., from the best rank
(left hand side) to the worst rank (right hand side) within each treatment.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Patients starting in remission A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase at 8–32 weeks for patients starting in remission.
Data were available from four studies comparing two or three treatments.45,48,49 Figure 19 presents the
network of evidence for the base-case maintenance phase at 8–32 weeks for patients starting in remission.
Figure 20 presents the effects of each treatment relative to PBO on the probit scale for the base-case
maintenance phase at 8–32 weeks for patients starting in remission. Figure 21 presents the probabilities of
treatment rankings for this analysis. The model fitted the data well, with the total residual deviance, 18.20,
being close to the total number of data points included in the analysis, 18. The between-study SD was
estimated to be 0.18 (95% CrI 0.01 to 0.64), which implies mild to moderate heterogeneity between
studies in treatment effects.
TABLE 14 Base case: probabilities of being in each category for the maintenance phase at 8–32 weeks for patients
starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.524 0.525 0.426 to 0.622 0.270 0.270 0.198 to 0.341 0.206 0.202 0.117 to 0.311
ADA 0.512 0.512 0.230 to 0.782 0.261 0.267 0.140 to 0.354 0.227 0.211 0.055 to 0.493
50mg of
GOL
0.403 0.399 0.173 to 0.660 0.283 0.285 0.176 to 0.374 0.313 0.303 0.108 to 0.588
100mg of
GOL
0.368 0.360 0.149 to 0.619 0.285 0.288 0.176 to 0.377 0.347 0.338 0.129 to 0.623
IFX 0.432 0.430 0.220 to 0.659 0.282 0.283 0.189 to 0.371 0.286 0.276 0.109 to 0.518
100 mg of GOL
50 mg of GOL
PBO
IFX
ADA
FIGURE 19 Base case: network of evidence for the maintenance phase at 8–32 weeks for patients starting in
remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.19 (– 0.75 to 1.09)
– 0.63 (– 1.36 to 0.11)
– 0.61 (– 1.32 to 0.11)
– 0.11 (– 0.78 to 0.56)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.79 (– 1.96 to 0.42)
– 0.82 (– 1.96 to 0.39)
– 0.29 (– 1.41 to 0.85)
0.02 (– 0.69 to 0.75)
0.52 (– 0.46 to 1.49)
0.51 (– 0.48 to 1.45)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 20 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 8–32 weeks for patients starting in remission [SD∼HN(0,0.322)].
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FIGURE 21 Base case: ranking probability histograms for the maintenance phase at 8–32 weeks for patients
starting in remission.
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All treatments except ADA were associated with beneficial treatment effects relative to PBO with the
greatest effects being associated with 50mg of GOL (–0.63, 95% CrI –1.36 to 0.11) and 100mg of GOL
(–0.61, 95% CrI –1.32 to 0.11). However, none of the treatment effects was statistically significant at a
conventional 5% level. 50mg and 100mg of GOL was most likely to be the most effective treatments
(probability of being the best= 0.47 and 0.42 respectively).
Table 15 presents the probabilities of achieving each of the following categories: no response, response
and remission for the base-case maintenance phase at 8–32 weeks for patients starting in remission.
50mg and 100mg of GOL were associated with the highest probability of staying in remission and the
smallest probability of moving from remission to response or remission no response at 8–32 weeks.
Base case: maintenance phase 32–52 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 32–52 weeks. Data
were available from three studies comparing two or three treatments.45,48,49 Figure 22 presents the network
of evidence for the base-case maintenance phase at 32–52 weeks for patients starting in response.
Figure 23 presents the effects of each treatment relative to PBO on the probit scale for the base-case
maintenance phase 32–52 weeks for patients starting in response. Figure 24 presents the probabilities
of treatment rankings for this analysis. The model fitted the data reasonably well, with the total residual
deviance, 12.88, being close to the total number of data points included in the analysis, 14. The
between-study SD was estimated to be 0.21 (95% CrI 0.01 to 0.71), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments except 100mg of ADA and GOL were associated with beneficial treatment effects relative
to PBO with the greatest effect being associated with 50mg of GOL; however, none of the treatment
effects was statistically significant at a conventional 5% level. IFX was associated with the greatest effect
–0.36 (95% CrI –1.33 to 0.62) and was most likely to be the most effective treatment (probability of being
the best= 0.56).
Table 16 presents the probabilities of achieving each of the following categories: no response, response
and remission for the base-case maintenance phase at 32–52 weeks for patients starting in response.
IFX was associated with the highest probability of moving from response to remission and the smallest
probability of moving from response to no response at 32–52 weeks. The probabilities of staying in the
response state were comparable among treatments at 32–52 weeks.
TABLE 15 Base case: probabilities of being in each category for the maintenance phase at 8–32 weeks for patients
starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.353 0.347 0.168 to 0.572 0.180 0.174 0.070 to 0.316 0.467 0.466 0.225 to 0.708
ADA 0.428 0.420 0.099 to 0.803 0.166 0.164 0.053 to 0.297 0.406 0.392 0.083 to 0.804
50mg of
GOL
0.177 0.152 0.027 to 0.457 0.136 0.131 0.028 to 0.283 0.687 0.708 0.321 to 0.933
100mg of
GOL
0.182 0.158 0.029 to 0.469 0.138 0.134 0.030 to 0.285 0.680 0.700 0.322 to 0.929
IFX 0.325 0.309 0.084 to 0.648 0.169 0.165 0.057 to 0.304 0.506 0.509 0.178 to 0.829
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FIGURE 22 Base case: network of evidence for the maintenance phase at 32–52 weeks for patients starting in
response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.31 (– 0.58 to 1.27)
– 0.17 (– 1.01 to 0.69)
0.20 (– 0.63 to 1.03)
– 0.36 (– 1.33 to 0.62)
vs. ADA
100 mg of GOL
50 mg of GOL
vs.100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.12 (– 1.36 to 1.11)
– 0.49 (– 1.77 to 0.77)
– 0.67 (– 2.04 to 0.66)
0.38 (– 0.47 to 1.20)
– 0.18 (– 1.51 to 1.10)
– 0.56 (– 1.85 to 0.73)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 23 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 32–52 weeks for patients starting in response [SD∼HN(0,0.322)].
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Patients starting in remission A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase at 32–52 weeks for patients starting in remission. Data
were available from three studies comparing two or three treatments.45,48,49 Figure 25 presents the network
of evidence for the base-case maintenance phase at 32–52 weeks for patients starting in remission.
Figure 26 presents the effects of each treatment relative to PBO on the probit scale for the base-case
maintenance phase at 32–52 weeks for patients starting in remission. Figure 27 presents the probabilities
of treatment rankings for this analysis. The model fitted the data well, with the total residual deviance,
18.46, being close to the total number of data points included in the analysis, 18. The between-study SD
was estimated to be 0.21 (95% CrI 0.01 to 0.72), which implies mild to moderate heterogeneity between
studies in treatment effects.
All treatments except 50mg of GOL were associated with beneficial treatment effects relative to PBO
with the greatest effect being associated with ADA. However, only the treatment effects of ADA were
statistically significant at a conventional 5% level. ADA was associated with the greatest effect –1.04
(95% CrI –1.93 to –0.12) and was most likely to be the most effective treatment (probability of being
the best= 0.84).
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FIGURE 24 Base case: ranking probability histograms for the maintenance phase at 32–52 weeks for patients
starting in response.
TABLE 16 Base case: probabilities of being in each category for the maintenance phase at 32–52 weeks for patients
starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.338 0.319 0.066 to 0.711 0.370 0.378 0.122 to 0.604 0.292 0.259 0.027 to 0.717
ADA 0.450 0.440 0.063 to 0.889 0.327 0.340 0.067 to 0.562 0.223 0.167 0.005 to 0.716
50mg of
GOL
0.295 0.258 0.025 to 0.750 0.353 0.363 0.081 to 0.616 0.352 0.319 0.021 to 0.842
100mg of
GOL
0.410 0.393 0.055 to 0.852 0.342 0.353 0.083 to 0.581 0.248 0.199 0.009 to 0.741
IFX 0.250 0.205 0.013 to 0.716 0.341 0.353 0.065 to 0.621 0.409 0.385 0.029 to 0.892
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FIGURE 25 Base case: network of evidence for the maintenance phase at 32–52 weeks for patients starting in
remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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FIGURE 26 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 32–52 weeks for patients starting in remission [SD∼HN(0,0.322)].
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Table 17 presents the probabilities of achieving each of the following categories: no response, response
and remission for the base-case maintenance phase at 32–52 weeks for patients starting in remission. ADA
was associated with the highest probability of staying in remission and the smallest probability of moving
from remission to response or from remission to no response at 32–52 weeks.
Sensitivity analysis 1: induction phase
Sensitivity analysis 1 involved replacing ULTRA2 anti-TNF-α-naive data with ULTRA2 ITT data. A NMA was
used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the induction
phase. Data were available from five studies comparing two treatments.44,45,47,49 Figure 28 presents the
network of evidence for the sensitivity analysis 1 induction phase.
Figure 29 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 1 induction phase. Figure 30 presents the probabilities of treatment rankings for this analysis.
The model fitted the data reasonably well, with the total residual deviance, 17.08, being close to the total
number of data points included in the analysis, 20. The between-study SD was estimated to be 0.11
(95% CrI 0.01 to 0.47), which implies mild heterogeneity between studies in treatment effects.
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FIGURE 27 Base case: ranking probability histograms for the maintenance phase at 32–52 weeks for patients
starting in remission.
TABLE 17 Base case: probabilities of being in each category for the maintenance phase at 32–52 weeks for patients
starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.301 0.296 0.174 to 0.449 0.164 0.147 0.029 to 0.449 0.536 0.548 0.237 to 0.734
ADA 0.081 0.059 0.005 to 0.288 0.084 0.061 0.005 to 0.337 0.834 0.874 0.447 to 0.985
50mg of
GOL
0.329 0.314 0.080 to 0.664 0.155 0.141 0.024 to 0.415 0.515 0.523 0.135 to 0.851
100mg of
GOL
0.266 0.245 0.052 to 0.604 0.147 0.132 0.020 to 0.417 0.587 0.604 0.169 to 0.894
IFX 0.247 0.220 0.033 to 0.613 0.140 0.126 0.017 to 0.413 0.613 0.634 0.174 to 0.928
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FIGURE 28 Sensitivity analysis 1: network of evidence for the induction phase. Note: solid line indicates a
two-arm trial.
vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.35 (– 0.68 to – 0.02)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 0.94 to – 0.09)
– 0.91 (– 1.25 to – 0.57)
– 0.14 (– 0.71 to 0.36)
– 0.56 (– 1.03 to – 0.08)
– 0.42 (– 0.94 to 0.15)
– 2 – 1 0 1 2
FIGURE 29 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼HN(0,0.322)].
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All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with IFX (–0.91, 95% CrI –1.25 to –0.57). All treatment effects were statistically
significant at a conventional 5% level. IFX was most likely to be the most effective treatment (probability
of being the best= 0.94).
Table 18 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 1 induction phase. IFX was associated with the highest probability
of moving from no response to response and from no response to remission.
Sensitivity analysis 1: maintenance phase 8–32 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 8–32 weeks. Data
were available from four studies comparing two or three treatments.45,48,49 Figure 31 presents the network
of evidence for the sensitivity analysis 1 maintenance phase at 8–32 weeks for patients starting
in response.
Figure 32 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity analysis 1
maintenance phase at 8–32 weeks for patients starting in response. Figure 33 presents the probabilities of
treatment rankings for this analysis. There was some suggestion that model did not represent the data well
with the total residual deviance, 11.54, being smaller than would be expected given the total number of data
points included in the analysis, 18. The probability of observing a value < 11.54 was 0.130, which means that
this could be a chance event. Similar to the base-case analysis, all four studies had smaller residual deviances
than expected. The between-study SD was estimated to be 0.17 (95% CrI 0.01 to 0.63), which implies mild to
moderate heterogeneity between studies in treatment effects.
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FIGURE 30 Sensitivity analysis 1: ranking probability histograms for the induction phase.
TABLE 18 Sensitivity analysis 1: probabilities of being in each category for the induction phase
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.649 0.649 0.586 to 0.710 0.255 0.255 0.212 to 0.298 0.096 0.095 0.062 to 0.140
ADA 0.513 0.512 0.372 to 0.652 0.315 0.317 0.240 to 0.375 0.173 0.169 0.088 to 0.286
GOL 0.456 0.456 0.283 to 0.631 0.330 0.334 0.250 to 0.389 0.214 0.207 0.101 to 0.368
IFX 0.302 0.298 0.180 to 0.441 0.351 0.353 0.281 to 0.409 0.347 0.345 0.208 to 0.506
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FIGURE 31 Sensitivity analysis 1: network of evidence for the maintenance phase at 8–32 weeks for patients
starting in response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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FIGURE 32 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼HN(0,0.322)].
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All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with 100mg of GOL (–0.41, 95% CrI –1.06 to 0.22); however, none of the treatment
effects was statistically significant at a conventional 5% level. A treatment of 100mg of GOL was
most likely to be the most effective (probability of being the best= 0.43).
Table 19 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 1 maintenance phase at 8–32 weeks starting in response.
A treatment of 100mg of GOL was associated with the highest probability of moving from response to
remission and the smallest probability of moving from response to no response at 8–32 weeks. The
probabilities of staying in the response state were comparable among treatments.
Patients starting in remission A NMA was used to compare the effects of ADA, GOL and IFX relative
to PBO on clinical response in the maintenance phase at 8–32 weeks for patients starting in remission.
Data were available from four studies comparing two or three treatments.45,48,49 Figure 34 presents the
network of evidence for the sensitivity analysis 1 maintenance phase at 8–32 weeks for patients starting
in remission.
1.00
0.75
0.50
Pr
o
b
ab
ili
ty
0.25
0.00
PBO ADA
Rank
50 mg 
of GOL
IFX
Best worst Best worst Best worst
100 mg 
of GOL
Best worst Best worst
FIGURE 33 Sensitivity analysis 1: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in response.
TABLE 19 Sensitivity analysis 1: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.548 0.548 0.447 to 0.649 0.269 0.267 0.199 to 0.361 0.183 0.181 0.085 to 0.282
ADA 0.468 0.467 0.210 to 0.744 0.279 0.283 0.158 to 0.391 0.252 0.240 0.059 to 0.525
50mg of
GOL
0.427 0.423 0.190 to 0.688 0.289 0.289 0.176 to 0.412 0.284 0.273 0.081 to 0.552
100mg of
GOL
0.390 0.384 0.162 to 0.649 0.293 0.292 0.182 to 0.421 0.318 0.310 0.098 to 0.591
IFX 0.453 0.451 0.237 to 0.685 0.286 0.287 0.186 to 0.403 0.260 0.252 0.082 to 0.490
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Figure 35 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 1 maintenance phase at 8–32 weeks for patients starting in remission. Figure 36 presents
the probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 15.29, being close to the total number of data points included in the analysis, 18.
The between-study SD was estimated to be 0.19 (95% CrI 0.01 to 0.65), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effects
being associated with 50mg of GOL (–0.62, 95% CrI –1.36 to 0.11) and 100mg of GOL (–0.61, 95% CrI
–1.34 to 0.13). However, none of the treatment effects was statistically significant at a conventional 5%
level. A treatment of 50mg and 100mg of GOL were most likely to be the most effective (probability of
being the best= 0.44 and 0.41 respectively).
Table 20 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 1 maintenance phase at 8–32 weeks starting in remission. A
treatment of 50mg and 100mg of GOL were associated with the highest probability of staying in
remission and the smallest probability of moving from remission to no response and from remission to
response at 8–32 weeks.
100 mg of GOL
50 mg of GOL
PBOIFX
ADA
FIGURE 34 Sensitivity analysis 1: network of evidence for the maintenance phase at 8–32 weeks for patients
starting in remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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FIGURE 36 Sensitivity analysis 1: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in remission.
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FIGURE 35 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼HN(0,0.322)].
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Sensitivity analysis 1: maintenance phase 32–52 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 32–52 weeks.
Data were available from three studies comparing two or three treatments.45,48,49 Figure 37 presents the
network of evidence for the sensitivity analysis 1 maintenance phase at 32–52 weeks for patients starting
in response.
Figure 38 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 1 maintenance phase 32–52 weeks for patients starting in response. Figure 39 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 12.32, being close to the total number of data points included in the analysis, 14.
The between-study SD was estimated to be 0.21 (95% CrI 0.01 to 0.72), which implies mild to moderate
heterogeneity between studies in treatment effects.
TABLE 20 Sensitivity analysis 1: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.392 0.389 0.217 to 0.584 0.180 0.175 0.078 to 0.309 0.428 0.426 0.218 to 0.650
ADA 0.379 0.365 0.096 to 0.736 0.167 0.164 0.06 to 0.3 0.454 0.450 0.128 to 0.807
50mg of
GOL
0.204 0.182 0.036 to 0.493 0.143 0.139 0.036 to 0.285 0.653 0.669 0.300 to 0.914
100mg of
GOL
0.207 0.188 0.038 to 0.494 0.144 0.140 0.037 to 0.287 0.648 0.662 0.303 to 0.911
IFX 0.359 0.347 0.107 to 0.679 0.170 0.166 0.065 to 0.301 0.471 0.470 0.165 to 0.793
100 mg of GOL
50 mg of GOL
PBO
IFX
ADA
FIGURE 37 Sensitivity analysis 1: network of evidence for the maintenance phase at 32–52 weeks for patients
starting in response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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FIGURE 38 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼HN(0,0.322)].
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FIGURE 39 Sensitivity analysis 1: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in response.
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All treatments except 100mg of GOL were associated with beneficial treatment effects relative to PBO
with the greatest effect being associated with IFX (–0.37; 95% CrI –1.30 to 0.59); however, none of the
treatment effects was statistically significant at a conventional 5% level. IFX was most likely to be
the most effective treatment (probability of being the best= 0.52).
Table 21 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 1 maintenance phase at 32–52 weeks starting in response.
IFX was associated with the highest probability of moving from response to remission and the smallest
probability of moving from response to no response at 32–52 weeks. The probabilities of staying in the
response state were comparable among treatments at 32–52 weeks.
Patients starting in remission
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
maintenance phase at 32–52 weeks for patients starting in remission. Data were available from three
studies comparing two or three treatments.45,48,49 Figure 40 presents the network of evidence for the
sensitivity analysis 1 maintenance phase at 32–52 weeks for patients starting in remission.
Figure 41 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 1 maintenance phase at 32–52 weeks for patients starting in remission. Figure 42 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 17.73, being close to the total number of data points included in the analysis, 14.
The between-study SD was estimated to be 0.22 (95% CrI 0.01 to 0.72), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments except 50mg of GOL were associated with beneficial treatment effects relative to PBO with
the greatest effect being associated with ADA (–0.86; 95% CrI –1.71 to 0.00); however, only the
treatment effects of ADA were statistically significant at a conventional 5% level. ADA was most likely to
be the most effective treatment (probability of being the best= 0.78).
Table 22 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 1 maintenance phase at 32–52 weeks starting in remission. ADA
was associated with the highest probability of staying in remission and the smallest probability of moving
from remission to response or from remission to no response at 32–52 weeks.
TABLE 21 Sensitivity analysis 1: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.338 0.317 0.064 to 0.718 0.373 0.378 0.118 to 0.628 0.29 0.259 0.019 to 0.714
ADA 0.332 0.300 0.031 to 0.790 0.354 0.363 0.084 to 0.625 0.314 0.276 0.013 to 0.812
50mg of
GOL
0.302 0.269 0.024 to 0.769 0.355 0.364 0.077 to 0.632 0.344 0.308 0.015 to 0.844
100mg of
GOL
0.417 0.401 0.053 to 0.854 0.341 0.352 0.077 to 0.595 0.242 0.192 0.006 to 0.742
IFX 0.249 0.201 0.012 to 0.730 0.343 0.353 0.063 to 0.643 0.408 0.387 0.022 to 0.898
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.86 (– 1.71 to 0.00)
0.02 (– 0.78 to 0.86)
– 0.18 (– 0.99 to 0.66)
– 0.22 (– 1.20 to 0.75)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.68 (– 0.51 to 1.90)
0.89 (– 0.32 to 2.14)
0.64 (– 0.67 to 1.92)
– 0.20 (– 1.00 to 0.60)
– 0.24 (– 1.54 to 1.06)
– 0.04 (– 1.35 to 1.25)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 41 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼HN(0,0.322)].
100 mg of GOL
50 mg of GOL
PBO
IFX
ADA
FIGURE 40 Sensitivity analysis 1: network of evidence for the maintenance phase at 32–52 weeks for patients
starting in remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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Sensitivity analysis 2: induction phase
Sensitivity analysis 2 involved including Suzuki et al.46 A NMA was used to compare the effects of ADA,
GOL and IFX relative to PBO on clinical response in the induction phase. Data were available from six
studies comparing two treatments.44–47,49 Figure 43 presents the network of evidence for the sensitivity
analysis 2 induction phase.
Figure 44 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 2 induction phase. Figure 45 presents the probabilities of treatment rankings for this analysis. The
model fitted the data well, with the total residual deviance, 24.36, being close to the total number of data
points included in the analysis, 24. The between-study SD was estimated to be 0.10 (95% CrI 0.01 to
0.41), which implies mild heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with IFX (–0.92, 95% CrI –1.24 to –0.60). All treatment effects were statistically
significant at a conventional 5% level. IFX was most likely to be the most effective treatment (probability of
being the best= 0.96).
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FIGURE 42 Sensitivity analysis 1: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in remission.
TABLE 22 Sensitivity analysis 1: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.302 0.299 0.177 to 0.448 0.167 0.155 0.030 to 0.396 0.530 0.539 0.270 to 0.727
ADA 0.104 0.082 0.010 to 0.324 0.098 0.081 0.008 to 0.308 0.797 0.828 0.426 to 0.974
50mg of
GOL
0.324 0.307 0.082 to 0.664 0.158 0.147 0.026 to 0.374 0.519 0.526 0.145 to 0.842
100mg of
GOL
0.260 0.239 0.053 to 0.591 0.149 0.136 0.022 to 0.374 0.591 0.605 0.200 to 0.890
IFX 0.254 0.225 0.035 to 0.620 0.144 0.132 0.019 to 0.367 0.603 0.620 0.186 to 0.918
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GOL
PBO
IFX
ADA
FIGURE 43 Sensitivity analysis 2: network of evidence for the induction phase. Note: solid line indicates a
two-arm trial.
vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.36 (– 0.62 to – 0.09)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 0.87 to – 0.08)
– 0.92 (– 1.24 to – 0.60)
– 0.12 (– 0.60 to 0.34)
– 0.56 (– 0.98 to – 0.15)
– 0.43 (– 0.95 to 0.07)
– 2 – 1 0 1 2
FIGURE 44 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼HN(0,0.322)].
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Table 23 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 2 induction phase. IFX was associated with the highest probability
of moving from no response to response and from no response to remission.
Sensitivity analysis 2: maintenance phase 8–32 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase response at 8–32 weeks for patients starting in
response. Data were available from five studies comparing two or three treatments.45,46,48,49 Figure 46
presents the network of evidence for the sensitivity analysis 2 maintenance phase at 8–32 weeks for
patients starting in response.
Figure 47 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity analysis
2 maintenance phase at 8–32 weeks for patients starting in response. Figure 48 presents the probabilities of
treatment rankings for this analysis. There was some suggestion that model did not represent the data well
with the total residual deviance, 14.80, being smaller than would be expected given the total number of
data points included in the analysis, 22. The probability of observing a value < 14.8 is 0.129, which means
that this could be a chance event. Similar to the base-case analysis, all five studies had smaller residual
deviance than expected. The between-study SD was estimated to be 0.16 (95% CrI 0.01 to 0.58), which
implies mild to moderate heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with 100mg of GOL (–0.43; 95% CrI–1.03 to 0.19); however, none of the treatment
effects was statistically significant at a conventional 5% level. A treatment of 100mg of GOL was most
likely to be the most effective (probability of being the best= 0.44).
1.00
0.75
0.50
0.25
0.00
Pr
o
b
ab
ili
ty
PBO ADA
Rank
GOL IFX
Best Worst Best Worst Best Worst Best Worst
FIGURE 45 Sensitivity analysis 2: ranking probability histograms for the induction phase.
TABLE 23 Sensitivity analysis 2: probabilities of being in each category for the induction phase
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.642 0.642 0.585 to 0.696 0.260 0.263 0.225 to 0.301 0.095 0.094 0.065 to 0.132
ADA 0.502 0.500 0.384 to 0.623 0.326 0.327 0.264 to 0.377 0.173 0.170 0.099 to 0.264
GOL 0.452 0.450 0.298 to 0.624 0.339 0.343 0.266 to 0.392 0.209 0.204 0.060 to 0.344
IFX 0.292 0.252 0.183 to 0.421 0.360 0.360 0.305 to 0.411 0.348 0.347 0.068 to 0.488
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FIGURE 46 Sensitivity analysis 2: network of evidence for the maintenance phase at 8–32 weeks for patients
starting in response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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– 0.21 (– 0.73 to 0.27)
– 0.34 (– 0.97 to 0.28)
– 0.43 (– 1.03 to 0.19)
– 0.25 (– 0.79 to 0.29)
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IFX
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IFX
– 0.22 (– 0.97 to 0.58)
– 0.12 (– 0.89 to 0.69)
– 0.04 (– 0.80 to 0.74)
– 0.09 (– 0.70 to 0.53)
0.08 (– 0.71 to 0.92)
0.18 (– 0.63 to 1.00)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 47 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼HN(0,0.322)].
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Table 24 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 2 maintenance phase at 8–32 weeks for patients starting in
response. A treatment of 100mg of GOL was associated with the highest probability of moving from
response to remission and the smallest probability of moving from response to no response at 8–32 weeks.
The probabilities of staying in the response state were comparable among treatments.
Patients starting in remission
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
maintenance phase at 8–32 weeks for patients starting in remission. Data were available from five studies
comparing two or three treatments.45,46,48,49 Figure 49 presents the network of evidence for the sensitivity
analysis 2 maintenance phase at 8–32 weeks for patients starting in remission.
Figure 50 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 2 maintenance phase at 8–32 weeks for patients starting in remission. Figure 51 presents the
probabilities of treatment rankings for this analysis. The model fitted the data well, with the total residual
deviance, 21.05, being close to the total number of data points included in the analysis, 22. The between-
study SD was estimated to be 0.17 (95% CrI 0.01 to 0.60), which implies mild to moderate heterogeneity
between studies in treatment effects.
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FIGURE 48 Sensitivity analysis 2: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in response.
TABLE 24 Sensitivity analysis 2: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.525 0.525 0.437 to 0.609 0.274 0.274 0.220 to 0.329 0.201 0.199 0.130 to 0.286
ADA 0.441 0.441 0.238 to 0.647 0.286 0.288 0.209 to 0.354 0.273 0.263 0.116 to 0.485
50mg of
GOL
0.398 0.393 0.174 to 0.649 0.289 0.292 0.199 to 0.357 0.313 0.305 0.116 to 0.569
100mg of
GOL
0.363 0.356 0.158 to 0.617 0.291 0.293 0.200 to 0.360 0.346 0.338 0.132 to 0.598
IFX 0.429 0.425 0.222 to 0.657 0.287 0.289 0.204 to 0.352 0.284 0.276 0.110 to 0.504
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FIGURE 49 Sensitivity analysis 2: network of evidence for the maintenance phase at 8–32 weeks for patients
starting in remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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–0.61 (–1.30 to 0.09)
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IFX
–0.67 (–1.61 to 0.36)
–0.68 (–1.62 to 0.35)
–0.13 (–1.11 to 0.80)
0.01 (–0.67 to 0.71)
0.52 (–0.40 to 1.46)
0.51 (–0.41 to 1.46)
Treatment comparison (probit scale) Effect (95% CrI)
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FIGURE 50 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼HN(0,0.322)].
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All treatments except ADA were associated with beneficial treatment effects relative to PBO with the
greatest effects being associated with 50mg of GOL (–0.61; 95% CrI –1.30 to 0.09) and 100mg of GOL
(–0.60; 95% CrI –1.29 to 0.09); however, none of the treatment effects was statistically significant at a
conventional 5% level. Treatments of 50mg and 100mg of GOL was most likely to be the most effective
(probability of being the best= 0.46 and 0.44 respectively).
Table 25 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 2 maintenance phase at 8–32 weeks starting in remission.
Treatments of 50mg and 100mg of GOL were associated with the highest probability of staying in
remission and the smallest probability of moving from remission to no response and from remission to
response at 8–32 weeks.
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FIGURE 51 Sensitivity analysis 2: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in remission.
TABLE 25 Sensitivity analysis 2: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.354 0.350 0.191 to 0.540 0.187 0.183 0.103 to 0.294 0.459 0.459 0.250 to 0.666
ADA 0.381 0.371 0.114 to 0.701 0.178 0.175 0.085 to 0.286 0.441 0.434 0.144 to 0.769
50mg of
GOL
0.179 0.159 0.034 to 0.442 0.143 0.139 0.043 to 0.264 0.678 0.695 0.353 to 0.915
100mg of
GOL
0.181 0.162 0.035 to 0.443 0.144 0.141 0.044 to 0.264 0.675 0.691 0.349 to 0.913
IFX 0.331 0.318 0.103 to 0.626 0.177 0.174 0.082 to 0.286 0.492 0.493 0.195 to 0.790
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Sensitivity analysis 2: maintenance phase 32–52 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 32–52 weeks. Data
were available from four studies comparing two or three treatments.45,46,48,49 Figure 52 presents the network
of evidence for the sensitivity analysis 2 maintenance phase at 32–52 weeks for patients starting in response.
Figure 53 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 2 maintenance phase 32–52 weeks for patients starting in response. Figure 54 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 15.92, being close to the total number of data points included in the analysis, 18.
The between-study SD was estimated to be 0.20 (95% CrI 0.01 to 0.67), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments except ADA and 100mg of GOL were associated with beneficial treatment effects relative
to PBO with the greatest effect being associated with IFX (–0.36; 95% CrI –1.29 to 0.58); however, none
of the treatment effects was statistically significant at a conventional 5% level. IFX was most likely to be
the most effective treatment (probability of being the best= 0.57).
Table 26 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 2 maintenance phase at 32–52 weeks for patients starting in
response. IFX was associated with the highest probability of moving from response to remission and the
smallest probability of moving from response to no response at 32–52 weeks. The probabilities of staying
in response were comparable among treatments at 32–52 weeks.
50 mg of GOL
PBO
IFX
ADA
100 mg of GOL
FIGURE 52 Sensitivity analysis 2: network of evidence for the maintenance phase for patients starting in response
at 32–52 weeks. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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FIGURE 54 Sensitivity analysis 2: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in response.
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FIGURE 53 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼HN(0,0.322)].
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Patients starting in remission
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
maintenance phase at 32–52 weeks for patients starting in remission. Data were available from four
studies comparing two or three treatments.45,48,49 Figure 55 presents the network of evidence for the
sensitivity analysis 2 maintenance phase at 32–52 weeks for patients starting in remission.
Figure 56 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 2 maintenance phase at 32–52 weeks for patients starting in remission. Figure 57 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 21.07, being close to the total number of data points included in the analysis, 18.
The between-study SD was estimated to be 0.18 (95% CrI 0.01 to 0.65), which implies mild to moderate
heterogeneity between studies in treatment effects.
100 mg of GOL
50 mg of GOL
PBO
IFX
ADA
FIGURE 55 Sensitivity analysis 2: network of evidence for the maintenance phase at 32–52 weeks for patients
starting in remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
TABLE 26 Sensitivity analysis 2: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.322 0.318 0.189 to 0.472 0.393 0.398 0.200 to 0.544 0.286 0.278 0.107 to 0.520
ADA 0.371 0.363 0.130 to 0.661 0.371 0.378 0.176 to 0.524 0.259 0.238 0.05 to 0.576
50mg of
GOL
0.283 0.265 0.066 to 0.606 0.370 0.378 0.153 to 0.545 0.347 0.332 0.069 to 0.713
100mg of
GOL
0.404 0.395 0.128 to 0.730 0.359 0.368 0.153 to 0.521 0.237 0.211 0.035 to 0.579
IFX 0.230 0.202 0.030 to 0.575 0.352 0.363 0.115 to 0.542 0.418 0.410 0.081 to 0.820
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FIGURE 57 Sensitivity analysis 2: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in remission.
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FIGURE 56 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼HN(0,0.322)].
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All treatments except 50mg of GOL were associated with beneficial treatment effects relative to PBO with
the greatest effect being associated with ADA (–0.93, 95% CrI –1.59 to –0.25); however, only the effect
of ADA was statistically significant at a conventional 5% level. ADA was most likely to be the most
effective treatment (probability of being the best= 0.84).
Table 27 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 2 maintenance phase at 32–52 weeks starting in remission.
ADA was associated with the highest probability of staying in remission and the smallest probability of
moving from remission to response or no response at 32–52 weeks.
Sensitivity analysis 3: induction phase
Sensitivity analysis 3 involved replacing ULTRA2 anti-TNF-α-naive data with ULTRA2 ITT data and including
data from Suzuki et al.46 A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on
clinical response in the induction phase. Data were available from six studies comparing two treatments.44–47,49
Figure 58 presents the network of evidence for the sensitivity analysis 3 induction phase.
GOL
PBO
IFX
ADA
FIGURE 58 Sensitivity analysis 3: network of evidence for the induction phase. Note: solid line indicates a
two-arm trial.
TABLE 27 Sensitivity analysis 2: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.296 0.294 0.183 to 0.422 0.198 0.184 0.043 to 0.445 0.505 0.514 0.233 to 0.71
ADA 0.085 0.070 0.013 to 0.239 0.111 0.092 0.012 to 0.339 0.804 0.830 0.493 to 0.963
50mg of
GOL
0.320 0.307 0.083 to 0.633 0.188 0.176 0.035 to 0.425 0.492 0.494 0.137 to 0.83
100mg of
GOL
0.258 0.24 0.059 to 0.558 0.180 0.165 0.030 to 0.425 0.563 0.573 0.186 to 0.872
IFX 0.239 0.214 0.040 to 0.581 0.171 0.157 0.026 to 0.416 0.590 0.609 0.176 to 0.906
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Figure 59 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 3 induction phase. Figure 60 presents the probabilities of treatment rankings for this analysis.
The model fitted the data well, with the total residual deviance, 23.63, being close to the total number of
data points included in the analysis, 24. The between-study SD was estimated to be 0.09 (95% CrI 0.00 to
0.38), which implies mild heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with IFX (–0.91; 95% CrI –1.21 to –0.62). All the treatment effects were statistically
significant at a conventional 5% level. IFX was most likely to be the most effective treatment (probability of
being the best= 0.97).
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FIGURE 60 Sensitivity analysis 3: ranking probability histograms for the induction phase.
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FIGURE 59 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼HN(0,0.322)].
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Table 28 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 3 induction phase. IFX was associated with the highest probability
of moving from no response to response and no response to remission.
Sensitivity analysis 3: maintenance phase 8–32 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 8–32 weeks. Data
were available from five studies comparing two or three treatments.45,46,48,49 Figure 61 presents the network
of evidence for the sensitivity analysis 3 maintenance phase at 8–32 weeks for patients starting in response.
Figure 62 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 3 maintenance phase at 8–32 weeks for patients starting in response. Figure 63 presents the
probabilities of treatment rankings for this analysis. There was some suggestion that model did not
represent the data well with the total residual deviance, 14.05, being smaller than would be expected given
the total number of data points included in the analysis, 22. The probability of observing a value < 14.05 is
0.100, which means that this could have occurred by chance. Similar to the base-case analysis, all 5 studies
had smaller residual deviance than expected. The between-study SD was estimated to be 0.15 (95% CrI
0.01 to 0.55), which implies mild to moderate heterogeneity between studies in treatment effects.
50 mg of GOL
100 mg of GOL
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ADA
FIGURE 61 Sensitivity analysis 3: network of evidence for the maintenance phase at 8–32 weeks for patients
starting in response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
TABLE 28 Sensitivity analysis 3: probabilities of being in each category for the induction phase
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.649 0.650 0.596 to 0.699 0.258 0.258 0.222 to 0.294 0.093 0.092 0.064 to 0.128
ADA 0.521 0.519 0.414 to 0.632 0.317 0.319 0.257 to 0.367 0.162 0.160 0.095 to 0.241
GOL 0.458 0.456 0.315 to 0.610 0.336 0.339 0.267 to 0.387 0.205 0.201 0.106 to 0.331
IFX 0.301 0.264 0.196 to 0.419 0.358 0.360 0.304 to 0.408 0.340 0.338 0.222 to 0.477
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.30 (– 0.78 to 0.16)
– 0.31 (– 0.91 to 0.28)
– 0.41 (– 1.00 to 0.17)
– 0.24 (– 0.76 to 0.26)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.11 (– 0.86 to 0.67)
– 0.01 (– 0.77 to 0.76)
0.06 (– 0.64 to 0.78)
– 0.10 (– 0.69 to 0.46)
0.08 (– 0.73 to 0.86)
0.18 (– 0.62 to 0.97)
Treatment comparison (probit scale) Effect (95% CrI)
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FIGURE 62 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼HN(0,0.322)].
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FIGURE 63 Sensitivity analysis 3: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in response.
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All treatments were associated with beneficial treatment effects relative to PBO with the greatest effect
being associated with 100mg of GOL; however, none of the treatment effects was statistically significant
at a conventional 5% level. A treatment of 100mg of GOL was most likely to be the most effective
(probability of being the best= 0.40).
Table 29 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 3 maintenance phase at 8–32 weeks starting in response.
A treatment of 100mg of GOL was associated with the highest probability of moving from response to
remission and the smallest probability of moving from response to no response at 8–32 weeks.
The probabilities of staying in response were comparable among treatments.
Patients starting in remission
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
maintenance phase at 8–32 weeks for patients starting in remission. Data were available from five studies
comparing two or three treatments.45,46,48,49 Figure 64 presents the network of evidence for the sensitivity
analysis 3 maintenance phase at 8–32 weeks for patients starting in remission.
Figure 65 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 3 maintenance phase at 8–32 weeks for patients starting in remission. Figure 66 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 17.77, being close to the total number of data points included in the analysis, 22.
The between-study SD was estimated to be 0.16 (95% CrI 0.01 to 0.59), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments were associated with beneficial treatment effects relative to PBO with the greatest effects
being associated with 50mg of GOL (–0.62, 95% CrI –1.33 to 0.06) and 100mg of GOL (–0.61, 95% CrI
–1.29 to 0.07); however, none of the treatment effects was statistically significant at a conventional 5%
level. A treatment of 50mg and 100mg of GOL were most likely to be the most effective treatments
(probability of being the best= 0.46 and 0.44 respectively).
Table 30 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 3 maintenance phase at 8–32 weeks starting in remission.
A treatment of 50mg and 100mg of GOL were associated with the highest probability of staying in
remission and the smallest probability of moving from remission to no response and from remission to
response at 8–32 weeks.
TABLE 29 Sensitivity analysis 3: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.545 0.545 0.459 to 0.630 0.270 0.270 0.223 to 0.32 0.185 0.183 0.120 to 0.260
ADA 0.427 0.425 0.243 to 0.626 0.292 0.293 0.223 to 0.353 0.280 0.274 0.129 to 0.470
50mg of
GOL
0.425 0.422 0.202 to 0.669 0.289 0.290 0.204 to 0.354 0.287 0.276 0.107 to 0.523
100mg of
GOL
0.386 0.382 0.176 to 0.628 0.293 0.294 0.213 to 0.356 0.321 0.313 0.129 to 0.560
IFX 0.451 0.449 0.246 to 0.664 0.287 0.289 0.211 to 0.349 0.262 0.255 0.109 to 0.465
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.07 (– 0.71 to 0.53)
– 0.62 (– 1.33 to 0.06)
– 0.61 (– 1.29 to 0.07)
– 0.09 (– 0.71 to 0.55)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.54 (–1.44 to 0.40)
– 0.54 (– 1.48 to 0.39)
– 0.02 (– 0.89 to 0.87)
0.01 (– 0.65 to 0.70)
0.53 (– 0.39 to 1.48)
0.52 (– 0.40 to 1.45)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 65 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼HN(0,0.322)].
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FIGURE 64 Sensitivity analysis 3: network of evidence for maintenance phase at 8–32 weeks for patients starting in
remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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Sensitivity analysis 3: maintenance phase 32–52 weeks
Patients starting in response A NMA was used to compare the effects of ADA, GOL and IFX relative to
PBO on clinical response in the maintenance phase for patients starting in response at 32–52 weeks.
Data were available from four studies comparing two or three treatments.45,46,48,49 Figure 67 presents the
network of evidence for the sensitivity analysis 3 maintenance phase at 32–52 weeks for patients starting
in response.
Figure 68 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 3 maintenance phase 32–52 weeks for patients starting in response. Figure 69 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 15.21, being close to the total number of data points included in the analysis, 18.
The between-study SD was estimated to be 0.18 (95% CrI 0.01 to 0.64), which implies mild to moderate
heterogeneity between studies in treatment effects.
All treatments except 100mg of GOL were associated with beneficial treatment effects relative to PBO
with the greatest effect being associated with IFX (–0.38, 95% CrI –1.27 to 0.55). However, none of the
treatment effects was statistically significant at a conventional 5% level. IFX was most likely to be
the most effective treatment (probability of being the best= 0.55).
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FIGURE 66 Sensitivity analysis 3: ranking probability histograms for the maintenance phase at 8–32 weeks for
patients starting in remission.
TABLE 30 Sensitivity analysis 3: probabilities of being in each category for the maintenance phase at 8–32 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.389 0.386 0.240 to 0.556 0.185 0.180 0.102 to 0.291 0.426 0.425 0.242 to 0.613
ADA 0.367 0.358 0.132 to 0.649 0.177 0.172 0.086 to 0.286 0.456 0.452 0.183 to 0.751
50mg of
GOL
0.199 0.182 0.043 to 0.451 0.147 0.144 0.047 to 0.264 0.654 0.664 0.342 to 0.900
100mg of
GOL
0.202 0.184 0.046 to 0.465 0.148 0.144 0.049 to 0.270 0.650 0.663 0.332 to 0.890
IFX 0.363 0.352 0.130 to 0.655 0.176 0.172 0.084 to 0.284 0.461 0.461 0.178 to 0.753
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FIGURE 67 Sensitivity analysis 3: network of evidence for the maintenance phase at 32–52 weeks for patients
starting in response. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.10 (– 0.72 to 0.50)
– 0.14 (– 0.90 to 0.66)
0.23 (– 0.54 to 1.02)
– 0.38 (– 1.27 to 0.55)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.34 (–0.65 to 1.33)
– 0.03 (– 0.98 to 0.96)
– 0.28 (– 1.35 to 0.84)
0.37 (– 0.42 to 1.16)
– 0.25 (– 1.41 to 0.93)
– 0.62 (– 1.76 to 0.58)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 68 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼HN(0,0.322)].
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Table 31 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 3 maintenance phase at 32–52 weeks for patients starting in
response. IFX was associated with the highest probability of moving from response to remission, and the
smallest probability of moving from response to no response at 32–52 weeks. The probabilities of staying
in response were comparable among treatments at 32–52 weeks.
Patients starting in remission
A NMA was used to compare the effects of ADA, GOL and IFX relative to PBO on clinical response in the
maintenance phase at 32–52 weeks for patients starting in remission. Data were available from four
studies comparing two or three treatments.45,46,48,49 Figure 70 presents the network of evidence for the
sensitivity analysis 3 maintenance phase at 32–52 weeks for patients starting in remission.
Figure 71 presents the effects of each treatment relative to PBO on the probit scale for the sensitivity
analysis 3 maintenance phase at 32–52 weeks for patients starting in remission. Figure 72 presents the
probabilities of treatment rankings for this analysis. The model fitted the data reasonably well, with the
total residual deviance, 20.55, being close to the total number of data points included in the analysis, 18.
The between-study SD was estimated to be 0.18 (95% CrI 0.01 to 0.65), which implies mild to moderate
heterogeneity between studies in treatment effects.
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FIGURE 69 Sensitivity analysis 3: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in response.
TABLE 31 Sensitivity analysis 3: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in response
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.344 0.340 0.218 to 0.484 0.393 0.395 0.252 to 0.514 0.263 0.257 0.114 to 0.449
ADA 0.314 0.304 0.109 to 0.580 0.382 0.385 0.219 to 0.520 0.305 0.290 0.086 to 0.605
50mg of
GOL
0.309 0.293 0.081 to 0.625 0.374 0.380 0.191 to 0.514 0.317 0.302 0.067 to 0.661
100mg of
GOL
0.436 0.431 0.149 to 0.759 0.354 0.363 0.172 to 0.490 0.210 0.187 0.031 to 0.520
IFX 0.240 0.213 0.041 to 0.575 0.358 0.369 0.151 to 0.513 0.402 0.392 0.088 to 0.771
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FIGURE 70 Sensitivity analysis 3: network of evidence for the maintenance phase at 32–52 weeks for patients
starting in remission. Note: solid line indicates a two-arm trial; dashed line indicates a three-arm study.
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50 mg of GOL
100 mg of GOL
IFX
– 0.85 (– 1.49 to – 0.16)
0.02 (– 0.77 to 0.79)
– 0.18 (– 0.97 to 0.59)
– 0.20 (– 1.19 to 0.72)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.67 (–0.36 to 1.66)
0.86 (– 0.17 to 1.86)
0.64 (– 0.55 to 1.75)
– 0.19 (– 0.95 to 0.53)
– 0.21 (– 1.48 to 0.97)
– 0.03 (– 1.28 to 1.16)
Treatment comparison (probit scale) Effect (95% CrI)
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FIGURE 71 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼HN(0,0.322)].
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All treatments except 50mg of GOL were associated with beneficial treatment effects relative to PBO with
the greatest effect being associated with ADA (–0.85, 95% CrI –1.49 to –0.16); however, only the effect
of ADA was statistically significant at a conventional 5% level. ADA was most likely to be the most
effective treatment (probability of being the best= 0.80).
Table 32 presents the probabilities of achieving each of the following categories: no response, response
and remission for the sensitivity analysis 3 maintenance phase at 32–52 weeks for patients starting in
remission. ADA was associated with the highest probability of staying in remission and the smallest
probability of moving from remission to response or no response at 32–52 weeks.
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FIGURE 72 Sensitivity analysis 3: ranking probability histograms for the maintenance phase at 32–52 weeks for
patients starting in remission.
TABLE 32 Sensitivity analysis 3: probabilities of being in each category for the maintenance phase at 32–52 weeks
for patients starting in remission
Treatment
No response Response Remission
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
PBO 0.296 0.293 0.187 to 0.422 0.202 0.188 0.042 to 0.44 0.502 0.511 0.246 to 0.706
ADA 0.097 0.082 0.016 to 0.267 0.123 0.104 0.014 to 0.343 0.781 0.805 0.464 to 0.955
50mg of
GOL
0.313 0.299 0.083 to 0.625 0.191 0.178 0.036 to 0.423 0.496 0.501 0.144 to 0.821
100mg of
GOL
0.252 0.235 0.057 to 0.544 0.182 0.168 0.03 to 0.418 0.566 0.577 0.197 to 0.868
IFX 0.250 0.229 0.037 to 0.588 0.176 0.163 0.025 to 0.413 0.574 0.582 0.178 to 0.911
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Biosimilars to infliximab
As defined by the EMA, a biosimilar is a biological medicine developed with the aim of being similar to an
already existing biological medicine (or reference medicine).71 In this assessment, the reference medicine
is IFX. Two biosimilars to IFX were also considered within the scope of this assessment: Remsima and
Inflectra. The EMA has stated that a biosimilar and reference medicine may display differences owing to
their complex nature and methods of production and that, in the approval process, any differences need
to be demonstrated not to affect safety or effectiveness.71
A submission72 was made to NICE for consideration as part of the current assessment by the manufacturers
of Remsima. However, no sponsor submission was presented by Hospira, the manufacturers of Inflectra.
EPAR reports were available for both Remsima73 and Inflectra.74
In June 2013, the EMA CHMP recommended authorisation of Remsima and Inflectra as biosimilars to IFX,
reported to be the first authorisation in the European Union for a biosimilar monoclonal antibody. Both
Remsima and Inflectra were developed as the product CT-P13.
It was stated in the EPARs for Remsima and Inflectra that an extensive comparability exercise between
CT-P13 and Remicade was undertaken, which found the major characteristics and biological activities of
Remsima/Inflectra to be comparable with Remicade.
The clinical programme to evaluate CT-P13 was based on two main clinical trials:
l a pharmacokinetic equivalence study performed in adult patients with AS [Study CT-P13 1.1,
Programme evaLuating the Autoimmune disease iNvEstigational drug CT-P13 in ankylosing spondylitis
patients (PLANET-AS)]
l a therapeutic equivalence study of CT-P13 compared with Remicade in adult patients with active
rheumatoid arthritis [Study CT-P13 3.1, Programme evaLuating the Autoimmune disease iNvEstigational
drug CT-P13 in rheumatoid arthritis patients (PLANET-RA)].
Both studies were planned with a 1-year treatment duration and primary endpoints were evaluated at
30 weeks. Further efficacy and safety data up to 54 weeks were submitted during the EMA assessment.
A third study (CT-P13 1.2) was a small pilot study in RA patients with purpose of facilitating pivotal trial
(CT-P13 3.1) conduct.
Study CT-P13 1.1, PLANET-AS
PLANET-AS was a prospective Phase I, randomised double-blind multicentre study, in which 250 patients
were randomised (CT-P13 n= 125, Remicade n= 125). Patients received CT-P13 (5mg/kg) or Remicade
(5mg/kg) at weeks 0, 2 and 6 and then every 8 weeks to week 54. The primary objective of the study was
to demonstrate comparable pharmacokinetics of CT-P13 and Remicade at steady state (between weeks 22
and 30). The primary parameters evaluated were the area under the plasma concentration time curve from
time zero to time t (AUCT) and maximum serum concentrations (Cmax) after dose 5 (weeks 22–30), with
secondary parameters being average concentration at steady state (Cav, ss), minimum concentration
immediately before next dose at steady state (Cmin ss), terminal elimination half-life (T1/2), total-body
clearance at steady state (CLss) and volume of distribution at steady state (Vss). Additional observed
parameters were maximum serum concentrations (Cmax), minimum concentration immediately before next
dose (Cmin) and time to reach maximum serum concentrations Cmax (Tmax) after each dose. Efficacy
parameters included the proportion of patients achieving clinical response according to the assessment in
AS response criteria (ASAS20 and ASAS40). The EPARs reported that PLANET-AS demonstrated that (at
5mg/kg) pharmacokinetic behaviour between CT-P13 and Remicade was similar, a view that was also
supported by pharmacokinetic data from RA patients in study CT-P13 3.1 (PLANET-RA). Furthermore, the
EPARs also stated that the proportions of patients experiencing clinical response according to the ASAS20
and ASAS40 criteria at weeks 14 and 30 were similar across the CT-P13 and Remicade groups.
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Study CT-P13 3.1, PLANET-RA
PLANET-RA was a prospective Phase III, randomised, double-blind, multicentre study, in which 302 patients
were randomised to CT-P13 and 304 to Remicade (randomisation was stratified by geographical region
and baseline CRP level). Patients received CT-P13 or Remicade at 3mg/kg at weeks 0, 2, 6 and then every
8 weeks up to 54 weeks (administered in combination with a stable dose of methotrexate and folic acid).
The primary objective of the trial was to demonstrate that CT-P13 was equivalent to Remicade up to
week 30 in efficacy as measured by ACR20. Secondary objectives were ACR20, ACR50 and ACR70
responses at weeks 14 and 30, Disease Activity Score 28 at weeks 14 and 30, European League Against
Rheumatism response at weeks 14 and 30, Simplified Disease Activity Index (SDAI) and Clinical Disease
Activity Index at weeks 14 and 30 and SF-36 at weeks 14 and 30.
Fewer patients randomised to the CT-P13 arm (n= 69, 22.8%) discontinued PLANET-RA by week 54 than
patients in Remicade arm (n= 82, 27.0%). Patients received CT-P13 and Remicade at the RA dose of
3mg/kg. It was stated in the EPARs that a similar proportion of patients at week 30 in the CT-P13
(184/302, 60.9%) and Remicade (178/304, 58.6%) arms achieved ACR20 response (Table 33).
Furthermore, at week 30, the findings for the secondary end points (including ACR50, ACR70 and
decrease in Disease Activity Score 28) were also described as being consistent with the results of the
primary end point. Efficacy results were reported to be comparable between treatment arms up to
week 54. It was concluded in the EPAR that PLANET-RA provided that robust evidence of therapeutic
equivalence between CT-P13 and Remicade. ACR responses between CT-P13 and Remicade remained
comparable through the 12-month PLANET-RA extension study.73
The safety profile of CT-P13 was evaluated in the clinical studies described above. A total of 871 patients
were included in the safety population. It was reported in the EPARs that the type and incidence of
adverse drug reactions with CT-P13 and Remicade were broadly similar and that no new safety concern
was identified. Additionally, it was stated that no marked differences in immunogenicity between CT-P13
and Remicade were observed up to 54 weeks, with comparable effects of antibodies on efficacy and
safety. Although there was a numerical imbalance described in SAEs observed in study CT-P13 3.1
(PLANET-RA) (with a higher number of serious infections), reported numbers were stated to be low and,
therefore, the CHMP concluded that this observed difference was likely to be due to chance.
In summary, the EMA considered CT-P13 to be biosimilar to the reference product Remicade and judged
that the submitted data in the submissions for Remsima and Inflectra allowed for extrapolation to all other
indications of Remicade.
TABLE 33 The ACR20/50/70 responders at week 30 in PLANET-RA (all randomised population)
Treatment arm n/N (%) Estimate of treatment difference 95% CI of treatment difference
ACR20: CT-P13 184/302 (60.9) 0.02 –0.06 to 0.10
ACR20: Remicade 178/304 (58.6)
ACR50: CT-P13 105/248 (42.3) 0.02 –0.07 to 0.10
ACR50: Remicade 102/251 (40.6)
ACR70: CT-P13 50/248 (20.2) 0.02 –0.05 to 0.09
ACR70: Remicade 45/251 (17.9)
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An ECCO position statement was presented by Danese and Gomollon75 stating that the use of biosimilars
in patients with IBD requires clinical trials in the IBD patient population to allow comparison between the
biosimilar and reference products, on the basis of potential differences in manufacturing and structure that
could lead to important differences in immunogenicity and efficacy. However, a subsequent statement
issued on behalf of the Working Party on Similar Biological (Biosimilar) Medicinal Products of the CHMP
argued that no pharmacokinetic and safety issues are known to be particular to IBD, the most responsive
known population (RA) was assessed for immunogenicity and that the data submitted allow extrapolation
to patients with IBD.76
Discussion
A total of 10 RCTs were identified in the clinical effectiveness systematic review, of which nine44–51 related
to adults and one52 was conducted in a paediatric population. All of the adult RCTs were performed
against PBO (with the exception of UC-SUCCESS51) and were a maximum of 1 year in study duration.
No head-to-head RCTs were identified in which interventions of interest were assessed against each other.
The risks of bias associated with included RCTs were assessed using the Cochrane risk-of-bias instrument.
Only three RCTs could be considered as being at overall low risk of bias as allocation concealment, blinded
outcome assessment and completeness of outcome data were all judged as low risk. It should be noted
that one of the maintenance trials (PURSUIT-Maintenance48) rerandomised patients who had previously
responded to GOL induction therapy in two previous trials; the extent of this potential bias on patient
outcomes is unclear.
The outcome measures pre-specified in the final NICE scope were all addressed by the included trial
evidence, with the exception of rates of relapse. Clinical response and remission data based on complete
Mayo scores were well reported across trials. Evidence was identified to demonstrate that patients
receiving IFX, ADA or GOL were more likely than patients receiving PBO to achieve clinical response and
remission at induction and maintenance time points. Patients in the UC-SUCCESS51 trial who received
combination treatment with IFX and AZA experienced the most favourable rates of steroid-free remission
compared with IFX and AZA treatment groups. Seven RCTs performed in adult populations contributed
data on clinical response and remission at induction or maintenance time points to NMAs.
Based on the NMA, in the induction phase, all treatments were associated with statistically significant
beneficial effects relative to PBO with the greatest effect being associated with IFX. IFX was also associated
with the highest probability of moving from no response to response and from no response to remission.
The effects of ADA and GOL on these two probabilities were broadly comparable.
For patients classified as responders at the end of the induction phase, treatment effects were not
statistically significant, although the greatest effect was associated with 100mg of GOL at 8–32 weeks.
A treatment of 100mg of GOL was associated with the highest probability of moving from response to
remission and staying in response and the smallest probability of moving from response to no response.
However, at 32–52 weeks, only IFX and 50mg of GOL were associated with beneficial effects on clinical
response, although the effects were not statistically significant. IFX was associated with the highest
probability of moving from response to remission and staying in response and the smallest probability of
moving from response to no response at 32–52 weeks. The probabilities of staying in response were
comparable among treatments at both 8–32 weeks and 32–52 weeks.
For patients classified as being in remission at the end of the induction phase, all treatments except for
ADA were associated with beneficial treatment effects relative to PBO with the greatest effect being
associated with 50mg and 100mg of GOL, although the effects were not statistically significant at
8–32 weeks. A treatment of 50mg and 100mg of GOL were associated with the highest probability of
staying in remission and the smallest probability of moving from remission to response and from remission
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to no response. At 32–52 weeks, all treatments except 50mg of GOL were associated with beneficial
treatment effects relative to PBO, with the greatest effect being associated with ADA (the only treatment
with statistically significant effect). ADA was associated with the highest probability of staying in remission
and the smallest probability of moving from remission to response and from remission to no response.
Sensitivity analyses were conducted by replacing ULTRA2 anti-TNF-α-naive data with ULTRA2 ITT data
(sensitivity analysis 1), including Suzuki et al.46 (sensitivity analysis 2), and replacing ULTRA2 anti-TNF-α-naive
data with ULTRA2 ITT data plus including Suzuki et al.46 (sensitivity analysis 3). The results suggested that
when ULTRA2 ITT data were replaced by ULTRA2 anti-TNF-α-naive data for patients starting in remission
at 8–32 weeks and in response at 32–52 weeks, the estimate of the effect of ADA on clinical response
changed from being slightly worse than PBO to being slightly better than PBO. However, the estimates were
associated with considerable uncertainty.
Available data on hospitalisation outcomes were very limited, but suggested that outcomes may be more
favourable for ADA-treated and IFX-treated patients than PBO-treated patients (with no data available
from GOL trials). Data on surgical intervention were also very sparse, with a potential inconclusive benefit
for intervention-treated patients compared with PBO. No trials reported whether surgical outcomes
were elective or emergency in nature; however, more data are required to demonstrate the impact of
interventions on hospitalisation and surgical intervention more conclusively. Data were available from a
single trial to support the use of IFX in induction and maintenance treatment in a paediatric population.
The main safety issues highlighted in the RCT evidence appeared to be generally consistent with those
previously discussed in the respective SmPCs (including serious infections, malignancies and administration
site reactions). Deaths occurring during and after the study period were described in some trials evaluating
GOL (PURSUIT-Maintenance48) and IFX (ACTs49), of which infection or malignancy were most commonly
implicated. This underlines the importance of monitoring and treating serious infections and malignancies
in patients receiving immunosuppressive treatment.
The trials included in the clinical effectiveness systematic review typically excluded patients with ulcerative
proctitis, patients with fulminant/acute severe disease, those with a history of or at imminent risk of bowel
surgery, pregnant or lactating women, and patients with diseases of the central nervous system (e.g.
demyelinating disease). Furthermore, patients with history of serious infection and immunodeficiency were
also typically excluded, as were individuals with a history of malignancy or signs of dysplasia. Therefore,
the effects of ADA, GOL or IFX in these UC populations are unknown.
Two biosimilars (Remsima and Inflectra) to Remicade were considered as part of the evidence base for IFX
as part of this assessment. The sponsor submission received from the manufacturers of Remsima and the
EPAR reports for Remsima and Inflectra indicated that both biosimilars were approved by the EMA on the
basis of reported similar pharmacokinetic and efficacy (demonstrated in AS and RA patients) profiles to
Remicade. No further trials of Remsima or Inflectra were identified in the course of this assessment.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
Methods
Identification of studies
A comprehensive search was undertaken to systematically identify literature relating to the
cost-effectiveness of IFX, ADA and GOL for treating moderate to severe UC after the failure of
conventional therapy. The search strategy comprised the following main elements:
l searching of electronic databases
l contact with experts in the field
l hand-searching of bibliographies of retrieved papers.
The following electronic databases were searched from inception for economic evaluations:
l MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations: via Ovid – 1946 to January 2014.
l EMBASE: via Ovid – 1974 to January 2014.
l Cochrane Library: via Wiley Interscience
¢ CDSR – 1996 to January 2014
¢ DARE – 1995 to January 2014
¢ CCRT – 1995 to January 2014
¢ Cochrane Methodology Register – 1904 to January 2014
¢ HTA database – 1995 to January 2014
¢ NHS EED – 1995 to January 2014.
l CINAHL: via EBSCOhost – 1982 to January 2014.
l Web of Science Citation Index: via Web of Knowledge – 1900 to January 2014.
l Conference Proceedings Citation Index: via Web of Knowledge – 1990 to January 2014.
l BIOSIS Previews: via Web of Knowledge – 1969 to January 2014.
l EconLit: via Ovid – 1886 to January 2014.
The MEDLINE search strategy is presented in Appendix 9. The search strategy combined free text and
MeSH or thesaurus terms relating to ulcerative colitis, with free text and MeSH or thesaurus terms relating
to infliximab, adalimumab and golimumab combined with highly sensitive economic filters to retrieve
economic evaluations. The search strategy was translated across all databases. No date or language
restrictions were applied. Literature searches were conducted during January 2014. References were
collected in a bibliographic management database and duplicates were removed.
Inclusion/exclusion criteria
Studies were included in the systematic review if they reported full economic evaluations comparing IFX,
ADA and/or GOL, against each other or against any other intervention, within their licensed indications for
the treatment of patients with moderate to severe UC. The inclusion and exclusion criteria applied within
the systematic review are presented in Box 1. Studies were included only if they were reported as full
papers; conference abstracts were excluded from the review as they present insufficient detail to allow for
a rigorous assessment of study quality.
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Review methods
The results of the economic searches were sifted by title and abstract. The full papers of studies that
potentially met the inclusion criteria were retrieved for further inspection. Studies included in the
systematic review were critically appraised using the Drummond checklist for economic evaluations.77 In
addition, the manufacturers of the products considered within this appraisal submitted economic evidence
to NICE; these models were assessed in terms of the extent to which they meet the NICE reference case.78
The structure and formulae included in the manufacturers’ submission models were scrutinised by two
members of the Assessment Group (PT and HB). It should be noted that this appraisal includes an update
of Technology Appraisal Guidance 140;79 the economic evaluation reported within the 2007 Schering
Plough submission to NICE80 is not included in this review as it has previously been critiqued for NICE;81
however, one of the studies included in the review82 reports an analysis of this model.
Results
The systematic searches identified a total of 907 potentially relevant citations (Table 34 and Figure 73). In
addition, 4 manufacturers’ submissions were received by NICE.62,64,66,72 Two of the four submissions were
submitted by the same manufacturer – one relating to GOL and one relating to IFX; as these relate to
TABLE 34 Summary of search results for existing economic evaluations
Database Date range Date searched Number of results
MEDLINE (via Ovid) 1946 to January 2014 15 January 2014 96
EMBASE (via Ovid) 1974 to January 2014 15 January 2014 372
CINAHL (via EBSCOhost) 1982 to January 2014 22 January 2014 23
Science Citation Index and Social Science
Citation Index (via Web of Knowledge)
1900 to January 2014 22 January 2014 243
BIOSIS (via Web of Knowledge) 1969 to January 2014 22 January 2014 186
Cochrane HTA (via Wiley) 1991 to January 2014 21 January 2014 30
Cochrane DARE (via Wiley) 1991 to January 2014 21 January 2014 28
Cochrane EED (via Wiley) 1991 to January 2014 21 January 2014 24
EconLit (via Ovid) 1886 to January 2014 15 January 2014 1
BOX 1 Inclusion and exclusion criteria for review of cost-effectiveness studies
Inclusion criteria
l Full economic evaluations comparing IFX, ADA and/or GOL against each other or any other intervention for
the treatment of patients with moderate to severe UC.
Exclusion criteria
l Studies assessing biologicals in the acute setting (e.g. management of UC exacerbations).
l Studies in which the same biological is used in all treatment groups within the analysis.
l Non-comparative studies and partial economic evaluations (e.g. costing studies).
l Abstracts, letters and commentaries.
l Studies not reported in English.
l Studies relating to patients with diseases other than UC.
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virtually identical models, they are considered as a single analysis within this assessment.64,66 Three of the
manufacturer’s submissions to NICE62,64,66 included economic analyses; the submission from Celltrion72 did
not include any economic analysis. Fourteen studies were excluded as they were available only in abstract
form. A total of three published studies and three manufacturers’ submissions reported economic analyses
relating to the use of biologicals for the treatment of moderate to severe UC (Table 35).
Review of published economic evaluations presents a summary and critical appraisal of the three published
economic studies included in this review.82–84 Cost-effectiveness evaluation of golimumab (with Patient
Access Scheme), infliximab and adalimumab relative to colectomy for moderate to severe ulcerative colitis
in the UK (MSD submissions64,66) and Adalimumab, golimumab and infliximab, for the treatment of
ulcerative colitis (subacute) – AbbVie submission62 present critical reviews of the individual manufacturers’
submissions from AbbVie and MSD, respectively.62,64,66
Review of published economic evaluations
Park et al.83
Park et al.83 report the methods and results of an economic analysis of early colectomy plus ileal pouch
anal anastomosis (IPAA) versus standard medical therapy in patients with severe UC in the USA. The model
population is intended to reflect 21-year old patients with newly diagnosed pancolitis UC confirmed by
colonoscopic biopsies. The economic analysis compares two sequences of treatments: (1) immediate
colectomy with IPAA; and (2) standard medical therapy, which is assumed to comprise a sequence of
(i) 2 g of mesalamine per day; (ii) 125mg of AZA per day; (iii) 5 mg/kg/dose of IFX every 8 weeks;
(iv) 1.5 mg of tacrolimus b.i.d.; and (v) colectomy+ IPAA. The analysis does not consider the comparative
cost-effectiveness of alternative sequences of medical treatments. The authors purport to have adopted a
societal perspective; however, it does not appear that any indirect costs borne outside the health sector
(e.g. lost productivity or out-of-pocket expenses) have been included in the economic analysis. It would be
Manufacturers’ submissions
received by NICE
(n = 4)
Studies identified by
systematic searches sifted
by title and abstract
(n = 907)
Studies excluded
(n = 900)
Submissions including
economic analysis
(n = 3)
Full texts of studies
obtained
(n = 8)
Studies excluded
(n = 5)
Published studies included
in systematic review
(n = 3)
Studies included in
final review
(n = 6)
(3 published studies,
3 submissions)
FIGURE 73 Study selection results for review of economic evaluations.
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more accurate to describe the adopted perspective as that of the health-care payer. Health economic
results are presented in terms of the incremental cost per quality-adjusted life-year (QALY) gained over a
lifetime horizon. In line with the reference case set out in Gold et al.,85 costs and health outcomes were
discounted at a rate of 3% per year. Costs were valued at 2009 prices.
The economic analysis uses a Markov approach to evaluate relevant events, costs and health outcomes.
The duration of each Markov cycle is not entirely clear from the paper;83 the text indicates that the first
cycle is 3 months in duration and the cycle length appears to be 8 weekly thereafter. However, the table
of parameter values presented within the paper suggests that probability parameters are defined according
to various time intervals. In addition, the text does not mention whether or not a half-cycle correction has
been applied. The precise health states adopted in the model are also not entirely clear from the text;
while a model diagram is presented in the paper, this details the sequences of treatments in each group
but does not specify the relevant clinical events that patients may experience. It appears that separate
states are assigned for patients who are on treatment, in remission, experiencing UC flare, postcolectomy
and experiencing death. With respect to medical treatment, the model appears to separate response and
remission based on the Simple Colitis Activity Index (SCAI) score.86 The model also includes the possibility
of patients developing colorectal cancer, which is assumed to result in colectomy. It appears that the
model does not include an excess risk of death due to colorectal cancer. Patients enter the model at the
point of being hospitalised during their initial flare definitively diagnosing them of pancolitis UC through
endoscopic biopsies. Although this may indicate a more severe population than that stated within the
scope of this appraisal, the model uses RCT evidence from studies that relate to a moderate to severe UC
population49 and assumes that the flare is resolvable without surgery. Following diagnosis, patients are
then assumed to receive i.v. methylprednisolone and subsequently mesalamine as maintenance therapy
once they are able to tolerate oral medicines. Patients progress along the treatment pathway to IFX,
tacrolimus and potentially colectomy+ IPAA if remission is not achieved. Patients in the intervention group
within the model bypass all medical treatments and immediately undergo surgery. Different cost and
HRQoL estimates are applied to each health state.
TABLE 35 Summary table of included published studies
Study
Year of
publication Perspective Economic comparisons
Outcome
measure
Time
horizon Conflicts of interest
Included published economic evaluations
Park et al.83 2012 USA (payer) Colectomy+ IPAA vs.
standard medical care
(including IFX)
QALYs Lifetime Non-commercial
Tsai et al.82 2008 UK NHS IFX vs. standard care QALYs 10 years Study funded by
Schering-Plough
Xie et al.84 2009 Canadian
(public payer)
IFX vs. usual care QALYs 5 years Three out of six authors
disclosed a conflict of
interest
Included manufacturers’ submissions
AbbVie
submission62
N/A UK NHS ADA vs. conventional
non-biological treatment
QALYs 10 years Manufacturer of ADA
(AbbVie)
MSD
submission64,66
N/A UK NHS Pairwise comparisons of
IFX, GOL, ADA and
immediate colectomy
QALYs 10 years Manufacturer of IFX
and GOL (MSD)
IPAA, Ileal pouch anal anastomosis; N/A, not applicable; QALY, quality-adjusted life-year.
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Treatment benefits are defined differently for surgery and medical treatment. For the standard medical
therapy group, treatment benefits are characterised as response, remission and UC flare rates. For the
surgery group, treatment benefits are determined according to colectomy success rates, the avoidance
of AEs (pouchitis and infertility), the requirement for antibiotics, and remission rates for antibiotics.
Effectiveness data were drawn from a number of sources including RCTs and non-randomised
studies.49,87–99 The effectiveness of IFX in inducing and maintaining response and remission was based on
the results of the ACT1 and ACT2 studies.49 The rate of developing colorectal cancer was derived from an
observational study.100 The approach for determining the effectiveness of medical and surgical treatment
options is essentially a naive indirect comparison and, as such, the results of the analysis should be
interpreted with a degree of caution.
Health utilities were assigned for the following events and states: UC flare (0.48), remission (0.91),
post-colectomy (0.87), and infertility following IPAA (0.74). Health utilities were drawn from a variety of
sources.101–104 The elicitation methods from which these estimates were derived were not consistently clear.
Although several studies used the time trade-off (TTO) method, the study reportedly used to derive a
disutility for female infertility is not a quality-of-life valuation study and actually relates to the medical costs
of epididymitis and orchitis in men;104 it is unclear how the information contained within this paper has
been used to inform the economic analysis.
The model includes resource costs associated with diagnosis of pancolitis UC, drug therapy,
colectomy+ IPAA, managing pouchitis and the diagnosis of colorectal cancer. The costs associated with
hospitalisations, outpatient visits, procedures and laboratory costs were estimated using national
reimbursements from the Centers for Medicare and Medicaid Services and average reimbursement rates
from all patient billing records in 2009 at Stanford University Medical Center. The Office of Statewide
Health Planning and Development tables were used to validate institutional rates with the intention of
reflecting national average cost estimates. Wholesale costs of medical therapies were estimated by prices
from online pharmacies and were validated against the drug costs at Lucile Packard Children’s
Hospital pharmacy.
The analysis includes deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA). Results are
presented as mean costs and QALYs, incremental cost-effectiveness ratios (ICERs), one-way deterministic
sensitivity analyses and summary results of the probability of achieving the greatest net benefit at a given
willingness-to-pay threshold.
Table 36 presents the headline results of the economic analysis. The analysis indicates that standard
medical treatment produces more health (0.06 QALYs) at a considerably greater cost than
colectomy+ IPAA (US$88,607). The incremental cost-effectiveness of standard medical treatment
versus colectomy+ IPAA is estimated to be US$1,476,783 per QALY gained.
TABLE 36 Headline cost-effectiveness results presented by Park et al.83
Strategy QALYs (95% CI) Costs (95% CI)
Incremental
QALYs (95% CI)
Incremental
costs (95% CI) ICER (95% CI)
Colectomy+ IPAA 20.72
(17.53 to 22.76)
US$147,763
(US$137,013 to
US$158,904)
– – US$1,476,783
(dominated to
US$3,281,923)
Standard medical
treatment
20.78
(18.45 to 22.37)
US$236,370
(US$219,057 to
US$255,328)
0.06
(–0.72 to 1.03)
US$88,607
(US$73,726 to
US$105,865)
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Assuming a willingness-to-pay threshold of US$50,000 per QALY gained, the probability that
colectomy+ IPAA produces the greatest net benefit is approximately 1.0. Assuming a willingness-to-pay
threshold of US$100,000 per QALY gained, the probability that colectomy+ IPAA produces the greatest
net benefit is approximately 0.96. The sensitivity analysis indicates that the utility of the cure state after
receiving colectomy+ IPAA was the only variable which reduced the ICER to below US$100,000 per QALY
gained. The authors state that the level of HRQoL for patients with UC would need to be very low in order
for exhaustive medical therapy in severe UC to be cost-effective.
The Park et al.83 study clearly addresses the question of whether or not colectomy+ IPAA is cost-effective
in comparison with medical management over a lifetime horizon. However, the description of the
mathematical model is unclear, hence the assumptions underpinning the analysis are not transparent and
their credibility is difficult to judge. The population reflected in the economic analysis is only partially
relevant to the scope of this appraisal as the patients considered within the model are by definition
hospitalised for UC flare. However, the model also appears to assume that the flare can be resolved;
hence, patients may go on to receive biological therapy in a non-acute setting. Given the absence of
head-to-head trials comparing medical and surgical management options, the need for an indirect
comparison is inevitable and may lead to bias in the model results. It is also noteworthy that the study
relates to a US setting and, therefore, its relevance to UK clinical practice may be questionable.
Tsai et al.82
Tsai et al.82 report the methods and results of an economic analysis that compares two IFX-based strategies
with standard care in patients with moderate to severe UC from the perspective of the UK NHS. The model
structure and parameter values appear to be very similar to the economic analysis submitted to NICE
to inform technology appraisal TA140,28 although it should be noted that the total cost estimates for each
group reported by Tsai et al.82 differ to those reported within the manufacturers’ submission.80 Patients
within the model were assumed to have a mean body weight of 73.1 kg. The base-case scenario
evaluated a treatment strategy of 5 mg/kg of IFX every 8 weeks only for patients achieving response
while a secondary analysis evaluated 5mg/kg of IFX every 8 weeks for patients achieving and maintaining
remission following induction. Standard care was assumed to include colectomy+ IPAA and other
medications (5-ASAs, corticosteroids and immunosuppressants). Cost-effectiveness was assessed in terms
of the incremental cost per QALY gained over a 10-year time horizon for each comparison of IFX versus
standard care. A fully incremental analysis was not undertaken between the two responder/remission
stopping rule treatment approaches. The perspective adopted was that of the NHS. Costs borne by
Personal Social Services (PSS) were not included in the model. The authors note that although productivity
costs are substantial for patients with UC, these were not included in the economic analysis. Costs and
health outcomes were discounted at a rate of 3.5% per year. Costs were valued at 2006–7 prices.
The economic evaluation takes the form of a Markov model, as shown in Figure 74. The model
appears to include eleven health states: (1) mild (responders); (2) moderate-severe (responders);
(3) remission (responders); (4) mild (non-responders); (5) moderate-severe (non-responders); (6) remission
(non-responders); (7) temporary discontinuers; (8) surgery (tunnel state); (9) post-surgery remission;
(10) post-surgery complications; and (11) death. The cycle length used within the model was specified
according to the time intervals of the assessment visits in the ACT1 and ACT2 studies.49 The first cycle was
8 weeks in duration, followed by 6 weeks in cycle 2, followed by 8 weeks for all subsequent cycles.
It should be noted that within the ACT trials, the assessments at these time points were based on partial
Mayo scores and may not correspond to full Mayo scores (the latter of which includes endoscopic
visualisation).105 The paper does not mention whether a half-cycle correction was applied to account for
the timing of events within the model.
All patients enter the model in the moderate to severe health state. At the end of each cycle, patients
achieving a Mayo score of 0–2 and 3–5 transit to the remission state and mild health state, respectively,
and continue to receive the same treatment. Patients who do not achieve remission or response are
classified as non-responders. A ‘temporary discontinuers’ state is included for patients experiencing
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temporary AEs, which is a tunnel state which is applied for one 8-week cycle. After resolution of AEs,
these patients return to their prior health state. Non-responders and patients permanently discontinuing
active treatment (e.g. owing to AEs) transit to the corresponding non-responder states and cannot restart
IFX treatment. Patients in the moderate to severe states can undergo surgery, which may result in
complications. Different costs and utilities are applied to each health state. The model does not include any
survival difference between the competing treatments hence the differences in QALYs are driven entirely
by differences in sojourn time in each health state.
Transition probabilities in each group were estimated using data from the ACT1 and ACT2 studies.49
No details are provided within the paper with respect to how these studies were pooled. Transition
probabilities for patients in the responder states for IFX and standard care were drawn from the treatment
and PBO arms of these trials, respectively. Transition probabilities for non-responders for both groups were
drawn from PBO arms of the ACT studies.49 As ACT1 employed a longer study duration than ACT2, the
former trial alone was used to estimate transition probabilities beyond 30 weeks. The ACT1 and ACT2
studies were also used to estimate the probabilities of temporary discontinuation based on the observed
AE rates. Transition probabilities for patients undergoing surgery were derived from the literature.106–108
None of the transition probabilities applied within the model are reported in the paper.
Health-related quality-of-life values are assigned for remission (0.88), mild (0.76), moderate-severe (0.42),
temporary discontinuers (0.42), surgery (0.61), post-surgery remission (0.61), post-surgery complications
(0.55). Utility values for UC states are stated to have been drawn from an EQ-5D survey of UC patients;
however, this appears to be misreferenced as the publication title relates to resource use in patients with
CD.109 Health utility values for patients who were temporary discontinuers and for those with post-surgical
complications were drawn from Arseneau et al.110 The text states that these utilities were indexed to the
Woehl utility set to avoid any implausible results using regression analysis. No further details are provided
regarding this regression analysis.
The model includes treatment- and state-specific costs associated with drug acquisition and administration,
consultant visits, hospitalisations, blood tests and endoscopy. The sources used to value the costs of drug
acquisition and administration are unclear. The model includes the costs of concomitant medications based
Remission Mild
Moderate-severe Moderate-severe
Postsurgery
remission
Postsurgery
complications
Treatment responders
(Infliximab/Standard care)
Remission Mild
Treatment nonresponders
Standard care
Surgery
Temporary
discontinuers
IFX nonresponders
Discontinuation
due to AEs
FIGURE 74 Model diagram presented by Tsai et al.82 Reproduced with permission from Tsai HH, Punekar YS, Morris J,
Fortun P, A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for
moderate-to-severe ulcerative colitis, Aliment Pharmacol Ther 2008;28:1230–9, © 2008 The Authors. Journal
compilation © 2008 Blackwell Publishing Ltd.
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on the baseline characteristics of patients in the ACT1 and ACT2 studies,49 and assumes that the use of
immunosuppressants and 5-ASAs remain constant while corticosteroid use declines linearly over time for
patients responding and achieving remission. The costs associated with non-SAEs were calculated
separately but are not detailed. The costs associated with severe AEs were assumed to be subsumed within
the costs of hospitalisation. The costs of colectomy+ IPAA were based on NHS Reference Costs.111
Hospitalisation rates for the IFX and standard care groups were based on the ACT1 and ACT2 trials49 and
were valued using NHS Reference Costs. In addition, health-care resource use associated with pre-surgical
UC states was estimated from a panel of six UK gastroenterologists; these resource-use estimates were
valued using national published cost estimates.
The model results are presented as mean costs and QALYs for each treatment group. The economic
analysis includes one-way deterministic sensitivity analysis and PSA. Decision uncertainty is represented
using cost-effectiveness planes.
Table 37 presents the results of the economic analysis. Within the base-case analysis, in which medical
treatment is assumed to be continued only for those patients in whom response is achieved, IFX is
estimated to produce an additional 0.75 QALYs at an additional cost of £20,662, which corresponds to an
ICER of £27,424 per QALY gained. Within the secondary analysis, in which patients are assumed to
continue treatment only if they achieve and maintain remission, IFX is estimated to produce an additional
0.39 QALYs at an additional cost of £7615, which corresponds to an ICER of £19,696 per QALY gained.
It should be noted that the estimates of absolute costs and absolute QALYs for the standard care group
differ between the two analyses. Although the alternative treatment stopping rules clearly influence which
patients continue to receive IFX and the duration over which patients would receive biological therapy, it is
unclear why this would affect outcomes for the standard care group.
In the responders sensitivity analysis, the ICER ranged from £21,066 per QALY gained (lower patient
weight) to £86,320 per QALY gained (1-year time horizon). The results of all other deterministic sensitivity
analyses in the responder comparison produced an ICER below £32,000 per QALY gained. In the more
stringent remission only analysis, the deterministic sensitivity analyses produced ICERs in the range £14,728
per QALY gained (lower patient weight) to £46,765 per QALY gained (1-year time horizon). The results
of all other deterministic sensitivity analyses in the remission only comparison produced ICERs below
£23,000 per QALY gained. The results of the probabilistic analysis are presented in the form of
cost-effectiveness planes. The authors state that ‘The PSA showed that the results were robust with [the]
majority of simulations clustered together. In both responder and remission treatment strategies, IFX SMT
resulted in additional QALYs at an additional cost compared to standard care.’82 The probabilistic results
for the remission only scenario appear somewhat dubious as the samples appear to be truncated at the
y-axis of the cost-effectiveness plane (the estimates of incremental QALYs for IFX vs. standard care cannot
drop below zero). The underlying reason for this within the model is unclear.
TABLE 37 Headline cost-effectiveness results presented by Tsai et al.82
Strategy QALYs Costs Incremental QALYs Incremental costs ICER
Base-case scenario (responders only)
IFX 4.591 £66,460 0.75 £20,662 £27,424
Standard care 3.838 £45,798 – –
Secondary analysis (remission only)
IFX 4.154 £53,874 0.39 £7615 £19,696
Standard care 3.767 £46,259 – –
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As noted earlier, the Tsai et al.82 analysis appears to be based on the same model submitted to NICE as
part of TA140 (not reviewed here).28 While the QALY estimates reported within Tsai et al.82 are virtually the
same as those reported within the manufacturers’ submission to NICE,80 the incremental costs reported
by Tsai et al.82 are lower than those contained within the manufacturers’ submission. Consequently, the
ICERs presented by Tsai et al.82 are lower than those reported within the NICE submission (responders only
analysis ICER= £27,424 per QALY gained82 vs. £33,866 per QALY gained;80 remission only analysis
£19,696 per QALY gained82 vs. £25,044 per QALY gained80).
Overall, the Tsai et al.82 model appears to follow a plausible model structure and includes the majority
of costs and outcomes relevant to the decision problem. It is also noteworthy that this is the only published
UK analysis included in this review. In general, the paper performs well against the Drummond checklist.
The two notable issues relate to the absence of other biological therapies (this is reasonable as GOL and
ADA did not have a UK marketing authorisation at the time of publication) and immediate colectomy
as comparators and the use of a short time horizon.
Xie et al.84
Xie et al.84 report a cost-effectiveness analysis comparing IFX plus ADA versus usual care in patients with
moderate to severe refractory UC in Canada. Patients were assumed to be 40 years of age with a mean
body weight of 80 kg. The model adopts a Markov approach and costs and outcomes are evaluated over a
5-year time horizon. Three options were compared within the economic analysis: (1) ‘strategy A’ – ‘usual
care’, which includes conventional medical treatment (5-ASAs plus immunosuppressants) without
anti-TNF-α drugs; (2) ‘strategy B’ – ‘5mg/kg of IFX plus ADA initial and maintenance therapy’, which
includes 5mg/kg of IFX followed by a switch to ADA if there is no response to initial therapy or if response
is lost during maintenance therapy; and (3) ‘strategy C’ – ‘5mg/kg and 10mg/kg of IFX+ADA’, which
involves initial therapy using 5mg/kg of IFX and, if there is no response, the dose is escalated to 10mg/kg
of IFX, then if response is lost during maintenance therapy, switch to ADA (Figure 75). Surgery is included
in the pathway for all three treatment groups within the model but is not included as a comparator. Costs
and health outcomes were discounted at a rate of 5% per year. All costs were valued at 2008 prices.
Strategy A
Usual care 5 mg/kg infliximab
(week 0, 2 and 6)
5 mg/kg infliximab
(every 8 weeks)
5 mg/kg infliximab
(every 8 weeks)
Surgery
Surgery
Response
Yes Yes
Yes
Yes
No
No
No
No
Response
Response
Response
5 mg/kg infliximab
(every 8 weeks)
10 mg/kg infliximab
(every 8 weeks)
5/10 mg/kg infliximab
(every 8 weeks)
Adalimumab
160 mg at week 0
80 mg at week 2
40 mg weekly
starting from week 4
Adalimumab
160 mg at week 0
80 mg at week 2
40 mg weekly
starting from week 4
5 mg/kg infliximab
(week 0, 2 and 6)
Strategy B Strategy C
FIGURE 75 Treatment sequences evaluated by Xie et al.84 This article is published under license to BioMed Central
Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
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The model includes five mutually exclusive health states: (1) remission, which is defined as a total Mayo
score of ≤ 2 points without individual subscores exceeding 1 point; (2) active UC, which includes those
patients who do not respond and those who do respond but do not achieve remission; (3) surgery, which
is a tunnel state; (4) surgical remission; and (5) surgical complication (Figure 76). The model adopts a
variable cycle length according to the timing of full Mayo score assessments adopted in the ACT1 and
ACT2 studies (0–8 weeks, 9–30 weeks, 31–54 weeks, then 27 weekly thereafter).49 Patients enter the
model in the active moderate to severe state and following initial therapy either achieve remission or not.
Those patients who achieve remission may subsequently lose response and transit to active UC or they
may maintain remission. For responders in the active UC state, patients may achieve remission or remain in
the active UC state with maintenance. Patients who are non-responders can undergo colectomy+ IPAA,
switch to ADA (strategy B) or receive an increased dose of IFX (strategy C). Following surgery, patients may
experience complications, which may or may not be resolved. These complications may arise immediately
after surgery or at a later timepoint. Death is not included as an event in the model owing to the short
time horizon. Different costs and utilities are applied to each model health state.
The majority of clinical parameters within the model were drawn from the ACT1 and ACT2 studies,49
derived using a fixed-effects meta-analysis. Remission rates in responders and non-responders were
estimated as time-independent parameters based on the ACT1 and ACT2 studies.49 The authors note
that remission rates drawn from the PBO arms of the ACT trials reflect the use of active concomitant
medications. Rates of early and late surgery were drawn from a RCT reported by Jarnerot et al.112 and a
non-randomised cohort study reported by Hoie et al.107 Rates of complications and the probability of
their resolution were derived from non-randomised studies.113,114 Remission rates, the probabilities of
maintaining remission over time and the proportion of non-responding patients in those with active UC
for each treatment group were modelled as time-dependent parameters based on the ACT1 and
ACT2 studies.49 Owing to the absence of randomised evidence at the time of the analysis, remission rates
for ADA were assumed to be equivalent those for 5 mg/kg of IFX. The model did not incorporate the
effects of AEs on health outcomes or costs as the ACT1 and ACT2 studies49 reported that the proportions
of patients with any AE were similar among the IFX and standard care groups.
The model includes four utility values: remission (0.79), active UC (0.32), surgical remission (0.68) and
surgical complications (0.49). The model makes no distinction between the HRQoL outcomes for patients
who achieve response but not remission and patients who do not achieve response; this may be
considered as a very pessimistic assumption that could bias against IFX and ADA therapy, particularly given
the low valuation of HRQoL for patients with active UC. All health utilities were drawn from a previous
economic modelling study reported by Arseneau et al.110 The method of utility elicitation within this study
appears to be TTO.
Remission
Active
ulcerative colitis
Surgical
remission
Surgical
complication
Surgery
FIGURE 76 Model diagram presented by Xie et al.84 This article is published under license to BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
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The model includes the costs associated with drug acquisition, drug administration, colectomy and IPAA,
medical examination and the management of surgical complications. Drug acquisition costs were drawn
from provincial drug benefit lists (including an 8% mark-up). The costs of medical examinations were
derived from the Ontario Schedule of Benefits. The costs of surgery were derived from the literature.115
The results of the economic analysis are presented as mean costs and QALYs and ICERs for each treatment
group based on point estimates of parameters. Pairwise comparisons are presented for the IFX and ADA
options versus usual care. A fully incremental analysis between all options in the model is reported in the
text. PSA was also conducted with decision uncertainty represented using cost-effectiveness acceptability
curves (CEACs).
Table 38 presents the headline cost-effectiveness results reported by Xie et al.84 The model analysis
suggests that the strategy B is expected to produce more health gain than strategies A and C. Strategy C
is dominated by strategy B. The incremental cost-effectiveness of strategy B versus usual care was
estimated to be approximately CA$358,823 per QALY gained.
The PSA suggests that assuming a willingness-to-pay threshold of CA$150,000 per QALY gained, the
probability that usual care is optimal is approximately 1.0. The deterministic sensitivity analysis suggests
that the lowest ICER is achieved by increasing the utility for remission (ICER=CA$273,081 per QALY
gained for strategy B vs. strategy A and CA$428,676 per QALY gained for strategy C vs. strategy A), while
the highest ICER is achieved by lowering the utility for remission (ICER=CA$527,236 per QALY for
strategy B vs. strategy A, CA$889,227 per QALY gained for strategy C vs. strategy A).
Overall, the analysis reported by Xie et al.84 appears to adequately address the decision problem using a
generally appropriate model. However, the analysis is limited by the use of a short time horizon, the
absence of surgery as a comparator and questionable assumptions regarding the health gains associated
with achieving response without remission.
Discussion of published economic evaluations
Three published economic analyses met the inclusion criteria for the systematic review. One analysis
compared early colectomy+ IPAA versus standard medical treatment,83 one compared IFX versus usual
care,82 and the third compared IFX plus ADA versus usual care.84 Only one study (Tsai et al.82) was
undertaken from the perspective of the UK NHS. The included studies were broadly consistent in terms of
the disease-specific factors included in the analyses; all analyses included remission and response, and
surgery as a consequence of ineffective medical treatment. Only one study (Park et al.83) included the
increased risk of colorectal cancer associated with UC within the analysis. One study (Xie et al.84) did not
include mortality for any patient group in the model. Only Park et al.83 included surgery as a treatment
option; the other options focused solely on medical treatment strategies. The study reported by Xie et al.84
included ADA as part of the pathway; however, owing to a lack of RCT evidence at the time of the
analysis, the authors assumed that ADA was equivalent to 5mg/kg of IFX and this assumption may not be
appropriate given more recent evidence.44,49 None of the included studies evaluated the cost-effectiveness
of GOL versus any other treatment. The time horizons considered in the economic analyses differ
considerably, ranging from 5 years to the patient’s remaining lifetime. It is also noteworthy that although
TABLE 38 Headline cost-effectiveness results reported by Xie et al.84
Strategy QALYs Cost Incremental QALYs Incremental cost ICER
Strategy B (IFX+ADA) 2.18 CA$82,756 0.16 CA$58,488 CA$358,823
Strategy C [IFX (plus dose
escalation)+ADA]
2.15 CA$101,272 – – Dominated
Strategy A (usual care) 2.02 CA$24,268 – – –
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the study reported by Tsai et al.82 reported favourable results for IFX (<£30,000 per QALY gained), Xie
et al.84 reported considerably less favourable estimates (>CA$350,000 per QALY gained). This contrasting
finding may in part be explained by differences in assumptions regarding the level of HRQoL attributable
to patients achieving response but not remission. Overall, none of the included studies present sufficient
evidence relating to the cost-effectiveness of IFX, ADA and GOL versus standard medical or surgical
treatment options for moderate to severe UC from the perspective of the UK NHS and PSS.
The next sections present a critique of the economic evidence submitted by the manufacturers of IFX, ADA
and GOL.
Cost-effectiveness evaluation of golimumab (with Patient Access Scheme),
infliximab and adalimumab relative to colectomy for moderate to severe
ulcerative colitis in the UK (MSD submissions64,66)
The MSD submissions include details of a systematic review of previous models together with the methods
and results of a de novo model developed to assess the cost-effectiveness of ADA, GOL and IFX and
standard non-biological treatment for moderate to severe UC. Although MSD submitted two de novo
models and two submission reports,64,66 these relate to virtually the same overall model and analysis, hence
they are detailed and critiqued together within this section.
Summary of manufacturers’ review of existing economic analyses
The MSD submissions include a systematic review of economic evaluations of treatments for UC. The
manufacturer undertook searches in EMBASE, PubMed and the NHS EED to identify published economic
evaluations in UC to help inform the model structure and relevant parameters. A total of 12 published
health economic analyses were included in the MSD review.82,84,116–125 Several of these studies do not
include biological treatment options and some of the analyses relate to the management of severe UC
exacerbations which is beyond the scope of this appraisal. The MSD review highlights the following points
with respect to previous health economic analyses:
l Markov models are commonly used to evaluate treatments for UC
l all of the published models report outcomes in terms of QALYs/life-years gained
l none of the studies included all relevant therapies
l there is variability in parameter sources and values between economic studies
l resource-use estimates used in published models are typically derived from experts in the field rather
than empirical research studies.
The MSD submissions also highlight a distinction between two distinct types of models: (1) Markov models
in which the model structure is based on sequences of therapies; and (2) Markov models in which the
model structure is based on severity. The MSD submissions do not report the results of these previous
economic analyses; hence they are not discussed further here.
MSD model scope
The MSD model compares 160mg/80mg/40mg of ADA, 5mg/kg of IFX, 200mg/100mg/50mg (100mg
for some patients with higher body weight after the initial induction dosing) of GOL and standard
non-biological treatment for patients with moderate to severe UC who have failed previous drug
treatment. Standard non-biological treatment is assumed to be immediate colectomy. The perspective of
the analysis is that of the UK NHS. GOL is assumed to be given at an initial dose of 200mg, followed by
100mg at week 2, then 50mg every 4 weeks thereafter for patients with body weight < 80 kg. For those
patients with body mass ≥ 80 kg, GOL is assumed to be given as an initial dose of 200mg, followed by
100mg at week 2, then 100mg every 4 weeks thereafter. IFX is assumed to be given at a dose of 5mg/kg
followed by additional 5mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks
thereafter. ADA is assumed to be given as 160mg at week 0 (the dose can be administered as four
injections in one day or as two injections per day for two consecutive days) and 80mg at week 2. After
induction treatment, 50% of patients are assumed to receive the recommended dose of 40mg every other
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week while the remainder are assumed to receive 40mg every week. The MSD submission states that
22.9% patients in the ULTRA2 trial require dose escalation but also states that experts advising on
the submission suggested that the actual proportion of patients in clinical practice may be as high as 80%.
The manufacturer argues that the assumption that 50% patients dose escalate is conservative.
Patients receiving biological treatments who achieve a response or remission at induction are assumed to
continue maintenance therapy with the same biological treatment. The model does not include sequences
in which alternative biologicals are used. GOL and ADA are assumed to be given as subcutaneous
injections while IFX is given as an i.v. infusion. For all treatment options, a proportion of patients are also
assumed to receive ongoing ‘background’ non-biological therapies including 5-ASAs, corticosteroids and
immunosuppressants. Standard clinical management, defined in the NICE scope as ‘a combination of
aminosalicylates (sulfasalazine, mesalazine, balsalazide or olsalazine), corticosteroids (beclomethasone,
budesonide, hydrocortisone or prednisolone), and thiopurines (mercaptopurine or AZA), calcineurin
inhibitors and surgical intervention’,36 is not included as a treatment option in the MSD economic analysis.
Upon model entry, patients are assumed to be 40 years of age and 56% are assumed to be male. The
model uses a 2-monthly cycle length. Costs and health outcomes are discounted at a rate of 3.5% each
year and are evaluated over a 10-year time horizon.
MSD model structure
The MSD model structure is shown in Figures 77 and 78. The model adopts a hybrid approach whereby an
initial decision tree is used to determine the probabilities of induction response or remission for biological
drug treatments, together with the probabilities of survival and the incidence of complications for patients
undergoing immediate colectomy, while a Markov component is used to estimate long-term outcomes
for maintenance drug therapy and surgery. The decision tree structure is identical for all biological drug
treatments and includes initial outcomes defined in terms of no response, response and remission.
No response
Adalimumab Remission
Response
No remission
No response
Remission
Golmumab
Response
No remission
Treatment?
No response
Remission
Infliximab
Response
No remission
No complications
Colectomy Die
Complications
Early complications
Markov (start in relapse state)
Markov (start in remission state)
Markov (start in response state)
Markov (start in relapse state)
Markov (start in remission state)
Markov (start in response state)
Markov (start in relapse state)
Markov (start in remission state)
Markov (start in response state)
Markov (start in post-colectomystate)
Transit to dead state
Markov (start in post-colectomy
complications state)
FIGURE 77 Merck Sharp & Dohme Ltd model structure (redrawn by the Assessment Group).
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For the standard care (colectomy) option, the decision tree outcomes are different and instead relate to the
probabilities of surviving surgery and experiencing early complications resulting from that surgery. The
Markov model comprises eight mutually exclusive health states: (1) response (pre-colectomy; maintenance);
(2) remission (pre-colectomy; maintenance); (3) response (relapse management); (4) relapse (relapse
management); (5) colectomy; (6) remission (post-colectomy); (7) late complications (post-colectomy);
and (8) death.
For the biological treatment groups, patients are initially allocated to no response, response or remission
based on the results of a de novo NMA of induction therapy trials44,47–49,126 undertaken by the
manufacturer. Patients in whom response or remission is achieved at induction are assumed to remain on
maintenance treatment using the same biological treatment. Subsequent model transitions are informed
by a separate NMA based on the results of the trials of biological maintenance therapies.44,47,49 Patients
who do not respond to induction therapy, and those who lose response during maintenance treatment,
are assumed to enter the relapse management state and receive i.v. steroids. Patients who respond to i.v.
steroids then transit to the ‘Response (relapse management)’ state at which time they either continue
responding or relapse. Patients who do not respond are assumed to undergo immediate colectomy.
Colectomy is dealt with as a tunnel state; following surgery a small proportion of patients are assumed to
die while the remainder are assumed to be in post-colectomy remission. Patients who survive their surgery
are assumed to be at ongoing risk of post-colectomy complications (anal fistula, bowel obstruction and
pouchitis). A small proportion of patients receiving drug treatment are assumed to be at risk of serious
infection and hospitalisation.
Death
ResponseRemission
Pre-colectomy; maintenance
Response
Relapse
Colectomy
Late 
complications
Remission
Relapse management
Post-colectomy
FIGURE 78 Merck Sharp & Dohme Ltd model Markov component.64,66 Reproduced with permission.
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The model uses simple matrix multiplication to determine health state populations during each model cycle
based on the state population in the previous Markov cycle and a single time-independent transition
matrix over the entire time horizon. Costs and utilities are attached to each health state. Total QALYs are
modelled as a function of sojourn time in each health state, mortality associated with colectomy and
other-cause (general population risk) mortality.
Evidence sources used to inform the MSD model parameters
A summary of evidence sources used to inform the model’s parameters is presented in Table 39.
Methods for modelling effectiveness
Estimates of relative effectiveness of biological treatments versus conventional non-biological non-surgical
treatment were derived from NMA models of induction and maintenance therapy undertaken by
the manufacturer.64,66
The baseline model employed within the MSD NMA model is not discussed within the submissions.64,66
The MSD economic model includes a worksheet named ‘Input Efficacy and Trans Prob’ in which the
probabilities of response and remission for non-biological therapy are inputted as 0.36 and 0.09 for
induction treatment, and 0.83 and 0.86 per 2-month cycle of maintenance therapy respectively. The
source is stated in the model as ‘Average study effect of PBO controlled trials in random effects NMA of
induction response’. No additional detail on the baseline model is provided within the MSD submissions;
thus, it is not possible to determine whether or not these estimates are appropriate.
Relative treatment effects were drawn from de novo NMAs undertaken by the manufacturer, based on the
results of a systematic literature review. Separate analyses were undertaken for induction and maintenance
therapy. For induction, a NMA was undertaken using data from six RCTs.44,45,47–49 For maintenance
treatment, relative treatment effects were based on a NMA of three RCTs.45,47,49 The evidence networks
employed in the manufacturer’s NMAs are presented in Figures 79 and 80 respectively. It should be noted
that the manufacturer’s NMA includes non-licensed indications of IFX, although these are not included in
the health economic analysis.
TABLE 39 Summary table of evidence sources used to inform the MSD model parameters
Parameter group Source
Pre-colectomy transition probabilities excluding
death: standard non-biological treatment
Manufacturer’s NMA: average study effect of PBO controlled trials in
random effects NMA of induction response64,66
ORs for biological treatment effects ORs derived from manufacturer’s NMA64,66
Effectiveness of i.v. steroids following failure of
biological treatment
Model fitted to ensure 27% relapsers require colectomy based on
Turner et al.126
Probability of serious infection Grijalva et al.127
Health utilities for pre-colectomy response/
remission
EQ-5D estimates from the PURSUIT trial47,48 in the GOL model,
EQ-5D estimates from the ACT1 and ACT249 trials in the IFX model
Health utilities for post-colectomy statesa Woehl et al.109 Tsai et al.82 Health Outcomes Data Analysis Repository,
Punekar and Hawkins,120 Chaudhary and Fan,116 Arseneau et al.110
Resource use PURSUIT trial,47 ACT1 and ACT2 trials49 and interviews with
nine gastroenterologists64,66
Unit costsa Curtis et al.128 NHS Reference Costs129
a Sources for some HRQoL parameters are not clear from the MSD submissions.
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The NMAs use logistic regression models to estimate treatment effects, given an assumption that the data
are binomial (separate models are used to estimate the odds of sustained response and the odds of
sustained remission respectively). Relative treatment effects were parameterised in terms of ORs and are
converted to relative risks in the health economic model. In instances whereby only one RCT informed
each treatment (which was predominantly the case for the maintenance outcomes), heterogeneity could
not be estimated and, therefore, a fixed-effects model was employed. When multiple studies were
available, a random-effects approach was used.64,66 The NMA model for maintenance therapy includes a
complex ‘novel’ imputation of estimates of sustained response and sustained remission for GOL from
the PURSUIT trial using data from the non-randomised PBO group (see MSD GOL submission p. 5566).
The results of the manufacturer’s NMA are presented in Tables 40 and 41 respectively.
Table 42 illustrates how the ORs are applied within the transition matrix for maintenance therapy within
the health economic model, using the ADA treatment group as an example.
It should be noted that the matrix employed within the MSD models does not match the transitions
implied by the diagram within the MSD submissions64,66 (see Figure 78). In the executable model, patients
who have previously achieved a response can either maintain or lose that response, but they cannot
improve (i.e. they cannot subsequently transit to the remission state). Patients who have previously
achieved remission can either maintain or lose that remission. However, upon losing remission, the patient
cannot transit directly to relapse – they transit to the response state first. This means that no additional
patients can achieve remission after induction and no patients with remission can completely lose response
during any given model cycle. It is also noteworthy that patients who discontinue treatment with a
40 mg
of ADA
10 mg/kg
of IFX
5 mg/kg
of IFX
PBO
1
1 1
1 1
1
1
50 mg of GOL 100 mg of GOL
FIGURE 80 Evidence network for maintenance therapy.64,66 Reproduced with permission.
400 mg/200 mg
of GOL
200 mg/100 mg
of GOL
160 mg/80 mg
of ADA
10 mg/kg
of IFX
5 mg/kg
of IFX
PBO
2
2
2 2
11
1
FIGURE 79 Evidence network for induction therapy.64,66 Reproduced with permission.
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TABLE 40 Manufacturer’s NMA results: induction treatment
Intervention OR Lower 95% CrI Upper 95% CrI
Induction response (reference PBO)
200mg/100mg of GOL 2.12 1.01 3.95
400mg/200mg of GOL 2.47 1.19 4.65
5mg/kg of IFX 4.12 2.08 8.14
10mg/kg of IFX 3.81 1.95 7.59
160mg/kg of ADA 1.87 0.96 3.65
Induction remission (reference PBO)
200mg/100mg of GOL 2.99 1.32 6.28
400mg/200mg of GOL 3.32 1.56 7.23
5mg/kg of IFX 5.27 2.60 11.64
10mg/kg of IFX 3.90 1.88 8.56
160mg/kg of ADA 2.25 1.08 4.72
TABLE 41 Manufacturer’s NMA results: maintenance treatment
Intervention OR Lower 95% CrI Upper 95% CrI
Sustained response (reference PBO)
40mg/kg of ADA 1.31 0.67 2.59
5mg/kg of IFX 2.12 1.02 4.54
10mg/kg of IFX 2.51 1.17 5.51
50mg of GOL 1.51 0.94 2.47
100mg of GOL 1.75 1.08 2.84
50–100mg of GOL 1.62 1.07 2.50
PBO following GOL 0.78 0.47 1.28
Sustained remission (reference PBO)
40mg/kg of ADA 0.76 0.22 2.56
5mg/kg of IFX 1.30 0.44 4.05
10mg/kg of IFX 2.26 0.73 7.49
50mg of GOL 0.83 0.29 2.40
100mg of GOL 0.98 0.36 2.78
50–100mg of GOL 0.92 0.36 2.45
PBO following GOL 0.45 0.15 1.34
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biological treatment transit very quickly to colectomy (27% of all non-responding relapsers during each
2-month cycle). This estimate was based on a meta-regression of studies describing the short-term
outcomes for adult and paediatric patients treated with i.v. corticosteroids, with or without ciclosporin, for
exacerbations of UC.126
The model also includes a small risk of experiencing serious infection owing to the use of immunosuppressants
and biological therapies based on Grijalva et al.127 The model assumes a hazard ratio of 1.10 for all biological
therapies and a baseline risk of 0.16 for non-biological therapy.
Health-related quality of life
The health utility values used in the MSD model are presented in Table 41. Health utilities associated with
failure, response, and remission as a result of induction and maintenance treatment, and utility values
assigned to the health states ‘Response (pre-colectomy; maintenance)’ and ‘Remission (pre-colectomy;
maintenance)’ are assumed to be the same for all biologicals, based on EQ-5D valuations derived from the
PURSUIT trial47 within the GOL model and the ACT1 trial49 within the IFX models. The MSD submission
suggests that disutilities for AEs associated with biologicals are likely to be captured within these estimates.
Different utilities are assumed for the achievement of the same outcome at induction and maintenance
(i.e. the utility for response at induction is not the same as the utility for response at maintenance).
Utility values for colectomy, postcolectomy and early and late complications of colectomy were based on
estimates reported within the literature, although the precise sources are not clear from the MSD
submissions64,66 (Table 43).
Resource use and costs
The model includes direct costs of drug acquisition, consultant visits, endoscopy, inpatient hospital
admissions, colectomy, management of surgery-related complications, AEs and other UC costs. A Patient
Access Scheme (PAS), in which the price of 100mg of GOL is assumed to be equal to that of 50mg of
GOL, is applied within the model. It should be noted that at the time of writing, this had not been
approved by the Department of Health.
TABLE 43 Health utility values used in the MSD models
Health state
Utility value
(GOL model; IFX model)
Valuation method and source
(GOL model; IFX model)
Response (pre-colectomy; induction) 0.80; 0.79 EQ-5D PURSUIT trial;47 ACT1 trial49
Remission (pre-colectomy; induction) 0.86; 0.84 EQ-5D PURSUIT trial;47 ACT1 trial49
No response (pre-colectomy; induction) 0.70; 0.70 EQ-5D PURSUIT trial;47 ACT1 trial49
Response (pre-colectomy; maintenance) 0.80; 0.82 EQ-5D PURSUIT trial;47 ACT1 trial49
Remission (pre-colectomy; maintenance) 0.89; 0.88 EQ-5D PURSUIT trial;47 ACT1 trial49
Response (relapse management) 0.76; 0.76 EQ-5D PURSUIT trial;47 ACT1 trial49
Relapse (relapse management) 0.42; 0.42 EQ-5D estimates from Tsai et al.;82 however, the
primary source of these estimates (Woehl et al.109)
appears to be misreferenced as the cited
reference is not a health valuation study and does
not report utilities
Colectomy 0.56; 056a Unclear. Appears to be based on data from
Health Outcomes Data Analysis Repository
reported within Punekar and Hawkins.120 Disutility
for early complications based on TTO study
reported by Arseneau et al.110
Remission (postcolectomy) 0.60; 0.60
Late complications (postcolectomy) 0.60; 0.60
a Includes disutility for proportion of patients experiencing early complications of surgery.
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Drug acquisition costs
Cost of non-biological ‘background’ therapies
The usage and per-cycle costs of non-biological background therapies assumed within the model are
presented in Tables 44 and 45. Patients in the standard non-biological treatment group are assumed to
receive 4 g of mesalazine daily (if acute) or 2 g of mesalazine daily (if chronic), 2–2.5 mg/kg of AZA daily,
1–1.5mg/kg of 6-MP daily, 500mg of ciprofloxacin twice daily and 25–50mg of prednisolone per day.
The same use of background therapies is assumed for all biological treatment arms. However, it should be
noted that in the colectomy group, patients are assumed to undergo immediate colectomy, so the actual
drug acquisition cost for the colectomy group is zero within the model. Patients in the biological treatment
groups are assumed to receive the same ‘background therapies’ with the exception of ciprofloxacin
(although as described above, this is applied as a zero cost in the colectomy group). Resource-use estimates
for these therapies appear to be based on the PBO arm of the PURSUIT trial47 within the GOL model and
from the PBO arm of the ACT1 and ACT2 trials49 within the IFX model. These are similar, but not the same
(see Tables 44 and 45); as with the utility values, the justification for using different assumptions concerning
resource use in each model is not clear. The source of the unit costs is not reported within the submission,
but estimates appear to be drawn from the British National Formulary (BNF37).
Biological therapies
Table 46 shows the biological acquisition costs per cycle for each treatment group. The table indicates that
the estimated costs of induction using IFX is markedly higher than that for ADA and GOL; however, the
costs of maintenance therapy per cycle are broadly similar for all biologicals.
TABLE 44 Background therapies resource use and costs used in MSD GOL model
Treatment group Background therapies included (proportion of patients) Cost per cycle (£)
Induction treatment
Standard non-biological
treatment
Mesalazine (0.83), AZA (0.15), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (1.00)
251.43a
ADA Mesalazine (0.81), AZA (0.16), 6-MP (0.16), prednisolone (0.44) 200.03
GOL Mesalazine (0.81), AZA (0.16), 6-MP (0.16), prednisolone (0.44) 200.03
IFX Mesalazine (0.81), AZA (0.16), 6-MP (0.16), prednisolone (0.44) 200.03
Maintenance treatment
Standard non-biological
treatment
Mesalazine (0.80), AZA (0.16), 6-MP (0.16), ciprofloxacin (0.00),
prednisolone (0.49)
121.15a
ADA Mesalazine (0.80), AZA (0.15), 6-MP (0.15), prednisolone (0.51) 120.98
GOL Mesalazine (0.80), AZA (0.15), 6-MP (0.15), prednisolone (0.51) 120.98
IFX Mesalazine (0.80), AZA (0.15), 6-MP (0.15), prednisolone (0.51) 120.98
Relapse management (following prior treatment failure)
Relapse management Mesalazine (0.80), AZA (0.16), 6-MP (0.16), ciprofloxacin (0.00),
prednisolone (0.49)
121.15
Relapse management
(i.v. steroids)
Mesalazine (0.83), AZA (0.15), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (1.00), i.v. prednisolone (1.00)
405.43
a Acquisition costs not included in model results for standard non-biological treatment.
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TABLE 45 Background therapies resource use and costs used in MSD IFX model
Treatment group Background therapies included (proportion of patients) Cost per cycle (£)
Induction treatment
Standard non-biological
treatment
Mesalazine (0.71), AZA (0.15), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (1.00)
233.57a
ADA Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 191.11
GOL Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 191.11
IFX Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 191.11
Maintenance treatment
Standard non-biological
treatment
Mesalazine (0.71), AZA (0.15), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (0.57)
118.10a
ADA Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 113.99
GOL Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 113.99
IFX Mesalazine (0.72), AZA (0.36), 6-MP (0.13), prednisolone (0.54) 113.99
Relapse management (following prior treatment failure)
Relapse management Mesalazine (0.71), AZA (0.29), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (0.57)
118.10
Relapse management
(i.v. steroids)
Mesalazine (0.71), AZA (0.29), 6-MP (0.15), ciprofloxacin (0.00),
prednisolone (1.00), i.v. prednisolone (1.00)
387.57
a Acquisition costs not included in model results for colectomy group.
TABLE 46 Biologic treatment resource use and costs used in MSD models
Treatment group Assumed regimen Cost per cycle (£)
Induction treatment (8-week cycle)
ADA All patients receive 1 × 160mg of ADA+ 1× 80mg of
ADA+ 3 × 40mg of ADA
3169.26
GOL All patients receive 2 × 100mg of GOL+ 1 × 100mg of GOL 3051.88
IFX All patients receive 12 × 100mg of IFX over three
administrations
5497.44
Maintenance treatment (2-month cycles)
ADA 50% patients receive 40mg of ADA EW (4.33 doses/cycle);
50% patients receive 40mg of ADA EW (8.67 doses/cycle)
2288.91
GOL 31.6% patients receive 100mg of GOL every 4 weeks; 68.4%
patients receive 50mg of GOL every 4 weeks
1653.10
IFX All patients receive 5mg/kg of IFX every 8 weeks 1985.19
EW, every week.
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Health state resource costs
Tables 47 and 48 present the health state costs (excluding drug acquisition) for the biological and
colectomy groups respectively. The resource-use estimates underpinning these cost estimates were
reported to be based on interviews with nine expert gastroenterologists. Resource use was costed using
standard costing sources.128,130
Model evaluation and uncertainty analysis
The results of the economic analysis are presented as pairwise ICERs and are interpreted as net monetary
benefits (NMBs) assuming a willingness-to-pay threshold of £30,000 per QALY gained. Incremental CEACs
are also presented within the submission (see MSD GOL submission,66 p. 122). Uncertainty surrounding
estimates of incremental costs and health outcomes was examined using deterministic sensitivity analyses
and PSA. The results of the deterministic analyses are presented as tornado diagrams and the results of the
PSA are presented as cost-effectiveness planes and CEACs.
MSD model results
Tables 49 and 50 present the results within the GOL and IFX submissions respectively64,66 (note: the fully
incremental analysis presented here has been undertaken by the Assessment Group rather than by
the manufacturer).
TABLE 47 Other health state costs (£) per 2-month cycle: biological treatments
State and
treatment
phase
Consultant
visit cost
Endoscopy
cost
Inpatient
cost
Colectomy
cost
Late
complications
cost
Other
UC cost AE cost
Total
cost per
cycle
Response;
induction phase
91.58 18.32 0.00 0.00 0.00 1.80 29.37 141.07
Remission;
induction phase
43.70 4.97 0.00 0.00 0.00 1.80 29.37 79.84
Failure;
induction phase
162.76 40.30 0.00 0.00 0.00 1.80 29.37 234.22
Response
(pre-colectomy;
maintenance)
91.58 18.32 0.00 0.00 0.00 1.80 29.37 141.07
Remission
(pre-colectomy;
maintenance)
43.70 4.97 0.00 0.00 0.00 1.80 29.37 79.84
Response
(relapse
management)
91.58 18.32 0.00 0.00 0.00 1.80 26.74 138.44
Relapse
(relapse
management)
162.76 40.30 350.86 0.00 0.00 3.44 26.74 584.09
Colectomy 162.76 40.30 0.00 8967.94 0.00 3.44 0.00 9174.42
Remission
(postcolectomy)
53.12 45.27 0.00 0.00 0.00 0.92 0.00 99.30
Late
complications
(postcolectomy)
67.77 26.17 0.00 0.00 2446.85 1.85 0.00 2542.64
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
TA
B
LE
48
O
th
er
h
ea
lt
h
st
at
e
co
st
s
(£
)
2-
m
o
n
th
cy
cl
e:
co
le
ct
o
m
y
g
ro
u
p
a
St
at
e
an
d
tr
ea
tm
en
t
p
h
as
e
C
o
n
su
lt
an
t
vi
si
t
co
st
En
d
o
sc
o
p
y
co
st
C
o
le
ct
o
m
y
co
st
w
it
h
o
u
t
ea
rl
y
co
m
p
lic
at
io
n
s
C
o
st
ea
rl
y
co
m
p
lic
at
io
n
s
o
f
co
le
ct
o
m
y
C
o
le
ct
o
m
y
co
st
La
te
co
m
p
lic
at
io
n
s
co
st
O
th
er
U
C
co
st
To
ta
l
co
st
p
er
cy
cl
e
D
ea
th
du
e
to
co
le
ct
om
y.
Re
m
is
si
on
(p
os
tc
ol
ec
to
m
y)
du
e
to
co
le
ct
om
y
16
2.
76
40
.3
0
76
19
.2
5
40
29
.6
1
89
67
.9
4
0.
00
3.
44
20
,8
23
.2
8
Re
m
is
si
on
(p
os
tc
ol
ec
to
m
y)
du
e
to
co
le
ct
om
y
16
2.
76
40
.3
0
76
19
.2
5
40
29
.6
1
89
67
.9
4
0.
00
3.
44
20
,8
23
.2
8
C
ol
ec
to
m
y
16
2.
76
40
.3
0
76
19
.2
5
40
29
.6
1
89
67
.9
4
0.
00
3.
44
20
,8
23
.2
8
Re
m
is
si
on
(p
os
tc
ol
ec
to
m
y)
53
.1
2
45
.2
7
0.
00
0.
00
0.
00
0.
00
0.
92
99
.3
0
La
te
co
m
pl
ic
at
io
ns
(p
os
tc
ol
ec
to
m
y)
67
.7
7
26
.1
7
0.
00
0.
00
0.
00
24
46
.8
5
1.
85
25
42
.6
4
a
Th
e
m
od
el
in
cl
ud
es
10
fu
rt
he
r
ro
w
s
of
co
st
s
by
st
at
e
fo
r
th
e
co
le
ct
om
y
gr
ou
p,
ho
w
ev
er
no
ne
of
th
es
e
in
flu
en
ce
s
th
e
m
od
el
re
su
lts
.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
The model results suggest that IFX is expected to produce the greatest QALY gain, followed by GOL and
ADA. ADA is expected to be less effective and more expensive than GOL, hence it is ruled out because of
simple dominance. The ICER for GOL versus colectomy is expected to be approximately £27,000–28,000
per QALY gained. The ICER for IFX versus GOL is expected to be approximately £76,000–80,000 per
QALY gained. The probabilistic results are slightly different from those derived from point estimates of
parameters, but the ICERs appear stable.
Figure 81 presents the results of the PSA in the form of a cost-effectiveness plane for each biological
treatment relative to immediate colectomy. It can be seen that the results overlap considerably for ADA
and GOL; however, the plane indicates a generally higher overall cost for IFX. The dispersion of sampled
incremental QALY gains for IFX versus colectomy is greater than that for ADA and GOL versus colectomy.
Figure 82 presents incremental CEACs for all options in the model. The CEACs suggest that at
willingness-to-pay thresholds of £25,000 per QALY gained or lower, immediate colectomy has the highest
probability of producing the greatest net benefit. At a willingness-to-pay threshold of £30,000 per QALY
gained, GOL has the highest probability of producing the greatest net benefit, although this is only very
slightly higher than 0.50.
TABLE 49 Model results from GOL submission66 (including PAS)
Treatment QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER (£)
Probabilistic model results
IFX 5.70 44,382.28 0.16 13,003.60 80,318
GOL 5.54 31,378.68 0.56 15,610.91 27,994
ADA 5.49 32,096.50 – – Dominated
Colectomy 4.98 15,767.78 – – –
Results based on point estimates of parameters
IFX 5.65 43,091.60 0.15 12,196.82 80,866
GOL 5.50 30,894.78 0.55 15,100.53 27,322
ADA 5.45 31,370.28 – – Dominated
Colectomy 4.95 15,794.26 – – –
TABLE 50 Model results from IFX submission64 (including PAS)
Treatment QALYs Costs (£) Incremental QALYs Incremental cost(£) ICER (£)
Probabilistic model results
IFX 5.71 44,189.50 0.17 12,841.74 75,998
GOL 5.54 31,347.76 0.57 15,522.79 27,163
ADA 5.48 32,123.34 – – Dominated
Colectomy 4.97 15,824.96 – – –
Results based on point estimates of parameters
IFX 5.66 42,919.73 0.16 12,166.45 77,599
GOL 5.51 30,753.28 0.56 14,963.69 26,569
ADA 5.45 31,237.38 – – Dominated
Colectomy 4.94 15,789.59 – – –
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FIGURE 81 Cost-effectiveness plane from MSD model.64,66 Reproduced with permission.
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A number of deterministic sensitivity analyses are also presented; however, these are difficult to interpret
as both IFX and GOL are compared in a pairwise manner against colectomy using incremental QALYs,
incremental costs and incremental NMB. Deterministic sensitivity analyses are not presented between
competing biological therapies. The deterministic sensitivity analyses indicate that the cost-effectiveness
results for GOL versus colectomy are sensitive to the utility values for post-colectomy remission,66
while the cost-effectiveness results for IFX versus colectomy are sensitive to the utility value for
post-colectomy remission.64
Critical appraisal of the MSD model
The main issues identified by the Assessment Group are presented in Box 2.
Deviations from NICE reference case and final NICE scope
The extent to which the economic analyses reported in the MSD submissions adhere to the NICE reference
case is presented in Table 51.
Overall, the MSD economic analyses are generally in line with the NICE reference case. However, the
analysis does make one important deviation from the final NICE scope with respect to the options included
in the economic analysis; non-biological treatment is assumed to be immediate colectomy. Standard clinical
management, which is defined in the NICE scope as ‘a combination of aminosalicylates (sulfasalazine,
mesalazine, balsalazide or olsalazine), corticosteroids (beclomethasone, budesonide, hydrocortisone or
prednisolone), and thiopurines (mercaptopurine or AZA), calcineurin inhibitors and surgical intervention’,36
is not included in the MSD model. The omission of non-biological non-surgical treatment options from the
MSD model is neither discussed nor justified in the MSD submissions.64,66
It is also noteworthy that the MSD model adopts a 10-year time horizon; at this point around 96% of
patients in the model are still alive in each treatment group. The MSD submissions state that the ‘. . . time
horizon of 10 years can be considered sufficiently long to capture differences in the distribution of health
states between the compared biologics; after 10 years of follow-up all patients are expected to have
discontinued biologic treatment’. The modelled profiles of incremental costs and benefits are slightly
different when a longer time horizon is adopted. It is reasonable to suggest that the manufacturer should
have examined the impact of using different time horizons within their economic analysis.
BOX 2 Main problems and concerns relating to the MSD model
1. Deviations from the NICE reference case and final NICE scope, particularly with respect to omission of
conventional non-surgical management as a comparator.
2. Assumption that treatment failure is equivalent to severe exacerbation.
3. Questionable use of evidence concerning improving and worsening of inflammation.
4. Questionable validity of use of novel methods for including non-randomised data from PURSUIT.
5. Lack of clarity regarding the NMA model.
6. Inconsistencies between results of the MSD GOL and IFX models.
7. Lack of clarity regarding the identification, selection and use of certain model parameters.
8. Complex implementation of the model.
9. Failure to undertake an incremental analysis.
10. Inclusion of a PAS for GOL which has not yet been agreed by the Department of Health.
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TABLE 51 Adherence of the MSD model to the NICE reference case78
Element of HTA Reference case Assessment Group comments
Defining the decision
problem
The scope developed by the Institute The scope of the analysis deviates from the final
scope from NICE. Non-biological treatment is
assumed to be immediate colectomy. Standard
clinical management, defined in the NICE scope as
‘a combination of aminosalicylates (sulfasalazine,
mesalazine, balsalazide or olsalazine), corticosteroids
(beclomethasone, budesonide, hydrocortisone or
prednisolone), and thiopurines (mercaptopurine
or AZA), calcineurin inhibitors and surgical
intervention’,36 is not included as a treatment option
within the model
Comparator(s) As listed in the scope developed by
NICE
Perspective on outcomes All direct health effects, whether for
patients or, when relevant, carers
Health outcomes reflect those of patients with UC
Perspective on costs NHS and PSS The economic analysis was undertaken from the
perspective of the UK NHS. PSS costs are not
mentioned in the submission
Type of economic
evaluation
Cost–utility analysis with fully
incremental analysis
The economic evaluation takes the form of a cost-
effectiveness analysis. Analyses are presented as
pairwise comparisons rather than a fully incremental
economic analysis of all options
Time horizon Long enough to reflect all important
differences in costs or outcomes
between the technologies being
compared
Costs and outcomes are evaluated over a 10-year
time horizon. Analyses over a lifetime horizon are
not presented in the manufacturers’ submission
Synthesis of evidence on
health effects
Based on systematic review Outcomes are synthesised using NMA models using
studies identified through a systematic review
Measuring and valuing
health effects
Health effects should be expressed in
QALYs. The EQ-5D is the preferred
measure of HRQoL in adults
Health outcomes are reported in terms of life-years
gained and QALYs gained
Source of data for
measurement of HRQoL
Reported directly by patients and/or
carers
All utilities except the disutility for surgery-related
complications are based on EQ-5D measurements
from UC patients and are valued by the general
publicSource of preference data
for valuation of changes
in HRQoL
Representative sample of the UK
population
Equity considerations An additional QALY has the same
weight regardless of the other
characteristics of the individuals
receiving the health benefit
No equity weighting is applied
Evidence on resource use
and costs
Costs should relate to NHS and PSS
resources and should be valued using
the prices relevant to the NHS and PSS
The economic analysis was undertaken from the
perspective of the UK NHS. The sources for prices
are not entirely clear
Discounting The same annual rate for both costs
and health effects (currently 3.5%)
The model uses a discount rate of 3.5% for costs
and health outcomes
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
145
Assumption that treatment failure is equivalent to severe exacerbation
Related to the issue regarding the lack of conventional drug therapies as the comparator for the economic
analysis (see Deviations from NICE reference case and final NICE scope), the MSD economic models appear
to also confuse the severity of the patient populations and the associated treatment pathway included in
the model. Although the scope of the appraisal relates to patients with moderate to severe UC who have
failed conventional treatment, the modelled pathway after failure of biological therapy, and the choice of
non-biological comparators included in the analysis, appear to relate to a population with more severe
disease and no further medical treatment options are considered. The pathway represented by the model
after failure of biological therapy (or in its absence) appears to assume that failure to achieve an induction
response, or that the loss of response during maintenance therapy, is synonymous with an acute UC
exacerbation. As noted by the MSD submissions, surgery for UC is typically indicated for (1) patients
with life-threatening complications (e.g. toxic megacolon or colonic perforation); (2) dysplasia or proven
cancer; or (3) severe disease characterised by treatment refractoriness, frequent flare-ups, extracolonic
manifestations, chronic corticosteroid dependence, side effects/intolerance/complications from medications
(in particular corticosteroids), or according to clinical judgement.64,66 After failing biological treatment, the
MSD model assumes that all patients who have failed biological therapy will receive i.v. steroids and rapidly
progress to colectomy (27% of all relapsing patients during each 2-month cycle). This fails to reflect the
possibility that patients may continue to receive, and may still obtain clinical benefit from, non-biological
medical treatment options as defined in the NICE scope (5-ASAs, immunotherapies and/or steroids).
After removing mortality, the MSD model suggests that within 1 year (the approximate duration of the
maintenance trials45,47,49), 15–20% patients are in the colectomy/post-colectomy health states (Figure 83).
This contrasts with the colectomy rates observed within the RCTs included in the systematic review [see
Chapter 3, Assessment of effectiveness, Rates of surgical intervention (both elective and emergency) 0.7%
to 5.8% in in individual trial arms at approximately 1 year]. The manufacturer’s model also suggests that
for patients receiving biological treatments, 59–70% will have undergone surgery within 5 years and
89–93% will have undergone surgery within 10 years (note: the precise values differ by biological
treatment group). These rates are very high and fail to reflect both the possibility of benefit from further
medical therapies and the element of patient choice in deciding whether or not to undergo colectomy.
If surgery really was the only remaining treatment option for these patients, it would not have been
possible (or ethical) to undertake any of the trials included in this assessment.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10
Pr
o
p
o
rt
io
n
 o
f 
p
at
ie
n
ts
 in
 p
o
st
-c
o
le
ct
o
m
y
 s
ta
te
s 
at
 t
im
e 
p
o
in
t
Time since model start (years)
ADA
GOL
IFX
FIGURE 83 Proportion of patients in post-colectomy states over time (excluding mortality).
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Further to this point, the study reported by Turner et al.,126 which is used to inform the probability of
requiring surgery for active UC, is a systematic review of studies describing the short-term outcome of
adult and paediatric patients treated with i.v. corticosteroids, with or without ciclosporin, for exacerbations
of UC. Within this published analysis, retrospective and prospective studies evaluating adult or paediatric
UC patients admitted for first or subsequent exacerbation, who were severe enough to require i.v.
corticosteroid therapy, were included if the short-term outcome and/or analysis of predictors of response
were reported. This appears to confuse treatment failure with acute exacerbation of UC. The Assessment
Group do not believe that either the narrow choice of remaining viable comparators or the treatment
pathways assumed within the MSD models are representative of the clinical management of patients with
moderate to severe UC in England and Wales.
Questionable use of evidence concerning improving and worsening of inflammation
The NMA model uses separate models to produce information on the probability of sustained remission
and the probability of sustained response. Within the health economic models, the ORs estimated using
the NMA models are applied to the probability of remaining in the states of remission and response,
respectively. The NMA logistic regression models treat these data as binomial – a patient either stays in
their existing state or they do not. However, the data are multinomial – the observed data from the trials
indicates that some patients who lost remission transited to response while others transited to no
response, and some patients in response subsequently achieved remission, some achieved sustained
response and some lost response. The structural assumptions employed within the transition matrix (see
Table 42) do not reflect this, with some plausible transitions being assigned probabilities of zero. Although
this problem is a likely consequence of the limitations of the published data from the ULTRA2 trial,45
it poorly reflects the characteristics of the actual observed data.
Questionable validity of use of methods for including non-randomised data
from PURSUIT
The MSD submissions state that ‘PURSUIT used a non-conventional trial design, and thus, conventional NMA
techniques would not have sufficed for producing comparative effect estimates between GOL, IFX, and
ADA. This NMA employed novel techniques of optimising the use of all available data.’64,66 This approach
was used to ‘downgrade’ the available evidence for PBO within the PURSUIT maintenance trial as patients
randomised to PBO were prior GOL induction responders. Based on the information provided in the
manufacturers’ submission (see MSD GOL submission,66 table 13 footnotes and text on pp. 55–7), the
Assessment Group was unable to logically follow or replicate the calculations used to generate hypothetical
values for the PBO group. However, the Assessment Group does believe that the manufacturer’s ‘novel’
method involves omitting the randomised data and instead uses a manipulation of the non-randomised PBO
arm data as an input into the NMA. Such manipulation of observed trial data should be viewed with
considerable caution. The Assessment Group believe that it would have been more appropriate to use more
established methods of bias adjustment (e.g. the methods adopted by Turner and Spiegelhalter131) and/or to
use the published ITT data and examine the likely impact of the bias using sensitivity analyses.
Lack of clarity regarding the network meta-analysis model
The NMA model is not reported in detail within either of the MSD submissions and the WinBUGS code
was not reported (although this was provided to the Assessment Group during the clarification process).
In addition, the baseline model is not described, although the health economic model indicates that
baseline probabilities of achieving induction response/remission and maintaining response/remission were
derived from ‘Average study effect of PBO controlled trials in random effects NMA of induction response’.
The appropriateness of these values is unclear.
Inconsistencies between results of the Merck Sharp & Dohme Ltd golimumab and
infliximab models
The IFX model and GOL model are based on the same structure and the same decision problem. However
the results are different between the models. In response to a request for clarification on the cause of this
discrepancy, the manufacturer stated that the two models use different inputs for health utilities; the IFX
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model uses utility data from the ACT1 and ACT2 trials while the GOL model uses utility data from the
PURSUIT trial. The IFX model also uses different assumptions about the use of conventional non-biological
therapies compared with the GOL model. The justification for using different utility and resource-use
assumptions in two models that are attempting to reflect exactly the same decision problem is
inappropriate. It should also be noted that when the PURSUIT utility vector and resource-use assumptions
were inserted into the IFX model, the results still did not coincide.
Lack of clarity regarding the identification, selection and use of certain
model parameters
In several instances, the justification for selecting particular parameter sources is unclear. In particular, the
justification of the dosing and frequency of background therapies, and the justification for unit costs is not
described within the MSD submissions.64,66
Complex implementation of the model
Conceptually, the submitted MSD models are simple Markov models employing eleven health states and
four treatment groups. However, the implementation of these models is complex. The model employs
30 worksheets, many of which were locked as read-only. This limited the ability of the Assessment Group
to verify the inputs and formulae used in the model.
Failure to undertake an incremental analysis
The MSD submissions do not include an incremental analysis in which each treatment option is compared
against its next best non-dominated alternative. Instead, pairwise comparisons are made using NMB given
a willingness-to-pay threshold of £30,000 per QALY gained. The IFX submission states that:
The ICER for infliximab versus standard non-biologic treatment (colectomy) is £37,682. The positive
impact of infliximab in terms of reducing the Burden of Illness and mitigating the Wider Societal
Impact of the condition represents additional value for consideration by the committee. Taking into
account the shortfall in quality of life, and in the ability of people to contribute to society as a result
of their experience with moderately to severely active UC, it is likely that infliximab represents a
cost-effective treatment in first-line biologic treatment of UC.
MSD. Manufacturer submission of evidence: IFX (Remicade)64
The GOL submission states that ‘At £27,322, the ICER for golimumab falls under a £30,000 threshold, and
thus golimumab can be considered a cost-effective treatment option for patients with moderately to
severely active UC’.66
Importantly, both of these economic conclusions are based on a comparison of biological therapy versus
immediate colectomy. A fully incremental analysis is presented in Tables 49 and 50. Given the ordering
of QALY gains across all treatment options, IFX should be compared against GOL, thus resulting in a
considerably higher ICER of approximately £75,000–80,000 per QALY gained (note: the discussion around
the discrepancy between model results, see Inconsistencies between results of the Merck Sharp & Dohme
Ltd golimumab and infliximab models).
Inclusion of a Patient Access Scheme for golimumab which has not yet been agreed by
the Department of Health
Both MSD submissions include a PAS in which 100mg of GOL will be made available at the same price as
50mg of GOL (see MSD GOL submission,66 p. 8). However, at the time of this assessment, the proposed
PAS had not been agreed with the Department of Health. Although the MSD submissions include a
secondary analysis in which the PAS is not included, the absence of fully incremental comparisons by
the manufacturer (see Failure to undertake an incremental analysis) clouds the correct interpretation of the
economic analysis. The amended results of this fully incremental analysis, which excludes the PAS,
are shown in Tables 52 and 53.
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The exclusion of the PAS discount for 100mg of GOL results in a situation whereby ADA is no longer
dominated and GOL is ruled out because of extended dominance. Based on this version of the model, the
ICER for ADA versus colectomy is approximately £30,000 per QALY gained. The ICER for IFX versus ADA is
at best £53,258 per QALY gained.
Adalimumab, golimumab and infliximab, for the treatment of ulcerative
colitis (subacute): AbbVie submission62
The AbbVie submission details the methods and results of a de novo health economic model developed to
assess the cost-effectiveness of ADA versus ‘standard of care’ (conventional non-biological therapies) for
the treatment of moderate to severe UC.
AbbVie model scope
The AbbVie model includes a comparison of two options: (1) ADA and (2) ‘standard of care’ (standard
non-biological therapies) for the treatment of moderate to severe UC from the perspective of the UK NHS.
The intervention arm (ADA plus standard non-biological therapies) begins with an induction dose of
160mg of ADA at week 0, followed by 80mg of ADA at week 2, and a maintenance dose of 40mg of
TABLE 53 Model results from IFX submission64 (excluding PAS)
Treatment QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER (£)
Probabilistic model results
IFX 5.68 44,126.44 0.22 11,920.92 53,258
GOL 5.51 37,198.73 – – Extendedly dominated
ADA 5.46 32,205.53 0.54 16,445.78 30,428
Colectomy 4.92 15,759.75 – – –
Results based on point estimates of parameters
IFX 5.66 42,919.73 0.21 11,682.36 55,5077
GOL 5.51 36,663.51 – – Extendedly dominated
ADA 5.45 31,237.38 0.51 15,447.78 30,319
Colectomy 4.94 15,789.59 – – –
TABLE 52 Model results from GOL submission66 (excluding PAS)
Treatment QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER (£)
Probabilistic model results
IFX 5.67 44,122.45 0.21 11,911.17 56,268
GOL 5.50 37,306.74 – – Extendedly dominated
ADA 5.45 32,211.28 0.53 16,409.68 30,724
Colectomy 4.92 15,801.60 – – –
Results based on point estimates of parameters
IFX 5.65 43,091.60 0.20 11,721.32 57,980
GOL 5.50 36,805.33 – – Extendedly dominated
ADA 5.45 31,370.28 0.50 15,576.02 31,069
Colectomy 4.95 15,794.26 – – –
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ADA every other week starting from week 4. At week 8, those patients who achieve remission or response
continue to receive ADA, and those patients who have lost response to the initial treatment can
dose-escalate to 40mg of ADA every week. At week 104, patients in the moderate to severe health state
are assumed to discontinue ADA and subsequently receive conventional non-biological treatment only.
The comparator group within the model comprises conventional non-biological drug treatments
(anti-inflammatory drugs or immunosuppressants). Patients without response or remission in either
treatment group can progress to colectomy at any time. Surgery is assumed to be reserved for patients
who have failed both biological and non-biological drug treatments but is not evaluated as a treatment
comparator in the model. Other biological agents used for the treatment of UC (GOL and IFX) are not
included in the AbbVie economic analysis.
The economic evaluation takes the form of a cost–utility analysis whereby the primary health economic
outcome is the incremental cost per QALY gained over a 10-year time horizon. The base-case population
considered relates to patients with moderate to severe UC who are have not previously been exposed to
anti-TNF-α therapy and those who have previously been exposed to anti-TNF-α therapy (excluding ADA).
Patients who are naive to anti-TNF-α agents were evaluated as a secondary sensitivity analysis. Patients are
assumed to have a mean body mass of 75 kg and the starting age of patients entering the model is
unclear in both the submission and the model. Costs and health outcomes are discounted at 3.5%. Costs
were valued at 2013 prices.
AbbVie model structure
The model adopts a Markov approach using a 2-week cycle length (Figure 84). The model includes a total
of 11 health states: three pre-surgery states for ADA, three pre-surgery states for conventional treatments,
one surgery state and four post-surgery states. These states are: (1) mild (ADA); (2) remission (ADA);
(3) moderate to severe (ADA); (4) mild (conventional treatment); (5) remission (conventional treatment);
(6) moderate to severe (conventional treatment); (7) surgery; (8) post surgery without complications;
(9) transient complications; (10) chronic complications; and (11) surgery-related death.
The three pre-surgery health states (remission, mild, and moderate to severe disease states) were defined
using the Mayo scoring system (or partial Mayo scores if full Mayo scores were not available).
The model comprises two treatment phases: (1) an induction phase; and (2) a maintenance phase. The
induction phase relates to the first 8 weeks of treatment, in line with recommendations from the EMA.132
For the ADA group, patients who are in the remission or mild disease states at this time point are assumed
to continue to receive ADA into the maintenance period (8–52 weeks). At the end of week 8, patients in
the moderate to severe disease state are assumed to be non-responders to ADA; these patients
Pre-Surgery States Surgery and Post-Surgery States
Remission
Surgery
Mild Moderate-to-
Severe
Transient
Complication
Chronic
Complication
Surgery-Related
Death
Post-Surgery
without
Complication
FIGURE 84 AbbVie model structure.62 Reproduced with permission.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
discontinue treatment with ADA and subsequently receive conventional non-biological therapy. Between
week 8 and week 104, patients who have previously achieved remission or response but subsequently
lost that response or remission are assumed to either discontinue ADA treatment or to dose escalate to
40mg of ADA every week. Within the conventional management group, patients transit between the
conventional management health states without entering the biological states.
For both the ADA and the conventional management groups, only patients in the moderate to severe
health state are allowed to transit to surgery. Surgery is treated as a tunnel state, whereby patients can
remain in that state for one cycle only. Patients can transit between the ‘transient complication’ state and
‘post-surgery without complication’ state during any cycle. Patients experiencing chronic complications are
assumed to remain in that state until the time horizon has been exhausted. Patients undergoing surgery
are assumed to be at an increased risk of death. Other-cause mortality is not included in the model. All
patients enter the model in the pre-surgery moderate to severe state, in line with the inclusion criteria for
the ULTRA2 trial.45 A half-cycle correction was applied to costs and QALYs. The main driver of health
benefits within the model relates to HRQoL benefits associated with increased sojourn time in the
pre-surgical health states.
Serious and severe AEs were not considered in the AbbVie model; the manufacturers’ submission notes
that most AEs experienced by patients in the ULTRA2 trial45 were non-serious and considered to be
unrelated to the study drugs.62 In addition, the manufacturer highlights that the ULTRA2 trial reported
slightly higher incidences of serious and severe AEs in the PBO arm than in the ADA arm of the trial;
therefore, considering serious and severe AEs in the model would have increased medical costs and
reduced health gains within the conventional management group.62 Therefore, the exclusion of these
events represents a conservative assumption.
The model includes the costs associated with drug acquisition, medical costs related to disease states,
hospitalisation, surgery, surgery-related complications and costs associated with surgery-related death.
The model uses simple matrix multiplication to determine health state populations during each model cycle
based on the state population in the previous Markov cycle and a series of time-dependent transition
matrices. Costs and utilities are attached to each health state. Total QALYs are modelled as a function of
sojourn time in each health state, together with an indirect survival benefit for ADA as a consequence
of reduced rates of surgery (and hence surgical-related mortality) for this group.
Evidence used to inform the model parameters
A summary of evidence sources used to inform the main groups of parameters within the model is
presented in Table 54.
Methods for modelling effectiveness
For the most part, estimates of baseline and relative effectiveness were taken from the ULTRA2 study and
the ULTRA1/2 extension study,45,62,126 although other literature was used to inform transitions that were not
observed within these studies.121,133 Efficacy data on response/remission from the ULTRA1 trial were not
used in the AbbVie model. Transition probabilities between pre-surgery health states were calculated using
trial data from ULTRA245,126 for weeks 8–104 while transitions between states for cycles from week 104
to 520 were based on data from the ULTRA1/2 extension study62 for ADA and ULTRA245,126 for
conventional management. Discontinuations owing to other reasons, such as AEs, were also considered
based on trial data.
Four matrices of time-dependent transition probabilities are used within the AbbVie model, according to
four time intervals; these are described below.
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Transition probabilities: adalimumab group
Period 1 (weeks 0–8)
In the induction period, transitions from the moderate to severe state were based on the ADA arm of the
ULTRA2 trial.45,126 As ULTRA2 did not recruit patients with prior response or remission (because it was an
induction trial), this study cannot provide information relating to transitions from these states to other
states within the first 8-week period. Instead, the probabilities of maintaining remission and response were
based on studies reported by Kane et al.133 (assuming the probability of maintaining remission reflects that
of ‘adherent patients’) and Odes et al.121 A constant hazard was assumed to obtain the 8-week probability
in both cases.
Period 2 (weeks 8–52)
Transition probabilities were based on a cross-tabulation of data on the number of patients in each health
state from the ADA arm of the ULTRA2 trial.45,126
Period 3 (weeks 52–104)
Data from the ULTRA1 and ULTRA2 extension study62 were used to derive transition probabilities for
the three pre-surgery health states. As patients in the moderate to severe state within the ADA group
of the model are assumed to discontinue biological treatment, only those patients who were randomised
to the ADA arm and who had remission or mild disease at week 8 in the ULTRA1/2 extension study62 were
included in the analysis.
TABLE 54 Summary table of evidence sources used to inform the AbbVie model parameters
Parameter group Source
Transition probabilities: pre-surgical states ULTRA2 trial45,126 and ULTRA1/2 extension study62 and other literature121,133
with the cycle length of matrix probabilities adjusted using Eigenvalue
decomposition
Transition probabilities: rate of surgery Hillson et al.134
Transition probabilities: post-surgery
complications and surgery related-mortality
Transition complications rates estimated from Swenson et al.115 Chronic
complication rates estimated using studies by Johnson et al.135 (fertility),
Kruasz andDuek136 (male impotence) and Abdelrazeq et al.137 (chronic
pouchitis). Perioperative and post-operative mortality risks were estimated
using a study reported by Roberts et al.138
Health utilities for pre-colectomy
response/remission
EQ-5D study published as a poster by Swinburn et al.139
Health utilities for post-colectomy states Utility values for postsurgery without complication and transient
complication based on estimates reported by Tsai et al.82 Utility values for
chronic complications based on Arseneau et al.,110 Hu et al.140 and Smith
and Roberts141
Resource use ADA dosing and dose escalation based on SmPC and experience within
the ULTRA2 trial.45,126 Use of conventional non-biological treatments was
based on UC-related medication usage rates for all subjects at baseline, as
observed in the ULTRA 2trial.45,126 Disease state resource use was based on
the estimates reported by Tsai et al.82 Rates of hospitalisation were based
on a mixed effects regression analysis of ULTRA1 and ULTRA2 trial data62
Unit costs Drug acquisition costs (biologicals and conventional treatments) were
taken from the MIMS.142 Hospitalisation costs were based on NHS
Reference Costs130 Other unit costs derived from literature82,115,143
MIMS, Monthly Index of Medical Specialities.
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Period 4 (weeks 104–260)
Data from week 48 to week 144 of the ULTRA1/2 extension study62 were used to generate the transition
matrix. A multinomial logit regression model was constructed to estimate the transition matrix during each
48-week interval. The dependent variables were the three pre-surgery health states and the independent
variables were the health states in the previous visit. The logit model estimates mean predicted
probabilities of being in one of the health states given a specific health state at the previous visit.
These four transition matrices were then converted to 2-week probabilities using Eigenvalue matrix
decomposition methods reported by Craig and Sendi.144 The resulting matrices are shown in Table 55.
Transition probabilities: conventional management group
Period 1 (weeks 0–8)
In the induction period, transitions from the moderate to severe state were based on the PBO group
outcomes within the ULTRA2 trial.45 As with the ADA matrix for the induction period, estimates of
maintaining remission and response were based on studies reported by Kane et al.133 (assuming the
probability of maintaining remission reflects that of ‘non-adherent patients’) and Odes et al.121 A constant
hazard was assumed to obtain the 8-week probability in both cases.
TABLE 55 Adalimumab group: 2-week transition probabilities for pre-surgery states by time interval
From state
To state
Remission Mild Moderate to severe Surgery
From week 0–8
Remission 0.9974 0.0007 0.0019 –
Mild 0.0003 0.9981 0.0016 –
Moderate to severe 0.0551 0.0986 0.8432 0.0031
From week 8–52
Remission 0.9700 0.0164 0.0136 –
Mild 0.0349 0.9400 0.0251 –
Moderate to severe 0.0001 0.0215 0.9753 0.0031
From week 52–104
Remission 0.9889 0.0000 0.0111 –
Mild 0.0178 0.9436 0.0385 –
Moderate to severe 0.0275 0.0217 0.9477 0.0031
Week 104 onward
Remission 0.9949 0.0047 0.0004a –
Mild 0.0113 0.9869 0.0018a –
Moderate to severe 0.0037 0.0019 0.9463a 0.0031
a A total of 4.54% of patients reaching the moderate to severe disease state after week 104 discontinue ADA treatment
and subsequently receive conventional treatment.
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Period 2 (weeks 8–52)
Transition probabilities were based on a cross-tabulation of data on the number of patients in each health
state from the PBO arm of the ULTRA2 trial.45,126
Periods 3 and 4 (weeks 52–260)
Transition probabilities for each cycle were assumed to reflect those estimated for period 2 (weeks 8–52).
As with the ADA group, these four transition matrices were then converted to 2-week probabilities using
Eigen matrix decomposition methods reported by Craig and Sendi.144 The resulting matrices are shown in
Table 56.
Transitions between surgery and post-surgical states
Transitions between surgery and post-surgical health states were based on the literature rather than the
clinical studies of ADA. Complication rates were estimated from a study reported by Swenson et al.115
Chronic complication rates were estimated using studies by Johnson et al.135 (fertility), Kruasz and Duek136
(male impotence) and Abdelrazeq et al.137 (chronic pouchitis). Perioperative and post-operative mortality
risks were estimated using a study reported by Roberts et al.138 taking account of background mortality
rates. The underlying transition rates are assumed to be time independent. The resulting matrix is shown in
Table 57.
TABLE 56 Conventional management group: 2-week transition probabilities for pre-surgery states by time interval
From state
To state
Remission Mild Moderate to severe Surgery
From week 0–8
Remission 0.9799 0.0044 0.0157 –
Mild 0.0013 0.9844 0.0143 –
Moderate to severe 0.0291 0.0882 0.8796 0.0031
From week 8–52 (and subsequent cycles)
Remission 0.9696 0.0028 0.0276 –
Mild 0.0170 0.9217 0.0613 –
Moderate to severe 0.0017 0.0074 0.9878 0.0031
TABLE 57 Transition matrix for surgery and post-surgical states (all time periods, both treatment groups)
From state
To state
Surgery
Post-surgery without
complication
Transient
complication
Chronic
complication Death
Surgery 0.0000 0.7708 0.0101 0.1919 0.0272
Post-surgery without complication 0.0000 0.9893 0.0101 0.0000 0.0006
Transient complication 0.0000 0.9994 0.0000 0.0000 0.0006
Chronic complication 0.0000 0.0000 0.0000 0.9994 0.0006
Death 0.0000 0.0000 0.0000 0.0000 1.0000
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Health-related quality of life
Table 58 reports the HRQoL values used in the AbbVie model and their sources.
The AbbVie submission argues that although it would have been possible to map SF-6D utility estimates
from the ULTRA2 trial onto the EQ-5D, this is likely to overestimate the level of HRQoL of patients with
more severe disease. Health utilities for the pre-surgery states were instead sourced from an EQ-5D study
of 230 patients with UC reported by Swinburn et al.139 This study has been published in abstract form only;
however, further details are provided in appendix 3 of the AbbVie submission.62 Utility values for the states
of post surgery without complications and post surgery with transient complications were taken from Tsai
et al.82 The utility for the chronic complication state was estimated by using a weighted value of rates and
HRQoL impacts of chronic pouchitis (Arseneau et al.110), infertility (Hu et al.140 and male sexual dysfunction
(Smith and Roberts141).
Resource use and costs
Table 59 summarises the values of the resource use and cost parameters used in the AbbVie model.
Drug acquisition costs (adalimumab and conventional management)
Usage of ADA was based on its licensed indication132 together with estimates of relative dose intensity for
dose escalating patients based on the primary analysis of data from the ULTRA2 trial45 and the ULTRA1/2
extension study.62 The use of conventional non-biological therapies was assumed to reflect the baseline
usage of these therapies within the ULTRA2 trial.45,126 The drug acquisition costs for ADA and conventional
non-biological therapies were obtained from the Monthly Index of Medical Specialities (MIMS) database.142
TABLE 58 Health utilities assumed in the AbbVie model62
Disease State Utility Source
Remission 0.91 Swinburn et al.139
Mild 0.80 Swinburn et al.139
Moderate to severe 0.55 Swinburn et al.139
Surgery 0.55 Assumed to same as moderate to severe state
Post-surgery without complication 0.61 Tsai et al.82
Transient complication 0.55 Tsai et al.82
Chronic complication 0.43 Weighted mean of Arseneau et al.,110 Hu et al.140 and Smith and Roberts141
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Health state resource costs
Other UC health state costs assumed in the AbbVie model are summarised in Table 60.
The frequency of hospitalisations per 2-week cycle was estimated according to treatment arm and disease
severity using mixed effects regression on pooled data from the ULTRA1 and ULTRA2 trials.44,126 Other
disease state resource use (consultant visits, blood tests and emergency/elective endoscopies) were taken
from Tsai et al.82 and uplifted to current prices.128 Hospitalisation and post-surgery terminal care costs were
obtained from NHS Reference Costs 2012/13.130 The costs of surgery and managing complications were
taken from Buchanan et al.143 and Swenson et al.115
Model evaluation and uncertainty analysis
The results of the AbbVie economic analysis are presented as an ICER; this is based on the point estimates
of parameters rather than the expectation of the mean. Uncertainty surrounding incremental costs and
outcomes was examined using deterministic sensitivity analyses and PSA. The PSA was undertaken over
1000 Monte Carlo samples. The results of the deterministic analyses are presented as tornado diagrams
while the results of the PSA are presented as cost-effectiveness planes and CEACs.
TABLE 59 Drug resource cost parameters used in the AbbVie model
Parametersa Parameter values Sources
ADA dose escalation: increased dose intensity compared with 40mg EOW
Week 8–52 maintenance phase 7.40% Primary analysis of ULTRA245 and
ULTRA1 and ULTRA2 extension study62
Week 52–104 maintenance phase 24.06%
Beyond week 104 maintenance phase 21.49%
Use of conventional therapies
Mesalazine 47.0% Based on baseline usage in ULTRA245,126
Sulfasalazine 7.3%
Balsalazide 5.9%
Olsalazine 0.2%
AZA 28.3%
Mercaptopurine 6.7%
Drug acquisition costs
ADA unit price (40mg) £352.14 MIMS (March 2014)
Mesalazine £20.59 MIMS (March 2014)
Sulfasalazine £2.93
Balsalazide £13.10
Olsalazine £9.88
AZA £2.89
Mercaptopurine £105.99
Total weighted conventional therapy cost
per 2-week cycle
£18.60
EOW, every other week; MIMS, Monthly Index of Medical Specialities.
a Assumptions regarding specific products, doses, frequency and price are not clear from the AbbVie submission.
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AbbVie model results
Tables 61 and 62 present the results of the AbbVie model for the base-case analysis and the secondary
analysis of the subgroup of patients who are anti-TNF-α naive. Note that the probabilistic ICERs presented
in these tables have been generated by the Assessment Group.
The base-case analysis of the model indicates that over a 10-year time horizon, ADA is expected to
generate an additional 0.73 QALYs at an incremental cost of £25,335 per patient. This leads to an ICER of
£34,590 per QALY gained. The results of the model based on the point estimates of parameters are very
similar to those produced using the probabilistic model.
The deterministic subgroup analysis of anti-TNF-α-naive patients indicates that over a 10-year time horizon,
ADA is expected to generate an additional 0.87 QALYs at an incremental cost of £31,140 per patient.
This leads to an ICER of £35,970 per QALY gained. It was not possible to generate probabilistic estimates
for the subgroup analysis as the subgroup model does not include a PSA subroutine.
Figures 85 and 86 present the cost-effectiveness plane and CEACs for the base-case analysis.
TABLE 60 Other health state costs used in the AbbVie model
Parameters Values Sources
Hospitalisations per 2-week cycle
Remission: ADA 0.0008 Mixed effects regression analysis of ULTRA1 and ULTRA2
trial data44,126
Mild: ADA 0.0013
Moderate to severe: ADA 0.0042
Remission: conventional management 0.0017
Mild: conventional management 0.0029
Moderate to severe: conventional management 0.0094
Hospitalisation costs
Cost per hospitalisation £3533 NHS Reference Costs 2012/13130 (Major Gastrointestinal
Disorders with CC score 0, elective inpatient, PA25B)
Pre-surgery disease state costs (excluding hospitalisation) per 2-week cycle
Remission £20.31 Derived using Tsai et al.82 Includes blood tests,
consultation visits, and endoscopies
Mild £67.87
Moderate to severe £203.27
Post-surgery disease state costs per 2-week cycle
Surgery £13,071 Based on Buchanan et al.143 and inflated to 2013 prices
Postsurgery without complication £118.63 Derived using Tsai et al.82 including blood tests,
consultation visits, and endoscopies
No hospitalisations were considered for post-surgery
without complication
Transient complication £8826.05 Based on Swenson et al.,115 inflated and exchange-rate
adjusted to 2013 prices
Chronic complication £118.63 Assumed to be the same as postsurgery without
complication
Terminal care £3533 NHS Reference Costs 2012/13130 (Major Gastrointestinal
Disorders with CC score 0, elective inpatient, PA25B)
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TABLE 62 Model results obtained from the AbbVie model: anti-TNF-α-naive subgroup
Treatment QALYs Costs Incremental QALYs Incremental costs ICER
Probabilistic model resultsa
ADA Subgroup model does not allow for PSA
Conventional management
Results based on point estimates of parameters
ADA 6.00 £79,799 0.87 £31,140 £35,970
Conventional management 5.140 £48,659 – –
a Generated by the Assessment Group.
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FIGURE 85 Cost-effectiveness plane reported by AbbVie: base-case analysis.62 Reproduced with permission.
TABLE 61 Model results obtained from the AbbVie model: base-case analysis
Treatment QALYs Costs Incremental QALYs Incremental costs ICER
Probabilistic model resultsa
ADA Treatment-specific costs and
QALYs not stored in PSA
subroutine
0.73 £25,335 £34,590
Conventional management – –
Results based on point estimates of parameters
ADA 5.73 £76,392 0.74 £25,446 £34,417
Conventional management 4.99 £50,946 – –
a Generated by the Assessment Group.
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The cost-effectiveness plane indicates that ADA is consistently expected to be more effective and more
expensive than conventional management. Assuming a willingness-to-pay threshold of £20,000 per
QALY gained, the probability that ADA produces more net benefit than conventional management is
approximately 0.01. Assuming a willingness-to-pay threshold of £30,000 per QALY gained, the probability
that ADA produces more net benefit than conventional management is approximately 0.30.
The deterministic sensitivity analysis undertaken by the manufacturer indicate that the model is most
sensitive to assumptions concerning disease state costs and the health state utilities. Given the narrow
scope of the AbbVie economic analysis, the cost-effectiveness of ADA compared with other biological
therapies or surgery is unknown.
Critical appraisal of the AbbVie model
The main issues identified by the Assessment Group are presented in Box 3 and discussed below.
Deviations from NICE reference case and final NICE scope
The extent to which the economic analyses reported in the AbbVie submissions adhere to the NICE
reference case is presented in Table 63.
Overall, the economic analysis undertaken by AbbVie is generally in line with the NICE reference case.
However, similar to the MSD submissions,64,66 the two most notable concerns relate to the choice of
comparators and the adoption of a short model time horizon (10 years).
1.0
0.9
0.8
0.7
0.6
0.5
Pr
o
b
ab
ili
ty
 A
D
A
 is
 c
o
st
-e
ff
ec
ti
ve
0.3
0.4
0.2
0.1
0.0
£0 £10,000 £20,000 £30,000 £40,000 £50,000
ICER per QALY
CEAC: ADA + SOC vs. SOC
£60,000 £80,000£70,000 £90,000 £100,000
FIGURE 86 Cost-effectiveness acceptability curve reported by AbbVie: base-case analysis. Adapted from
AbbVie submission.62
BOX 3 Main problems and concerns relating to the AbbVie model
1. Deviations from the NICE reference case and final NICE scope, particularly with respect to omission of other
biologicals and surgery as comparators.
2. Questionable choice of cycle length necessitating the use of other external evidence on transition
probabilities, which should not be required.
3. Concerns regarding the selection and use of evidence to inform HRQoL parameters.
4. Questionable source of surgery rate.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
159
TABLE 63 Adherence of the AbbVie model to the NICE reference case78
Element of HTA Reference case Assessment Group comments
Defining the decision problem The scope developed by the institute
(NICE)
The scope of the analysis deviates from the final
scope from NICE
Comparator(s) As listed in the scope developed
by NICE
The comparator is limited to ‘standard of care’
(conventional non-biological therapies) only. The
model does not include other biological agents
(IFX and GOL) included in the final NICE scope.
The model does not include surgery as a
comparator
Perspective on outcomes All direct health effects, whether for
patients or, when relevant, carers
Health outcomes reflect those of patients
with UC
Perspective on costs NHS and PSS The economic analysis was undertaken from the
perspective of the UK NHS. PSS costs are not
mentioned in the submission
Type of economic evaluation Cost–utility analysis with fully
incremental analysis
The economic analysis takes the form of a
cost–utility analysis of the two included options
Time horizon Long enough to reflect all important
differences in costs or outcomes
between the technologies being
compared
Costs and outcomes are evaluated over a
10-year time horizon. Analyses over a lifetime
horizon are not presented in the manufacturers’
submission nor are they possible within the
implemented model structure
Synthesis of evidence on
health effects
Based on systematic review Although the submission mentions other
relevant trials of IFX and GOL, the manufacturer
opted to undertake a ‘within-trial’ analysis of
ADA vs. conventional management using
efficacy data from the ULTRA2 trial45,126 only
Measuring and valuing
health effects
Health effects should be expressed in
QALYs. The EQ-5D is the preferred
measure of HRQoL in adults
Health effects are assessed in terms of QALYs.
The EQ-5D has been used to assign specific
utility values for health states, but weighted
averages from other instruments (i.e. TTO) have
also been used to value the post-surgery
chronic complications health state
Source of data for
measurement of HRQoL
Reported directly by patients and/or
carers
It would have been possible to map from the
SF-6D in the ULTRA2 trial45,126 to the EQ-5D.
Instead, the manufacturer used data from
Swinburn et al.139 to value pre-surgery statesSource of preference data for
valuation of changes in HRQoL
Representative sample of the UK
population
Equity considerations An additional QALY has the same
weight regardless of the other
characteristics of the individuals
receiving the health benefit
No equity weighting is applied
Evidence on resource use
and costs
Costs should relate to NHS and PSS
resources and should be valued
using the prices relevant to the NHS
and PSS
The economic analysis was undertaken from the
perspective of the UK NHS
Discounting The same annual rate for both costs
and health effects (currently 3.5%)
The model uses a discount rate of 3.5% for
costs and health outcomes
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The AbbVie economic analysis includes only two treatment options: (1) ADA; and (2) conventional
non-biological treatments. The analysis excludes other relevant biological therapies for the treatment of UC
(IFX and GOL) and elective surgery. The appendix to the main submission states that:
Other anti-TNF therapies which are being appraised as part of this NICE MTA, namely infliximab and
golimumab, were not considered as comparators in the present evaluation as they are not NICE
recommended for this patient population and therefore would not form routine standard of care
at present.
AbbVie submission to NICE62
However, IFX and GOL were listed in the final NICE scope and hence they should have been included in
the economic analysis. As a consequence of their omission, the AbbVie model adopts a very narrow scope
and provides no information regarding the comparative cost-effectiveness of the full range of biological
treatment options within this appraisal.
The main submission from AbbVie states a number of arguments regarding why it would not be appropriate
to undertake a formal NMA (see AbbVie submission,62 pp. 67–8). The main arguments stated are:
l Differences in Mayo score estimation between the relevant trials.
l PBO responses have been shown to differ markedly depending on the severity of the trial population,
study design and country or region in which the trial was conducted.
l Other differences in trial design, that is, the use of adaptive design in the PURSUIT trial,47 differences in
time points for the assessment of induction response, eligibility criteria relating to prior treatment
failures, prior use of biologicals, steroid tapering, open-label escape allowance, timing of efficacy
assessments and study durations.
However the Assessment Group do not agree that a NMA is inappropriate and AbbVie’s justifications for
not undertaking such an analysis appear to be flawed. Notably, UC is a chronic disease characterised by
ongoing inflammation over time; fluctuations in Mayo score evaluations over the course of 3 days are likely
to be minor and hence the use of alternative scoring systems between trials is unlikely to produce any
substantial bias. Furthermore, no two trials are identical. Although it is useful to highlight potential sources
of heterogeneity between studies (and this is done well by AbbVie), the Assessment Group does not
believe that the presence of this heterogeneity provides a sufficient basis for ignoring treatment options
relevant to the decision problem.
In addition, the AbbVie model explicitly excludes elective colectomy as a comparator from the analysis.
The appendix to the main AbbVie submission states that:
Surgery is an important treatment option in UC clinical management and is reserved for patients who
have an inadequate response with, are contraindicated to or intolerant of conventional standard of care.
Surgery is unlikely to be a first line option for moderately to severely active UC patients. Consistent with
this approach, surgery is included in the model as the treatment option for a proportion of patients who
failed SOC or ADA+SOC treatment, but not as a comparator to ADA+SOC.
AbbVie submission to NICE62
As this option was specified in the final agreed NICE scope, and because the appraisal does not relate to
first-line treatment, it should have been included in the economic analysis.
It should also be noted that the AbbVie model time horizon is constrained to 10 years (260 2-week cycles).
This shorter time horizon is used as a justification for excluding other-cause mortality from the model.
The model does not include the functionality to consider longer time horizons; it is unclear whether or not
the profiles of incremental costs and health outcomes for ADA versus conventional management would be
similar over longer time horizons.
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Questionable choice of cycle length necessitating the use of other evidence on
transition probabilities
The cycle length adopted within the AbbVie model is 2 weeks. This short cycle length was selected
‘to accommodate the ADA dosing schedule.’62 Given that all patients enter the model in the
‘moderate to severe’ health state in line with the ULTRA2 trial, this choice of cycle length leads to a
necessity to incorporate data from other literature121,133 to populate the transition probabilities from the
‘mild’ and ‘remission’ health states to other health states. As a consequence, there is some discrepancy
between the observed pre-surgery health state distribution following induction in the ULTRA2 trial45,126 and
the pre-surgery health state distribution following induction estimated by the model (Table 64). Given a
longer cycle length for induction, that is the 6 weeks used in the trial, it would have been unnecessary to
include other data on transition probabilities and the predictions of the model would have likely been
more accurate.
Concerns regarding the selection and use of evidence to inform health-related
quality-of-life parameters
The ULTRA2 trial45,126 did not collect HRQoL data from patients using the EQ-5D; however, the SF-36
instrument was included and could be used to derive SF-6D utility values. The manufacturer explored
mapping the SF-6D values to the EQ-5D but noted that this would likely overestimate the level of HRQoL
of patients with more severe disease. Instead, the manufacturer used data from Swinburn et al.139 to
value the pre-surgery health states in the model. Although the Swinburn et al.139 study has been published
only in abstract and poster form, more detail is provided in appendix 3 of the main AbbVie submission.62 It
is noteworthy that the difference in utility for the post-surgery state and the active UC state in the selected
utility values within the AbbVie model (0.61–0.55= 0.06) is smaller than that observed within other EQ-5D
UC valuation studies (e.g. Woehl et al.145 estimated this difference to be approximately 0.71 – 0.41= 0.30).
Therefore, the AbbVie model does not assume that surgery results in a substantial increase in HRQoL in
patients with active disease.
It is also noteworthy that the choices made with respect to the HRQoL values for other post-surgery
health states are not clear from the submission. In particular, the methods for identifying and selecting
studies to value the chronic complications,110,140,141 and the weightings given to each, are unclear from
the AbbVie submission.62 What is clear is that the three valuation studies used to inform the chronic
complications utility values used different health instruments; Hu et al.140 is based on committee valuations
using the Health Utility Index, Arseneau et al.110 reported TTO valuations by UC patients and Smith and
Roberts141 report TTO and VAS valuations. Producing a weighted mean utility from studies that use
different elicitation methods may produce conceptually inconsistent rankings of identical health states.
However, this parameter does not have a material impact on the ICER.
TABLE 64 Comparison of observed and predicted induction outcomes
Treatment group No response Response Remission
ADA group (observed) 0.52 0.33 0.16
ADA group (predicted) 0.51 0.31 0.17
Discrepancy in ADA group (observed – predicted) 0.01 0.02 –0.01
PBO group (observed) 0.67 0.24 0.09
PBO group (predicted) 0.61 0.29 0.09
Discrepancy in PBO group (observed – predicted) 0.07 –0.05 –0.01
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Questionable source of surgery rate
The AbbVie model estimates the 2-week probability of undergoing surgery from a 1-year study reported by
Hillson et al.134 This study was a retrospective analysis of medical claims with and without UC identified
from a population of approximately 500,000 employees, retirees and dependants in the USA. This does
not specifically relate to a moderate to severe UC population and the use of a 1-year study to estimate
long-term risk is concerning, particularly given the availability of other longer studies undertaken in more
relevant UC populations (see Evidence used to inform the model’s parameters).
De novo Assessment Group model
Introduction
In light of the limitations of the models submitted by the manufacturers (see Systematic review of existing
cost-effectiveness evidence), the Assessment Group developed a de novo health economic model to assess
the cost-effectiveness of second-line IFX, ADA and GOL, conventional non-biological therapies and
immediate colectomy for the treatment of patients with moderate to severe UC.
Methods
Model scope
The scope of the economic analysis follows the NICE reference case (summarised in Box 4).
The analysis compares IFX, ADA and GOL against each other and against conventional non-biological
therapy (comprising a mix of 5-ASAs, immunosuppressants and corticosteroids) and immediate colectomy.
IFX is assumed to be given at a dose of 5mg/kg on three visits during induction and subsequently at a
dose of 5mg/kg every 8 weeks for patients who go on to receive maintenance therapy. ADA is assumed
to be given at one dose of 160mg, one dose of 80mg and two doses of 40mg during the induction
phase; a dose of 40mg every other week is assumed for patients who go on to receive maintenance
therapy. A fixed proportion of ADA patients (27%) are assumed to escalate to a 40mg every week dosing
regimen, based on data reported in the AbbVie submission.62 GOL is assumed to be given as one dose of
200mg and one dose of 100mg during induction treatment, with subsequent maintenance therapy given
BOX 4 Scope of the Assessment Group economic analysis
Population: patients with moderate to severe UC who have failed at least one prior therapy.a
Interventions and comparators: 160mg/80mg/40mg of ADA; 5mg/kg of IFX; 200mg/100mg/100mg (50mg)
of GOL; conventional non-biological therapy (comprising a mix of 5-ASAs, immunosuppressants and
corticosteroids); and elective surgery.
Economic outcome: incremental cost per QALY gained.
Perspective: NHS and PSS.
Time horizon: lifetime.
Discount rate: 3.5%.
a The base-case analysis relates to an adult UC population; a secondary analysis is considered for the
paediatric population.
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at a dose of 100mg every 4 weeks for patients with body mass ≥ 80 kg or 50mg every 4 weeks for
patients with body mass < 80 kg. IFX is assumed to be administered in a day-case setting while the
administration of GOL and ADA is not assumed to require any additional NHS resources (no costs are
included for training patients to self-inject). Patients in the non-surgical treatment groups are assumed to
receive conventional background therapies (5-ASAs, immunosuppressants and corticosteroids). Surgery is
included in the economic analysis both as a comparator within the analysis and also as a downstream
component of the pathway for patients in the biological and non-biological treatment groups.
The population within the economic analysis relates specifically to patients with moderate to severe UC
who have failed at least one prior therapy, as reflected in the RCTs included in the systematic review
of clinical effectiveness (see Chapter 3). Patient characteristics are based on the trials included in the
systematic review.44,47–49,126 Patients are assumed to enter the model aged 40 years with a mean body mass
of 77 kg. Thirty two per cent of patients are assumed to have a body mass > 80 kg. Although the main
economic analysis relates to adult patients with UC, a scenario analysis is also presented which compares
IFX with conventional drug treatment and immediate colectomy in paediatric patients with
UC (note: GOL and ADA do not currently have marketing authorisations in paediatric patients66,132).
This secondary analysis should be considered exploratory as the efficacy data are drawn from trials
undertaken within an adult UC population. The economic evaluation takes the form of a cost–utility
analysis; the primary health economic outcome is the incremental cost per QALY gained. All treatment
options are evaluated within a fully incremental analysis within the base case. The perspective of the
economic analysis relates to that of the NHS and PSS. All costs and outcomes are discounted at 3.5%.
Costs and health outcomes are evaluated over a lifetime horizon in the base case; shorter time horizons
are considered as secondary scenario analyses.
Model structure
The Assessment Group model adopts a Markov structure with eight mutually exclusive health states
(Figure 87). The model health states are defined according to whether the patient is alive or dead,
the non-surgical treatment the patient is currently receiving (biological therapy or non-biological therapy),
their prior history of colectomy and their current level of disease control (remission, response and active
UC). Remission and response to treatment are classified according to the Mayo score, as defined within
the trials included in the systematic review (see Chapter 3). Remission is defined as a Mayo score of
≤ 2 points with no individual subscore of > 1 point. Response is defined as a decrease from baseline in the
total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for
rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1. As remission is a
subset of the broader category of response, these are dealt with as mutually exclusive ordered categorical
data (see Chapter 3, Methods for network meta-analysis). Patients without either response or remission are
defined as having active (moderate to severe) UC. The model includes the following health states: (1) on
biological treatment – active UC; (2) on biological treatment – response; (3) on biological treatment –
remission; (4) on conventional treatment – active UC; (5) on conventional treatment – response; (6) on
conventional treatment – remission; (7) post-surgery (with or without complications); and (8) dead. Surgery
is not included as a state but rather it is incorporated as an event; patients undergoing colectomy are
assumed to transit to the post-surgery state if they survive their surgery and the dead state if they do not.
The model time horizon is divided into two main phases: (1) induction and (2) maintenance. The model
adopts an 8-week cycle length for the induction phase and a 26-week cycle length during the subsequent
maintenance phase. During the induction phase, patients receiving biological treatment who achieve
response or remission are assumed to continue receiving the same biological treatment as maintenance
therapy. Patients who do not achieve response or remission during biological induction therapy are
assumed to discontinue that biological treatments and subsequently receive conventional non-biological
treatments. Patients in the conventional treatment group are assumed to continue receiving conventional
therapy irrespective of their response to induction therapy. Patients in the immediate colectomy group are
assumed to undergo surgery during the induction phase of the model and subsequently remain in the
post-surgery state. All patients have a probability of dying from other causes during the induction cycle.
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During the maintenance phase, patients receiving biological therapy are assumed to continue receiving
the same biological treatment for as long as they continue to maintain response/remission. If patients
receiving biological therapy lose their response at any point they are assumed to transit to the active UC
state and subsequently receive conventional therapy. Patients in the conventional treatment group, and
those who have previously achieved but lost response to biological therapy, are assumed to continue
receiving conventional therapy irrespective of whether they achieve response or remission to that
conventional therapy. A time-independent probability of undergoing surgery is applied to those patients
receiving conventional treatment with active UC; the model assumes that this only possible within the
active UC state. Patients in the immediate colectomy group, and those who have undergone surgery after
receiving biological/conventional treatment, remain in the post-surgery state for the remainder of the
model time horizon. All patients have a probability of dying from other causes during each model cycle.
On biological treatment
Non-biological treatment
Post surgery
Dead
Dead
Post surgery
(with/without
complications)c
Active UCb Response Remission
Active UCa
Patient dies
Achieves remission (induction only)
Achieves response (induction only)
Fails to achieve remission/
response (induction only)
Loses remission but
maintains response
Loses response Loses response
Achieves remission
Achieves
response
Loses response Loses remission
Loses remission and response
Achieves
remission
Achieves remission
Response Remission
FIGURE 87 Assessment Group model structure (induction and maintenance phases). a, Patients in the IFX, ADA and
GOL groups begin in this portion of the model; b, patients in the conventional non-biological management group begin
in this portion of the model; and c, patients in the immediate colectomy group begin in this portion of the model.
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Different levels of HRQoL are assigned to each model health state. Disutilities are assigned to those
patients who develop chronic pouchitis – other complications of surgery are assumed to be transient and
are assumed not to have a long-term impact on patients’ HRQoL. QALY gains in each arm of the model
are driven by sojourn time in each of the model’s health states and differential rates of surgery across
the biological groups, the conventional management group and the immediate colectomy group. Resource
costs are assigned in terms of drug acquisition, drug administration (IFX only), surgery and related
complications and UC health state costs (elective/emergency endoscopy, blood tests, consultant visits
and hospitalisations.
The probability of residing in each health state during a given model cycle is estimated using simple matrix
multiplication. Transitions between states are handled within a three-stage competing risks framework
whereby (1) patients undergo transitions between each of the pre-surgical UC treatment states based
on individual transition probabilities estimated using the NMAs (see Chapter 3, Assessment of
effectiveness) and the estimated colectomy rate; (2) the populations of the post-surgery and dead states
are adjusted to reflect surgical mortality rates; and (3) the remaining surviving population is adjusted to
account for other-cause mortality conditional on the patient cohort’s current age. Given the different
durations of the induction and maintenance phases, a half-cycle correction is not applied within the model.
Key model assumptions
The Assessment Group model makes the following key assumptions:
l At the beginning of the maintenance phase, the decision to continue therapy with IFX, ADA and GOL
is determined by the achievement of response or remission at the end of induction.
l During each maintenance cycle, the decision to continue therapy with IFX, ADA and GOL is determined
by the achievement/maintenance of response or remission at the end of the previous
maintenance cycle.
l Patients who discontinue biological therapy are assumed to receive conventional treatment.
l Patients with active UC receiving conventional treatment may undergo colectomy during any cycle;
patients receiving biological therapy will receive at least one cycle of conventional treatment before
transiting to surgery.
l Patients’ HRQoL is assumed to be determined by their level of disease control, whether or not they
have previously undergone colectomy, and the incidence of post-surgical complications.
l With the exception of chronic pouchitis, all surgery-related complications are assumed to occur during
the first cycle following surgery.
l With the exception of chronic pouchitis, surgical complications are assumed to be transient and can be
resolved either through further surgery or through medical management.
l The medical management of surgery-related complications is assumed to require a 7-day admission on
a gastroenterology ward.
l The incidence of chronic pouchitis is assumed to be associated with ongoing additional treatment costs
and a decrement in patients’ level of HRQoL.
Evidence used to inform the model’s parameters
Table 65 summarises the evidence sources used to inform the groups of parameters within the model.
These are described in further detail in the following sections.
Patient characteristics
Patient characteristics were based on data reported within the trials included in the systematic
review44,47–49,126 (see Chapter 3). Patients are assumed to enter the model aged 40 years, 43% of patients
are assumed to be female and patients are assumed to have a mean body mass of 77 kg. Thirty two
per cent of patients are assumed to have a body mass > 80 kg; this estimate was drawn from the MSD
GOL model.66
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Transition probabilities for biological and non-biological therapies
The methods for the NMA models are described in Chapter 3, Methods for network meta-analysis.
Table 66 presents the means and 95% CrIs for transitions within the model (note: all patients in the
colectomy group who survive their surgery are assumed to transit immediately to the post-surgery group).
It should be noted that beyond 1 year, the model repeatedly uses the transition probabilities derived within
the maintenance phase 2 NMA.
Surgery rate
The rate at which patients with moderate to severe UC progress to colectomy was based on estimates
from the literature. A focused MEDLINE search was undertaken to identify studies reporting long-term
rates of colectomy in patients with moderate to severe UC. MEDLINE was searched from inception to
April 2014 using a simple search comprising two search terms: ‘ulcerative colitis/exp’ and ‘colectomy
rate.tw.’ Studies were considered for inclusion in the economic model if they reported on long-term
colectomy rates and if they either related to the moderate to severe population as a collective group of
patients, or if they reported on colectomy rates in moderate and severe UC populations separately.
The MEDLINE search identified 70 citations. Of these, only six studies were identified that reported
on long-term colectomy rates for patients in a selected moderate to severe UC population (Table 67).
TABLE 65 Summary of evidence sources used to inform the model’s parameter values
Parameter group Source(s) used to inform parameter values
Patient characteristics (starting age, mean body mass,
proportion of patients with body mass > 80 kg,
proportion of patients who are female)
Patient age, mean body mass and the probability that a
patient is female were derived from the RCTs included in the
systematic review of clinical effectiveness (see Chapter 3).
The proportion of patients with body mass > 80 kg was taken
from the MSD GOL model66
Pre-surgical health state transition rates induction phase De novo NMA of induction trials
Pre-surgical health state transition rates maintenance
phase
De novo NMA of maintenance trials
Surgery rate during each maintenance cycle Solberg et al.10
Probability of perioperative mortality UK IBD Audit 2012146
Probability of other-cause mortality conditional on
age and sex
ONS life tables for England and Wales 2009–2011147
Health state utilities for all pre-surgical and post-surgical
states
Woehl et al.145
Disutility associated with chronic pouchitis Arseneau et al.110
Biological drug regimen schedules Based on the SmPCs and trials for IFX, ADA and GOL132,148,149
Biological drug regimen usage, duration and dosing Expert opinion (personal communication: Professor Alan Lobo,
Consultant Gastroenterologist, Sheffield Teaching Hospitals)
Probability of surgery-related complications and
proportion of cases requiring surgery/medical treatment
Arai et al.108
Use of other related resources for the management of UC Tsai et al.82
Relative risk of hospitalisation for biologicals vs.
conventional treatment
MSD submissions64,66
Unit costs BNF37 and NHS Reference Costs 2012/13130
ONS, Office for National Statistics.
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TABLE 66 Transition probabilities applied in the Assessment Group model
Transition
Conventional
non-biological
treatment
(95% CrI)
5mg/kg of IFX
(95% CrI)
160mg/80mg/
40mg of ADA
(95% CrI)
200mg/100mg/
50mg of GOL
(95% CrI)
200mg/100mg/
100mg of GOL
(95% CrI)
Induction phase
TP no response to
no response
0.64
(0.57 to 0.71)
0.29
(0.17 to 0.44)
0.49
(0.33 to 0.64)
0.45
(0.26 to 0.64)
0.45
(0.26 to 0.64)
TP no response to
response
0.26
(0.21 to 0.31)
0.35
(0.28 to 0.41)
0.32
(0.25 to 0.39)
0.33
(0.24 to 0.39)
0.33
(0.24 to 0.39)
TP no response to
remission
0.10
(0.06 to 0.15)
0.36
(0.21 to 0.52)
0.19
(0.09 to 0.32)
0.22
(0.09 to 0.39)
0.22
(0.09 to 0.39)
Maintenance phase 1
TP no response to
no response
0.85
(0.75 to 0.92)
1.00a 1.00a 1.00a 1.00a
TP no response to
response
0.10
(0.04 to 0.17)
0.00 0.00 0.00 0.00
TP no response to
remission
0.06
(0.02 to 0.11)
0.00 0.00 0.00 0.00
TP response to
no response
0.52
(0.43 to 0.62)
0.43
(0.22 to 0.66)
0.51
(0.23 to 0.78)
0.40
(0.17 to 0.66)
0.37
(0.15 to 0.62)
TP response to
response
0.27
(0.20 to 0.34)
0.28
(0.19 to 0.37)
0.26
(0.14 to 0.35)
0.28
(0.18 to 0.37)
0.29
(0.18 to 0.38)
TP response to
remission
0.21
(0.12 to 0.31)
0.29
(0.11 to 0.52)
0.23
(0.05 to 0.49)
0.31
(0.11 to 0.59)
0.35
(0.13 to 0.62)
TP remission to
no response
0.35
(0.17 to 0.57)
0.32
(0.08 to 0.65)
0.43
(0.10 to 0.80)
0.18
(0.03 to 0.46)
0.18
(0.03 to 0.47)
TP remission to
response
0.18
(0.07 to 0.32)
0.17
(0.06 to 0.30)
0.17
(0.05 to 0.30)
0.14
(0.03 to 0.28)
0.14
(0.03 to 0.28)
TP remission to
remission
0.47
(0.23 to 0.71)
0.51
(0.18 to 0.83)
0.41
(0.08 to 0.80)
0.69
(0.32 to 0.93)
0.68
(0.32 to 0.93)
Maintenance phase 2
TP no response to
no response
0.97
(0.93 to 1.00)
1.00a 1.00a 1.00a 1.00a
TP no response to
response
0.02
(0.00 to 0.05)
0.00 0.00 0.00 0.00
TP no response to
remission
0.01
(0.00 to 0.04)
0.00 0.00 0.00 0.00
TP response to
no response
0.34
(0.07 to 0.71)
0.25
(0.01 to 0.72)
0.45
(0.06 to 0.89)
0.30
(0.02 to 0.75)
0.41
(0.05 to 0.85)
TP response to
response
0.37
(0.12 to 0.60)
0.34
(0.06 to 0.62)
0.33
(0.07 to 0.56)
0.35
(0.08 to 0.62)
0.34
(0.08 to 0.58)
TP response to
remission
0.29
(0.03 to 0.72)
0.41
(0.03 to 0.89)
0.22
(0.01 to 0.72)
0.35
(0.02 to 0.84)
0.25
(0.01 to 0.74)
TP remission to
no response
0.30
(0.17 to 0.45)
0.25
(0.03 to 0.61)
0.08
(0.01 to 0.29)
0.33
(0.08 to 0.66)
0.27
(0.05 to 0.60)
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TABLE 66 Transition probabilities applied in the Assessment Group model (continued )
Transition
Conventional
non-biological
treatment
(95% CrI)
5mg/kg of IFX
(95% CrI)
160mg/80mg/
40mg of ADA
(95% CrI)
200mg/100mg/
50mg of GOL
(95% CrI)
200mg/100mg/
100mg of GOL
(95% CrI)
TP remission to
response
0.16
(0.03 to 0.45)
0.14
(0.02 to 0.41)
0.08
(0.00 to 0.34)
0.16
(0.02 to 0.41)
0.15
(0.02 to 0.42)
TP remission to
remission
0.54
(0.24 to 0.73)
0.61
(0.17 to 0.93)
0.83
(0.45 to 0.99)
0.52
(0.14 to 0.85)
0.59
(0.17 to 0.89)
TP, transition probability.
a Patients on biological treatment in active UC (no response) are assumed to discontinue and subsequently receive
conventional non-biological treatments.
TABLE 67 Summary of studies reporting on long-term colectomy rates in UC population
Study Population
Follow-up
duration Reported colectomy rate
Actis et al.150 Patients admitted consecutively
to study unit with an attack of
UC and treated with ciclosporin
between January 1991 and
December 1999 (responders
available for analysis, n= 34)
7 years 24/34 (65%)
Gower-Rousseau
et al.151
All patients from the EPIMAD
registry diagnosed with UC
between January 1988 and
December 2002 and who were
< 17 years old at the time of
diagnosis (n= 113)
Median 6.42 years
(range 3.83–
10.42 years)
Approximately 25% (Kaplan–Meier estimate)
Molnár et al.152 UC patients admitted between
1998 and 2005 to tertiary clinic
because of severe exacerbation
of UC requiring parenteral CS
therapy (n= 183)
Average 4.4 years
(range 1.1–10 years)
16/110 (14.5%) steroid-responders,
29/73 (39.7%) steroid- refractory,
overall= 24.6%
Mocciaro et al.153 Two historical cohorts of UC
patients with severe relapse
refractory to i.v. steroid
treatment administered
according to the ‘Oxford
regimen’ (n= 65)
Mean 6.23 years
(± 5.07 years)
IFX group= 60%, ciclosporin group= 30%
Gustavsson et al.13 158 patients with UC treated in
1975–82 with i.v. CS treatment
Median 14.42 years
(range 0.33–
22.58 years)
All UC (n=147): colectomy
rate= approximately 50%, mild UC (n=20):
colectomy rate= approximately 40%,
moderate UC (n=45): colectomy
rate= approximately 50%, severe UC (n=61):
colectomy rate= approximately 62%
Solberg et al.10 Population-based cohort of
843 patients with IBD was
enrolled in south-eastern Norway
Cohort followed up
at 1, 5 and 10 years
Cumulative colectomy rate after
10 years= 9.8% (95% CI 7.4% to12.4%)
CS, corticosteroid.
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Several studies report estimates for patients who have been hospitalised for UC flare; these are likely
to overestimate the true colectomy rate in the moderate to severe population. On consideration of the
remaining studies, the study reported by Solberg et al.10 was selected for inclusion in the model as this
study was large (423 patients completed 10-year follow-up) and did not specifically relate to patients
who had experienced UC flare. A constant 6-month colectomy rate of 0.0051 was applied within the
model. Uncertainty surrounding this probability was modelled using a beta distribution.
Mortality
The model includes two types of mortality: perioperative mortality associated with colectomy and
other-cause mortality. Additional risks of death, for example owing to the increased risk of colorectal
cancer, are excluded from the model as this risk is likely to be small. Perioperative mortality rates were
taken from the third round of the UK IBD audit.146 Within the 2012 publication of the UK IBD audit, there
were 28 deaths reported among 807 elective and emergency surgical episodes in adult patients with UC;
a probability of death of 0.03 is assumed within the cycle in which the patient undergoes surgery.
Other-cause mortality was modelled according to age- and sex-specific life tables from the Office for
National Statistics.147 The annual probability of death during each model cycle was adjusted to reflect the
duration of induction and maintenance cycles (8 weeks and 26 weeks respectively) using standard
methods.154 Uncertainty surrounding the perioperative mortality rate was modelled using a beta
distribution. No uncertainty was modelled for other-cause mortality.
Probability of experiencing surgery-related complications
The trials used to inform the efficacy parameters do not include details of surgery-related complications.
Instead, the model uses data reported in Arai et al.108 to inform parameters relating to the probability
of experiencing transient and chronic surgery-related complications and the probabilities that these
complications are treated using medical or surgical approaches. Given the types of complications reported
in Arai et al.108 (Table 68), the model assumes that all are transient with the exception only of pouchitis.
Therefore, the model assumes that 47.3% (140/296) patients will develop transient complications, with a
further 5% of patients developing chronic pouchitis. Based on the reported timing of complications within
the Arai et al. study,108 the model assumes that all transient complications will arise and will be resolved
during the first cycle following surgery (in those patients who survive their surgery). Chronic pouchitis
is assumed to continue for the remainder of the patient’s lifetime. The model assumes that 19% of
complications require further surgery, while the remaining 81% require medical treatment only.
TABLE 68 Surgery-related complication frequency and treatment approach108
Complication type
Complication frequency Treatment approach
Number of participants
with early complication
Number of participants
with late complication Medical Surgical
Anastomotic stricture 7 56 63 0
Staple line ulcer 9 31 38 2
Pouchitis 0 16 16 0
Bowel obstruction 6 15 16 5
Proctitis 1 17 18 0
Pelvic sepsis 12 2 1 13
Peritoneal abscess 3 0 0 3
Anal fistula 0 12 2 8
Incisional hernia 1 11 0 4
Total 39 160 154 35
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Health-related quality of life
Within the model, HRQoL is assigned according to the level of disease control achieved with drug therapy
(active UC, response, remission), whether or not the patient has previously undergone colectomy and
whether or not the patient is experiencing post-surgical complications. The same utility values are used for
all biological and non-biological drug treatments. The Assessment Group undertook a systematic review
of studies reporting valuations of states relating to different levels of UC control and postsurgery.
Searches were undertaken to identify utilities literature relating to UC, specifically using the EQ-5D
instrument. The following electronic databases were searched from inception for utility published studies:
l MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations: via Ovid – 1946 to January 2014.
l EMBASE: via Ovid – 1974 to January 2014.
l Cochrane Library: via Wiley Interscience
¢ CDSR – 1996 to January 2014
¢ DARE – 1995 to January 2014
¢ CCRT – 1995 to January 2014
¢ Cochrane Methodology Register – 1904 to January 2014
¢ HTA database – 1995 to January 2014
¢ NHS EED – 1995 to January 2014.
l CINAHL: via EBSCOhost – 1982 to January 2014.
l Web of Science Citation Index: via Web of Knowledge – 1900 to January 2014.
l Conference Proceedings Citation Index: via Web of Knowledge – 1990 to January 2014.
l BIOSIS Previews: via Web of Knowledge – 1969 to January 2014.
l EconLit: via Ovid – 1886 to January 2014.
The MEDLINE search strategies are presented in Appendix 10. The search strategy combined free text
and MeSH or thesaurus terms relating to UC combined with terms for specific utility measures or more
general utility terms. The search strategy was translated across all databases. No date or language
restrictions were applied. Literature searches were conducted during January and February 2014.
References were collected in a bibliographic management database, and duplicates were removed.
The results of the search are summarised in Table 69.
TABLE 69 European Quality of Life-5 Dimensions utilities search results
Database Date range Date searched Number of results
MEDLINE (via Ovid) 1946 to January 2014 29 January 2014 52
EMBASE (via Ovid) 1974 to January 2014 29 January 2014 113
CINAHL (via EBSCOhost) 1982 to January 2014 4 February 2014 0
Science Citation Index and Social Science
Citation Index (via Web of Knowledge)
1900 to January 2014 4 February 2014 5
BIOSIS (via Web of Knowledge) 1969 to January 2014 4 February 2014 4
CDSR (via Wiley) 1991 to January 2014 29 January 2014 0
CENTRAL (via Wiley) 1991 to January 2014 29 January 2014 2
Cochrane HTA (via Wiley) 1991 to January 2014 29 January 2014 0
Cochrane DARE (via Wiley) 1991 to January 2014 29 January 2014 0
Cochrane EED (via Wiley) 1991 to January 2014 29 January 2014 0
EconLit (via Ovid) 1886 to January 2014 29 January 2014 1
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Studies were considered potentially includable if they reported EQ-5D utility estimates for multiple UC
health states or if they reported valuations of post-surgery states. The study selection process is shown
in Figure 88.
Of the 177 deduplicated, potentially relevant studies, the full papers of 53 citations were retrieved for more
detailed examination by the Assessment Group based on their titles and abstracts. Of these 53 citations,
10 studies reported EQ-5D estimates for one or more health states relevant to the model.47,49,139,145,155
Seven of these studies reported estimates for multiple pre-surgery UC health states64,66,139,145,155–157 and
the remaining three studies reported estimates only for post-surgery state only (Table 70).158–160 Of the
10 potentially relevant EQ-5D studies, those reported by Woehl et al.145 and Swinburn et al.139 appear to be
the most useful as they are UK based, included a fairly large number of patients (n= 180 and n= 230,
respectively) and have the greatest coverage of the health states in the model (see Table 70).
The study reported by Swinburn et al.139 examines the impact of colectomy on the HRQoL of patients with
UC. A total of 330 participants were recruited into the study, comprising 230 UC patients (30 of whom
had previously undergone surgery) together with 100 age- and sex-matched controls. EQ-5D utilities were
collected via online survey. For both post-surgery patients versus non-surgery patients and post-surgery
patients versus controls, EQ-5D utility scores were compared across IBDQ disease severity. Seventy-eight
patients had remission, 47 patients had mild disease, 31 patients had moderate disease and 44 patients
had severe disease. The utility for patients post surgery was reported to be 0.59 (95% CI 0.55 to 0.63).
For patients who had not undergone surgery, the scores for each disease severity are: remission
utility= 0.91 (95% CI 0.87 to 0.95), mild disease utility= 0.80 (95% CI 0.70 to 0.85), moderate disease
utility= 0.68 (95% CI 0.58 to 0.78) and severe disease utility= 0.45 (95% CI 0.35 to 0.55). Across the
total UC pre-surgery population, the mean EQ-5D utility was reported to be 0.75 (95% CI 0.71 to 0.79).
Similarly, for the matched controls, the mean EQ-5D utility was estimated to be 0.79 (95% CI 0.75 to
0.83). Swinburn et al.139 report that, on average, post-surgery patients reported lower HRQoL scores than
non-surgery patients (p= 0.016) and matched controls (p= 0.03).
Woehl et al.145 collected EQ-5D utility scores from 180 patients with active UC. Within this study
population, the mean age was 55.0 years (SD 14.2) and the mean age at diagnosis was 34.1 years (SD
14.6). UC disease severity groups were categorised by SCAI-2 and were compared with patients with IPAA
and ileostomy. The mean EQ-5D score was 0.73 (SD 0.29). Mean EQ-5D utilities were reported to be 0.87
(SD 0.15) for remission, 0.76 (SD 0.18) for mild disease, and 0.41 (SD 0.34) for moderate to severe
disease. Patients who had undergone IPAA reported an EQ-5D utility of 0.71 (SD 0.29) while patients with
an ileostomy reported an EQ-5D score of 0.72 (SD 0.35). Therefore, the health utility scores for these
surgery states were slightly below a mild disease severity. The difference between these five groups was
statistically significant (p= 0.001).
Potentially relevant citations
identified by the search
(n = 195)
Duplicates removed
(n = 18, records excluded on
title/abstract sift n = 124)
Full papers retrieved
(n = 53)
Studies considered
not relevant
(n = 43)
Full papers considered for
use in the model
(n = 10)
FIGURE 88 Study selection results.
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In the base-case analysis of the Assessment Group model, the Woehl et al.145 study was selected as the
valuation for the surgery state (0.71 to 0.72) is more consistent with the other post-surgery valuations
identified158–160 as compared with the Swinburn et al.139 study.
In order to maintain the ordinal ranking of remission, response and active UC states, remission was
modelled as a baseline utility score parameter, with disutilities used to value the reductions in health
associated with the loss of remission and the loss of response relative to a baseline of remission. The utility
parameter for response is therefore modelled as Utility (remission) minus disutility (loss of remission) while
the utility parameter for active UC is modelled as Utility (remission) minus disutility (loss of remission) minus
disutility (loss of response). The utility score for post-surgery was based on the mean value reported by
Woehl et al.145 (this parameter was not characterised as a health decrement). Uncertainty surrounding the
parameters describing remission utility and post-surgery utility was modelled using beta distributions,
assuming that an equal number of patients were in each UC state. The disutility parameters were based
on the mean and variance of the differences between the health states; this method ensures that the
notionally better health state always has a monotonically better valuation than that for the notionally
worse health state.
As the studies identified for inclusion in the review did not identify any studies that employed the EQ-5D
to value the health loss associated with surgery-related complications, other sources were required.
The Assessment Group model adopts a similar approach to the AbbVie model to value this health decrement
based on the difference between the surgery and chronic pouchitis valuations reported by Arseneau et al.110
(TTO valuation: 0.57 – 0.40= 0.17). It should be noted that this study used scenario-based TTO elicitation
methods and, therefore, deviates from the NICE reference case.78 Health losses associated with transient
complications of surgery are assumed not to last long enough to decrease HRQoL. The utility values in the
model were not adjusted by age. The final utility vector for each treatment option is shown in Table 71.
Resource costs
The model includes resource costs related to drug acquisition, drug administration (IFX only), consultant
visits, emergency and elective endoscopy, hospitalisations, blood tests, surgery and the management of
surgery-related complications.
Biological drug resource use, acquisition and cost
Table 72 shows the dosing regimens and associated costs for each of the biological options within the
model. With the exception of GOL induction therapy, the biological regimen assumed reflects the wording
of the SmPC for that product.132,148,149 It should be noted that the SmPC for GOL recommends that
continued therapy should be reconsidered in patients who show no evidence of therapeutic benefit within
12–14 weeks (after four doses). However, the PURSUIT-SC trial47 evaluated clinical benefits at 6 weeks
TABLE 71 Utility vectors for all states and treatment options
Treatment
Receiving biological treatment Receiving standard care
Post surgeryaNo response Response Remission No response Response Remission
Conventional
management
0.41 0.76 0.87 0.41 0.76 0.87 0.70
IFX 0.41 0.76 0.87 0.41 0.76 0.87 0.70
ADA 0.41 0.76 0.87 0.41 0.76 0.87 0.70
GOL 0.41 0.76 0.87 0.41 0.76 0.87 0.70
Colectomy 0.41 0.76 0.87 0.41 0.76 0.87 0.70
a Including a proportion of patients with chronic pouchitis.
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(after two doses). The costs and benefits of GOL induction are modelled in line with the design of the
PURSUIT-SC trial and, therefore, the costs within the induction phase relate only to the first two doses of
GOL. The dose adjustments for ADA were based on the estimate reported within the AbbVie submission.62
Non-biological drug resource use
The costs of conventional therapies in each UC state are shown in Table 73. These resource costs
were assumed to be the same for all biological options and for the conventional management group.
The treatments, doses and their frequencies were based on expert opinion (Professor Alan Lobo, Sheffield
Teaching Hospitals, April 2014, personal communication) and BNF dosing recommendations. When multiple
products were available, the least expensive was included in the analysis. The model assumes that all
patients would receive 5-ASAs using Ipocol® (Sandoz Ltd) at a dose of 2.4mg/day during induction and
1.2mg/day during maintenance. Ninety per cent of patients are also assumed to receive topical 5-ASAs
(80% enemas, 10% suppositories) during induction; these are assumed to be given for a maximum of
28 days per cycle. Following loss of response, the same therapies may also be used to reinduce response/
remission; these same assumptions are applied during each maintenance cycle to the conventional
management active UC state only. Eighty per cent of patients are assumed to receive 2.5mg/kg of AZA
daily, with the remaining 20% receiving 6-MP at a dose of 1.5 mg/kg daily (note: it is likely that a lower
proportion of patients will actually fulfil the criteria for treatment hence this may be an overestimate). All
patients are also assumed to require one course of oral prednisolone during induction with the dose starting
at 40mg being tapered by 5mg each week until the dose is zero (again, the same assumption is made with
respect to reinduction of response/remission in patients in the conventional management active UC state
during each maintenance cycle). The model does not include estimates of uncertainty around drug usage.
Other ulcerative colitis health state resource use
Health state costs relating to the use of elective and emergency endoscopy, hospitalisations, consultant
visits and blood tests were taken from the previous economic analysis reported by Tsai et al.82 (Table 74).
As Tsai et al.82 did not report any uncertainty around these resource-use estimates, the standard error
was arbitrarily assumed to be equal to 10% of the mean.
TABLE 72 Dosing regimens and costs for biological options
Treatment group
Mean doses and frequency
within cycle Cycle cost (£)
Induction phase (8-week duration)
5mg/kg of IFX 12 × 100mg of IFX
(3 outpatient appointments)
5035.44 (acquisition)+ 893.18
(administration)= 5928.44
160mg/80mg of ADA 4× 40mg ofADA+ 2 × 40mg
of ADA (self-administered)
2817.12
200mg/100mg of GOL 4 × 50mg of GOL+ 2 × 50mg
of GOL (self-administered)
4577.82
Maintenance phase (26-week duration)
5mg/kg of IFX 13.04 × 100mg of IFX
(3.26 outpatient appointments)
5473.79 (acquisition)+ 970.94
(administration)= 6444.73
40mg of ADA EOW dosing (72.6% patients) 13.04 × 40mg of ADA 4593.54
40mg of ADA EW dosing (27.4% patients) 26.08 × 40mg of ADA 9187.08
100mg of GOL (body mass > 80 kg, 31.60% patients) 13.04 × 50mg of GOL 9952.67
50mg of GOL (body mass < 80 kg, 68.40% patients) 6.52 × 50mg of GOL 4976.34
EOW, every other week; EW, every week.
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TABLE 73 Conventional drug regimen costs per induction/maintenance cycle
Drug, brand Regimen assumed (% use) Unit cost
Cost per cycle
(for those
receiving
treatment)
Induction phase (8 weeks)
5-ASAs (oral), Ipocol® 2.4mg/day for 56 days
(100% patients)
400mg (120 tablets)= £17.68 £49.50
5-ASAs (enema), Asacol®
(Warner Chilcott UK Ltd)
1 metered application/day for
28 days (80% patients)
1mg (14 application canister)= £26.72 £53.44
5-ASAs (suppository), Asacol 1.5 g/day for 28 days
(10% patients)
250mg (20 suppository pack)= £4.82 £20.24
AZA, non-proprietary 2.5mg/kg daily for 56 days
(80% patients)
50mg (56 tablets)= £3.85 £14.82
6-MP, Puri-Nethol®
(Teva Pharmaceuticals)
1.5mg/kg daily for 56 days
(20% patients)
50mg (25 tablets)= £50.47 £261.15
Prednisolone (oral),
non-proprietary
40mg tapered by 5mg/week
until dose is zero after 56 days
(100% patients)
5mg (28 tablets)= £1.03 £9.27
Maintenance phase (26 weeks)
5-ASAs (oral), Ipocol® 1.2 g/day for 182.63 days
(100% patients)
400mg (120 tablets)= £17.68 £80.72
5-ASAs (enema), aAsacol® 1 metered application/day for
28 days (80% patients)
1mg (14 application canister)= £26.72 £53.44
5-ASAs (suppository),a
Asacol®
1.5 g/day for 28 days
(10% patients)
250mg (20 suppository pack)= £4.82 £20.24
AZA, non-proprietary 2.5mg/kg daily for 182.63
days (80% patients)
50mg (56 tablets)= £3.85 £48.34
6-MP, Puri-Nethol® 1.5mg/kg daily for 182.63
days (20% patients)
50mg (25 tablets)= £50.47 £851.66
Prednisolone (oral),
non-proprietarya
40mg tapered by 5mg/week
until dose is zero after 56 days
(100% patients)
5mg (28 tablets)= £1.03 £9.27
a Costs included for patients in conventional management active UC state only to reinduce response/remission.
TABLE 74 Ulcerative colitis resource use per year82
Resource item Remission Response No response Post-surgery remission
Post-surgery
complications
Consultant visit 2.00 4.50 6.50 1.50 1.75
Hospitalisation episode 0.30 0.30 0.30 0.00 3.25
Blood tests 3.25 3.90 6.50 1.50 3.25
Elective endoscopy 0.20 0.50 2.00 1.25 0.65
Emergency endoscopy 0.00 0.25 0.75 0.50 0.13
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The MSD submissions to NICE included a meta-analysis in which relative risks were derived for hospitalisations
for 160mg/80mg/40mg of ADA and 5mg/kg of IFX versus conventional treatment.64,66 The MSD NMA did
not include estimates of the relative risk of hospitalisation for GOL versus conventional treatment as this was
not measured in the PURSUIT-Maintenance trial. The relative risk for GOL was assumed to be the same as that
for ADA (the least favourable option); this assumption favours GOL compared with the other options included
in the economic analysis. The relative risks used in the model are shown in Table 75.
Unit costs for ulcerative colitis health state resource use,
surgery and complications
The unit costs for UC health state resource use, surgery and complications were taken from NHS Reference
Costs130 and are shown in Table 76.
Methods for model evaluation
The base-case analysis relates to use of IFX, ADA and GOL within an adult population, based on the
expectation of the mean. The cost-effectiveness of competing options are evaluated within a fully
incremental analysis according to standard cost-effectiveness decision rules.77 Results of the probabilistic
analyses are presented separately for patients for whom colectomy is a potential option and those for whom
it is not. Decision uncertainty is represented using cost-effectiveness planes and CEACs.
TABLE 75 Relative risks of hospitalisation for IFX, ADA and GOL64,66
Drug
Relative risk of
hospitalisation Estimated standard error Comment
IFX 0.64 0.13 Taken from MSD submission NMA64,66
ADA 0.70 0.12
GOL 0.70 0.12 Assumed to be the same as relative risk for ADA
TABLE 76 Unit costs for UC health state resource use, surgery and complications
Item Unit cost (£)
Standard
error (£) Source
Consultant visit 123.43 3.30 NHS Reference Costs 2013,130 WF01A, Gastroenterology,
Non-Admitted Face to Face Attendance, Follow-up
Hospitalisation 2722.96 101.66 NHS Reference Costs 2013,130 FZ37N, Gastroenterology, Inflammatory
Bowel Disease, with Single Intervention, with CC score 0–3
Elective endoscopy 462.36 14.96 NHS Reference Costs 2013,130 FZ51Z, Gastroenterology, Diagnostic
Colonoscopy, 19 years and over
Emergency
endoscopy
512.62 26.20 NHS Reference Costs 2013,130 FZ51Z, Gastroenterology, Diagnostic
Colonoscopy, 19 years and over
Blood tests 1.94 0.26 NHS Reference Costs 2013,130 DAPS03, Integrated Blood Services
Colectomy 13,451.60 1345.16 Buchanan et al.143
Stoma care per
maintenance cycle
214.95 21.49 Buchanan et al.143
Surgical management
of complications
8792.85 473.03 NHS Reference Costs 2013,130 FZ73F, Colorectal Surgery,
Very Complex Large Intestine Procedures with CC Score 0–2
Medical management
of complicationsa
4170.95 464.59 NHS Reference Costs 2013,130 WA12D, Colorectal Surgery,
Complications of Procedures, with CC score 0
a Assumes a length of stay of 7 days.
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A secondary analysis is presented for the paediatric population; this analysis compares IFX with standard
non-biological treatments versus colectomy. Given the absence of head-to-head trials of IFX versus any
other therapy, this analysis is exactly the same as the base-case analysis except that the patients’ starting
age is set to 15 years (the median age within Hyams et al.52).
In addition to the main analyses, a number of secondary scenario analyses and sensitivity analyses are
presented (Box 5). It should be noted that although the base-case economic analysis utilises the results of
the NMA models, sensitivity analysis number 4 presents pairwise estimates of cost-effectiveness using
direct head-to-head transition probabilities sourced from the individual clinical trials of IFX, ADA and GOL.
The pairwise analysis of IFX uses simple pooling of the ACT1 and ACT2 trial data. The pairwise analysis of
ADA is based on the anti-TNF-α-naive subgroup from ULTRA2. The GOL analysis is based on the data from
the PURSUIT-SC47 trial and the PURSUIT-Maintenance48 trial.
Unless otherwise stated, all results are discounted at a rate of 3.5%.
BOX 5 Sensitivity/scenario analyses undertaken using the Assessment Group model
l Base-case analysis: NMA using anti-TNF-α-naive subgroup from ULTRA245,126 and excluding Suzuki et al.46
(probabilistic).
l Sensitivity analysis 1: NMA using ITT population from ULTRA245 and excluding Suzuki et al.46 (probabilistic).
l Sensitivity analysis 2: NMA using anti-TNF-α-naive subgroup from ULTRA245,126 and including Suzuki
et al.46 (probabilistic).
l Sensitivity analysis 3: NMA using ITT population from ULTRA245,126 and including Suzuki et al.46
(probabilistic).
l Sensitivity analysis 4: pairwise head-to-head comparisons of IFX, GOL and ADA vs. conventional
management using direct trial evidence from ACT1 and ACT2, ULTRA2 and PURSUIT45,47,49,126 (deterministic).
l Sensitivity analysis 5: base case using point estimates of parameters (deterministic).
l Sensitivity analysis 6: time horizon= 20 years (deterministic).
l Sensitivity analysis 7: time horizon= 10 years (deterministic).
l Sensitivity analysis 8: time horizon= 5 years (deterministic).
l Sensitivity analysis 9: all utilities except post-surgical complications drawn from Swinburn et al.139
(deterministic).
l Sensitivity analysis 10: utilities of response/remission drawn from ACT1 trial49 (deterministic).
l Sensitivity analysis 11: utilities of response/remission drawn from PURSUIT-Maintenance
trial47 (deterministic).
l Sensitivity analysis 12: relative risk of hospitalisation for GOL vs. conventional treatment assumed to be
1.0 (deterministic).
l Sensitivity analysis 13: UC health state costs doubled (deterministic).
l Sensitivity analysis 14: UC health state costs halved (deterministic).
l Sensitivity analysis 15: probability of chronic pouchitis doubled (deterministic).
l Sensitivity analysis 16: probability of chronic pouchitis halved (deterministic).
l Sensitivity analysis 17: cost of surgery doubled (deterministic).
l Sensitivity analysis 18: cost of surgery halved (deterministic).
l Sensitivity analysis 19: probability of surgery in drug groups halved (deterministic).
l Sensitivity analysis 20: probability of surgery in drug groups based on Gower-Rousseau et al.151
(deterministic).
l Sensitivity analysis 21: disutility of pouchitis doubled (deterministic).
l Sensitivity analysis 22: disutility of pouchitis tripled (deterministic).
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Model verification and validation
The Assessment Group undertook a number of measures to ensure the credibility of the model
(author/advisor initials are shown in brackets).
l Peer review of economic analysis by two internal clinical advisors (SH, AL), one external clinical expert
(MH) and one external methodological expert (SD).
l Verification of executable model by a second modeller not involved in its implementation (HB).
l Double programming of separate Markov models for all five treatment options by the lead modeller (PT).
l Scrutiny of implemented model coding and formulae by lead modeller (PT).
l Double-checking of accuracy of all model inputs against sources.
l Comparison of model results using point estimates of parameters and expectation of the mean.
l Comparison of mean of all parameter samples against point estimates of parameters.
l Examination of all identified sources of discrepancy.
l Model testing using sensitivity analysis and use of extreme parameter values.
l Comparison of model results against manufacturers’ models (see Systematic review of existing
cost-effectiveness evidence).
Assessment Group model results
Central estimates of cost-effectiveness (base-case analysis: adults)
Table 77 presents the base-case results generated using the probabilistic version of the model within an
adult population in whom colectomy is an acceptable option. The base-case analysis of the model suggests
that colectomy is expected to produce 14.71 QALYs at a cost of approximately £56,268 over the patient’s
remaining lifetime. All medical options are expected to produce substantially fewer QALYs at a greater
cost than colectomy, hence colectomy is expected to dominate IFX, ADA, GOL and conventional
non-biological treatments.
Figure 89 presents CEACs for IFX, ADA, GOL, conventional treatment and colectomy for the adult population.
Assuming a willingness-to-pay threshold of £20,000 per QALY gained, the probability that colectomy produces
the greatest amount of expected net benefit is approximately 1.0. The probability that any of the biological
treatments produce the greatest amount of expected net benefit at this threshold is approximately zero.
Assuming a willingness-to-pay threshold of £30,000 per QALY gained, the probability that colectomy produces
the greatest amount of expected net benefit is approximately 1.0. The probability that any of the biological
treatments produce the greatest amount of expected net benefit at this threshold is approximately zero.
Table 78 presents the probabilistic base-case model results within an adult population in whom colectomy
is not an acceptable option, thus relevant treatment options are restricted to medical treatments only
(IFX, ADA, GOL and conventional non-biological treatments). The model results suggest that within this
population, IFX is expected to be dominated by ADA (note: the difference in QALYs is very small), while
GOL is expected to be ruled out because of extended dominance. The incremental cost-effectiveness of
ADA versus conventional treatment is expected to be £50,278 per QALY gained.
TABLE 77 Probabilistic cost-effectiveness results, base-case analysis, adult patients in whom colectomy is an option
(medical and surgical treatments)
Option QALYs Costs (£) Incremental QALYs Incremental cost ICER
Colectomy 14.71 56,267.73 – – Dominating
ADA 10.82 91,221.71 – – Dominated
IFX 10.81 96,594.62 – – Dominated
GOL 10.63 90,086.69 – – Dominated
Conventional treatment 10.47 73,619.77 – – Dominated
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Figure 90 presents CEACs for IFX, ADA, GOL and conventional treatment within a population in whom
colectomy is not an option. Assuming a willingness-to-pay threshold of £20,000 per QALY gained, the
probability that conventional non-biological treatment produces the greatest expected net benefit is
approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained, the probability that
conventional management produces the greatest expected net benefit is approximately 0.98.
Central estimates of cost-effectiveness (base-case analysis:
paediatric population)
Table 79 presents the base-case results generated using the probabilistic version of the model within a
paediatric population in whom colectomy is an acceptable option. The base-case analysis of the model
suggests that colectomy is expected to produce 17.54 QALYs at a cost of approximately £64,097 over the
patient’s remaining lifetime. IFX and conventional management are expected to produce substantially
fewer QALYs at a greater cost than colectomy, hence colectomy is expected to dominate these
medical options.
Figure 91 presents CEACs for IFX, conventional treatment and colectomy for the paediatric population.
Assuming a willingness-to-pay threshold of £20,000 per QALY gained, the probability that colectomy
produces the greatest amount of expected net benefit is approximately 1.0. Assuming a willingness-to-pay
threshold of £30,000 per QALY gained, the probability that colectomy produces the greatest amount of
expected net benefit is approximately 1.0. The probability that IFX produces the greatest amount of
expected net benefit at these thresholds is approximately zero.
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FIGURE 89 Cost-effectiveness acceptability curves, base-case analysis, adult patients in whom colectomy is an
option (medical and surgical treatments).
TABLE 78 Probabilistic cost-effectiveness results, base-case analysis, adult patients in whom colectomy is not an
option (medical treatments only)
Option QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER
ADA 10.82 91,221.71 0.35 17,601.94 £50,278
IFX 10.81 96,594.62 – – Dominated
GOL 10.63 90,086.69 – – Ext dom
Conventional treatment 10.47 73,619.77 – – –
Ext dom, extendedly dominated.
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FIGURE 90 Cost-effectiveness acceptability curves, base-case analysis, adult patients in whom colectomy is not an
option (medical treatments only).
TABLE 79 Probabilistic cost-effectiveness results, base-case analysis, paediatric patients in whom colectomy is an
option (medical and surgical treatments)
Option QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER
Colectomy 17.54 64,097.18 – – Dominating
IFX 13.00 109,438.73 – – Dominated
Conventional treatment 12.65 86,280.28 – – Dominated
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FIGURE 91 Cost-effectiveness acceptability curves, base-case analysis, paediatric patients in whom colectomy is an
option (medical and surgical treatments).
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Table 80 presents the probabilistic base-case model results within a paediatric population in whom
colectomy is not an acceptable option, thus relevant treatment options are restricted to IFX and
conventional non-biological treatments. The model indicates that within this population, IFX is expected
to produce an additional 0.34 QALYs at an additional cost of £23,158 over the patient’s remaining
lifetime; the ICER for IFX versus conventional management is expected to be £68,007 per QALY gained.
Figure 92 presents CEACs for IFX and conventional treatment for the paediatric population. Assuming
willingness-to-pay thresholds of £20,000 and £30,000 per QALY gained, the probability that conventional
management produces the greatest amount of expected net benefit is approximately 1.0. The probability
that IFX produces the greatest amount of expected net benefit at these thresholds is approximately zero.
Network meta-analysis sensitivity analyses (sensitivity analyses 1–3,
probabilistic)
Table 81 summarises the results of the economic analysis for the adult population based on the three
alternative sensitivity analyses.
In the circumstances for which colectomy is an option, the three NMA sensitivity analyses produce very
similar results to the base-case analysis. In all three analyses, colectomy is consistently expected to
dominate all medical treatment options. Assuming a WTP threshold of £20,000 per QALY gained, the
probability that colectomy produces the greatest amount of net benefit is expected to be approximately
1.0. Assuming a WTP threshold of £30,000 per QALY gained, the probability that colectomy produces
the greatest amount of net benefit is expected to be approximately 1.0. When colectomy is not an
acceptable option, the results are influenced by which studies are included in the NMA, as the difference
in effectiveness between ADA and IFX is very small. GOL is consistently expected to be ruled out of the
analysis because of extended dominance. In sensitivity analyses 1 and 2, IFX is expected to produce slightly
more QALYs than ADA; however, the ICER for IFX versus ADA is expected to be > £236,000 per QALY
gained. In these sensitivity analyses, the ICER for ADA versus conventional non-biological treatment is
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FIGURE 92 Cost-effectiveness acceptability curves, base-case analysis, paediatric patients in whom colectomy is not
an option (medical options only).
TABLE 80 Probabilistic cost-effectiveness results, base-case analysis, paediatric patients in whom colectomy is not
an option (medical treatments only)
Option QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER (£)
IFX 13.00 109,438.73 0.34 £23,158.45 68,007
Conventional treatment 12.65 86,280.28 – – –
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TABLE 81 Results of probabilistic NMA sensitivity analyses
Colectomy IFX ADA GOL
Conventional
management
Adult population in whom colectomy is an option
NMA sensitivity analysis number 1: ULTRA2 ITT population, excluding Suzuki et al.46
ICER Dominating Dominated Dominated Dominated Dominated
P(optimal £20,000/QALY) 1.00 0.00 0.00 0.00 0.00
P(optimal £30,000/QALY) 1.00 0.00 0.00 0.00 0.00
NMA sensitivity analysis number 2: ULTRA2 anti-TNF-α-naive subgroup, including Suzuki et al.46
ICER Dominated Dominated Dominated Dominated Dominated
P(optimal £20,000/QALY) 1.00 0.00 0.00 0.00 0.00
P(optimal £30,000/QALY) 1.00 0.00 0.00 0.00 0.00
NMA sensitivity analysis number 3: ULTRA2 ITT population, including Suzuki et al.46
ICER Dominated Dominated Dominated Dominated Dominated
P(optimal £20,000/QALY) 1.00 0.00 0.00 0.00 0.00
P(optimal £30,000/QALY) 1.00 0.00 0.00 0.00 0.00
Adult population in whom colectomy is an not option
NMA sensitivity analysis number 1: ULTRA2 ITT population, excluding Suzuki et al.46
ICER N/A £236,340 (1) £54,066 (2) Ext dom(3) –(4)
P(optimal £20,000/QALY) N/A 0.00 0.00 0.00 1.00
P(optimal £30,000/QALY) N/A 0.00 0.01 0.00 0.99
NMA sensitivity analysis number 2: ULTRA2 anti-TNF-α-naive subgroup, including Suzuki et al.46
ICER N/A £546,051 (1) £56,284 (2) Ext dom(3) –(4)
P(optimal £20,000/QALY) N/A 0.00 0.00 0.00 1.00
P(optimal £30,000/QALY) N/A 0.00 0.00 0.00 1.00
NMA sensitivity analysis number 3: ULTRA2 ITT population, including Suzuki et al.46
ICER N/A Dominated (2) £55,637 (1) Ext dom(3) –(4)
P(optimal £20,000/QALY) N/A 0.00 0.00 0.00 1.00
P(optimal £30,000/QALY) N/A 0.00 0.00 0.00 1.00
Ext dom, extendedly dominated; N/A, not applicable.
When different from the base-case analysis, the QALY rank is shown in parentheses.
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expected to be > £54,000 per QALY gained. In sensitivity analysis 3, IFX is expected to be ruled out owing
to simple dominance; the ICER for ADA versus conventional non-biological treatments is expected to be
approximately £55,637 per QALY gained.
Head-to-head analyses (sensitivity analysis 4)
Table 82 presents the results of the economic analysis using the direct head-to-head trial data.
The head-to-head analyses indicate that colectomy is expected to dominate all medical options. Within a
population in whom colectomy is not an acceptable option, the incremental cost-effectiveness of IFX versus
conventional non-biological treatments is estimated to be £96,403 per QALY gained, the ICER for ADA
versus conventional non-biological treatments is estimated to be £69,782 per QALY gained and the ICER
for GOL versus conventional non-biological treatments is estimated to be £90,413 per QALY gained.
Sensitivity analyses 5–22: other deterministic sensitivity analyses (medical and
surgical options)
Table 83 presents the results of the remaining deterministic sensitivity analysis (analyses 5–22).
The analyses indicate that the model results remain largely unaffected by changes in the model time
horizon, assumed patient age, utilities for remission and response, assumptions regarding UC resource use,
and the colectomy rate. However, the model is very sensitive to assumptions regarding the relative utilities
of remission, response, active UC and postsurgery. Within the sensitivity analysis in which utility values
are drawn from Swinburn et al.139 (analysis number 9), the rank ordering of QALY gains is altered such that
colectomy moves from being the most effective option to the least effective option. In this scenario, GOL
and conventional non-biological treatments are expected to be ruled out of the analysis, the ICER for ADA
versus colectomy is estimated to be approximately £79,714 per QALY gained while the ICER for IFX versus
ADA is estimated to be approximately £178,982 per QALY gained.
TABLE 82 Head-to-head analysis: adult population, IFX versus conventional management
Option QALYs Costs (£) Incremental QALYs Incremental cost (£) ICER
IFX versus conventional management and colectomy
Colectomy 14.69 56,342.42 – – Dominating
IFX 11.62 86,609.58 – – Dominated
Conventional treatment 11.44 69,583.06 – – Dominated
ADA versus conventional management and colectomy
Colectomy 14.69 56,342.42 – – Dominating
ADA 10.23 90,538.92 – – Dominated
Conventional treatment 10.02 75,416.12 – – Dominated
GOL versus conventional management and colectomy
Colectomy 14.69 56,342.42 – – Dominating
GOL 10.16 91,395.09 – – Dominated
Conventional treatment 9.99 75,541.49 – – Dominated
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TABLE 83 Other deterministic sensitivity analyses
Sensitivity analysis
Incremental cost per QALY gained
IFX ADA GOL
Conventional
management Colectomy
SA5: base case using point estimates
of parameters
Dominated Dominated Dominated Dominated Dominating
SA6: time horizon= 20 years Dominated Dominated Dominated Dominated Dominating
SA7: time horizon= 10 years Dominated Dominated Dominated – £886.44
SA8: time horizon= 5 years Dominated Dominated Dominated – £8840.14
aSA9: all utilities except post-surgical
complications drawn from Swinburn
et al.139
£178,982 (1) £79,714 (2) Dominated (3) Ext dom (4) –
SA10: utilities of response/remission
drawn from ACT1 trial49 (0.88, 0.82
for remission and response
respectively)
Dominated Dominated Dominated Dominated Dominating
SA11: utilities of response/remission
drawn from PURSUIT-Maintenance
trial47 (0.89, 0.80 for remission and
response respectively)
Dominated Dominated Dominated Dominated Dominating
SA12: relative risk of hospitalisation
for GOL vs. conventional treatment
assumed to be 1.0
Dominated Dominated Dominated Dominated Dominating
SA13: UC health state resource use
doubled
Dominated Dominated Dominated Dominated Dominating
SA14: UC health state resource use
halved
Dominated Dominated Dominated Dominated Dominating
SA15: probability of chronic pouchitis
doubled
Dominated Dominated Dominated Dominated Dominating
SA16: probability of chronic pouchitis
halved
Dominated Dominated Dominated Dominated Dominating
SA17: cost of surgery doubled Dominated Dominated Dominated Dominated Dominating
SA18: cost of surgery halved Dominated Dominated Dominated Dominated Dominating
SA19: probability of undergoing
surgery in drug groups halved
Dominated Dominated Dominated Dominated Dominating
SA20: colectomy rate based on
Gower-Rousseau et al.151
Dominated Dominated Dominated Dominated Dominating
SA21: disutility of pouchitis doubled Dominated Dominated Dominated Dominated Dominating
SA22: disutility of pouchitis tripled Dominated Dominated Dominated Dominated Dominating
Ext dom, extendedly dominated.
a QALY rank shown in parentheses.
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Budget impact analysis
This section presents an analysis of the expected net budget impact of introducing IFX, ADA and GOL for
the treatment of moderate to severe UC in England and Wales. Budget impact estimates are presented
annually for a 5-year period. The analysis makes the following assumptions:
l The prevalence of UC is 240 per 100,000 population.
l The incidence of UC is 10 per 100,000 population.
l The population of England and Wales is approximately 56 million.
l A total of 14.5% of all UC patients would be eligible to receive biological treatments.80
l All patients who are eligible for treatment with biologicals will receive these therapies.
l Discounting is not applied.
These assumptions suggest an eligible prevalent UC cohort of approximately 19,488 patients and an
eligible incident cohort of approximately 812 patients per year. Based on the cost distribution over time
estimated for each treatment using the Assessment Group model, combined with the estimated eligible
prevalent and incident cohorts in each year, this gives rise to the budget impact estimates presented
in Table 84. Assuming full uptake of these drugs, the estimated net budget impact of IFX, ADA and GOL
for the treatment of moderate to severe UC is estimated to be between £269M and £434M.
TABLE 84 Estimated absolute and net budgetary impact of introducing biologicals for the treatment of
moderate to severe UC in England and Wales
Year IFX ADA GOL
Conventional non-biological
treatments
Absolute budget impact for each treatment
Year 1 £320,465,072 £212,829,031 £274,600,660 £75,051,491
Year 2 £145,622,769 £114,284,053 £130,417,738 £69,748,947
Year 3 £124,230,659 £108,603,021 £109,713,744 £74,396,609
Year 4 £113,140,687 £105,994,793 £101,177,679 £77,850,322
Year 5 £107,896,081 £104,691,559 £98,410,165 £80,753,619
Net budget impact for costs of biological less costs of conventional treatments
Year 1 £245,413,582 £137,777,540 £199,549,169 –
Year 2 £75,873,822 £44,535,106 £60,668,791 –
Year 3 £49,834,050 £34,206,412 £35,317,135 –
Year 4 £35,290,365 £28,144,472 £23,327,357 –
Year 5 £27,142,461 £23,937,940 £17,656,546 –
Total cost over 5 years £433,554,281 £268,601,470 £336,518,999 –
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Discussion
The manufacturers of ADA, IFX and GOL submitted economic models to assess the cost-effectiveness of
biological therapies versus conventional treatment. The MSD IFX submission model indicates that the
estimated ICER for IFX versus standard non-biological treatment (colectomy) is £37,682 per QALY gained.64
The MSD GOL submission reports an estimated ICER of £27,322 per QALY gained.66 The AbbVie
submission reports a base-case ICER for ADA versus conventional therapy of £34,590 per QALY gained.62
The Assessment Group scrutinised these models and critiqued the evidence and assumptions which
underpin the cost-effectiveness estimates reported by the manufacturers. A number of problems with
these models were identified by the Assessment Group, particularly with respect to the exclusion of
relevant treatment options specified in the final NICE scope36 and the use of a short time horizon. In
addition, the MSD model does not include a fully incremental analysis, confuses evidence from populations
with varying degrees of UC severity and inadequately reflects likely UK treatment pathways. As a
consequence of these problems, the Assessment Group do not consider that the cost-effectiveness
evidence produced by either manufacturer adequately addresses the specified decision problem.
In light of the problems with the manufacturers’ submitted economic analyses, the Assessment Group
developed a de novo cost-effectiveness model to assess IFX, ADA, GOL, conventional non-biological
treatments and elective surgery within the moderate to severe UC population. The Assessment Group
model differs from both the manufacturers’ models in that all relevant medical and surgical options are
evaluated over a lifetime horizon, as specified in the final NICE scope. Underpinning the Assessment Group
model is a series of complex NMAs, which synthesise all relevant evidence relating to IFX, ADA, GOL and
conventional non-biological therapies. A summary of the key differences between the Assessment Group
model and the manufacturers’ models is presented in Table 85.
TABLE 85 Summary of key differences between the Assessment Group model and the manufacturers’ models
Element of
evaluation
Assessment Group model
(base case) MSD models64,66 AbbVie model62
Options evaluated l IFX
l ADA
l GOL
l Conventional
non-biological treatments
l Colectomy
l IFX
l ADA
l GOL
l Conventional
non-biological treatments
l ADA
l Conventional non-biological
treatments
Time horizon Lifetime 10 years 10 years
Source of efficacy
evidence
NMA using unpublished
ordered categorical data
NMA using published
binomial data (includes
manipulation of
PURSUIT-Maintenance
trial data)
Unpublished data from ULTRA2
and ULTRA1 and ULTRA2
extension study supplemented
using estimates from Kane et al.133
and Odes et al.121
Treatment options
following failure of
biologic
Conventional non-biological
treatments and possible
colectomy
Relapse management and
imminent colectomy
Conventional non-biological
treatments and possible colectomy
Possible transitions
between active UC
states (remission,
response, no
response)
All transitions in matrix
allowed
Patients losing remission
transit to response, patients
achieving response cannot
achieve remission
All transitions in matrix allowed
Source of health
utilities
Woehl et al.145 (chronic
pouchitis valued using
Arseneau et al.110)
ACT1/PURSUIT-Maintenance,
Woehl et al.,145 complications
valued using Arseneau
et al.110
Swinburn et al.,139 Tsai et al.,82
complications valued using
weighted average of Arseneau
et al.,110 Hu et al.140 and Smith
and Roberts141
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The base-case analysis of the Assessment Group model suggests that within an adult UC population,
colectomy is expected to produce 14.71 discounted QALYs at a discounted cost of approximately £56,300
over the patient’s remaining lifetime. All medical options are expected to produce substantially fewer
QALYs at a greater cost than colectomy, hence colectomy is expected to dominate IFX, ADA, GOL and
conventional non-biological treatments. Importantly however, elective colectomy may not be considered an
acceptable or preferable option for some patients. In circumstances whereby only drug options are
considered acceptable, the base-case version of the Assessment Group model suggests that IFX and GOL
are expected to be ruled out because of dominance, while the incremental cost-effectiveness of ADA
versus conventional non-biological treatment is expected to be approximately £50,300 per QALY gained.
The Assessment Group also undertook a separate probabilistic economic analysis of IFX, conventional
non-biological treatments and colectomy within a paediatric population (mean age= 15 years).
When colectomy is an acceptable treatment option, the economic analysis suggests that this option
dominates IFX and conventional non-biological treatments. When colectomy is not an acceptable option,
the economic analysis suggests that the incremental cost-effectiveness of IFX versus conventional
treatments is approximately £68,000 per QALY gained. However, this analysis is based on adult efficacy
evidence, hence it should be interpreted with some degree of caution.
Three separate PSAs were undertaken using data from the Japanese trial reported by Suzuki et al.46 and
using the ITT data rather than anti-TNF-α-naive patients from ULTRA2.45 Across these three scenarios,
the general conclusions of the economic analysis remain unchanged. The Assessment Group also
undertook separate comparisons of (1) IFX versus colectomy and conventional treatments; (2) ADA versus
colectomy and conventional treatments; and (3) GOL versus colectomy and conventional treatments using
the head-to-head trials rather than the NMA models. These analyses indicate that where colectomy is an
acceptable option, it is expected to dominate the drug options. When colectomy is not an acceptable
option, the ICERs produced from these analyses are all in excess of £69,000 per QALY gained.
A number of simple sensitivity analyses were also undertaken using the point estimates of model
parameters. Across these scenarios, the model results appear to be insensitive to changes in these
assumptions, with the exception of the HRQoL values assumed. Within the scenario whereby utilities from
Swinburn et al.139 are used in the model (rather than those reported by Woehl et al.145 as per the base-case
analysis), colectomy produces the lowest QALY gain and conventional management and GOL are ruled out
because of extended dominance. Within this scenario, the incremental cost-effectiveness of ADA versus
elective colectomy is estimated to be £79,714 per QALY gained, while the incremental cost-effectiveness
of IFX versus ADA is estimated to be £178,982 per QALY gained. Although these results are very different
from the Assessment Group’s base-case analysis, the economic conclusions that should be drawn from this
sensitivity analysis are not.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Surgery and patient choice
Surgery may be considered as an option for patients with UC for a number of reasons including
complications of disease, perceived risk of or identified dysplasia/neoplasia or lack or loss of efficacy of
medical treatments. For a proportion of patients without emergency symptoms, surgery may not represent
an acceptable treatment option.
Administration route: intravenous infusions versus
subcutaneous injection
The method of drug administration differs between the interventions included in this appraisal. IFX is given
via i.v. infusion while ADA and GOL are administered via subcutaneous injection. IFX therefore requires
outpatient attendances, additional nursing care and monitoring. These resources are not required for the
administration of ADA or GOL. Pre-infusion prophylaxis may be required to minimise the risk of infusion
reactions associated with IFX.
Training for subcutaneous injections
When considered appropriate (by the physician), patients, family members and/or carers require training
for the administration of subcutaneous injections. This training is associated with additional resource use
and costs.
Screening for tuberculosis and other infectious diseases
(e.g. hepatitis B)
All of the biological therapies considered in this assessment report may be associated with the reactivation
of TB. Patients should be screened for TB (and other infectious disease, e.g. hepatitis B) before initiation
of treatment.
Off-license use in children for golimumab and adalimumab
Currently, IFX is the only biological treatment option that is licensed for the treatment of moderate to
severe UC in children in the UK.
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Chapter 6 Discussion
Statement of principal findings
Principal findings: clinical effectiveness
A total of 10 RCTs were identified in the clinical effectiveness systematic review, of which nine44–51 related
to adults and one52 was conducted in a paediatric population. All of the adult RCTs were performed against
PBO (with the exception of UC-SUCCESS) and were a maximum of 1 year in duration. No head-to-head
RCTs were identified in which interventions of interest were assessed against each other.
The risks of bias associated with included RCTs were assessed using the Cochrane risk of bias instrument.
Only three RCTs could be considered as being at overall low risk of bias (as allocation concealment,
blinded outcome assessment and completeness of outcome data were all judged as low risk). It should
be noted that one of the maintenance trials (PURSUIT- Maintenance) rerandomised patients who had
previously responded to GOL induction therapy in two previous trials; the extent of this potential bias on
patient outcomes is unclear.
The outcome measures pre-specified in the final NICE scope were all addressed by the included trial
evidence, with the exception of rates of relapse. Clinical response and remission data based on complete
Mayo scores were well reported across trials. Evidence was identified to demonstrate that patients
receiving IFX, ADA or GOL were more likely than patients receiving PBO to achieve clinical response and
remission at induction and maintenance time points. Patients in the UC-SUCCESS trial who received
combination treatment with IFX and AZA experienced the most favourable rates of steroid-free remission
compared with IFX and AZA treatment groups. Seven RCTs performed in adult populations contributed
data on clinical response and remission at induction or maintenance time points to NMAs.44–49
Based on the NMA, in the induction phase, all treatments were associated with statistically significant
beneficial effects relative to PBO with the greatest effect being associated with IFX. IFX was also associated
with the highest probability of moving from no response to response and from no response to remission.
The effects of ADA and GOL on these two probabilities were broadly comparable.
For patients classified as responders at the end of the induction phase, treatment effects were not
statistically significant, although the greatest effect was associated with 100mg of GOL at 8–32 weeks.
A treatment of 100mg of GOL was associated with the highest probability of moving from response to
remission and staying in response and the smallest probability of moving from response to no response.
However, at 32–52 weeks, only IFX and 50mg of GOL were associated with beneficial effects on clinical
response, although the effects were not statistically significant. IFX was associated with the highest
probability of moving from response to remission and staying in response and the smallest probability
of moving from response to no response at 32–52 weeks. The probabilities of staying in response were
comparable among treatments at both 8–32 weeks and 32–52 weeks.
For patients classified as being in remission at the end of the induction phase, all treatments except for
ADA were associated with beneficial treatment effects relative to PBO with the greatest effect being
associated with 50mg and 100mg of GOL, although the effects were not statistically significant at
8–32 weeks. A treatment of 50mg and 100mg of GOL were associated with the highest probability of
staying in remission and the smallest probability of moving from remission to response and from remission
to no response. At 32–52 weeks, all treatments except 50mg of GOL were associated with beneficial
treatment effects relative to PBO, with the greatest effect being associated with ADA (the only treatment
with statistically significant effect). ADA was associated with the highest probability of staying in remission
and the smallest probability of moving from remission to response and from remission to no response.
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Available data on hospitalisation outcomes were very limited, but suggested that outcomes may be more
favourable for ADA-treated and IFX-treated patients than PBO (with no data available from GOL trials).
Data on surgical intervention were also very sparse, with a potential inconclusive benefit for intervention-
treated patients compared with PBO. No trials reported whether surgical outcomes were elective or
emergency in nature; however, more data are required to demonstrate the impact of interventions on
hospitalisation and surgical intervention more conclusively. Data were available from a single trial to
support the use of IFX in induction and maintenance treatment in a paediatric population.
The main safety issues highlighted in the RCT evidence appeared to be generally consistent with those
previously discussed in the respective SmPC (including serious infections, malignancies and administration
site reactions). Deaths occurring during and after the study period were described in some trials evaluating
GOL (PURSUIT-Maintenance) and IFX (ACT1 and ACT2), of which infection or malignancy was most
commonly implicated. This underlines the importance of monitoring and treating serious infections and
malignancies in patients receiving immunosuppressive treatment.
The trials included in the clinical effectiveness systematic review typically excluded patients with ulcerative
proctitis, patients with fulminant/acute severe disease, those with a history of or at imminent risk of
bowel surgery, pregnant or lactating women, and patients with diseases of the central nervous system
(e.g. demyelinating disease). Furthermore, patients with a history of serious infection and/or
immunodeficiency were also typically excluded, as were individuals with a history of malignancy or signs of
dysplasia. Therefore, the effects of ADA, GOL or IFX in these UC populations are unknown.
Two biosimilars (Remsima and Inflectra) to Remicade were considered as part of the evidence base for
IFX as part of this assessment. The sponsor submission received from the manufacturers of Remsima and
the EPAR reports for Remsima and Inflectra indicated that both biosimilars were approved by the EMA on
the basis of reported similar pharmacokinetic and efficacy (demonstrated in AS and RA patients) profiles to
Remicade. No further trials of Remsima or Inflectra were identified over the course of this assessment.
Principal findings: cost-effectiveness
The manufacturers of ADA, IFX and GOL submitted economic models to assess the cost-effectiveness of
biological therapies versus conventional treatment. The MSD IFX submission model indicates that the
estimated ICER for IFX versus standard non-biological treatment (colectomy) is £37,682 per QALY gained.64
The MSD GOL submission reports an estimated ICER of £27,322 per QALY gained.66 The AbbVie
submission reports a base-case ICER for ADA versus conventional therapy of £34,590 per QALY gained.62
The Assessment Group identified several issues with the manufacturers’ submitted models, in particular,
the exclusion of relevant treatment options specified in the final NICE scope36 and the use of a short time
horizon. Given the missing comparators within each of the manufacturers’ submitted economic analyses,
it is unclear how these models should be used to inform NICE decision-making.
The Assessment Group developed a de novo cost-effectiveness model to assess IFX, ADA, GOL,
conventional non-biological treatments and elective surgery within the moderate to severe UC population.
The base-case analysis of the Assessment Group model suggests that within an adult UC population,
colectomy is expected to produce 14.71 discounted QALYs at a discounted cost of approximately £56,300
over the patient’s remaining lifetime. All medical options are expected to produce substantially fewer
QALYs at a greater cost than colectomy, hence colectomy is expected to dominate IFX, ADA, GOL and
conventional non-biological treatments. When colectomy is not considered to be an acceptable option, the
base-case analysis of the Assessment Group model suggests that IFX and GOL are expected to be ruled out
because of dominance, while the incremental cost-effectiveness of ADA versus conventional non-biological
treatment is expected to be approximately £50,300 per QALY gained.
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The Assessment Group also undertook a separate probabilistic economic analysis of IFX, conventional
non-biological treatments and colectomy within a paediatric population (mean age= 15 years). When
colectomy is an acceptable treatment option, the economic analysis suggests that this option dominates
IFX and conventional non-biological treatments. When colectomy is not an acceptable option, the
economic analysis suggests that the incremental cost-effectiveness of IFX versus conventional treatments is
approximately £68,000 per QALY gained.
The results of the Assessment Group model were largely insensitive to changes in model parameter values
with the exception of the HRQoL values for each state. The use of utility estimates from Swinburn et al.139
results in a situation whereby colectomy produces the lowest QALY gain and conventional management
and GOL are ruled out because of extended dominance. Within this scenario, the incremental
cost-effectiveness of ADA versus elective colectomy is estimated to be £79,714 per QALY gained, while
the incremental cost-effectiveness of IFX versus ADA is estimated to be £178,982 per QALY gained.
Strengths and limitations of the assessment
The systematic review was based on rigorous methods, with comprehensive searches for evidence, a good
level of consistency between reviewers in study selection and double-checking of data extraction. Clinical
response and remission data were widely reported across included trials and study authors were consistent
in their use of the complete Mayo score, which aided the comparison of trials. Although no head-to-head
RCT evidence was available, NMAs were performed to permit a comparison of the efficacy of interventions
in terms of clinical response and remission.
The economic analysis presented by the Assessment Group has several strengths:
l The treatment pathway represented within the model was based on considerable expert opinion of
several leading UC experts.
l The Assessment Group model is underpinned by a complex NMA across all drug options thereby
synthesising relevant efficacy outcomes data within a single network of evidence.
l The model generally adheres to the NICE reference case and fully addresses the decision problem set
out in the final NICE scope.
l When appropriate and possible, systematic search methods have been used to identify, select and use
evidence to inform the model’s parameters (efficacy, HRQoL and colectomy rates).
l The Assessment Group have undertaken extensive sensitivity analyses to examine the impact of
alternative assumptions and sources of evidence on the robustness of the results of the model.
The Assessment Group model is also subject to a number of limitations:
l There is considerable uncertainty associated with Assessment Group’s extrapolation of short-term trial
data (maximum 54 weeks) to a lifetime horizon.
l The model does not consider an explicit sequential pathway of non-biological treatments; rather, during
any cycle, a proportion of patients are assumed to receive 5-ASAs, immunomodulators and prednisolone.
l Evidence relating to complications of colectomy was identified through consideration of approaches
used within previous models rather than through a full systematic review; however, these assumptions
were tested within the sensitivity analyses.
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Uncertainties
Key uncertainties in this assessment include:
l the optimal duration of intervention treatment in responding patients
l the maintenance of efficacy outcomes and safety of interventions beyond the limited study
lengths available
l the maintenance of outcomes in responding patients following cessation of anti-TNF-α treatment
l the relationship between post-surgical outcomes and HRQoL.
DISCUSSION
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Chapter 7 Conclusions
Based on the NMA for clinical response and remission in the induction phase, all treatments wereassociated with statistically significant beneficial effects relative to PBO, with the greatest effect being
associated with IFX. For patients classified as responders at the end of the induction phase, treatment
effects were not statistically significant, although the greatest effect at 8–32 weeks was associated with
100mg of GOL. At 32–52 weeks, only 50mg of IFX and GOL were associated with beneficial effects on
clinical response. For patients classified as being in remission at the end of the induction phase, all
treatments except for ADA were associated with beneficial treatment effects relative to PBO with the
greatest effect being associated with 50mg and 100mg of GOL, although the effects were not statistically
significant at 8–32 weeks. At 32–52 weeks, all treatments except 50mg of GOL were associated with
beneficial treatment effects relative to PBO, with the greatest effect being associated with ADA (the only
treatment with statistically significant effect). ADA was associated with the highest probability of staying in
remission and the smallest probability of moving from remission to response and from remission to
no response.
Available data on hospitalisation outcomes were very limited, but suggested that outcomes may be more
favourable for ADA-treated and IFX-treated patients than PBO (with no data available from GOL trials).
Data on surgical intervention were also very sparse, with a potential inconclusive benefit for
intervention-treated patients compared with PBO. No trials reported whether surgical outcomes were
elective or emergency in nature; however, further data are required to demonstrate the impact of
interventions on hospitalisation and surgical intervention more conclusively. Data were available from a
single trial to support the use of IFX in induction and maintenance treatment in a paediatric population.
The main safety issues highlighted in the RCT evidence appeared to be generally consistent with those
previously discussed in the respective SmPCs for each product (including serious infections, malignancies
and administration site reactions). Deaths occurring during and after the study period were described in
some trials evaluating GOL (PURSUIT-Maintenance) and IFX (ACT1 and ACT2), of which infection or
malignancy commonly appeared to be implicated. This underlines the importance of monitoring and
treating serious infections and malignancies in patients receiving immunosuppressive treatment.
The base-case analysis of the Assessment Group model suggests that within an adult UC population,
colectomy is expected to dominate IFX, ADA, GOL and conventional non-biological treatments. When
elective colectomy is not an acceptable option, the Assessment Group model suggests that IFX and GOL
are expected to be ruled out because of dominance, while the incremental cost-effectiveness of ADA
versus conventional non-biological treatment is expected to be approximately £50,300 per QALY gained.
The base-case analysis of the Assessment Group model suggests that within a paediatric UC population,
colectomy is expected to dominate IFX and conventional non-biological treatments. When colectomy
is not an acceptable option, the incremental cost-effectiveness of IFX versus conventional treatments is
approximately £68,000 per QALY gained.
Implications for service provision
The Assessment Group is unaware of any further implications for service provision beyond those addressed
in Chapter 5 of this report.
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Suggested research priorities
l Assessment of maintenance of outcomes in responding patients following cessation of anti-TNF-α treatment.
l Assessment of efficacy, safety and immunogenicity following reintroduction of interventions after
interruption in treatment.
l Assessment of efficacy of interventions under assessment in specific subgroups (e.g. according to
disease duration, as specified in the appraisal scope).
l Head-to-head RCTs of interventions under assessment against each other in the treatment of moderate
to severe UC after the failure of conventional therapy.
l RCTs evaluating use of interventions under assessment in biological switching (i.e. after failure of first
anti-TNF-α agent).
l RCTs of longer duration of follow-up to assess maintenance of outcomes over the longer term.
l RCTs assessing the clinical effectiveness of biologicals in paediatric patients.
l Surgical intervention and hospitalisation to be incorporated as outcomes in future RCTs and associated
extension studies of interventions in the treatment of moderately to severely active UC after the failure
of conventional therapy.
l Definition of factors that predict an improved patient response to anti-TNF-α treatment.
l Further exploration of comparative clinical and economic outcomes (including the use of a
preference-based utility instrument) associated with medical versus surgical treatments for patients
with moderate to severe UC.
l Consideration of unified universally agreed primary end points in future UC RCTs.
CONCLUSIONS
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Appendix 1 MEDLINE search for clinical
effectiveness evidence
Database: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations (via Ovid).
Searched: 1946 to December 2013.
URL: Gateway.ovid.com.
Search strategy
1. Colitis, Ulcerative/
2. ulcerative colitis.tw.
3. colitis ulcerosa.tw.
4. uc.tw.
5. colitis ulcerative.tw.
6. Colitis/
7. colitis.tw.
8. colitides.tw.
9. Inflammatory Bowel Diseases/
10. inflammatory bowel disease$.tw.
11. ibd.tw.
12. (col* and ulcer*).tw.
13. colitis gravis.tw.
14. proctocolitis.tw.
15. or/1-14
16. adalimumab.af.
17. humira.af.
18. d 2e7.af.
19. d2e7.af.
20. 331731-18-1.rn.
21. infliximab.af.
22. remicade.af.
23. 170277-31-3.rn.
24. ta650.af.
25. ta 650.af.
26. inx.af.
27. remsima.af.
28. inflectra.af.
29. ct p13.af.
30. ctp13.af.
31. golimumab.af.
32. simponi.af.
33. cnto148.af.
34. cnto 148.af.
35. 476181-74-5.rn.
36. tnf inhibitor$.tw.
37. anti tnf.tw.
38. antitnf.tw.
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39. tnf antagonist$.tw.
40. tnf-alpha blocker$.tw.
41. antitumo?r necrosis factor.tw.
42. Biosimilar Pharmaceuticals/
43. (biosimilar$ or biologic$).tw.
44. or/16-43
45. 15 and 44
Terms 1–14 are terms for the condition (ulcerative colitis) which are then combined using OR in term 15.
Terms 16–43 are terms for the interventions (infliximab, adalimumab and golimumab) which are then
combined using OR in term 44. Terms 15 and 44 are then combined using AND to find studies on the
condition and interventions in term 45.
To retrieve RCTs and systematic reviews specially designed highly sensitive search filter were combined
with term 45. RCT filter and systematic review filter below.
Randomised controlled trial filter
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. 49 placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Systematic review filter
1. Meta-Analysis/
2. meta analy$.tw.
3. metaanaly$.tw.
4. meta analysis.pt.
5. (systematic adj (review$1 or overview$1)).tw.
6. exp Review Literature/
7. or/1-6
8. cochrane.ab.
9. embase.ab.
10. (psychlit or psyclit).ab.
11. (psychinfo or psycinfo).ab.
12. (cinahl or cinhal).ab.
13. science citation index.ab.
14. bids.ab.
15. cancerlit.ab.
16. or/8-15
17. reference list$.ab.
18. bibliograph$.ab.
19. hand-search$.ab.
20. relevant journals.ab.
21. manual search$.ab.
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22. or/17-78
23. selection criteria.ab.
24. data extraction.ab.
25. 23 or 24
26. review.pt.
27. 25 and 26
28. comment.pt.
29. letter.pt.
30. editorial.pt.
31. animal/
32. human/
33. 31 not (31 and 32)
34. or/28-30,33
35. 7 or 16 or 22 or 27
36. 35 not 34
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Appendix 2 Table of excluded studies
Author and year/NCT number Reason for exclusion
Actis et al., 2002161 Not a RCT
Actis, 2003162 Not a RCT
Afif et al., 2009163 Not a RCT
Allez et al., 2010164 Not a RCT
(No authors listed) 2007165 Not a RCT
Armuzzi et al., 2004166 Not protocol-eligible population. No prior immunosuppressant
use reported
Baert et al., 2007167 Not a RCT
Barbato et al., 2006168 Not a RCT
Barreiro-de et al., 2009169 Not a RCT
Baumgart, 2010170 Not a RCT
Ben-Horin, 2012171 Not treatment of interest (rituximab)
Bengi and Akpinar, 2012172 Not a RCT
Biancone et al., 2009173 Not a RCT
(No authors listed) 2012174 Not a RCT
Bordeianou, 2009175 Not a RCT
Borruel et al., 2013176 Not a RCT
Brooklyn et al., 2006177 Not UC trial population
Bujanover and Weiss, 2008178 Not a RCT
Busquets and Aldeguer, 2013179 Not a RCT
Carbone et al., 2009180 Not a RCT
Cariñanos et al., 2011181 Not a RCT
Casteele et al., 2012182,183 Evaluation of two IFX dosing strategies
Charles et al., 2010184 Not a RCT
Chen et al., 2013185 Not a RCT
Chey and Shah, 2005186 Not a RCT
Chowers et al., 2010187 Not a RCT
Chuang et al., 2010188 Not a RCT
Cohen, 2003189 Not a RCT
Colombel et al., 2011190 No protocol-eligible outcome data
Colombel et al., 2011190 Not a RCT
Colombel et al., 2012191 Parallel publication, duplicate outcome data
Cottone, et al., 2008192 Not a RCT
Croft et al., 2013193 Population outside scope of appraisal (use of biological in acute
severe UC following failure of i.v. steroids)
Cross et al., 2008194 Not a RCT
Danese, 2013195 Unable to obtain
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Author and year/NCT number Reason for exclusion
De Vos et al., 2012196 Not a RCT
de Vries et al., 2009197 Not a RCT
D’Haens, 2005198 Not a RCT
Dean et al., 2012199 Not a RCT
Dignass et al., 2012200 Not a RCT
Domènech et al., 2010201 Not a RCT
Dranitsaris et al., 2012202 Not a RCT
Eidelwein et al., 2005203 Not a RCT
Erikkson et al., 2012204 Not a RCT
Esteve et al., 2011205 Not a RCT
EUCTR2007–006692–37-GB206 Not UC trial population
EUCTR2007–007702–30-IT206 Not a RCT
EUCTR2007–000842–11-AT206 Not a RCT
EUCTR2008–007519–34-SE206 Not a RCT
EUCTR2011–002411–29-SE206 Not a RCT
EUCTR2011–006084–22-GB206 Not a RCT
Fanjiang et al., 2007207 Not a RCT
Fasanmade et al., 2009208 No protocol-eligible outcome data
Fasanmade et al., 2010209 No protocol-eligible outcome data
Feagan et al., 2005210 Not a RCT
Feagan, 2006211 Not a RCT
Florholmen et al., 2011212 Population outside scope of appraisal (use of biological in acute
severe UC following failure of i.v. steroids)
Ford et al., 20133 Not a RCT
Gao and Jiang, 2013213 Not available in English language
Gavalas et al., 2007214 Population outside scope of appraisal (use of biological in acute
severe UC)
Gearry and Falvey, 2012215 Not a RCT
Gies et al., 2010216 Not a RCT
Ginard et al., 2008217 Not a RCT
Grosen et al., 2013218 Not a RCT
Gustavsson et al., 2010219 Follow-on study to excluded Järnerot et al., 2005112
Ha et al., 2011220 Not a RCT
Halpin et al., 2010221 Not a RCT
Halpin and Hamlin, 2012222 Not a RCT
Hämäläinen et al., 2011223 Not a RCT
Hanauer, 2005224 Not a RCT
Hanauer et al., 2008225 Not a RCT
Hanauer et al., 2008226 Not a RCT
Heraganahally et al., 2009227 Not a RCT
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Author and year/NCT number Reason for exclusion
Herrlinger et al., 2010228 Not a RCT
Honeywell et al., 2007229 Unable to obtain
Hyams et al., 2010230 Not a RCT
Hyams et al., 2011231 Unable to obtain
Assasi, 2009232 Not a RCT
Jackson, 2007233 Not a RCT
Järnerot et al., 2005112 Population outside scope of appraisal (use of biological in acute
UC following failure of i.v. steroids)
Järnerot, 2006234 Not a RCT
Jiménez, 2004235 Not a RCT
Joob and Wiwanikit, 2013236 Not a RCT
JPRN-UMIN000006169206 Not a RCT
JPRN-UMIN000007256206 Not a RCT
JPRN-UMIN000007806206 Not a RCT
JPRN-UMIN000010205206 Not a RCT
JPRN-UMIN000013033206 Not a RCT
Kaser and Tilg, 2008237 Not a RCT
Kaur and Targan, 2013238 Not a RCT
Kerbleski and Gottlieb, 2009239 Not a RCT
Klotz, et al., 2007240 Not a RCT
Kohn et al., 2004241 Not a RCT
Kohn et al., 2007242 Not a RCT
Kohn, 2008243 Not a RCT
Laharie et al., 2012244,245 Population outside scope of appraisal (use of biological in acute
severe UC following failure of i.v. steroids)
Leal et al., 2012246 Not a RCT
LeBlanc et al., 2013247 Not a RCT
Leblanc et al., 2011248 Not a RCT
Levesque and Sandborn, 2012249 Not a RCT
Levy, 2009250 Not a RCT
Li et al., 2013251 No protocol-eligible outcome data
Lichtenstein, 2001252 Not a RCT
Lichtenstein, 2009253 Not a RCT
Liu et al., 2013254 Not a RCT
Löfberg et al., 2012255 Not UC trial population
Lorenzo-Zúñiga et al., 2013256 Not a RCT
Mallow et al., 2013257 Not a RCT
Mallow et al., 2013258 Not a RCT
Maser et al., 2008259 Not a RCT
Matsumoto, 2007260 Not a RCT
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Author and year/NCT number Reason for exclusion
Mazumdar and Greenwald, 2009261 Not a RCT
McCann and Smith, 2013262 Not a RCT
Molnár et al., 2010263 Not a RCT
Molnár et al., 2011264 Not a RCT
Molnár et al., 2011265 Not a RCT
Moss and Farrell, 2006266 Not a RCT
Nakase et al., 2010267 Not a RCT
National Institute for Health Research, 2011268 Not a RCT
National Institute for Health Research, 2011269 Not a RCT
National Institute for Health Research, 2013270 Not a RCT
NCT00207688206 Not a RCT
NCT00421642206 Not a RCT
NCT00488774271 Unlicensed route of administration for intervention
NCT00573794271 Not a RCT
NCT00586599271 Not a RCT
NCT00586807271 Not a RCT
NCT00606346271 Not a RCT
NCT00705484271 Not a RCT
NCT00745329271 Not a RCT
NCT00791557271 Not a RCT
NCT00955123271 Not a RCT
NCT00984568271 Evaluation of different IFX treatment strategies
NCT01346826271 Evaluation of accelerated IFX infusions
NCT01408810271 Not a RCT
NCT01417728271 Not a RCT
NCT01494857271 Not a RCT
NCT01550965271 Not a RCT
NCT01585155271 Not a RCT
NCT01670240271 Evaluation of biological in treatment of chronic pouchitis
(trial currently recruiting)
NCT01716039271 Study evaluating ADA–MTX interaction
NCT01787786271 Not a RCT
NCT01846026271 Not protocol-eligible intervention
NCT01848561271 Not a RCT
NCT01851343206 Not a RCT
NCT01900574271 Not a RCT
NCT01947816271 Not a RCT
NCT01960426271 Evaluation of two dosing methods
NCT01971814271 Not a RCT
NCT01988961271 Not a RCT
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Author and year/NCT number Reason for exclusion
NCT02057016206 Not a RCT
NCT02073526206 Not a RCT
Nguyen and Prather, 2009272 Not a RCT
Nielsen and Jess, 2013273 Unable to obtain
Ochsenkühn et al., 2004274 Population outside scope of appraisal: (1) use of biological in
acute severe UC, (2) no patients were receiving
immunosuppressants/immunomodulators > 10mg/day
prednisolone at baseline and, therefore, not inadequate
responders/stated intolerant to conventional therapy options
Orlando et al., 2012275 Not UC trial population
Oussalah et al., 2008276 Not a RCT
Oussalah et al., 2010277 Not a RCT
Panncione et al., 2011278 Parallel publication, duplicate outcome data
Panncione et al., 2013279 Parallel publication, duplicate outcome data
Pardi and Sandborn, 2008280 Not a RCT
Pastore et al., 2010281 Not a RCT
Pastorelli et al., 2009282 Not a RCT
Pearce and Lawrance, 2007283 Not a RCT
Peyrin-Biroulet et al., 2007284 Not a RCT
Pola et al., 2013285 Not a RCT
Reinisch and Sandborn 2012286 No protocol-eligible outcome data
Rizzello et al., 2013287 Not a RCT
Rostholder et al., 2012288 Not a RCT
Rubin et al., 2012289 Not UC trial population
Russell and Katz, 2004290 Not a RCT
Rutgeerts, 2002291 Not a RCT
Rutgeerts et al., 2010292 Not a RCT
Rutgeerts et al., 2013293 Parallel publication, duplicate outcome data
Rutgeerts et al., 2013294 Parallel publication, duplicate outcome data
Salvana and Salata, 2009295 Not a RCT
Sandborn et al., 2007296 Not a RCT
Sandborn et al., 200967 Not a RCT
Sandborn, 2012297 Not a RCT
Sandborn et al., 2011298 Parallel publication, duplicate outcome data
Sandborn et al., 2011299 Parallel publication, duplicate outcome data
Sandborn et al., 2012300 Parallel publication, duplicate outcome data
Sandborn et al., 2012301 Parallel publication, duplicate outcome data
Sandborn et al., 2012302 Parallel publication, duplicate outcome data
Sandborn et al., 201260 Parallel publication, duplicate outcome data
Sandborn et al., 2012303 Unable to obtain
Sandborn et al., 2012304 Unable to obtain
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Author and year/NCT number Reason for exclusion
Sandborn and Loftus, 2004305 Not a RCT
Sands et al., 2001306 Population outside scope of appraisal (use of biological in acute
severe UC following failure of i.v. steroids)
Scholmerich, 2009307 Not a RCT
Sciaudone et al., 2010308 Not a RCT
Sciaudone et al., 2011309 Not a RCT
Seirafi et al., 2011310 Not a RCT
Siemanowski and Regueiro, 2007311 Not a RCT
Simmons and Jewell, 2002312 Not a RCT
Singh and Loftus, 2013313 Not a RCT
Sjöberg et al., 2012314 Not a RCT
Smith, 2013315 Unable to obtain
Sokol et al., 2010316 Not a RCT
Stein and Stein 2013317 Unable to obtain
Su et al., 2002318 Not a RCT
Taxonera et al., 2011319 Not a RCT
Thorlund et al., 2013320 Not a RCT
Toedter et al., 2010321 No protocol-eligible outcome data
Toedter et al., 2011322 No protocol-eligible outcome data
Travis, 2011323 Not a RCT
Tursi et al., 2010324 Not a RCT
Van Assche, 2008325 Not a RCT
Van Assche, et al., 2008326 Not a RCT
van Casteren-Messidoro et al., 2012327 Not a RCT
Velayos and Mahadevan, 2007328 Not a RCT
Vermeire et al., 2011329 Not treatment of interest (antibody PF-00547,659)
Warner and Harris, 2012330 Not a RCT
Waters et al., 2008331 Unable to obtain
Waters et al., 2009332 Not a RCT
Willert and Lawrance, 2008333 Not a RCT
Wolf et al., 2007334 Not a RCT
Wolf et al., 2012335 Parallel publication, duplicate outcome data
Yamamoto and Shiraki, 2012336 Not a RCT
Yamamoto-Furusho and Uzcanga, 2008337 Not a RCT
Yapali and Hamzaoglu, 2007338 Not a RCT
NCT, National Clinical Trial.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
232
Appendix 3 Table of numbers withdrawing and
reasons for withdrawal
Participants withdrawing from treatment arms, reasons for
withdrawal and risk of attrition bias assessment judgement
Study
number
Treatment
arm
Number completing:
n/N (%) Reasons for withdrawal
Attrition bias
judgement
ULTRA144 PBO ITT-A3 (amendment):
121/130 (93%)
ITT-A3 (amendment):
AE, 5/130 (4%); lack of
efficacy, 4/130 (3%) –
overall, 9/130 (7%)
Low risk: ≤ 10%
attrition in each group,
numbers balanced
across groups, ITT
analysis presented
ULTRA144 160mg/80mg
of ADA
ITT-A3 (amendment):
118/130 (91%)
ITT-A3 (amendment):
AE, 6/130 (5%);
withdrew consent, 2/130
(1.5%); lost to follow-up,
2/130 (1.5%); lack of
efficacy, 2/13 (1.5%) –
overall, 12/130 (9%)
ULTRA245 PBO 135/260 (52%) switched
to open label of which
n= 84 dose escalated to
40mg per week overall,
131/260 (50.4%);
completed on 16mg/
80mg/40mg dosing,
56/260 (21.5%); switched
to open label 40mg every
other week at week 12
(n=135), 30/260 (11.5%);
dose escalated to 40mg
weekly (n=68), 45/260
(17.3%)
Site non-compliance,
10/258 (4%); lack of
efficacy, 63/258 (24%);
AE, 12/258 (5%);
withdrew consent,
8/258 (3%); lost to
follow-up, 1/258 (< 1%);
protocol violation, 1/258
(< 1%); other, 9/258 (3%)
High risk: although ITT
analysis was undertaken,
there was a high level
of attrition and an
imbalance between
treatment groups (PBO,
50%; ADA, 59%)
ULTRA245 160mg of ADA
at week 0,
80mg at
week 2
and then
40mg EOW
beginning at
week 4
116/258 (45%) switched
to open label of which
n=68 dose escalated
to 40mg week overall,
154/258 (59.7%);
completed on 16mg/
80mg/40mg dosing,
82/258 (31.7%); switched
to open label 40mg every
other week at week 12
(n=116), 32/258 (12.4%);
dose escalated to 40mg
weekly (n=68), 40/258
(15.5%)
Site non-compliance,
14/260 (5%); lack of
efficacy, 70/260 (27%);
AE, 25/260 (10%);
withdrew consent,
4/260 (1.5%); protocol
violation, 5/260 (2%);
other, 11/260 (4%)
Suzuki46 PBO Week 8: 92/96 (96%),
week 52: 73/96 (77%)
Week 8: total
discontinued, 4/96 (4%) –
lack of efficacy n= 2,
AE n= 2. Week 52: total
discontinued, 23/96
(23%) – withdrew
consent n= 2, lack of
efficacy n= 14, AE n= 7;
moved to rescue therapy
n= 63
Induction: low risk –
< 10% attrition in each
group and numbers
reasonably balanced
across groups.
All patients accounted
for in the primary
outcome analysis
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Study
number
Treatment
arm
Number completing:
n/N (%) Reasons for withdrawal
Attrition bias
judgement
Suzuki46 80mg/40mg
of ADA
Week 8: 85/87 (98%)
(unlicensed), week 52:
58/87 (67%)
Week 8: total
discontinued, 2/87 (2%) –
withdrew consent n= 1,
lack of efficacy n= 1.
Week 52: total
discontinued, 29/87
(33%) – withdrew
consent n= 3, lack of
efficacy n= 17, AE n= 9;
moved to rescue therapy
n= 50
Maintenance: high risk –
PBO, 23%; ADA, 33%
Suzuki46 160mg/80mg
of ADA
Week 8: 86/90 (96%),
week 52: 60/90 (67%)
Week 8: total
discontinued, 4/90 (4%) –
lack of efficacy n= 1, AE
n= 3. Week 52: total
discontinued, 30/90
(33%) – lack of efficacy
n= 16, AE n= 13, other
n= 1; moved to rescue
therapy n= 46
ULTRA354 PBO 91/121 (75%) Lack of efficacy, 21/121
(17%); AE, 16/121
(13%); withdrew consent,
3/121 (2%); protocol
violation, 1/121 (1%)
Extension study not
included in risk of bias
assessment
ULTRA354 80mg/40mg
of ADA
86/118 (73%) Lack of efficacy, 17/118
(14%); AE, 12/118 (10%);
withdrew consent, 5/118
(4%); lost to follow-up,
1/118 (1%); protocol
violation, 1/118 (1%);
other, 4/118 (3%)
ULTRA354 160mg/80mg
of ADA
95/121 (79%) Lack of efficacy,
15/121 (%); AE,
10/121 (%); withdrew
consent, 4/121 (%); lost
to follow-up, 1/121 (%);
protocol violation,
1/121 (%)
PURSUIT-SC47 Phase II PBO 41/42 plus 26/31 enrolled
while Phase II data being
analysed
2/42 ‘other’ reasons Low risk: ITT reported
and withdrawal < 10%
across all groups and
n balanced
PURSUIT-SC47 Phase II
200mg/100mg
of GOL all
randomised
41/42 plus 31/31 enrolled
while Phase II data being
analysed
1/42 withdrew consent
PURSUIT-
Maintenance48
PBO PBO 115/156 (73%)
randomised completed
through week 54
Discontinued treatment
prior to week 52 (n= 43):
17 AE, 19 unsatisfactory
therapeutic effect, 1 lost
to follow-up, 6 other.
Terminated study
before week 54 (n= 18):
5 withdrew consent,
3 lost to follow-up,
10 other
High risk: although ITT
reported, withdrawal
> 10% across all groups
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Study
number
Treatment
arm
Number completing:
n/N (%) Reasons for withdrawal
Attrition bias
judgement
PURSUIT-
Maintenance48
50mg of GOL 50mg of GOL. 120/154
(78%) randomised
completed through
week 54
Discontinued treatment
prior to week 52 (n= 43):
12 AE, 17 unsatisfactory
therapeutic effect, 2 lost
to follow-up, 12 other.
Terminated study before
week 54 (n= 18): 10
withdrew consent, 2 lost
to follow-up, 6 other
PURSUIT-
Maintenance48
100mg of GOL 100mg of GOL. 116/154
(75%) randomised
completed through
week 54
Discontinued treatment
prior to week 52 (n= 45):
12 AE, 22 unsatisfactory
therapeutic effect, 1 lost
to follow-up, 10 other.
Terminated study before
week 54 (n= 21):
11 withdrew consent, 2
lost to follow-up, 8 other
UC-SUCCESS51 AZA 53/79 (66%) AE, 11/80 (14%);
withdrew consent, 8/80
(10%); non-compliance
with protocol, 5/80 (6%);
protocol ineligible,
3/80 (4%)
High risk: although ITT
analysis was undertaken,
there was a high level
of attrition and an
imbalance between
treatment groups (AZA,
34%; IFX, 18%;
IFX/AZA, 21%)
UC-SUCCESS51 IFX 65/78 (82%) AE, 7/79 (9%); clinical
event, 1/79 (1%); lost to
follow-up, 1/79 (1%);
withdrew consent, 3/79
(4%); non-compliance
with protocol, 1/79 (1%);
protocol ineligible,
1/79 (1%)
UC-SUCCESS51 IFX/AZA 63/80 (79%) AE, 8/80 (10%);
withdrew consent, 4/80
(5%); non-compliance
with protocol, 1/80 (1%);
protocol ineligible, 2/80
(3%); administrative
reasons, 2/80 (3%)
Probert et al.50 PBO 20/20 (100%) No withdrawals reported Low risk: all patients
accounted for in the
primary outcome
analysis
Probert et al.50 IFX 23/23 (100%)
Hyams et al.52 5mg of IFX
every 8 weeks
18/22 (82%) completed
infusions and follow-up
AE, 3/22 (14%); lack of
efficacy, 1/22 (5%)
High risk: numbers
withdrawing >10% and
unbalanced across groups
(every 8 weeks, 21%;
every 12 weeks, 51%)
Hyams et al.52 5mg of IFX
every 12 weeks
12/23 (52%) complete
infusions; 11/23 (49%)
completed follow-up
AE, 6/23 (26%); lack of
efficacy, 4/23 (17%);
other, 1/23 (4%)
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Study
number
Treatment
arm
Number completing:
n/N (%) Reasons for withdrawal
Attrition bias
judgement
ACT149 PBO 47 completed study
infusions, of whom
46/121 completed
follow-up. 74
discontinued study
infusions, of whom 18
completed follow-up
In ACT1, similar numbers
of patients in each group
discontinued treatment
because of an AE
High risk: although ITT
reported, > 50% in PBO
and > 30% in IFX 5 and
10mg did not complete
ACT149 5mg/kg of IFX 76/121 completed study
infusions, of whom
76 completed follow-up.
45 discontinued study
infusions, of whom six
completed follow-up
ACT249 PBO 67 completed study
infusions, of whom 64/123
completed follow-up.
56 discontinued study
infusion, nine completed
follow-up
In ACT2, more patients in
the PBO group than
in the two IFX groups
discontinued treatment
because of an AE
High risk: although ITT
reported, > 50% in PBO
and > 30% in IFX 5mg
and 10mg did not
complete
ACT249 5mg/kg of IFX 97 completed study
infusions, of whom 94/121
completed follow-up.
24 discontinued study
infusions, of whom three
completed follow-up
EOW, every other week; ITT-A3, intention to treat-amendment 3.
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Appendix 4 Additional efficacy outcomes tables
Additional efficacy outcomes (adult population trials)
Study name Treatment arm Time point Outcome measure
ULTRA144 PBO Week 8 Subgroup analysis results: remission n/N (%): Mayo score < 10:
10/83 (12.0%) Mayo score ≥ 10: 2/47 (4.3%); extensive colitis:
11/73 (15.1%); no extensive colitis: 1/57 (1.8%); CS (without IMM%):
6/55 (10.9%); IMM (AZA and 6-MP without CS%): 0/18 (0%)
2/25 (8.0%) 6/28 (21.4%); IMM+CS: 2/34 (5.9%); no CS+ no
IMM: 4/23 aminosalicylates: 11/98 (11.2%); no aminosalicylates:
1/32 (3.1%); CRP < 10mg/l: 7/95 (7.4%); CRP ≥ 10mg/l: 4/32
(12.5%); weight < 70.0 kg: 5/35 (14.3%); weight ≥ 70.0 kg,
< 82.0 kg: 3/43 (7.0%); weight ≥ 82.0 kg: 4/52 (7.7%)
Change from baseline in CRP mg/l: median –0.09 (range –274.79 to
88.71)
Rectal bleeding subscore of ≤ 1, 86/130 (66.2%)
PGA subscore of ≤ 1, 61/130 (46.9%)
Stool frequency subscore, 49/130 (37.7%)
Reinisch et al.61
Change from baseline:
Haemoglobin g/l, 4.4; p-value vs. PBO < 0.001
Haematocrit fraction, 0.014; p-value vs. PBO < 0.001
Red blood cells × 1012/l, 0.16; p-value vs. PBO < 0.01
Total protein g/l, 1.5; p-value vs. PBO < 0.05
Albumin g/l, 1.3
CRP mg/l, –0.47
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Study name Treatment arm Time point Outcome measure
ULTRA1 160mg/80mg
of ADA
Week 8 Reinisch et al.44
Subgroup analysis results: remission n/N (%): Mayo score < 10:
17/85 (20.0%), difference from PBO (95% CI) 1.5 (–8.7 to 11.8) 8.0
(–3.1 to 19.0) Mayo score ≥ 10: 7/45 (15.6%), difference from PBO
(95% CI) 11.3 (–0.8 to 23.4); extensive colitis: 12/60 (20.0%),
difference from PBO (95% CI) 4.9 (–8.1 to 18.0); no extensive colitis:
12/70 (17.1%), difference from PBO (95% CI) 15.4 (5.9 to 24.9); CS
(without IMM%): 10/48 (20.8%), difference from PBO (95% CI)
11.3 (–3.0 to 25.7) IMM (AZA and 6-MP without CS%): 6/28
(21.4%), difference from PBO (95% CI) 20.7 (5.9 to 35.4);
IMM+CS: 2/23 (8.7%), difference from PBO (95% CI) 4.1 (–11.2 to
19.5); no CS+ no IMM: 6/31 (19.4%), difference from PBO (95% CI)
–1.0 (–20.5 to 18.5); aminosalicylates: 18/105 (17.1%), difference
from PBO (95% CI) 5.9 (–3.6 to 15.5); no aminosalicylates: 6/25
(24.0%), difference from PBO (95% CI) 20.9 (3.1 to 38.7); CRP
< 10 mg/l: 21/101 (20.8%), difference from PBO (95% CI) 13.4
(3.9 to 22.9); CRP ≥ 10 mg/l: 2/25 (8.0%), difference from PBO
(95% CI) –4.5 (–20.1 to 11.1); weight < 70.0 kg: 11/45 (24.4%),
difference from PBO (95% CI) 10.2 (–6.9 to 27.2); weight ≥ 70.0 kg,
< 82.0 kg: 8/33 (24.2%), difference from PBO (95% CI) 17.3 (0.8 to
33.8); weight ≥ 82.0 kg: 5/52 (9.6%), difference from PBO (95% CI)
1.9 (–8.9 to 12.7)
Change from baseline in CRP mg/l: median –0.77 (range –95.09 to
130.41)
Rectal bleeding subscore of ≤ 1, 101/130 (77.7%)
PGA subscore of ≤ 1, 78/130 (60.0%)
Stool frequency subscore, 63/130 (48.5%)
Reinisch et al.61
Change from baseline:
Haemoglobin g/l, 4.9; p-value vs. PBO < 0.001
Haematocrit fraction, 0.014; p-value vs. PBO < 0.001
Red blood cells × 1012/l, 0.19; p-value vs. PBO < 0.001
Total protein g/l, 1.7; p-value vs. PBO < 0.01
Albumin g/l, 1.7; p-value vs. PBO < 0.01
CRP mg/l, –0.87; p-value vs. PBO < 0.001
ULTRA2 PBO Week 8 Sandborn et al.45
No prior anti-TNF-α treatment:
PGA ≤ 1, 63/145 (43.4%); SFS ≤ 1, 43/145 (29.7%);
RBS ≤ 1, 86/145 (59.3%); prior anti-TNF-α treatment:
PGA ≤ 1, 29/101 (28.7%); SFS ≤ 1, 27/101 (26.7%);
RBS ≤ 1, 57/101 (56.4%)
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Study name Treatment arm Time point Outcome measure
ULTRA2 PBO Week 32 EPAR (Humira)34
Number and percentage of subjects taking CSs at baseline who
discontinued CS use and achieved clinical remission per Mayo
score at week 32 (ITT analysis): clinical remission at week 32 –
discontinued CS at any time prior to week 32, 10/140 (7.1%) clinical
remission at week 32 – discontinued CS for ≥ 90 days prior to
week 32, 9/140 (6.4%)
ULTRA2 PBO Week 52 Sandborn et al.45
Discontinued CS use before week 52 and achieved clinical remission
at week 52 among patients with baseline CS use, 5/81 (6.2%);
discontinued CS use for ≥ 90 days before week 52 and achieved
remission at week 52 among patients with baseline CS use, 5/81
(6.2%); discontinued CS use and achieved sustained clinical
remission at both weeks 32 and 52 among patients with baseline CS
use, 1/81 (1.2%); IBDQ responders at week 52, 31/145 (21.4%);
prior anti-TNF-α treatment: discontinued CS use before week 52 and
achieved clinical remission at week 52 among patients with baseline
CS use, 3/59 (5.1%); discontinued CS use for ≥ 90 days before
week 52 and achieved remission at week 52 among patients with
baseline CS use, 3/59 (5.1%); discontinued CS use and achieved
sustained clinical remission at both weeks 32 and 52 among patients
with baseline CS use, 1/59 (1.7%); IBDQ responders at week 52,
9/101 (8.9%)
EPAR (Humira)34
Discontinued corticosteroid use for ≥ 90 days before week 52 and
achieved remission at week 52, 8/246 (5.7%); discontinued
corticosteroid use and sustained remission at both week 32 and
week 52, 2/246 (1.4%); IBDQ responders at week 52, 40/246
(16.3%); number and percentage of subjects taking CSs at baseline
who discontinued CS use and achieved clinical remission per Mayo
score at week 52 (ITT analysis): clinical remission at week 52 –
discontinued CS at any time prior to week 52, 8/140 (5.7%); clinical
remission at week 52 – discontinued CS for ≥ 90 days prior to
week 52, 8/140 (5.7%)
Sandborn et al.304
Week 52 CS-free remission: all PBO, 8/140 (5.7%); anti-TNF-α-naive
PBO, 5/81 (6.2%); anti-TNF-α-exposed PBO, 3/59 (5.1%) week 52
CS-free: all PBO, 32/140 (22.9%); anti-TNF-α-naive PBO, 20/81
(24.7%); anti-TNF-α-exposed PBO, 12/59 (20.3%)
Sandborn et al.60
Post-hoc analysis, week 52 n= 246: mean days in IBDQ remission
(IBDQ score of ≥ 170), 79.00; mean SAE adjusted days in clinical
remission, 48.23
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Study name Treatment arm Time point Outcome measure
ULTRA2 160mg of ADA
at week 0,
80mg at week
2 and then
40mg EOW
Week 8 Sandborn et al.45
Serum trough concentrations over time by remission status, mean
(SD) [min., max.], Nnmiss: 40mg EOW patients who were remitters
(n= 43): 11.4 (5.15) [0.000, 22.8], 41
40mg EOW patients who were non-remitters (n= 153): 8.49 (4.35)
[0.000, 21.8], 110
No prior anti-TNF-α treatment: PGA ≤ 1, 88/150 (58.7%); p-value vs.
PBO, 0.009SFS ≤ 1, 69/150 (46.0%); p-value vs. PBO, 0.004RBS ≤ 1,
116/150 (77.3%); p-value vs. PBO, 0.001
IBDQ responders, 102/150 (68.0%); p-value vs. PBO, 0.004 Prior
anti-TNF-α treatment: PGA ≤ 1, 26/98 (26.5%); p-value vs. PBO,
0.731SFS ≤ 1, 25/98 (25.5%); p-value vs. PBO, 0.844 RBS ≤ 1, 58/98
(59.2%); p-value vs. PBO, 0.695IBDQ responders, 42/98 (42.9%);
p-value vs. PBO, 0.370
ULTRA2 160mg of ADA
at week 0,
80mg at week
2 and then
40mg EOW
Week 32 Sandborn et al.45
Serum trough concentrations over time by remission status, mean
(SD) [min., max.], Nnmiss: 40mg EOW patients who were remitters
(n= 43), 10.6 (5.64) [0.000, 26.9], 39
40mg EOW patients who were non-remitters (n= 153), 6.95 (3.98)
[0.000, 18.1], 70
ULTRA2 160mg of ADA
at week 0,
80mg at week
2 and then
40mg EOW
Week 52 Sandborn et al.45
Serum trough concentrations over time by remission status, mean
(SD) [min., max.], Nnmiss: 40mg EOW patients who were remitters
(n= 43), 10.8 (7.45) [0.000, 39.3], 39
40mg EOW patients who were non-remitters (n= 153), 6.18 (4.22)
[0.000, 16.1], 62
No prior anti-TNF-α treatment: discontinued CS use before week 52
and achieved clinical remission at week 52 among patients with
baseline CS use, 15/110 (13.6%); p-value vs. PBO, 0.096
discontinued CS use for ≥ 90 days before week 52 and achieved
remission at week 52 among patients with baseline CS use, 15/110
(13.6%); p-value vs. PBO, 0.096; discontinued CS use and achieved
sustained clinical remission at both weeks 32 and 52 among patients
with baseline CS use, 11/110 (10.0%); p-value vs. PBO, 0.014; IBDQ
responders at week 52, 48/150 (32.0%); p-value vs. PBO, 0.039;
prior anti-TNF-α treatment: discontinued CS use before week 52 and
achieved clinical remission at week 52 among patients with baseline
CS use, 5/40 (12.5%); p-value vs. PBO, 0.263; discontinued CS use
for ≥ 90 days before week 52 and achieved remission at week 52
among patients with baseline CS use, 5/40 (12.5%); p-value vs. PBO,
0.263; discontinued CS use and achieved sustained clinical remission
at both weeks 32 and 52 among patients with baseline CS use, 4/40
(10.0%); p-value vs. PBO, 0.155; IBDQ responders at week 52,
17/98 (17.3%); p-value vs. PBO, 0.078
EPAR (Humira)34
Discontinued CS use before week 52 and achieved remission at
week 52, 20/248 (13.3%); p-value vs. PBO, 0.035; discontinued
corticosteroid use for ≥ 90 days before week 52 and achieved
remission at week 52, 20/248 (13.3%); p-value vs. PBO, 0.035;
discontinued corticosteroid use and sustained remission at both
week 32 and week 52, 15/248 (10.0%); p-value vs. PBO, 0.002;
IBDQ responders at week 52, 65/248 (26.2%); p-value vs. PBO, 0.007
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Study name Treatment arm Time point Outcome measure
Number and percentage of subjects taking CSs at baseline who
discontinued CS use and achieved clinical remission per Mayo score
(ITT analysis): clinical remission at week 52 – discontinued CS at any
time prior to week 52, 20/150 (13.3%); p-value vs. PBO, 0.035;
clinical remission at week 52 – discontinued CS for ≥ 90 days prior to
week 52, 20/150 (13.3%); p-value vs. PBO, 0.035
Van et al.59
Week 52 CS-free remission – full Mayo: all ADA, 18/90 (20.0%);
p-value vs. PBO, < 0.05; anti-TNF-α-naive ADA, 14/69 (20.3%);
p-value vs. PBO, < 0.05; anti-TNF-α-exposed ADA, 4/21 (19.0%).
Week 52 CS-free remission – partial Mayo: all ADA, 19/90 (21.1%);
p-value vs. PBO, < 0.001; anti-TNF-α-naive ADA, 14/68 (20.6%);
p-value vs. PBO, < 0.05; anti-TNF-α-exposed ADA, 5/22 (22.7%);
p-value vs. PBO, < 0.05 week 52 CS-free – full Mayo: all ADA, 4/90
(45.6%); p-value vs. PBO, < 0.001; anti-TNF-α-naive ADA, 31/69
(44.9%); p-value vs. PBO, < 0.05; anti-TNF-α-exposed ADA, 10/21
(47.6%); p-value vs. PBO, < 0.05 week 52 CS-free – partial Mayo: all
ADA, 43/90 (47.8%); p-value vs. PBO, < 0.001; anti-TNF-α-naive
ADA, 31/68 (45.6%); p-value vs. PBO, < 0.05; anti-TNF-α-exposed
ADA, 12/22 (54.5%); p-value vs. PBO, < 0.05
Sandborn et al.60
Post-hoc analysis, week 52 n= 248: mean days in IBDQ remission
(IBDQ score of ≥ 170), 103.93; p-value vs. PBO, 0.025; mean SAE
adjusted days in clinical remission, 81.21; p-value vs. PBO, < 0.001
ULTRA3 40mg of ADA
EOW or EW
Week 52 Sandborn et al.339
Clinical remission at week 52 in patients who responded per partial
Mayo score at week 8 – ITT-A3 protocol: non-responder imputation,
76/196 (38.8%); modified non-responder imputation, 84/196
(42.9%); as observed 76/131 (58.0%) clinical response at week 52 in
patients who responded per partial Mayo score at week 8 – ITT-A3
protocol: non-responder imputation, 113/196 (57.7%); modified
non-responder imputation, 131/196 (66.8%); as observed 113/131
(86.3%) proportion of patients in the ITT-A3 population with Mayo
subscores indicative of mild disease or remission at week 52: rectal
bleeding subscore of ≤1: non-responder imputation, 185/390
(47.4%); modified non-responder imputation, 246/390 (63.1%);
as observed, 185/279 (67.0%) stool frequency subscore of ≤1:
non-responder imputation, 145/390 (37.2%); modified non-responder
imputation, 175/390 (44.9%); as observed, 145/276 (52.5%);
physician’s global assessment ≤1: non-responder imputation, 169/390
(43.3%); modified non-responder imputation, 215/390 (55.1%); as
observed, 169/276 (61.2%) proportion of patients in the ITT-A3 and
ITT-E populations with Mayo subscores indicative of mild disease or
remission at week 52: rectal bleeding subscore of ≤1: non-responder
imputation, 270/575 (47.0%); modified non-responder imputation,
348/575 (60.5%); as observed, 270/290 (93.1%); stool frequency
subscore of ≤1: non-responder imputation, 210/575 (36.5%);
modified non-responder imputation, 251/575 (43.7%); as observed,
210/290 (72.4%); physician’s global assessment ≤1: non-responder
imputation, 240/575 (41.7%); modified non-responder imputation,
299/575 (52.0%) 240/290 (82.8%); steroid-free remission at week 52;
patients using steroids at baseline in the ITT-A3 population (modified
non-responder imputation): steroid-free at week 52, 131/234 (56.0%);
remission at week 52, 66/234 (28.2%); steroid-free for ≥90 days at
week 52, 118/234 (50.4%); remission at week 52, patients who were
steroid-free for ≥90 days, 61/234 (26.1%)
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Study name Treatment arm Time point Outcome measure
ULTRA3 ADA 40mg
EOW or EW
Weeks 0 to
156
Sandborn et al.339
Remission per partial Mayo score presented graphically for weeks 0,
8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 and 156.
Samples below from:
Week 0:
All non-responder imputation, 307/588 (52.2%)
Entered ULTRA 3 on EOW modified non-responder imputation,
252/447 (56.4%)
Week 36:
All non-responder imputation, 334/588 (56.8%)
Entered ULTRA 3 on EOW modified non-responder imputation,
254/447 (56.8%)
Week 60:
All non-responder imputation, 325/588 (55.3%)
Entered ULTRA 3 on EOW modified non-responder imputation,
229/447 (51.2%)
Week 156:
All non-responder imputation, 273/588 (46.4%)
Entered ULTRA 3 on EOW modified non-responder imputation,
187/447 (41.8%)
Suzuki PBO Week 8 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 65/96 (67.7%); PGA subscore of
≤ 1, 43/96 (44.8%);stool frequency subscore of ≤ 1, 31/96 (32.3%);
IBDQ response (increase in IBDQ score of ≥ 16 points from baseline),
38/96 (39.6%); remission by baseline CS use, 10/58 (17.2%);
non-use, 1/38 (2.6%); remission by baseline immunomodulator use,
1/52 (1.9%); non-use, 10/44 (22.7%)
Suzuki PBO Week 32 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 27/96 (28.1%) PGA subscore of
≤ 1, 27/96 (28.1%); stool frequency subscore of ≤ 1, 20/96 (20.8%);
IBDQ response (increase in IBDQ score of ≥ 16 points from baseline),
2196 (21.9%); steroid-free, 12/58 (n at baseline) (20.7%);
steroid-free remission, 5/58 (n at baseline) (8.6%)
Suzuki PBO Week 52 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 22/96 (22.9%) PGA subscore of
≤ 1, 19/96 (19.8%); stool frequency subscore of ≤ 1, 13/96 (13.5%);
IBDQ response (increase in IBDQ score of ≥ 16 points from baseline),
12/96 (12.5%); steroid-free, 12/58 (n at baseline) (20.7%);
steroid-free remission, 4/58 (n at baseline) (6.9%); remission by
baseline CS use, 4/58 (6.9%); non-use, 3/38 (7.9%); remission by
baseline immunomodulator use, 1/52 (1.9%); non-use, 6/44 (13.6%)
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Study name Treatment arm Time point Outcome measure
Suzuki 160mg/80mg
of ADA
Week 8 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 64/90 (71.1%); PGA subscore of
≤ 1, 55/90 (61.1%); p-value vs. PBO ≤ 0.05; stool frequency
subscore of ≤ 1, 36/90 (40.0%); IBDQ response (increase in IBDQ
score of ≥ 16 points from baseline), 38/90 (42.2%); remission by
baseline CS use, 5/57 (8.8%); non-use, 4/33 (12.1%); remission by
baseline immunomodulator use, 6/41 (14.6%), p-value vs. PBO
≤ 0.05; non-use, 3/49 (6.1%)
Suzuki 80mg/40mg of
ADA or 160mg/
80mg of ADA
to week 8 then
40mg ADA
EOW
Week 32 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 74/177 (41.8%); PGA subscore of
≤ 1, 66/177 (37.3%); stool frequency subscore of ≤ 1, 57/177
(32.2%); p-value vs. PBO, ≤ 0.05; IBDQ response (increase in IBDQ
score of ≥ 16 points from baseline), 55/177 (31.1%); steroid-free,
35/120 (n at baseline) (29.2%); steroid-free remission, 12/120
(n at baseline) (10.0%)
Suzuki 80mg/40mg of
ADA or 160mg/
80mg of ADA
to week 8 then
40mg ADA
EOW
Week 52 Suzuki et al.46
Rectal bleeding subscore of ≤ 1, 59/177 (33.3%); PGA subscore of
≤ 1, 57/177 (32.2%); p-value vs. PBO, ≤ 0.05; stool frequency
subscore of ≤ 1, 51/177 (28.8%); p-value vs. PBO, ≤ 0.05; IBDQ
response (increase in IBDQ score of ≥ 16 points from baseline),
45/177 (25.4%); p-value vs. PBO, ≤ 0.01; steroid-free; p-value vs.
PBO, ≤ 0.05; p-value vs. PBO, ≤ 0.05, 39/120 (n at baseline) (32.5%);
steroid-free remission; p-value vs. PBO, ≤ 0.05; p-value vs. PBO,
≤ 0.05, 17/120 (n at baseline) (14.2%); remission by baseline CS use,
24/120 (20.0%); non-use, 17/57 (29.8%); p-value vs. PBO use and
non-use, ≤ 0.05; remission by baseline immunomodulator use, 24/79
(30.4%), p-value vs. PBO ≤ 0.001; non-use, 17/98 (17.3%)
PURSUIT-SC Phase II PBO Week 6 Sandborn et al.47
Mean change (SD) –1.8 (2.96), median change from baseline in
Mayo score (IQR) –1.0 (–4.0 to 1.0)
PURSUIT-SC Phase II 200mg/
100mg of GOL
all randomised
Week 6 Sandborn et al.47
Mean (SD) –2.6 (2.73), median change from baseline in Mayo score
(IQR) –2.0 (–4.0 to 0.0); p= 0.219
PURSUIT-SC Phase III PBO Week 6 Sandborn et al.47
Phase III: mean change in CRP concentration at week 6 (mg/l)
PBO= 1.59
Phase III: week 6 Mayo score change from baseline PBO, mean
(SD)= –1.6 (2.53), median (IQR)= –1.0 (–3.0 to 0.0)
Phase III: normal or inactive mucosal disease (endoscopy score= 0) at
week 6 PBO= 10/251 (4.0)
PURSUIT-SC Phase III
200mg/100mg
of GOL phase III
Week 6 Sandborn et al.47
Phase III: mean change in CRP concentration at week 2 (mg/l)
200mg/100mg of GOL= – 6.57 (p< 0.0001)
Phase III: mean change in CRP concentrationat week 6 (mg/l)
200mg/100mg of GOL= – 3.35 (p< 0.0001)
Phase III: week 6 Mayo score change from baseline 200mg/100mg
of GOL, mean (SD)= –3.1 (2.90), median (IQR)= –3.0 (–6.0 to 0.0)
(p< 0.0001)
Phase III: normal or inactive mucosal disease (endoscopy score= 0) at
week 6 200mg/100mg of GOL= 21/253 (8.3) (p= 0.0437)
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Study name Treatment arm Time point Outcome measure
PURSUIT-SC PBO Weeks 0
to 6
Sandborn et al.340
Stool frequency at week 0 [all mean (SD)] PBO= 2.3 (0.8)
Stool frequency at week 2 PBO= 2.1 (0.9)
Stool frequency at week 4 PBO= 1.9 (0.9)
Stool frequency at week 6 PBO= 2 (1) (as reported)
Rectal bleeding score at week 0 [all mean (SD)] PBO= 1.50 (0.86)
Rectal bleeding score at week 2 PBO= 1.20 (0.91)
Rectal bleeding score at week 4 PBO= 1.04 (0.94)
Rectal bleeding score at week 6 PBO= 1.04 (0.94)
PURSUIT-M PBO Week 54 Sandborn et al.48
PBO: 18.4% (n= 87) were in CS-free clinical remission at week 54
(among those who were receiving CSs at baseline) 31.2% (n= 154)
maintained clinical response through week 54. 169 (37.1%) patients
in primary analysis population had dose adjustment. PBO= 75
(48.7%)
Reduction in median partial Mayo scores observed at baseline
of PURSUIT-Maintenance among GOL-induction responders
(i.e. decrease of 4 points from induction baseline) maintained in
100mg and 50mg groups through weeks 52 and 48, respectively,
(but in PBO group increased after week 8 and increased to value
approaching that an induction baseline at week 54
Proportion of patients with normal or inactive mucosal disease
(i.e. endoscopy score= 0) at week 54= 13.0%
PURSUIT-M 50mg of GOL Week 54 Sandborn et al.48
28.2% (n= 78, p= 0.279) were in CS-free clinical remission at
week 54. 47.0% (n= 151, p< 0.001) maintained clinical response
through week 54. 51 (33.8%) had dose adjustment
Proportion of patients with normal or inactive mucosal disease
(i.e. endoscopy score= 0) at week 54= 25.8% (p= 0.011)
PURSUIT-M 100mg of GOL Week 54 Sandborn et al.48
23.3% were in CS-free clinical remission at week 54 (n= 82;
p= 0.423). 49.7% (n= 151, p< 0.001) maintained clinical response
through week 54. 43 (28.5%) had dose adjustment
Proportion of patients with normal or inactive mucosal disease
(i.e. endoscopy score= 0) at week 54= 21.9% (p= 0.033)
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Study name Treatment arm Time point Outcome measure
UC-SUCCESS AZA Week 8 Panaccione et al.51
Patients with partial Mayo score decrease of ≥ 1: 50/76 (65.79%);
p-value between IFX, 0.002 and IFX/AZA, 0.003; patients with partial
Mayo score decrease of ≥ 2: 28/76 (36.84%)
Change (SD) in partial Mayo scores from baseline –2.81 (2.46)
Faecal calprotectin ≤ 50 µg/g, 12/62 (19.4%); ≤ 250 µg/g, 24/62
(38.7%) ≥ 251 µg/g
UC-SUCCESS AZA Week 16 Panaccione et al.51
Patients with Mayo score response: 38/76 (50.00%); p-value
between IFX, 0.018 and IFX/AZA, 0.001; total Mayo score change
from baseline, mean; n= 71: –3.00 (baseline 8.50); p-value between
IFX, 0.013 and IFX/AZA, 0.001
Change (SD) in partial Mayo scores from baseline–2.34 (2.70)
A post-hoc analysis was conducted to determine the proportion of
patients who achieved a Mayo endoscopy subscore of 0 only at
week 16. A greater proportion of patients treated with IFX/AZA
combination therapy (29.5%) achieved a Mayo endoscopy subscore
of 0 than patients given monotherapy with IFX (11.7%; p= 0.006)
and AZA (13.2%; p= 0.014). The difference between the IFX group
and the AZA group was not statistically significant (p= 0.783)
Faecal calprotectin ≤ 50 µg/g, 12/66 (18.2%); ≤ 250 µg/g, 29/66
(43.9%)
Panaccione et al.341
Change from baseline (assume mean): stool frequency –0.97,
rectal bleeding –0.77, physician global assessment –0.59, total
Mayo score –3.00
UC-SUCCESS IFX Week 8 Panaccione et al.51
Patients with partial Mayo score decrease of ≥ 1: 68/77 (88.31%);
p-value IFX/AZA, 0.654; patients with partial Mayo score decrease of
≥ 2: 38/77 (49.35%)
Change (SD) in partial Mayo scores from baseline –3.52 (2.25)
Faecal calprotectin ≤ 50 µg/g, 15/66 (22.7%); ≤ 250 µg/g, 33/66
(50.7%) ≥ 251 µg/g
UC-SUCCESS IFX Week 16 Panaccione et al.51
Patients with Mayo score response: 53/77 (68.83%); p-value
IFX/AZA, 0.514; total Mayo score change from baseline, mean;
n= 70: –4.27 (baseline 8.08); p-value IFX/AZA, 0.001
Change (SD) in partial Mayo scores from baseline –3.43 (2.26)
Faecal calprotectin ≤ 50 µg/g, 11/62 (17.7%); ≤ 250 µg/g, 19/62
(30.6%)
Panaccione et al.341
Change from baseline (assume mean): stool frequency –1.23;
rectal bleeding –1.14; p-value vs. AZA < 0.05; physician global
assessment –1.06; p-value vs. AZA< 0.05; total Mayo –4.27; p-value
vs. AZA < 0.05
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Study name Treatment arm Time point Outcome measure
UC-SUCCESS IFX/AZA Week 8 Panaccione et al.51
Patients with partial Mayo score decrease of ≥ 1: 67/78 (85.90%);
patients with partial Mayo score decrease of ≥ 2: 41/78 (52.56%)
Change (SD) in partial Mayo scores from baseline –4.01 (SD 2.04);
p-value vs. AZA 0.005
Faecal calprotectin ≤ 50 µg/g, 26/63 (41.3%); ≤ 250 µg/g, 42/63
(66.7%) ≥ 251 µg/g
UC-SUCCESS IFX/AZA Week 16 Panaccione et al.51
Patients with Mayo score response: 60/78 (76.92%); total Mayo
score change from baseline, mean (SD); n= 76: –5.28 (baseline 8.54)
Change (SD) in partial Mayo scores from baseline –4.09 (SD 2.18);
p-value vs. IFX < 0.001
Faecal calprotectin ≤ 50 µg/g, 22/70 (31.4%); ≤ 250 µg/g, 41/70
(58.6%)
Panaccione et al.341
Change from baseline (assume mean): stool frequency –1.54;
p-value vs. AZA < 0.05; rectal bleeding –1.25; p-value vs. AZA
< 0.05; physician global assessment –1.30; p-value vs. AZA and IFX
< 0.05; total Mayo score –5.28; p-value vs. AZA and IFX < 0.05
Probert PBO Week 6 Probert et al.50
UCSS mean (SD), 5 (3); improvement in UCSS, 4 (SD 3); median
improvement, 3. Median between-group difference, p= 0.82; Baron
score mean (SD), 1 (1); proportion of patients with a Baron score
of 0, 6/20 (30%). 95% CI for difference, −30% to 23%; p= 0.96.
Mean (SD) improvement in Baron score, 1 (SD 1). Baron score
improved by a decrease in score of at least 1 in 3/20 (13%); seven
(37%) remained the same and one underwent colectomy; p= 0.67.
When remission rates of patients with total disease in each of the
two groups were compared, no significant difference was found
(p= 0.9). Remission rate in patients receiving AZA, 2/6 (33%).
95% CI for difference, −79% to 45%; p= 0.89
Mean reduction in daily dose of glucocorticoid was equivalent to
14mg prednisolone (SD 12); p= 0.037 compared with IFX
Week 6: CRP median value did not change (data not reported);
p-value 0.96 but unclear if change from baseline or between IFX
Probert IFX Week 6 Probert et al.50
UCSS mean (SD), 5 (3); improvement in UCSS (n= 18), 4 (SD 3);
median improvement, 2.5 for the 18 assessable patients; Baron score
mean (SD), 1 (1); proportion of patients with a Baron score of 0,
6/23 (26%). Mean (SD) improvement in Baron score, 1 (1). Baron
score improved by a decrease in score of at least 1 in 13/23 (57%);
seven (30%) remained the same, and three (13%) deteriorated
5/14 (36%) with total colitis went into remission, 3/5 (60%) with
left-sided colitis and 1/4 (25%) with distal colitis (p= 0.5). Remission
rate in patients receiving AZA, 4/6 (67%)
Mean reduction in daily dose of glucocorticoid was equivalent to
19mg prednisolone (SD 15)
Week 6: CRP median levels rose from 6.5mg/l to 10mg/l
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Study name Treatment arm Time point Outcome measure
ACT1 PBO Week 2 Rutgeerts et al.49
Partial Mayo score median (IQR) at baseline, 6.0 (5.0–7.0)
Partial Mayo score median (IQR) at week 2, 5.0 (4.0–6.0)
ACT1 PBO Week 6 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 6, 5.0 (3.0–6.0)
ACT1 PBO Week 8 Rutgeerts et al.49
Refractory to CS therapy, 35.3 (12/34)
Not refractory to CS therapy, 37.9 (33/87)
Partial Mayo score median (IQR) at week 8, 5.0 (3.0–6.0)
Daily CS dose in mg (median, IQR) at baseline, 20.0 (10.0–30.0)
Daily CS dose in mg (median, IQR) at week 8, 20.0 (10.0–30.0)
ACT1 PBO Week 30 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 30, 5.0 (3.0–6.0)
Daily CS dose in mg, median (IQR), 10.0 (0.8–30.0)
ACT1 PBO Week 54 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 54, 5.0 (4.0–7.0)
Clinical remission and discontinued use of CSs at week 54, 7/79 (8.9)
Daily CS dose in mg, median (IQR), 20.0 (0.0–30.0)
Lichtenstein et al.342
Clinical response: baseline IMM use: 26% (14/53), no baseline IMM
use: 15% (10/68)
Clinical remission: baseline IMM use: 21% (11/53), no baseline IMM
use: 13% (9/68)
ACT1 5mg/kg of IFX Week 2 Rutgeerts et al.49
Partial Mayo score median (IQR) at baseline, 6.0 (5.0–7.0)
Partial Mayo score median (IQR) at week 2, 3.0 (2.0–5.0)
ACT1 5mg/kg of IFX Week 6 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 6, 3.0 (2.0–5.0)
ACT1 5mg/kg of IFX Week 8 Rutgeerts et al.49
Refractory to CS therapy, 77.4 (24/31) (p< 0.001)
Not refractory to CS therapy, 66.7 (60/90) (p< 0.001)
Partial Mayo score median (IQR) at week 8, 2.0 (1.0–4.0)
Daily CS dose in mg, median (IQR), at baseline, 20.0 (10.0–25.0)
Daily CS dose in mg, median (IQR), at week 8, 20.0 (10.0–25.0)
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Study name Treatment arm Time point Outcome measure
ACT1 5mg/kg of IFX Week 30 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 30, 3.0 (1.0–6.0)
Clinical remission and discontinued use of CSs at week 30, 17/70
(24.3) (p= 0.030)
Daily CS dose in mg, median (IQR), at week 30, 5.6 (0.0–20.0)
ACT1 5mg/kg of IFX Week 54 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 54, 3.0 (1.0–6.0)
Clinical remission and discontinued use of CSs at week 54, 18/70
(25.7) (p= 0.006)
Daily CS dose in mg (median, IQR) at week 54, 5.0 (0.0–20.0)
Rutgeerts et al.49
Clinical response: baseline IMM use: 48% (32/66), OR 2.62 (95% CI
1.20 to 5.71); no baseline IMM use: 42% (23/55), OR 4.17 (95% CI
1.77 to 9.84)
Clinical remission: baseline IMM use: 35% (23/66), OR 2.04 (95% CI
0.89 to 4.71); no baseline IMM use: 35% (19/55), OR 3.46 (95% CI
1.41 to 8.47)
ACT1 IFX combined Week 54 Rutgeerts et al.49
Clinical response: baseline IMM use: 45% (56/125), OR 2.26 (95% CI
1.12 to 4.58); no baseline IMM use: 45% (53/118), OR 4.73 (95% CI
2.21 to 10.1)
Clinical remission: baseline IMM use: 34% (42/125), OR 1.93
(95% CI 0.90 to 4.13); no baseline IMM use: 36% (42/118), OR 3.62
(95% CI 1.63 to 8.03)
ACT2 PBO Week 2 Rutgeerts et al.49
Partial Mayo score median (IQR) at baseline, 6.0 (5.0–7.0)
Partial Mayo score median (IQR) at week 2, 5.0 (4.0–7.0)
ACT2 PBO Week 6 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 6, 5.0 (4.0–7.0)
ACT2 PBO Week 8 Rutgeerts et al.49
Refractory to CS therapy, 37.5 (12/32); not refractory to CS therapy,
37.5 (12/32); partial Mayo score median (IQR) at week 8, 5.0
(3.0–7.0)
Daily CS dose in mg, median (IQR), at baseline, 20.0 (15.0–30.0)
Daily CS dose in mg, median (IQR), at week 8, 20.0 (15.0–30.0)
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Study name Treatment arm Time point Outcome measure
ACT2 PBO Week 30 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 30, 6.0 (3.0–7.0)
Daily CS dose in mg, median (IQR), 20.0 (5.6–30.0)
Clinical remission and discontinued use of CSs, 2/60 (3.3)
Rutgeerts et al.49
Clinical response: baseline IMM use: 26% (14/54); no baseline IMM
use: 26% (18/69)
Clinical remission: baseline IMM use: 9% (5/54); no baseline IMM
use: 12% (8/69)
ACT2 PBO Week 54 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 54, NR
Daily CS dose in mg, median (IQR), at week 54, NR
Rutgeerts et al.49
Clinical response at week 54 with baseline immunomodulator use
OR= 3.09 (95% CI 1.36 to 6.98)
ACT2 5mg/kg of IFX Week 2 Rutgeerts et al.49
Partial Mayo score median (IQR) at baseline, 6.0 (5.0–7.0)
Partial Mayo score median (IQR) at week 2, 4.0 (2.0–5.0)
ACT2 5mg/kg of IFX Week 6 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 6, 3.0 (1.0–5.0)
ACT2 5mg/kg of IFX Week 8 Rutgeerts et al.49
Refractory to CS therapy, 63.3 (19/30) (p= 0.053); not refractory to
CS therapy, 63.3 (19/30) (p= 0.053)
Partial Mayo score median (IQR) at week 8, 2.0 (1.0–4.0)
Daily CS dose in mg, median (IQR), at baseline, 5mg/kg of IFX= 20.0
(10.0–30.0)
Daily CS dose in mg, median (IQR), at week 8, 5mg/kg of IFX= 20.0
(10.0–30.0)
ACT2 5mg/kg of IFX Week 30 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 30, 4.0 (1.0–6.0)
Daily CS dose in mg, median (IQR), 7.5 (0.0–20.0)
Clinical remission and discontinued use of CSs, 11/60 (18.3)
(p= 0.010)
Rutgeerts et al.49
Clinical response: baseline IMM use: 52% (27/52), OR 3.09 (95% CI
1.36 to 6.98); no baseline IMM use: 43% (30/69), OR 2.18 (95% CI
1.06 to 4.47)
Clinical remission: baseline IMM use: 35% (18/52), OR 5.19 (95% CI
1.76 to 15.3); no baseline IMM use: 19% (13/69), OR 1.77 (95% CI
0.68 to 4.59)
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Study name Treatment arm Time point Outcome measure
ACT2 5mg/kg of IFX Week 54 Rutgeerts et al.49
Partial Mayo score median (IQR) at week 54, NR
Daily CS dose in mg, median (IQR), NR
Rutgeerts et al.49
Clinical response without baseline immunomodulator use, OR= 2.18
(95% CI 1.06 to 4.47)
ACT2 IFX combined Week 54 Rutgeerts et al.49
Clinical remission with baseline immunomodulator use, OR= 5.19
(95% CI 1.76 to 15.3)
Rutgeerts et al.49
Clinical remission without baseline immunomodulator use, OR= 1.77
(95% CI 0.68 to 4.59)
ACT1 and
ACT2
extension
studies
Randomised
patients in the
IFX group of the
ACT1 or ACT2
trials who
entered the
extension
studies
Weeks 0 to
152
Reinisch et al.55
Patients with no disease activity (PGA assessment of no disease):
Week E0: ACT1, 55.7% (64/115); ACT2, 27.9% (31/111)
Week E24: ACT1, 66.4% (73/110); ACT2, 43.3% (42/97)
Week E48: ACT1, 70.8% (75/106); ACT2, 52.3% (46/88)
Week E72: ACT1, 72.7% (72/99); ACT2, 52.9% (45/85)
Week E104: ACT1, 69.5% (57/82); ACT2, 66.2% (51/77)
Week E128: ACT1, 79.5% (35/44); ACT2, 66.0% (35/53)
Week E152: ACT1, 88.9% (8/9); ACT2, 45.5% (5/11)
Patients with no or mild disease activity (PGA assessment of no or
mild disease):
Week E0: ACT1, 84.3% (97/115); ACT2, 68.5% (76/111)
Week E24: ACT1, 90.9% (100/110); ACT2, 91.8% (89/97)
Week E48: ACT1, 96.2% (102/106); ACT2, 92.0% (81/88)
Week E72: ACT1, 94.9% (94/99); ACT2, 88.2% (75/85)
Week E104: ACT1, 96.3% (79/82); ACT2, 92.2% (71/77)
Week E128: ACT1, 95.5% (42/44); ACT2, 90.6% (48/53)
Week E152: ACT1, 100.0% (9/9); ACT2, 81.8% (9/11)
Randomised patients in the IFX group of the extension studies with
and without a gap in treatment of > 8 weeks between the last
infusion of the main studies and the extension studies week 0
infusions (n= 134)
Patients with no disease activity:
Week E0: patients without treatment gap (n= 134), 52.3% (69/132);
patients with treatment gap (n= 95), 27.7% (26/94)
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Study name Treatment arm Time point Outcome measure
Week E8: patients without treatment gap (n= 134), 59.4% (76/128);
patients with treatment gap (n= 95), 44.6% (41/92)
Week E24: patients without treatment gap (n= 134), 55.6%
(69/124); patients with treatment gap (n= 95), 55.4% (46/83)
Week E48: patients without treatment gap (n= 134), 64.8%
(79/122); patients with treatment gap (n= 95), 58.3% (42/72)
Week E72: patients without treatment gap (n= 134), 64.6%
(73/113); patients with treatment gap (n= 95), 62.0% (44/71)
Week E104: patients without treatment gap (n= 134), 70.5%
(67/95); patients with treatment gap (n= 95), 64.1% (41/64)
Week E128: patients without treatment gap (n= 134), 72.5%
(37/51); patients with treatment gap (n= 95), 71.7% (33/46)
Week E152: patients without treatment gap (n= 134), 62.5% (5/8);
patients with treatment gap (n= 95), 66.7% (8/12)
Patients with no or mild disease activity:
Week E0: patients without treatment gap (n= 134), 84.1%
(111/132); patients with treatment gap (n= 95), 66.0% (62/94)
Week E8: patients without treatment gap (n= 134), 87.5%
(112/128); patients with treatment gap (n= 95), 81.5% (75/92)
Week E24: patients without treatment gap (n= 134), 92.7%
(115/124); patients with treatment gap (n= 95), 89.2% (74/83)
Week E48: patients without treatment gap (n= 134), 94.3%
(115/122); patients with treatment gap (n= 95), 94.4% (68/72)
Week E72: patients without treatment gap (n= 134), 91.2%
(103/113); patients with treatment gap (n= 95), 93.0% (66/71)
Week E104: patients without treatment gap (n= 134), 90.5%
(86/95); patients with treatment gap (n= 95), 100% (64/64)
Week E128: patients without treatment gap (n= 134), 94.1%
(48/51); patients with treatment gap (n= 95), 91.3% (42/46)
Week E152: patients without treatment gap (n= 134), 87.5% (7/8);
patients with treatment gap (n= 95), 91.7% (11/12)
All randomised patients in the IFX group who entered the extension
studies (n= 229):
Week E8: patients with no disease activity (PGA assessment of no
disease), 46.4% (102/220); patients with no or mild disease activity
(PGA assessment of no or mild disease), 70.9% (156/220)
Week E24: patients with no disease activity (PGA assessment of no
disease), 50.7% (105/207); patients with no or mild disease activity
(PGA assessment of no or mild disease), 80.7% (167/207)
Week E48: patients with no disease activity (PGA assessment of no
disease), 56.7% (110/194); patients with no or mild disease activity
(PGA assessment of no or mild disease), 82.0% (159/194)
Week E72: patients with no disease activity (PGA assessment of no
disease), 58.7% (108/184); patients with no or mild disease activity
(PGA assessment of no or mild disease), 83.2% (153/184)
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Study name Treatment arm Time point Outcome measure
Week E104: patients with no disease activity (PGA assessment of no
disease), 66.0% (105/159); patients with no or mild disease activity
(PGA assessment of no or mild disease), 88.1% (140/159)
Week E128: patients with no disease activity (PGA assessment of no
disease), 69.1% (67/97); patients with no or mild disease activity
(PGA assessment of no or mild disease), 87.6% (85/97)
Week E152: patients with no disease activity (PGA assessment of no
disease), 65.0% (13/20); patients with no or mild disease activity
(PGA assessment of no or mild disease), 90.0% (18/20)
Number of randomised patients in the extension studies (n= 229)
who used CSs in the past 8 weeks for UC:
Week E8: 0 days, 179/223 (80.3%); 1 to 7 days, 4/223 (1.8%);
8 to 30 days, 8/223 (3.6%); > 30 days, 32/223 (14.3%)
Week E24: 0 days, 179/208 (86.1%); 1 to 7 days, 1/208 (0.5%);
8 to 30 days, 2/208 (1.0%); > 30 days, 26/208 (12.5%)
Week E48: 0 days, 167/194 (86.1%); 1 to 7 days, 2/194 (1.0%);
8 to 30 days, 4/194 (2.1%); > 30 days, 21/194 (10.8%)
Week E72: 0 days, 165/188 (87.8%); 1 to 7 days, 3/188 (1.6%);
8 to 30 days, 4/188 (2.1%); > 30 days, 16/188 (8.5%)
Week E104: 0 days, 149/161 (92.5%); 1 to 7 days, 0/161 (0.0%);
8 to 30 days, 1/161 (0.6%); > 30 days, 11/161 (6.8%)
Week E128: 0 days, 92/99 (92.9%); 1 to 7 days, 0/99 (0.0%);
8 to 30 days, 0/99 (0.0%); > 30 days, 7/99 (7.1%)
Week E152: 0 days, 20/20 (100.0%); 1 to 7 days, 0/20 (0.0%);
8 to 30 days, 0/20 (0.0%); > 30 days, 0/20 (0.0%)
CS, corticosteroid; E, extension; EOW, every other week; EW, every week; IMM, immunomodulator; IQR, interquartile
range; ITT-A3, intention to treat-amendment 3; ITT-E, intention to treat original population prior to protocol amendment;
max., maximum; min., minimum; NR, not reported.
Additional efficacy outcomes (paediatric population trial)
Study name Treatment arm Time point Outcome measure
Hyams 5mg/kg of IFX
q8w
Week 8 Hyams et al.52
Median reduction in partial Mayo score 4 points median
corticosteroid use mg/kg/day: 0
Hyams 5mg/kg of IFX
q8w
Week 30 Hyams et al.52
Median reduction in partial Mayo score: approximately 2.5 points
(read from source graph). Remission (PUCAI) without CSs: 5/12
(41.7%)
EPAR73
Remission (PUCAI) by age (n= 20 evaluable): 6 years, 0/0 (0%);
7 years, 2/2 (100%); 8 years, 0/0 (0%); 9 years, 1/1 (100%); 10 years,
0/1 (0%); 11 years, 1/1 (100%); 12 years, 0/1 (0%); 13 years, 2/4
(50%); 14 years, 0/0 (0%); 15 years, 1/3 (33.3%); 16 years, 0/3 (0%);
17 years, 1/4 (25%)
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Study name Treatment arm Time point Outcome measure
Hyams 5mg/kg of IFX
q8w
Week 54 Hyams et al.52
Median reduction in partial Mayo score: approximately 2.5 points
(read from source graph). Remission (PUCAI) without CSs: 5/13
(38.5%). Efficacy after step-up decrease of ≥ 2 points in partial
Mayo score – patients with data at week 54: 9/10 (90%). Unclear
if this value is for IFX 5mg/q8d group or both groups median
corticosteroid use mg/kg/day: 0.04
EPAR73
Clinical response: 3/4 patients who had endoscopy at week 54
(optional)
Remission (PUCAI) by age (n= 20 evaluable): 6 years, 0/0 (0%);
7 years, 1/2 (50%); 8 years, 0/0 (0%); 9 years, 1/1 (100%); 10 years,
0/1 (0%); 11 years, 1/1 (100%); 12 years, 0/1 (0%); 13 years,
3/4 (75%); 14 years, 0/0 (0%); 15 years, 1/4 (25.3%); 16 years,
0/3 (0%); 17 years, 1/4 (25%)
Hyams 5mg/kg of IFX
q12w
Week 8 Hyams et al.52
Median reduction in partial Mayo score: 4 points median
corticosteroid use mg/kg/day: 0.15
Hyams 5mg/kg of IFX
q12w
Week 30 Hyams et al.52
Median reduction in partial Mayo score: approximately 1 point
(read from source graph). Remission (PUCAI) without CSs: 1/13 (7.7%)
EPAR73
Remission (PUCAI) by age (n=21 evaluable): 6 years, 0/1 (0%);
7 years, 0/0 (0%); 8 years, 0/1 (0%); 9 years, 0/0 (0%); 10 years,
0/1 (0%); 11 years, 0/1 (0%); 12 years, 0/0 (0%); 13 years, 0/0 (0%);
14 years, 0/2 (0%); 15 years, 3/4 (75%); 16 years, 1/5 50 (20%);
17 years, 0/5 (0%)
Hyams 5mg/kg of IFX
q12w
Week 54 Hyams et al.52
Median reduction in partial Mayo score: approximately 1 point
(read from source graph). Remission (PUCAI) without CSs: 0/13 (0%)
Median CS use mg/kg/day: same as baseline 4
EPAR73
Clinical response: 3/4 patients who had endoscopy at week 54
(optional)
Remission (PUCAI) by age (n= 22 evaluable): 6 years, 0/1 (0%);
7 years, 0/0 (0%); 8 years, 0/1 (0%); 9 years, 0/0 (0%); 10 years,
0/1 (0%); 11 years, 0/1 (0%); 12 years, 0/2 (0%); 13 years, 0/0 (0%)
3/4 (75%); 14 years, 0/2 (0%); 15 years, 2/4 (50%); 16 years,
1/5 (20%) 1/8 (12.5%); 17 years, 1/5 (20%) 2/9 (22.2%)
Hyams All patients
(n= 60)
Week 8 Hyams et al.52
Disease activity was more severe at the last visit for patients who
discontinued after week 8 [no disease, 1 of 10 (10%); mild, 1 of 10
(10%); moderate, 6 of 10 (60%); severe, 2 of 10 (20%)] than for
patients who discontinued before week 8 [mild, 4 of 13 (30.8%);
moderate, 4 of 13 (30.8%); and severe disease, 5 of 13 (38.5%)]
CS, corticosteroid; q8w, every 8 weeks; q12w, every 12 weeks.
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Hospitalisation, surgery and mortality data (adult population
trials)
Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
ADA
ULTRA1 PBO From submission62
Week 8 (n= 222, PYs= 19.6)
Physician visits number of
events (visits) (events/PY),
21 (0.619)
Emergency room visits number
of events (visits) (events/PY),
8 (0.236)
Hospital admissions number of
events (admissions)
(events/PY), 7 (0.206)
Days in hospital number of
events (days) (events/PY),
73 (2.153)
Colectomy, 8/130 (3.6%)
during induction, week 8
Elective/emergency NR
0/223 (0%)
ULTRA1 160mg/80mg
of ADA
From submission62
Week 8 (n= 223, PYs= 34.0)
Physician visits number of
events (visits) (events/PY),
15 (0.441); p-value 0.559
Emergency room visits number
of events (visits) (events/PY),
2 (0.059); p-value NA
Hospital admissions number of
events (admissions)
(events/PY), 5 (0.147);
p-value NA
Days in hospital number of
events (days) (events/PY),
26 (0.764); p-value 0.297
Colectomy, 5/130 (1.4%)
during induction, week 8
Elective/emergency NR
0/223 (0%)
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
ULTRA2 PBO From submission62
(n= 246, PYs= 101.6)
Physician visits number of
events (visits) (events/PY),
169 (1.663)
Emergency room visits number
of events (visits) (events/PY),
10 (0.098)
Hospital admissions number of
events (admissions)
(events/PY), 13 (0.128)
Days in hospital number of
events (days) (events/PY),
105 (0.837)
Colectomy, 12/246 (4.9%)
during follow-up week 52
Elective/emergency NR
0/260 (0%)
ULTRA2 160mg/80mg
of ADA
From submission62
(n= 248, person years= 125.5)
Physician visits number of
events (visits) (events/PY), 169
(1.347); p-value vs. PBO 0.035
Emergency room visits
number of events (visits)
(events/PY), 12 (0.096);
p-value vs. PBO 0.847
Hospital admissions number
of events (admissions) (events/
PY), 13 (0.104); p-value vs.
PBO 0.418
Days in hospital number of
events (days) (events/PY), 120
(1.181); p-value vs. PBO 0.467
Colectomy, 10/248 (4%)
during follow-up, week 52
Elective/emergency NR
0/257 (0%)
ULTRA1 and
ULTRA2
ADA Feagan et al.63
ADA Hospitalisation and Colectomy Rates in ULTRA 1 and
2: week 8 ADA responders:
All-cause hospitalisation (n/PYs at risk), 46/260.4
All-cause hospitalisation incidence rate (n/PYs at risk), 0.18;
All-cause hospitalisation p-value vs. PBO, 0.047
UC-related hospitalisation (n/PYs at risk), 29/266.5
UC-related hospitalisation incidence rate (n/PYs at risk), 0.11
UC-related hospitalisation p-value vs. PBO, 0.002
Colectomy (n/PYs at risk), 6/271.9
Elective/emergency, NR
Colectomy incidence rate (n/PYs at risk), 0.02
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
Colectomy p-value vs. PBO, 0.122
Hospitalisations – all-cause events/PYs, 55/272.7
Hospitalisations – all-cause incidence rate (events/PYs), 0.20
Hospitalisations – all-cause relative risk ADA/PBO, 0.65
p= 0.021
Hospitalisations – UC-related events/PYs, 32/272.7
Hospitalisations – UC-related incidence rate (events/person
years), 0.12
Hospitalisations – UC-related relative risk ADA/PBO, 0.48
p< 0.001
Feagan et al.65
Non-UC-related hospitalisation categories week 52:
General disorder; gastroestinal tract disorder, 3 (0.63%);
gynaecological disorder and pregnancy, 1 (0.21%);
musculoskeletal and connective tissue disorder;
hepatobiliary disorder, 1 (0.21%); neurological disorder,
1 (0.21%); urogenital tract disorder, 3 (0.63%);
cardiovascular disorder, 2 (0.42%); endocrine and
metabolic disorder; hematologic disorder, 1 (0.21%);
infection, 11 (2.28%) 9 (1.88%); malignancy, 1 (0.21%);
skin disorder, 2 (0.42%); trauma and surgical/medical
procedure, 3 (0.63%)
Feagan et al.65
UC-related hospitalisation categories week 52:
UC flare, 47 (9.73%) 31 (6.46%); UC leading to colectomy,
19 (3.93%) 15 (3.13%); extraintestinal complication of UC,
6 (1.25%); sequelae of colectomy, 1 (0.21%)
Feagan et al.65
Hospitalisation and colectomy analysis: induction period
(8 weeks)
All-cause hospitalisation, 22 (4.6)
UC-related hospitalisation, 17 (3.5%)
UC- or drug-related hospitalisation, 19 (4.0%)
Colectomy, 5 (1.0%).
Elective/emergency, NR
Feagan et al.65
Hospitalisation and colectomy analysis: 52-week period,
n/PYs at risk (incident rate); RR (relative risk) (95% CI):
All-cause hospitalisation, 69/387.5 (0.18); RR, 0.7 (95% CI
0.5 to 1.0); p= 0.03
UC-related hospitalisation, 47/398.1 (0.12); RR, 0.5
(95% CI 0.4 to 0.8); p= 0.002
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
UC- or drug-related hospitalisation, 55/393.8 (0.14); RR, 0.6
(0.4 to 0.9); p= 0.005
Colectomy, 15/408.1 (0.04)
Sensitivity analysis 1: all events that occurred during the
open-label period (during ADA therapy) were excluded for
the PBO group
All-cause hospitalisation, 69/387.5 (0.18); RR, 0.6
(0.4 to 0.9); p= 0.007
UC-related hospitalisation, 47/398.1 (0.12); RR, 0.5
(0.3 to 0.7); p< .0001
UC- or drug-related hospitalisation, 55/393.8 (0.14); RR, 0.5
(0.4 to 0.8); p= 0.001
Colectomy, 15/408.1 (0.04)
Elective/emergency, NR
Sensitivity analysis 2: all events were attributed to the
randomised groups regardless of whether or not patients
treated with PBO had switched to open-label ADA therapy
All-cause hospitalisation, 69/387.5 (0.18); RR, 0.8
(0.6 to 1.0); p= 0.08
UC-related hospitalisation, 47/398.1 (0.12) 0.7; RR,
(0.5 to 1.0); p= 0.03
UC- or drug-related hospitalisation, 55/393.8 (0.14);
RR, 0.7 (0.5 to 1.0); p= 0.045
Colectomy, 15/408.1 (0.04)
Elective/emergency, NR
Reinisch et al.343
Incidence rates for all-cause and UC-related hospitalisations
for ADA-treated patients by Mayo subscores at week 8:
Mayo subscore 0 (n= 433): stool frequency – all-cause,
0.08 UC-related, 0.05; rectal bleeding – all-cause, 0.13
UC-related, 0.06; PGA – all-cause, 0.11 UC-related, 0.05;
endoscopy – all-cause, 0.14 UC-related, 0.06
Mayo subscore 1 (n= 433): stool frequency – all-cause,
0.11 UC-related, 0.05; rectal bleeding – all-cause, 0.13
UC-related, 0.10; PGA – all-cause, 0.11 UC-related, 0.06;
endoscopy – all-cause, 0.11 UC-related, 0.06
Mayo subscore 2 (n= 433): stool frequency – all-cause,
0.15 UC-related, 0.11; rectal bleeding – all-cause, 0.22
UC-related, 0.13; PGA – all-cause, 0.20 UC-related, 0.14;
endoscopy – all-cause, 0.16 UC-related, 0.10
Mayo subscore 3 (n= 422): stool frequency – all-cause,
0.22 UC-related, 0.16; rectal bleeding – all-cause, 0.29
UC-related, 0.29; PGA – all-cause, 0.23 UC-related, 0.19;
endoscopy – all-cause, 0.27 UC-related, 0.21
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
ULTRA 1 and 2 PBO Feagan et al.63
PBO hospitalisation and colectomy rates in ULTRA 1 and 2:
week 8 ADA responders:
All-cause hospitalisation (n/PYs at risk), 58/222.3
All-cause hospitalisation incidence rate (n/PYs at risk), 0.26
UC-related hospitalisation (n/PYs at risk), 49/223.6
UC-related hospitalisation incidence rate (n/PYs at risk),
0.22
Colectomy (n/PYs at risk), 11/231.7
Elective/emergency, NR
Colectomy incidence rate (n/PYs at risk), 0.05
Hospitalisations – all-cause events/PYs, 71/232.8
Hospitalisations – all-cause incidence rate (events/PYs), 0.31
Hospitalisations – UC-related events/PYs, 59/232.8
Hospitalisations – UC-related incidence rate (events/PYs), 0.25
Feagan et al.65
Non-UC-related hospitalisation categories week 52:
General disorder, 1 (0.21%); gastrointestinal tract disorder,
1 (0.21%); gynaecological disorder and pregnancy,
2 (0.41%); musculoskeletal and connective tissue disorder,
1 (0.21%); hepatobiliary disorder, 0 (0%); neurological
disorder, 0 (0%); urogenital tract disorder, 3 (0.62%);
cardiovascular disorder, 1 (0.21%); endocrine and metabolic
disorder, 1 (0.21%); hematologic disorder, 0 (0%);
infection, 11 (2.28%); malignancy, 1 (0.21%); skin disorder,
1 (0.21%); trauma and surgical/medical procedure,
3 (0.62%)
Feagan et al.65
UC-related hospitalisation categories week 52:
UC flare, 47 (9.73%); UC leading to colectomy, 19
(3.93%); extraintestinal complication of UC, 8 (1.66%);
sequelae of colectomy, 1 (0.21%)
Feagan et al.65
Hospitalisation and colectomy analysis: induction period
(8 weeks)
All-cause hospitalisation, 37 (7.7%); p= 0.46
UC-related hospitalisation, 34 (7.0%); p= 0.02
UC- or drug-related hospitalisation, 36 (7.5); p= 0.02
Colectomy, 6 (1.2%); p= 0.77
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
Feagan et al.65
Hospitalisation and colectomy analysis: 52-week period,
n/PYs at risk (incident rate):
All-cause hospitalisation, 58/222.3 (0.26)
UC-related hospitalisation, 49/223.6 (0.22)
UC- or drug-related hospitalisation, 53/223.2 (0.24)
Colectomy, 11/231.7 (0.05)
Elective/emergency, NR
Sensitivity analysis 1: all events that occurred during the
open-label period (during ADA therapy) were excluded for
the PBO group
All-cause hospitalisation, 47/159.2 (0.30)
UC-related hospitalisation, 40/159.8 (0.25)
UC- or drug-related hospitalisation, 43/159.5 (0.27)
Colectomy, 7/166.3 (0.04)
Elective/emergency, NR
Sensitivity analysis 2: all events were attributed to the
randomised groups regardless of whether or not patients
treated with PBO had switched to open-label ADA therapy
All-cause hospitalisation, 89/377.7 (0.24)
UC-related hospitalisation, 68/384.2 (0.18)
UC- or drug-related hospitalisation, 76/382.2 (0.20)
Colectomy, 19/400.0 (0.05)
Elective/emergency NR
Suzuki PBO NR NR NR
Suzuki 80mg/40mg of
ADA
NR NR NR
Suzuki 160mg/80mg
of ADA
NR NR NR
Suzuki 40mg of ADA
EOW
NR NR NR
Suzuki Rescue arm NR NR NR
PURSUIT-SC All randomised
PBO
NR NR NR
PURSUIT-SC All randomised
200mg/100mg
of GOL
NR NR NR
PURSUIT-SC Phase II PBO NR NR NR
PURSUIT-SC Phase II 200mg/
100mg of GOL
all randomised
NR NR NR
PURSUIT-SC Phase III PBO NR NR NR
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
259
Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
PURSUIT-SC Phase III
200mg/100mg
of GOL phase III
NR NR NR
PURSUIT-
Maintenance
PBO randomised NR NR Deaths reported through
week 54. PBO= 0
deaths reported after
week 54. PBO SC
induction and
maintenance= 1
(pneumonia and heart
failure)
PURSUIT-
Maintenance
50mg of GOL
randomised
NR From submission
In the PURSUIT trial, only
2–3% of GOL induction
responders re-randomised
to 50mg or 100mg of
GOL had a colectomy at
the end of maintenance
Deaths reported through
week 54. 50mg of
GOL= 0 deaths reported
after week 54. s.c.
100mg/50mg of GOL
induction, 50mg
maintenance= 1 (heart
dysfunction in the
presence of pronounced
atherosclerosis and
stenosis affecting aorta,
large arteries and
coronary arteries)
PURSUIT-
Maintenance
100mg of GOL
randomised
NR NR Deaths reported through
week 54. 100mg
of GOL= 3
(causes=malnutrition
and sepsis (GOL 2mg/kg
i.v. induction), cardiac
failure with history of
thrombosis (400mg/
200mg of GOL s.c.
induction), disseminated
TB in patient who tested
positive for latent TB on
induction study entry
and was receiving
isoniazid at time of
event (200mg/100mg
of GOL s.c. induction)
Deaths reported after
week 54. PBO SC
induction, 100mg of
GOL maintenance= 1
(myocardial infarction in
patient with history of
myocardial infarction).
2mg/kg of GOL i.v.
induction, 100mg of
GOL maintenance=2
(gallbladder
adenocarcinoma with
liver metastasis), (sepsis).
200mg/100mg of GOL
s.c. induction, 100mg of
GOL maintenance=1
(accidental nitrous oxide
overdose)
ACT1 PBO From submission64
UC-related hospitalisation,
mean (SD): 0.22 (0.57)
From submission64
Colectomy n (%), 9 (7.4)
Ostomy n (%), 5 (4.1)
NR
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Study acronym Treatment arm Rates of hospitalisation
Rates of surgical
intervention Death
ACT1 5mg/kg of IFX From submission64
UC-related hospitalisation,
mean (SD): 0.11 (0.34);
p-value (assume vs. PBO),
0.061
From submission64
Colectomy n (%), 7 (5.8)
Ostomy n (%), 3 (2.5)
1 during ACT2
extension
ACT2 PBO From submission64
UC-related hospitalisation,
mean (SD): 0.21 (0.55)
From submission64
Colectomy n (%), 1 (0.7)
Ostomy n (%), 1 (0.7)
NR
ACT2 5mg/kg of IFX From submission64
UC-related hospitalisation,
mean (SD): 0.07 (0.29);
p-value (assume vs. PBO),
0.009
From submission64
Colectomy n (%), 0 (0.0)
Ostomy n (%), 0 (0.0)
NR
UC-SUCCESS AZA NR NR NR
UC-SUCCESS IFX NR NR NR
UC-SUCCESS IFX/AZA NR NR NR
Probert PBO One PBO patient
underwent colectomy
during the intervention
period and was recorded
as a treatment failure.
One patient (unclear
which group) refused
sigmoidoscopic assessment
but by other clinical
measures was deemed to
be a treatment failure
NR
Probert IFX NR NR NR
EOW, every other week; NR, not reported; s.c., subcutaneous.
Hospitalisation, surgery and mortality data (paediatric
population trial)
Study acronym Treatment arm
Rates of
hospitalisation Rates of surgical intervention Death
IFX
Hyams 5mg/kg of IFX q8w NR Patients requiring colectomy in
the 54-week period: 1/22 (4.5%)
NR
Hyams 5mg/kg of IFX q12w NR Patients requiring colectomy in
the 54-week period: 2/23 (8.7%)
NR
Hyams All patients to week 8
(n= 60)
NR Patients requiring colectomy in
the 54-week period: 5/60 (8%)
(2 out of 15 non-randomised)
NR
q8w, every 8 weeks; q12w, every 12 weeks; NR, not reported.
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Appendix 5 Safety data tables
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
263
S
a
fe
ty
:
p
a
rt
ic
ip
a
n
ts
e
x
p
e
ri
e
n
ci
n
g
a
d
v
e
rs
e
e
v
e
n
ts
,
se
ri
o
u
s
a
d
v
e
rs
e
e
v
e
n
ts
a
n
d
w
it
h
d
ra
w
a
l
d
u
e
to
a
d
v
e
rs
e
e
v
e
n
ts
(a
d
u
lt
p
o
p
u
la
ti
o
n
tr
ia
ls
)
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
U
LT
RA
1
PB
O
N
R
W
ee
k
8
Re
in
is
ch
et
al
.4
4
A
ny
se
ve
re
(n
ot
de
fin
ed
)
17
/2
23
(7
.6
%
);
an
y
se
rio
us
[n
ot
de
fin
ed
,
17
/2
23
(7
.6
%
)]
Su
bm
is
si
on
62
17
/2
23
(7
.6
%
);
dr
ug
-r
el
at
ed
SA
E,
4/
22
3
(1
.8
%
)
Re
in
is
ch
et
al
.4
4
10
8/
22
3
(4
8.
4%
)
Su
bm
is
si
on
62
10
8/
22
3
(4
8.
1%
);
po
ss
ib
ly
dr
ug
re
la
te
d,
48
/2
23
(2
1.
5%
)
Re
in
is
ch
et
al
.4
4
12
/2
23
(5
.4
%
)
Su
bm
is
si
on
62
12
/2
23
(5
.4
%
)
U
LT
RA
1
16
0
m
g/
80
m
g
of
A
D
A
N
R
W
ee
k
8
Re
in
is
ch
et
al
.4
4
A
ny
se
ve
re
(n
ot
de
fin
ed
)
19
/2
23
(8
.5
%
);
an
y
se
rio
us
(n
ot
de
fin
ed
,
9/
22
3
(4
.0
%
)
Re
in
is
ch
et
al
.4
4
11
2/
22
3
(5
0.
2%
)
Re
in
is
ch
et
al
.4
4
12
/2
23
(5
.4
%
)
U
LT
RA
1
16
0
m
g/
80
m
g
of
A
D
A
N
R
W
ee
k
8
Su
bm
is
si
on
62
97
/2
23
(4
.0
%
);
dr
ug
-r
el
at
ed
SA
E,
1/
22
3
(0
.4
%
)
Su
bm
is
si
on
62
11
2/
22
3
(5
0.
2%
);
po
ss
ib
ly
dr
ug
re
la
te
d,
43
/2
23
(1
9.
3%
)
Su
bm
is
si
on
62
12
/2
23
(5
.4
%
)
U
LT
RA
2
PB
O
N
R
W
ee
k
52
Sa
nd
bo
rn
et
al
.4
5
A
ny
se
ve
re
(n
ot
de
fin
ed
)
37
/2
60
(1
4.
2%
);
an
y
se
rio
us
[n
ot
de
fin
ed
,
32
/2
60
(1
2.
3%
)]
Su
bm
is
si
on
62
32
/2
60
(1
2.
3%
)
Sa
nd
bo
rn
et
al
.4
5
21
8/
26
0
(8
3.
8%
);
po
ss
ib
ly
dr
ug
-r
el
at
ed
,
86
/2
60
(3
3.
1%
)
Su
bm
is
si
on
62
21
8/
26
0
(8
3.
8%
)
Sa
nd
bo
rn
et
al
.4
5
34
/2
60
(1
3.
1%
)
Su
bm
is
si
on
62
34
/2
60
(1
3.
1%
)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
264
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
U
LT
RA
2
16
0
m
g
of
A
D
A
at
w
ee
k
0,
80
m
g
at
w
ee
k
2
an
d
th
en
40
m
g
EO
W
be
gi
nn
in
g
at
w
ee
k
4
N
R
W
ee
k
52
Sa
nd
bo
rn
et
al
.4
5
A
ny
se
ve
re
(n
ot
de
fin
ed
)
41
/2
57
(1
6.
0%
);
an
y
se
rio
us
[n
ot
de
fin
ed
,
31
/2
57
(1
2.
1%
)]
Su
bm
is
si
on
62
31
/2
57
(1
2.
1%
)
Sa
nd
bo
rn
et
al
.4
5
21
3/
25
7
(8
2.
9%
);
po
ss
ib
ly
dr
ug
-r
el
at
ed
,
10
1/
25
7
(3
9.
3%
)
Su
bm
is
si
on
62
21
3/
25
7
(8
2.
9%
)
Sa
nd
bo
rn
et
al
.4
5
23
/2
57
(8
.9
%
)
Su
bm
is
si
on
62
23
/2
57
(8
.9
%
)
U
LT
RA
3
40
m
g
of
A
D
A
EO
W
or
EW
N
R
W
ee
k
52
Re
in
is
ch
et
al
.5
4
76
/5
77
(1
3.
6%
)
ev
en
ts
,
93
(e
ve
nt
s
pe
r
10
0
PY
,
21
.8
)
Re
in
is
ch
et
al
.5
4
42
1/
57
7
(7
5.
6%
)
ev
en
ts
,
21
87
(e
ve
nt
s
pe
r
10
0
PY
,
51
2.
3)
Re
in
is
ch
et
al
.5
4
78
/5
77
(1
4.
0%
)
ev
en
ts
,
90
(e
ve
nt
s
pe
r
10
0
PY
,
21
.1
)
U
LT
RA
3
40
m
g
of
A
D
A
EO
W
or
EW
N
R
W
ee
k
52
Su
bm
is
si
on
62
40
m
g
of
A
D
A
EO
W
/E
W
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
41
4
(1
7.
7)
Su
bm
is
si
on
62
40
m
g
of
A
D
A
EO
W
/E
W
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
80
57
(3
44
.6
)
Su
bm
is
si
on
62
40
m
g
of
A
D
A
EO
W
/E
W
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
24
9
(1
0.
7)
Su
zu
ki
PB
O
52
w
ee
ks
W
ee
k
8
Su
zu
ki
et
al
.4
6
W
ee
k
8:
7/
96
(7
.3
%
)
Su
zu
ki
et
al
.4
6
W
ee
k
8:
45
/9
6
(4
6.
9%
)
Su
zu
ki
et
al
.4
6
W
ee
k
8:
4/
96
(4
.2
%
)
Su
zu
ki
PB
O
52
w
ee
ks
W
ee
k
52
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s
=
44
.8
):
ev
en
ts
,
27
3
(e
ve
nt
s/
10
0
PY
s,
60
9.
4)
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s=
44
.8
):
ev
en
ts
,
14
(e
ve
nt
s/
10
0
PY
s,
31
.3
)
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s
=
44
.8
):
ev
en
ts
,
6
(e
ve
nt
s/
10
0
PY
s,
13
.4
)
Su
zu
ki
16
0
m
g/
80
m
g
of
A
D
A
52
w
ee
ks
W
ee
k
8
Su
zu
ki
et
al
.4
6
W
ee
k
8:
4/
90
(4
.4
%
)
Su
zu
ki
et
al
.4
6
W
ee
k
8:
40
/9
0
(4
4.
4%
)
Su
zu
ki
et
al
.4
6
W
ee
k
8:
6/
90
(6
.7
%
)
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
265
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
Su
zu
ki
80
m
g/
40
m
g
of
A
D
A
or
16
0
m
g/
80
m
g
of
A
D
A
to
w
ee
k
8
th
en
40
m
g
of
A
D
A
EO
W
52
w
ee
ks
W
ee
k
52
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,3
3
(e
ve
nt
s/
10
0
PY
s,
33
.6
)
A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,P
Y
s,
68
.7
):
20
(e
ve
nt
s/
10
0
PY
s,
29
.1
)
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
53
8
(e
ve
nt
s/
10
0
PY
s,
54
7.
9)
;
A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
34
3
(e
ve
nt
s/
10
0
PY
s,
49
9.
3)
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
22
(e
ve
nt
s/
10
0
PY
s,
22
.4
);
A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
11
(e
ve
nt
s/
10
0
PY
s,
16
.0
)
PU
RS
U
IT
-S
C
PB
O
6.
05
w
ee
ks
M
ea
n
1.
98
W
ee
k
6
Sa
nd
bo
rn
et
al
.4
7
Pa
tie
nt
s
w
ith
≥
1
SA
E
(n
ot
de
fin
ed
)
20
/3
30
(6
.1
)
Sa
nd
bo
rn
et
al
.4
7
12
6/
33
0
(3
8.
2)
H
ea
da
ch
e,
17
/3
30
(5
.2
);
na
so
ph
ay
ng
iti
s,
11
/3
30
(3
.3
);
py
re
xi
a
7/
33
0,
(2
.1
);
na
us
ea
7/
33
0,
(2
.1
);
ex
ac
er
ba
tio
n
of
U
C
,1
3/
33
0
(3
.9
)
Sa
nd
bo
rn
et
al
.4
7
3/
33
0
(0
.9
)
(v
ira
l
in
fe
ct
io
n
=
er
yt
he
m
a
no
do
su
m
,
ex
ac
er
ba
tio
n
of
U
C
)
PU
RS
U
IT
-S
C
20
0
m
g/
10
0
m
g
of
G
O
L
6.
08
w
ee
ks
M
ea
n
1.
99
W
ee
k
6
Sa
nd
bo
rn
et
al
.4
7
9/
33
1
(2
.7
)
Sa
nd
bo
rn
et
al
.4
7
12
4/
33
1
(3
7.
5)
H
ea
da
ch
e,
10
/3
31
(3
.0
);
na
so
ph
ay
ng
iti
s,
11
/3
31
(3
.3
);
py
re
xi
a,
6/
33
1
(1
.8
);
na
us
ea
,3
/3
31
(0
.9
);
ex
ac
er
ba
tio
n
of
U
C
7/
33
1,
(2
.1
)
Sa
nd
bo
rn
et
al
.4
7
1/
33
1
(0
.3
)
(w
or
se
ni
ng
of
U
C
/c
lo
st
rid
ia
in
fe
ct
io
n)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
266
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
PU
RS
U
IT
-M
PB
O
,
n
=
15
6
32
.7
w
ee
ks
8.
2
To
ta
ln
um
be
r
of
st
ud
y
ag
en
t
in
je
ct
io
ns
.
PB
O
,
33
33
W
ee
k
54
Sa
nd
bo
rn
et
al
.4
8
≥
1
SA
E.
PB
O
,1
2
(7
.7
)
Sa
nd
bo
rn
et
al
.4
8
10
3
(6
6.
0)
(a
ll
ar
e
tr
ea
tm
en
t-
em
er
ge
nt
A
Es
)
Ex
ac
er
ba
tio
n
of
U
C
,2
9
(1
8.
6)
;
na
so
ph
ar
yn
gi
tis
,1
1
(7
.1
);
he
ad
ac
he
,
14
(9
.0
);
ar
th
ra
lg
ia
,1
2
(7
.7
);
ab
do
m
in
al
pa
in
=
4
(2
.6
);
up
pe
r
re
sp
ira
to
ry
tr
ac
t
in
fe
ct
io
n,
4
(2
.6
);
ra
sh
,3
(1
.9
);
ph
ar
yn
gi
tis
,4
(2
.6
);
co
ug
h,
5
(3
.2
)
Sa
nd
bo
rn
et
al
.4
8
PB
O
,
10
(6
.4
)
PU
RS
U
IT
-M
50
m
g
of
G
O
L,
n
=
15
4
44
.3
To
ta
ln
um
be
r
of
st
ud
y
ag
en
t
in
je
ct
io
ns
,
11
.1
.
G
O
L
50
m
g,
43
92
W
ee
k
54
Sa
nd
bo
rn
et
al
.4
8
50
m
g
of
G
O
L,
13
(8
.4
)
Sa
nd
bo
rn
et
al
.4
8
11
2
(7
2.
7)
Ex
ac
er
ba
tio
n
of
U
C
,2
7
(1
7.
5)
;
na
so
ph
ar
yn
gi
tis
,1
4
(9
.1
);
he
ad
ac
he
,
12
(7
.8
);
ar
th
ra
lg
ia
,1
1
(7
.1
);
ab
do
m
in
al
pa
in
=
11
(7
.1
);
up
pe
r
re
sp
ira
to
ry
tr
ac
t
in
fe
ct
io
n
=
8
(5
.2
);
ra
sh
,9
(5
.8
);
ph
ar
yn
gi
tis
,8
(5
.2
);
co
ug
h,
5
(3
.2
)
Sa
nd
bo
rn
et
al
.4
8
50
m
g
of
G
O
L,
8
(5
.2
)
PU
RS
U
IT
-M
10
0
m
g
of
G
O
L,
n
=
15
4
46
.3
To
ta
ln
um
be
r
of
st
ud
y
ag
en
t
in
je
ct
io
ns
,
11
.3
.
G
O
L
10
0
m
g,
44
40
W
ee
k
54
Sa
nd
bo
rn
et
al
.4
8
10
0
m
g
of
G
O
L,
22
(1
4.
3)
Sa
nd
bo
rn
et
al
.4
8
11
3
(7
3.
4)
Ex
ac
er
ba
tio
n
of
U
C
,2
4
(1
5.
6)
;
na
so
ph
ar
yn
gi
tis
,2
1
(1
3.
6)
;h
ea
da
ch
e,
12
(7
.8
);
ar
th
ra
lg
ia
,8
(5
.2
);
ab
do
m
in
al
pa
in
=
11
(7
.1
);
up
pe
r
re
sp
ira
to
ry
tr
ac
t
in
fe
ct
io
n
=
9
(5
.8
);
ra
sh
,7
(4
.5
);
ph
ar
yn
gi
tis
,5
(3
.2
);
co
ug
h,
9
(5
.8
)
Sa
nd
bo
rn
et
al
.4
8
10
0
m
g
of
G
O
L,
14
(9
.1
)
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
267
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
U
C
-S
U
C
C
ES
S
A
ZA
W
ee
k
8
an
d
w
ee
k
8
to
16
W
ee
k
8
an
d
w
ee
k
8
to
16
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
6/
79
(8
%
)
no
de
fin
iti
on
W
ee
k
8
to
16
:
0/
42
(0
%
);
A
FX
to
IF
X
/A
ZA
,
1/
20
(5
%
)
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
41
/7
9
(5
2%
)
W
ee
k
8
to
16
:
11
/4
2
(2
6%
);
A
FX
to
IF
X
/A
ZA
,
7/
20
(3
5%
)
W
ee
k
8:
ab
do
m
in
al
pa
in
,
4/
79
(5
%
);
ab
do
m
in
al
pa
in
,
up
pe
r
4/
79
(5
%
);
an
ae
m
ia
,
4/
79
(5
%
);
fa
tig
ue
,
4/
79
(5
%
);
he
ad
ac
he
,
8/
79
(1
0%
);
na
us
ea
,
10
/7
9
(1
3%
);
py
re
xi
a,
3/
79
(4
%
);
vo
m
iti
ng
,
6/
79
(8
%
)
W
ee
k
8
to
16
:
ar
th
ra
lg
ia
3/
42
(7
%
);
as
pe
rg
ill
os
is
,
ch
es
t
di
sc
om
fo
rt
,
co
nj
un
ct
iv
al
ha
em
or
rh
ag
e,
dr
ug
hy
pe
rs
en
si
tiv
ity
,
dy
sp
no
ea
,
le
uc
op
oe
ni
a,
na
so
ph
ar
yn
gi
tis
,
pa
in
fu
l
de
fe
ca
tio
n
=
py
re
xi
a,
U
C
–
al
l0
/4
2
(0
%
);
pa
in
in
ex
tr
em
ity
2/
42
(5
%
)
W
ee
k
8
to
16
:
A
FX
to
IF
X
/A
ZA
:
ar
th
ra
lg
ia
,
0/
20
(0
%
);
as
pe
rg
ill
os
is
,
1/
20
(5
);
ch
es
t
di
sc
om
fo
rt
,
1/
20
(5
);
co
nj
un
ct
iv
al
ha
em
or
rh
ag
e,
1/
20
(5
);
dr
ug
hy
pe
rs
en
si
tiv
ity
,
1/
20
(5
);
dy
sp
no
ea
,
1/
20
(5
);
le
uc
op
oe
ni
a,
1/
20
(5
);
na
so
ph
ar
yn
gi
tis
,
1/
20
(5
);
pa
in
fu
ld
ef
ec
at
io
n,
1/
20
(5
);
pa
in
in
ex
tr
em
ity
,
0;
py
re
xi
a,
1/
20
(5
);
U
C
,
1/
20
(5
)
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
6/
79
(8
%
)
W
ee
k
8
to
16
:
1/
42
(2
%
);
A
FX
to
IF
X
/A
ZA
,
3/
20
(1
5%
)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
268
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
U
C
-S
U
C
C
ES
S
IF
X
N
R
W
ee
k
8
an
d
w
ee
k
8
to
16
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
2/
78
(3
%
)
W
ee
k
8
to
16
:
4/
74
.5
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
26
/7
8
(3
3%
)
W
ee
k
8
to
16
:
22
/3
0
(2
9%
)
W
ee
k
8:
ab
do
m
in
al
pa
in
,
3/
78
(4
%
);
ab
do
m
in
al
pa
in
,
up
pe
r
0/
78
(0
%
);
an
ae
m
ia
,
3/
78
(4
%
);
fa
tig
ue
,
0/
78
(0
%
);
he
ad
ac
he
,
4/
78
(5
%
);
na
us
ea
,
1/
78
(1
%
);
py
re
xi
a,
5/
78
(6
%
);
vo
m
iti
ng
,
0/
78
(0
%
)
W
ee
k
8
to
16
:
A
rt
hr
al
gi
a,
2/
74
(3
%
);
as
pe
rg
ill
os
is
,
ch
es
t
di
sc
om
fo
rt
,
co
nj
un
ct
iv
al
ha
em
or
rh
ag
e,
dr
ug
hy
pe
rs
en
si
tiv
ity
,
dy
sp
no
ea
,
le
uc
op
oe
ni
a,
pa
in
fu
ld
ef
ec
at
io
n
=
pa
in
in
ex
tr
em
ity
–
al
l0
/7
4
(0
%
);
na
so
ph
ar
yn
gi
tis
1/
74
(1
%
);
py
re
xi
a,
2/
74
(3
%
);
U
C
,
4/
74
(5
%
)
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
2/
79
(3
%
)
W
ee
k
8
to
16
:3
/7
4
(4
%
)
U
C
-S
U
C
C
ES
S
IF
X
/A
ZA
N
R
W
ee
k
8
an
d
w
ee
k
8
to
16
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
3/
80
(4
%
)
W
ee
k
8
to
16
:
1/
72
(1
%
)
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
30
/8
0
(3
8%
)
W
ee
k
8
to
16
:
21
/7
2
(2
9%
)
W
ee
k
8:
ab
do
m
in
al
pa
in
,
0/
80
(0
%
);
ab
do
m
in
al
pa
in
,
up
pe
r
0/
80
(0
%
);
an
ae
m
ia
,
1/
80
(1
%
);
fa
tig
ue
,
1/
80
(1
%
);
he
ad
ac
he
,
4/
80
(5
%
);
na
us
ea
,
7/
80
(9
%
);
py
re
xi
a,
2/
80
(3
%
);
vo
m
iti
ng
,
1/
80
(1
%
)
Pa
na
cc
io
ne
et
al
.5
1
W
ee
k
8:
3/
79
(4
%
)
W
ee
k
8
to
16
:3
/7
2
(4
%
)
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
269
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
W
ee
k
8
to
16
:A
rt
hr
al
gi
a,
2
(3
);
as
pe
rg
ill
os
is
,c
he
st
di
sc
om
fo
rt
,
co
nj
un
ct
iv
al
ha
em
or
rh
ag
e,
dr
ug
hy
pe
rs
en
si
tiv
ity
,d
ys
pn
oe
a,
le
uc
op
oe
ni
a,
pa
in
fu
ld
ef
ec
at
io
n
=
pa
in
in
ex
tr
em
ity
,
py
re
xi
a
–
al
l0
/7
2
(0
%
);
na
so
ph
ar
yn
gi
tis
,
1/
72
(1
%
);
U
C
,3
/7
2
(4
%
)
Pr
ob
er
t
PB
O
W
ee
k
6
W
ee
k
6
2/
20
(1
0%
);
1
se
pt
ic
co
m
pl
ic
at
io
n,
1
co
le
ct
om
y
du
e
to
to
xi
c
ex
ac
er
ba
tio
n
an
d
sp
on
ta
ne
ou
s
pe
rf
or
at
io
n
A
C
T1
PB
O
36
.2
w
ee
ks
(a
ll
m
ea
n
=
SD
N
R)
24
.2
w
ee
ks
tr
ea
tm
en
t
(m
ea
n
=
SD
N
R
fo
r
al
l)
W
ee
k
54
Ru
tg
ee
rt
s
et
al
.4
9
31
/1
21
(2
5.
6)
st
at
es
SA
Es
m
os
t
co
m
m
on
ly
re
la
te
d
to
ga
st
ro
in
te
st
in
al
sy
st
em
in
bo
th
st
ud
ie
s
(n
o
fu
rt
he
r
de
ta
ils
)
Ru
tg
ee
rt
s
et
al
.4
9
10
3/
12
1
(8
5.
1)
A
Es
oc
cu
rr
in
g
in
≥
10
%
of
an
y
tr
ea
tm
en
t
gr
ou
p
on
ly
re
po
rt
ed
.
W
or
se
ni
ng
U
C
,4
0/
12
1
(3
3.
1)
;
ab
do
m
in
al
pa
in
,1
6/
12
1
(1
3.
2
na
us
ea
,
14
/1
21
(1
1.
6)
;u
pp
er
RT
I,
28
/1
21
(2
3.
1)
;
ph
ar
yn
gi
tis
,1
0/
12
1
(8
.3
);
si
nu
si
tis
,
4/
12
1
(3
.3
);
pa
in
=
19
/1
21
(1
5.
7)
;r
as
h,
16
/1
21
(1
3.
2)
;a
rt
hr
al
gi
a,
18
/1
21
(1
4.
9)
;
he
ad
ac
he
,2
7/
12
1
(2
2.
3)
;f
ev
er
,1
0/
12
1
(8
.3
);
an
ae
m
ia
,1
2/
12
1
(9
.9
);
fa
tig
ue
,
11
/1
21
(9
.1
)
Ru
tg
ee
rt
s
et
al
.4
9
11
/1
21
(9
.1
)
A
C
T1
PB
O
M
ea
n
du
ra
tio
n
of
tr
ea
tm
en
t,
23
w
ee
ks
(n
o
SD
re
po
rt
ed
)m
ea
n
du
ra
tio
n
of
fo
llo
w
-u
p,
32
w
ee
ks
(n
o
SD
re
po
rt
ed
)
N
R
W
ee
k
54
Sa
nd
bo
rn
et
al
.6
7
57
/2
44
(2
3)
pa
tie
nt
s
w
ith
lo
ng
-t
er
m
fo
llo
w
-u
p
(m
ea
n
30
w
ee
ks
)
pa
tie
nt
s
w
ith
≥
1
SA
E
(%
),
6/
14
(4
3)
;
U
C
,
6/
14
(4
3)
;
fe
ve
r,
1/
14
(7
)
Sa
nd
bo
rn
et
al
.6
7
A
ny
A
E
(%
)
19
6/
24
4
(8
0)
A
Es
oc
cu
rr
in
g
in
>
10
%
of
an
y
tr
ea
tm
en
t
gr
ou
p:
w
or
se
ni
ng
U
C
61
/2
44
(2
5)
;
ab
do
m
in
al
pa
in
,
31
/2
44
(1
3)
;
na
us
ea
,
23
/2
44
(9
);
up
pe
r
RT
I,
43
/2
44
(1
8)
;
ph
ar
yn
gi
tis
,
16
/2
44
(7
);
si
nu
si
tis
,
12
/2
44
(5
);
pa
in
,
30
/2
44
(1
2)
;
fa
tig
ue
,
19
/2
44
(8
);
ar
th
ra
lg
ia
,
26
/2
44
(1
1)
;
fe
ve
r,
22
/2
44
(9
);
he
ad
ac
he
,
45
/2
44
(1
8)
;
an
ae
m
ia
,
25
/2
44
(1
0)
Sa
nd
bo
rn
et
al
.6
7
23
/2
44
(9
)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
270
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
A
C
T1
5
m
g/
kg
of
IF
X
44
.9
w
ee
ks
34
.8
w
ee
ks
W
ee
k
54
Ru
tg
ee
rt
s
et
al
.4
9
26
/1
21
(2
1.
5)
Ru
tg
ee
rt
s
et
al
.4
9
10
6/
12
1
(8
7.
6)
W
or
se
ni
ng
U
C
,
23
/1
21
(1
9.
0)
;
ab
do
m
in
al
pa
in
,
11
/1
21
(9
.1
);
na
us
ea
,
14
/1
21
(1
1.
6)
;
up
pe
r
RT
I,
20
/1
21
(1
6.
5)
;
ph
ar
yn
gi
tis
,
12
/1
21
(9
.9
);
si
nu
si
tis
,
8/
12
1
(6
.6
);
pa
in
=
14
/1
21
(1
1.
6)
;
ra
sh
,
14
/1
21
(1
1.
6)
;
ar
th
ra
lg
ia
,
21
/1
21
(1
7.
4)
;
he
ad
ac
he
,
22
/1
21
(1
8.
2)
;
fe
ve
r,
14
/1
21
(1
1.
6)
;
an
ae
m
ia
,
4/
12
1
(3
.3
);
fa
tig
ue
,
14
/1
21
(1
1.
6)
Ru
tg
ee
rt
s
et
al
.4
9
10
/1
21
(8
.3
)
A
C
T1
5
m
g/
kg
of
IF
X
M
ea
n
du
ra
tio
n
of
tr
ea
tm
en
t,
33
w
ee
ks
(n
o
SD
re
po
rt
ed
);
m
ea
n
du
ra
tio
n
of
fo
llo
w
-u
p,
41
w
ee
ks
(n
o
SD
re
po
rt
ed
)
N
R
W
ee
k
54
Sa
nd
bo
rn
et
al
.6
7
43
/2
42
(1
8)
pa
tie
nt
s
w
ith
lo
ng
-t
er
m
fo
llo
w
-u
p
(m
ea
n
25
w
ee
ks
)
pa
tie
nt
s
w
ith
1
or
m
or
e
SA
Es
(%
)
(A
Es
in
cl
ud
ed
,
IF
X
-r
el
at
ed
A
Es
or
th
os
e
re
qu
iri
ng
ho
sp
ita
lis
at
io
n
fo
r
tr
ea
tm
en
t
of
U
C
(in
cl
ud
in
g
co
le
ct
om
y)
5/
15
(3
3)
;
U
C
5/
15
(3
3)
;
fe
ve
r
0
Sa
nd
bo
rn
et
al
.6
7
A
ny
A
E
(%
)
20
8/
24
2
(8
6)
A
Es
oc
cu
rr
in
g
in
>
10
%
of
an
y
tr
ea
tm
en
t
gr
ou
p:
w
or
se
ni
ng
U
C
36
/2
42
(1
5)
ab
do
m
in
al
pa
in
22
/2
42
(9
)n
au
se
a
21
(2
42
(9
)u
pp
er
RT
I3
9/
16
(1
6)
ph
ar
yn
gi
tis
23
/2
42
(1
0)
si
nu
si
tis
20
/2
42
(8
)p
ai
n
25
/2
42
(1
0)
fa
tig
ue
21
/2
42
(9
)a
rt
hr
al
gi
a
40
/2
42
(1
7)
fe
ve
r
27
/2
42
(1
1)
he
ad
ac
he
44
/2
42
(1
8)
an
ae
m
ia
11
/2
42
(5
)
Sa
nd
bo
rn
et
al
.6
7
14
/2
42
(6
)
A
C
T2
PB
O
21
.9
w
ee
ks
(M
ea
n
fo
r
al
l,
SD
N
R)
14
.4
w
ee
ks
D
ur
at
io
n
of
tr
ea
tm
en
t
(M
ea
n
fo
r
al
l,
SD
N
R)
W
ee
k
54
Ru
tg
ee
rt
s
et
al
.4
9
Ru
tg
ee
rt
s
et
al
.4
9
A
Es
se
le
ct
ed
as
fo
r
A
C
T1
:
PB
O
90
/1
23
(7
3.
2)
w
or
se
ni
ng
U
C
,
20
/1
23
(1
6.
3)
ab
do
m
in
al
pa
in
=
14
/1
23
(1
1.
4)
na
us
ea
,
9/
12
3
(7
.3
)
up
pe
r
RT
I,
14
/1
23
(1
1.
4)
ph
ar
yn
gi
tis
,
3/
12
3
(2
.4
)
si
nu
si
tis
,
7/
12
3
(5
.7
)
pa
in
=
11
/1
23
(8
.9
)
ra
sh
,
3/
12
3
(2
.4
)
ar
th
ra
lg
ia
,
6/
12
3
(4
.9
)
he
ad
ac
he
,
18
/1
23
(1
4.
6)
fe
ve
r,
12
/1
23
(9
.8
)
an
ae
m
ia
,
13
/1
23
(1
0.
6)
fa
tig
ue
,
6/
12
3
(4
.9
)
Ru
tg
ee
rt
s
et
al
.4
9
12
/1
23
(9
.8
)
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
271
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
o
n
e
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
D
is
co
n
ti
n
u
at
io
n
o
w
in
g
to
A
E(
s)
,n
/N
(%
)
A
C
T2
5
m
g/
kg
of
IF
X
27
.5
w
ee
ks
99
/1
21
(8
1.
8)
W
ee
k
54
Ru
tg
ee
rt
s
et
al
.4
9
Ru
tg
ee
rt
s
et
al
.4
9
5
m
g/
kg
of
IF
X
99
/1
21
(8
1.
8)
;
w
or
se
ni
ng
U
C
,
11
/1
21
(9
.1
);
ab
do
m
in
al
pa
in
,
m
g/
kg
of
IF
X
10
/1
21
(8
.3
);
na
us
ea
,
6/
12
1
(5
.0
);
up
pe
r
RT
I,
16
/1
21
(1
3.
2)
;
ph
ar
yn
gi
tis
,
7/
12
1
(5
.8
);
si
nu
si
tis
,
11
/1
21
(9
.1
);
pa
in
,
9/
12
1
(7
.4
);
ra
sh
,
2/
12
1
(1
.7
);
ar
th
ra
lg
ia
,
16
/1
21
(1
3.
2)
;
he
ad
ac
he
,
19
/1
21
(1
5.
7)
;
fe
ve
r,
13
/1
21
(1
0.
7)
;
an
ae
m
ia
,
6/
12
1
(5
.0
);
fa
tig
ue
,
6/
12
1
(5
.0
)
Ru
tg
ee
rt
s
et
al
.4
9
2/
12
1
(1
.7
)
A
C
T1
,
A
C
T2
ex
te
ns
io
n
st
ud
ie
s
IF
X
co
m
bi
ne
d
gr
ou
p,
n
=
23
0
M
ea
n
(S
D
)d
ur
at
io
n
of
fo
llo
w
-u
p
of
11
3
(6
42
)w
ee
ks
(r
an
ge
,
4–
18
4
w
ee
ks
;
m
ed
ia
n,
12
8
w
ee
ks
;2
5–
75
in
te
rq
ua
rt
ile
ra
ng
e,
96
–
14
4
w
ee
ks
).
M
ea
n
2.
16
ye
ar
s
(n
o
SD
)
Tr
ea
tm
en
t
du
ra
tio
n
m
ea
n
(n
o
SD
)
1.
99
ye
ar
s
Re
in
is
ch
et
al
.5
5
49
/2
30
(2
1.
3%
)
ex
pe
rie
nc
ed
SA
E.
N
um
be
r
SA
Es
,
21
pe
r
10
0
PY
s.
SA
E
ex
pe
rie
nc
ed
by
>
1
pa
tie
nt
:
U
C
fla
re
,
n
=
11
;
(4
.8
%
),
pn
eu
m
on
ia
;
n
=
5,
(2
.2
%
);
ga
st
ro
in
te
st
in
al
bl
ee
di
ng
,
n
=
4
(1
.7
%
);
na
us
ea
,
n
=
3
(1
.3
%
);
bo
ne
fr
ac
tu
re
,
n
=
3
(1
.3
%
);
ab
do
m
in
al
pa
in
,
n
=
2
(0
.9
%
);
in
te
st
in
al
ob
st
ru
ct
io
n,
n
=
2
(0
.9
%
);
fe
ve
r,
n
=
2
(0
.9
%
)
Re
in
is
ch
et
al
.5
5
N
um
be
r
of
A
Es
,
50
6
pe
r
10
0
PY
s
Re
in
is
ch
et
al
.5
5
4.
63
pe
r
10
0
PY
s
EO
W
,
ev
er
y
ot
he
r
w
ee
k;
EW
,
ev
er
y
w
ee
k.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
272
S
a
fe
ty
:
p
a
rt
ic
ip
a
n
ts
e
x
p
e
ri
e
n
ci
n
g
a
d
v
e
rs
e
e
v
e
n
ts
,
se
ri
o
u
s
a
d
v
e
rs
e
e
v
e
n
ts
a
n
d
w
it
h
d
ra
w
a
l
o
w
in
g
to
a
d
v
e
rs
e
e
v
e
n
ts
(p
a
e
d
ia
tr
ic
p
o
p
u
la
ti
o
n
tr
ia
l)
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Le
n
g
th
o
f
sa
fe
ty
fo
llo
w
-u
p
/m
ea
n
n
u
m
b
er
o
f
ad
m
in
is
tr
at
io
n
s
Ti
m
e
p
o
in
t
D
is
co
n
ti
n
u
at
io
n
d
u
e
to
A
E(
s)
,n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
1
o
r
m
o
re
A
E,
n
/N
(%
)
N
u
m
b
er
o
f
p
at
ie
n
ts
ex
p
er
ie
n
ci
n
g
1
o
r
m
o
re
SA
E,
n
/N
(%
)
(i
n
cl
u
d
in
g
d
ef
in
it
io
n
)
H
ya
m
s
5
m
g
of
IF
X
q8
w
M
ea
n
w
ee
ks
,
50
.4
M
ea
n
ex
po
su
re
w
ee
ks
,
41
.0
.
To
ta
li
nf
us
io
ns
,
16
5
W
ee
k
8
H
ya
m
s
et
al
.5
2
22
/2
2
(1
00
)
22
/2
2
(1
00
)
H
ya
m
s
et
al
.5
2
4/
22
(1
8.
2)
(1
,
se
rio
us
in
fe
ct
io
n;
1,
pa
nc
re
at
iti
s
an
d
U
C
fla
re
du
rin
g
in
du
ct
io
n
pl
us
vi
ra
l
in
fe
ct
io
n
af
te
r
st
ep
-u
p;
1,
U
C
fla
re
af
te
r
st
ep
-u
p;
1,
an
ae
m
ia
du
rin
g
m
ai
nt
en
an
ce
)
H
ya
m
s
et
al
.5
2
3/
22
(1
3.
6)
H
ya
m
s
5
m
g
of
IF
X
q1
2w
M
ea
n
w
ee
ks
,
44
.6
M
ea
n
ex
po
su
re
w
ee
ks
,
34
.3
.
To
ta
li
nf
us
io
ns
,
13
5
W
ee
k
8
H
ya
m
s
et
al
.5
2
23
/2
3
(1
00
)
H
ya
m
s
et
al
.5
2
5/
23
(2
1.
7)
[1
,
ph
ar
yn
gi
tis
du
rin
g
in
du
ct
io
n;
1,
ur
in
ar
y
tr
ac
t
in
fe
ct
io
n
du
rin
g
in
du
ct
io
n;
1,
U
C
fla
re
du
rin
g
in
du
ct
io
n
(×
1)
an
d
U
C
fla
re
du
rin
g
m
ai
nt
en
an
ce
(×
1)
;
1,
U
C
fla
re
s
du
rin
g
in
du
ct
io
n
(×
2)
;
1,
U
C
fla
re
af
te
r
st
ep
-u
p
(×
1)
]
H
ya
m
s
et
al
.5
2
6/
23
(2
6.
1)
H
ya
m
s
A
ll
pa
tie
nt
s
to
w
ee
k
8
(n
=
60
)
M
ea
n
w
ee
ks
,
38
.0
W
ee
k
8
H
ya
m
s
et
al
.5
2
57
/6
0
(9
5)
H
ya
m
s
et
al
.5
2
14
/6
0
(2
3.
3)
H
ya
m
s
et
al
.5
2
13
/6
0
(2
1.
7)
q8
w
,
ev
er
y
8
w
ee
ks
;
q1
2w
,
ev
er
y
12
w
ee
ks
.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
273
S
a
fe
ty
:
in
fe
ct
io
n
s,
se
ri
o
u
s
in
fe
ct
io
n
s,
in
fe
ct
io
n
s
re
q
u
ir
in
g
tr
e
a
tm
e
n
t,
re
a
ct
iv
a
ti
o
n
o
f
TB
o
r
h
e
p
a
ti
ti
s,
in
je
ct
io
n
si
te
re
a
ct
io
n
s,
in
fu
si
o
n
re
a
ct
io
n
s,
se
ri
o
u
s
a
ll
e
rg
ic
re
a
ct
io
n
s
(a
d
u
lt
p
o
p
u
la
ti
o
n
tr
ia
ls
)
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
U
LT
RA
1
PB
O
W
ee
k
8
Re
in
is
ch
et
al
.4
4
35
/2
23
(1
5.
7%
)
N
R
Re
in
is
ch
et
al
.4
4
3/
22
3
(1
.3
%
)
(p
ne
um
on
ia
,
1;
se
ps
is
,
1;
w
ou
nd
in
fe
ct
io
n
st
ap
hy
lo
co
cc
al
,
1)
N
R
N
R
Re
in
is
ch
et
al
.4
4
7/
22
3
(3
.1
%
)
N
R
N
R
U
LT
RA
1
80
m
g/
40
m
g
of
A
D
A
W
ee
k
8
Re
in
is
ch
et
al
.4
4
26
/1
30
(2
0.
0%
)
N
R
Re
in
is
ch
et
al
.4
4
2/
13
0
(1
.5
%
)
(a
bs
ce
ss
ru
pt
ur
e,
1;
pe
rir
ec
ta
la
bs
ce
ss
,
1)
N
R
N
R
Re
in
is
ch
et
al
.4
4
7/
13
0
(5
.4
%
)
N
R
N
R
U
LT
RA
1
16
0
m
g/
80
m
g
A
D
A
W
ee
k
8
Re
in
is
ch
et
al
.4
4
32
/2
23
(1
4.
3%
);
op
po
rt
un
is
t
in
fe
ct
io
n
(o
es
op
ha
ge
al
ca
nd
id
ia
si
s)
1/
22
3
(0
.4
%
)
N
R
Re
in
is
ch
et
al
.4
4
0/
22
3
(0
%
)
N
R
N
R
Re
in
is
ch
et
al
.4
4
13
/2
23
(5
.8
%
)
N
R
N
R
U
LT
RA
2
PB
O
W
ee
k
52
Sa
nd
bo
rn
et
al
.4
5
10
3/
26
0
(3
9.
6%
);
op
po
rt
un
is
tic
in
fe
ct
io
n-
re
la
te
d
A
E
(e
xc
lu
di
ng
TB
)
3/
26
0
(1
.2
%
)
N
R
Sa
nd
bo
rn
et
al
.4
5
5/
26
0
(1
.9
%
)
N
R
N
R
Sa
nd
bo
rn
et
al
.4
5
10
/2
60
(3
.8
%
)
N
R
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
274
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
U
LT
RA
2
16
0
m
g/
80
m
g
A
D
A
W
ee
k
52
Sa
nd
bo
rn
et
al
.4
5
11
6/
25
7
(4
5.
1%
);
op
po
rt
un
is
tic
in
fe
ct
io
n-
re
la
te
d
A
E
(e
xc
lu
di
ng
TB
)
5/
25
7
(1
.9
%
)
N
R
Sa
nd
bo
rn
et
al
.4
5
4/
25
7
(1
.6
%
)
N
R
N
R
Sa
nd
bo
rn
et
al
.4
5
31
/2
57
(1
2.
1%
)
N
R
N
R
U
LT
RA
3
80
m
g/
40
m
g
A
D
A
Re
in
is
ch
et
al
.5
4
21
3/
57
7
(3
8.
2%
)
ev
en
ts
,
38
2
(e
ve
nt
s
pe
r
10
0
PY
,
89
.5
)
op
po
rt
un
is
tic
in
fe
ct
io
n:
5/
57
7
(0
.9
%
)
ev
en
ts
,
6
(e
ve
nt
s
pe
r
10
0
PY
,
1.
4)
N
R
Re
in
is
ch
et
al
.5
4
17
/5
77
(3
.1
%
)
ev
en
ts
,
17
(e
ve
nt
s
pe
r
10
0
PY
,
4.
0)
N
R
N
R
Re
in
is
ch
et
al
.5
4
8/
57
7
(1
.4
%
)
ev
en
ts
,
8
(e
ve
nt
s
pe
r
10
0
PY
,
1.
9)
N
R
N
R
U
LT
RA
3
16
0
m
g/
80
m
g
A
D
A
W
ee
k
52
N
R
N
R
Su
bm
is
si
on
62
A
D
A
40
m
g
EO
W
/
EW
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
se
rio
us
in
fe
ct
io
n
=
79
(3
.4
);
op
po
rt
un
is
tic
in
fe
ct
io
n
ex
cl
ud
in
g
TB
,
6
(0
.3
)
A
D
A
40
m
g
EO
W
/E
W
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
1
(<
0.
1)
N
R
Su
bm
is
si
on
62
A
D
A
40
m
g
EO
W
/E
W
n
=
10
10
;
PY
s,
23
38
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
24
6
(1
0.
5)
N
R
N
R
Su
zu
ki
PB
O
W
ee
k
8
Su
zu
ki
et
al
.4
6
W
ee
k
8:
15
/9
6
(1
5.
6%
)o
pp
or
tu
ni
st
ic
in
fe
ct
io
n
(e
xc
lu
di
ng
TB
);
W
ee
k
8:
0/
96
(0
%
)
N
R
Su
zu
ki
et
al
.4
6
W
ee
k
8:
0/
96
(0
%
)
Su
zu
ki
et
al
.4
6
W
ee
k
8:
0/
96
(0
%
)
N
R
Su
zu
ki
et
al
.4
6
W
ee
k
8:
2/
96
(2
.1
%
)
N
R
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
275
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
Su
zu
ki
PB
O
W
ee
k
52
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
70
(e
ve
nt
s/
10
0
PY
s,
15
6.
3)
.
O
pp
or
tu
ni
st
ic
in
fe
ct
io
n
(e
xc
lu
di
ng
TB
);
w
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
0
(e
ve
nt
s/
10
0
PY
s,
0)
N
R
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
2
(e
ve
nt
s/
10
0
PY
s,
4.
5)
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,0
(e
ve
nt
s/
10
0
PY
s,
0)
N
R
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
4
(e
ve
nt
s/
10
0
PY
s,
8.
9)
N
R
N
R
Su
zu
ki
80
m
g/
40
m
g
of
A
D
A
W
ee
k
8
W
ee
k
8:
11
/8
7
(1
2.
6%
).
O
pp
or
tu
ni
st
ic
in
fe
ct
io
n
(e
xc
lu
di
ng
TB
);
w
ee
k
8:
0/
87
(0
%
)4
6
N
R
W
ee
k
8:
0/
87
(0
%
)4
6
W
ee
k
8:
0/
87
(0
%
)4
6
N
R
W
ee
k
8:
5/
87
(5
.7
%
)4
6
N
R
N
R
Su
zu
ki
16
0
m
g/
80
m
g
A
D
A
W
ee
k
8
W
ee
k
8:
17
/9
0
(1
8.
9%
).
O
pp
or
tu
ni
st
ic
in
fe
ct
io
n
(e
xc
lu
di
ng
TB
);
w
ee
k
8:
1/
90
(1
.1
%
)4
6
N
R
W
ee
k
8:
3/
90
(3
.3
%
)46
W
ee
k
8:
1/
90
(1
.1
%
)4
6
N
R
W
ee
k
8:
7/
90
(7
.8
%
)4
6
N
R
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
276
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
Su
zu
ki
40
m
g
of
A
D
A
EO
W
W
ee
k
52
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
13
4
(e
ve
nt
s/
10
0
PY
s,
13
6.
5)
.A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
rf
ul
l
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
90
(e
ve
nt
s/
10
0
PY
s,
13
1.
0)
.O
pp
or
tu
ni
st
ic
in
fe
ct
io
n
(e
xc
lu
di
ng
TB
);
w
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,2
(e
ve
nt
s/
10
0
PY
s,
2.
0)
.A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
rf
ul
l
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
2
(e
ve
nt
s/
10
0
PY
s,
2.
9)
46
Su
zu
ki
et
al
.4
6
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
8
(e
ve
nt
s/
10
0
PY
s,
8.
1)
.A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
6
(e
ve
nt
s/
10
0
PY
s,
8.
7)
46
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
1
(e
ve
nt
s/
10
0
PY
s,
1.
0)
.
A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
0
(e
ve
nt
s/
10
0
PY
s,
0)
46
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,
20
(e
ve
nt
s/
10
0
PY
s,
20
.4
).
A
D
A
w
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
9
(e
ve
nt
s/
10
0
PY
s,
13
.1
)4
6
N
R
PU
RS
U
IT
-S
C
PB
O
W
ee
k
6
Pa
tie
nt
s
w
ith
≥
1
in
fe
ct
io
n
40
/3
30
(1
2.
1)
.1
op
po
rt
un
is
tic
in
fe
ct
io
n
(c
yt
om
eg
al
ov
iru
s
in
fe
ct
io
n)
(n
ot
re
po
rt
ed
as
se
rio
us
)4
7
Pa
tie
nt
s
w
ith
≥
1
in
fe
ct
io
n
re
qu
iri
ng
tr
ea
tm
en
t
23
/3
30
(7
.0
)4
7
Pa
tie
nt
s
w
ith
≥
1
se
rio
us
in
fe
ct
io
n
6/
33
0
(1
.8
)
(1
pn
eu
m
on
ia
)4
7
N
R
N
R
Pa
tie
nt
s
w
ith
≥
1
in
je
ct
io
n
si
te
re
ac
tio
n
5/
33
0
(1
.5
)4
7
N
R
N
R
PU
RS
U
IT
-S
C
10
0
m
g/
50
m
g
of
G
O
L
8/
71
(1
1.
3)
47
04
7
04
7
N
R
N
R
4/
71
(5
.6
)4
7
N
R
N
R
PU
RS
U
IT
-S
C
20
0
m
g/
10
0
m
g
of
G
O
L
W
ee
k
6
39
/3
31
(1
1.
8)
47
15
/3
31
(4
.5
)4
7
1/
33
1
(0
.3
)
(1
pn
eu
m
on
ia
)4
7
N
R
N
R
11
/3
31
(3
.3
)4
7
N
R
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
277
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
PU
RS
U
IT
-S
C
40
0
m
g/
20
0
m
g
of
G
O
L
W
ee
k
6
41
/3
32
(1
2.
3)
;
1
op
po
rt
un
is
tic
in
fe
ct
io
n
(o
es
op
ha
ge
al
ca
nd
id
ia
si
s)
(n
ot
re
po
rt
ed
as
se
rio
us
)4
7
25
/3
32
(7
.5
)4
7
3/
33
2
(0
.9
)4
7
N
R
N
R
10
/3
32
(3
.0
)4
7
N
R
N
R
PU
RS
U
IT
-M
PB
O
.
n
=
15
6
W
ee
k
54
≥
1
in
fe
ct
io
n
(a
s
as
se
ss
ed
by
in
ve
st
ig
at
or
),
44
(2
8.
2)
48
24
(1
5.
4)
48
3
(1
.9
)
se
rio
us
op
po
rt
un
is
tic
in
fe
ct
io
n;
20
0
m
g/
10
0
m
g
of
G
O
L
s.
c.
in
du
ct
io
n
=
PB
O
m
ai
nt
en
an
ce
,
1
(c
yt
om
eg
al
ov
iru
s
in
fe
ct
io
n
ap
pr
ox
im
at
el
y
3
m
on
th
s
af
te
r
la
st
G
O
L
do
se
)4
8
TB
re
po
rt
ed
th
ro
ug
h
w
ee
k
54
.G
O
L
4
m
g/
kg
i.v
.
in
du
ct
io
n
=
PB
O
m
ai
nt
en
an
ce
,1
48
N
R
In
je
ct
io
ns
w
ith
in
je
ct
io
n
si
te
re
ac
tio
ns
,
18
(0
.5
)≥
1;
in
je
ct
io
n
si
te
re
ac
tio
ns
,
3
(1
.9
)4
8
N
R
N
R
PU
RS
U
IT
-M
50
m
g
of
G
O
L,
n
=
15
4
W
ee
k
54
60
(3
9.
0)
48
39
(2
5.
3)
48
5
(3
.2
)s
er
io
us
op
po
rt
un
ist
ic
in
fe
ct
io
n;
50
m
g
of
G
O
L
m
ai
nt
en
an
ce
,0
48
0
N
R
In
je
ct
io
ns
w
ith
in
je
ct
io
n
si
te
re
ac
tio
ns
,
18
(0
.4
)
≥
1;
in
je
ct
io
n
si
te
re
ac
tio
ns
,
3
(1
.9
)4
8
N
R
N
R
PU
RS
U
IT
-M
10
0
m
g
of
G
O
L,
n
=
15
4
W
ee
k
54
60
(3
9.
0)
48
44
(2
8.
6)
48
5
(3
.2
)s
er
io
us
op
po
rt
un
is
tic
in
fe
ct
io
n;
20
0
m
g/
10
0
m
g
of
G
O
L
in
du
ct
io
n
=
10
0
m
g
of
G
O
L
m
ai
nt
en
an
ce
,
1
(S
ta
ph
yl
oc
oc
cu
s
au
re
us
an
d
N
oc
ar
di
a
cu
ltu
re
d
fr
om
a
br
ai
n
ab
sc
es
s)
48
3
(1
.9
)
10
0
m
g
of
G
O
L
m
ai
nt
en
an
ce
(1
ea
ch
40
0
m
g/
20
0
m
g
of
G
O
L
s.
c.
,4
m
g/
kg
i.v
.
an
d
20
0
m
g/
10
0
m
g
s.
c.
in
du
ct
io
n)
(in
cl
ud
in
g
fa
ta
l
ca
se
re
po
rt
ed
pr
ev
io
us
ly
)4
8
N
R
In
je
ct
io
ns
w
ith
in
je
ct
io
n
si
te
re
ac
tio
ns
,
28
(0
.6
)
≥
1;
in
je
ct
io
n
si
te
re
ac
tio
ns
,
11
(7
.1
)4
8
N
R
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
278
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
U
C
-
SU
C
C
ES
S
A
ZA
W
ee
k
8
N
R
N
R
1/
79
(1
%
)5
1
N
R
N
R
N
R
1/
79
(1
%
)5
1
N
R
U
C
-
SU
C
C
ES
S
IF
X
W
ee
k
8
N
R
N
R
1/
78
(1
%
)5
1
N
R
N
R
N
R
0/
78
(0
%
)5
1
N
R
U
C
-
SU
C
C
ES
S
IF
X
/A
ZA
W
ee
k
8
N
R
N
R
0/
80
(0
%
)5
1
N
R
N
R
N
R
0/
80
(0
%
)5
1
N
R
A
C
T1
PB
O
W
ee
k
54
47
/1
21
(3
8.
8)
;f
un
ga
l
de
rm
at
iti
s,
8/
12
1
(6
.6
);
pn
eu
m
on
ia
,0
;
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
1/
12
1
(0
.8
);
he
rp
es
zo
st
er
,
04
9
25
/1
21
(2
0.
7)
49
Se
rio
us
in
fe
ct
io
ns
,
5/
12
1
(4
.1
);
ba
ct
er
ia
l
in
fe
ct
io
n
=
1/
12
1
(0
.8
);
up
pe
r
RT
I,
1/
12
1
(0
.8
);
pn
eu
m
on
ia
,0
;T
B,
0;
ab
sc
es
s,
1/
12
1
(0
.8
);
ph
ar
yn
gi
tis
,1
/1
21
(0
.8
);
ga
st
ro
en
te
rit
is
,
0;
ea
ra
ch
e,
0;
fe
ve
r,
0;
va
gi
ni
tis
,0
;
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
0;
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n,
1/
12
1
(0
.8
);
pa
nc
re
at
iti
s,
0;
pl
eu
ris
y,
0;
si
nu
si
tis
,
1/
12
1
(0
.8
)4
9
N
R
N
R
N
R
A
cu
te
in
fu
si
on
re
ac
tio
n
(a
ny
A
E
oc
cu
rr
in
g
≤
2
ho
ur
s
af
te
r
st
ar
t
of
in
fu
si
on
),
13
/1
21
(1
0.
7)
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
279
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T1
PB
O
A
C
T1
an
d
A
C
T2
,
an
d
A
C
T2
ex
te
ns
io
n
th
ro
ug
h
54
w
ee
ks
80
/2
44
(3
3)
67
N
R
Se
rio
us
in
fe
ct
io
ns
(%
),
6/
24
4
(2
);
ba
ct
er
ia
l
in
fe
ct
io
n,
1/
24
4
(0
.4
);
up
pe
r
RT
I,
1/
24
4
(0
.4
);
pn
eu
m
on
ia
,0
;
TB
,0
;a
bs
ce
ss
,2
/2
44
(1
);
ph
ar
yn
gi
tis
,1
/2
44
(0
.4
);
ga
st
ro
en
te
rit
is
,
0;
ea
ra
ch
e,
0;
fe
ve
r,
0;
va
gi
ni
tis
,0
;
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
0;
in
fe
ct
io
n,
1/
24
4
(0
.4
);
(n
o
fu
rt
he
r
de
ta
ils
);
pa
nc
re
at
iti
s,
0;
pe
ric
ar
di
tis
,0
;
pl
eu
ris
y,
0;
py
el
on
ep
hr
iti
s,
0;
si
nu
si
tis
,1
/2
44
(0
.4
)67
N
R
N
R
N
R
Po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
re
ac
tio
ns
(%
),
2/
24
2
(1
)
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
280
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T1
5
m
g/
kg
of
IF
X
W
ee
k
54
53
/1
21
(4
3.
8)
;
fu
ng
al
de
rm
at
its
,
1/
12
1
(0
.8
);4
9
pn
eu
m
on
ia
,
2/
12
1
(1
.7
);
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
1/
12
1
(0
.8
);
he
rp
es
zo
st
er
,
1/
12
1
(0
.8
)
n
=
12
1
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:3
2/
66
(4
8.
5%
);
al
li
nf
ec
tio
ns
no
ba
se
lin
e
IM
M
:
21
/5
5
(3
8.
2%
)3
42
39
/1
21
(3
2.
2)
49
Se
rio
us
in
fe
ct
io
ns
,
3/
12
1
(2
.5
);
ba
ct
er
ia
l
in
fe
ct
io
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,
0;
TB
,
0;
ab
sc
es
s,
0;
ph
ar
yn
gi
tis
,
0;
ga
st
ro
en
te
rit
is
,
1/
12
1
(0
.8
);
ea
ra
ch
e,
0;
fe
ve
r,
0;
va
gi
ni
tis
,
0;
ap
pe
nd
ic
iti
s,
1/
12
1
(0
.8
);
co
lit
is
,
0;
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n,
0
(0
.8
);
pa
nc
re
at
iti
s,
1/
12
1
(0
.8
);
pl
eu
ris
y,
0;
si
nu
si
tis
,
04
9
n
=
12
1
se
rio
us
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
3/
66
(4
.5
%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
0/
55
(0
.0
%
)4
9
N
R
N
R
N
R
12
1
(9
.9
);
po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
re
ac
tio
ns
2/
12
1
(1
.7
)
49
n
=
12
1:
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:7
/4
23
(1
.7
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:8
/3
64
(2
.2
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:6
/6
6
(9
.1
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:6
/5
5
(1
0.
9%
);
n
=
12
1:
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/3
64
(0
.0
%
);
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/4
23
(0
.0
%
);
pa
tie
nt
s
n
w
ith
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/6
6
(0
.0
%
);
pa
tie
nt
s
n
w
ith
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/5
5
(0
.0
%
)
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
281
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T1
5
m
g/
kg
of
IF
X
A
C
T1
an
d
A
C
T2
,
an
d
A
C
T2
ex
te
ns
io
n
th
ro
ug
h
54
w
ee
ks
94
/2
42
(3
9)
67
Sa
nd
bo
rn
et
al
.6
7
Se
rio
us
in
fe
ct
io
ns
,
(%
)
7/
24
2
(3
);
ba
ct
er
ia
li
nf
ec
tio
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,
2/
24
2
(1
);
TB
,
0;
ab
sc
es
s,
0;
ph
ar
yn
gi
tis
,
0;
ga
st
ro
en
te
rit
is
,
2/
24
2
(1
);
ea
ra
ch
e,
1/
24
2
(0
.4
);
fe
ve
r,
1/
24
2
(0
.4
);
va
gi
ni
tis
,
0;
ap
pe
nd
ic
iti
s,
1/
24
2
(0
.4
);
co
lit
is
,
0;
in
fe
ct
io
n,
0;
pa
nc
re
at
iti
s,
1/
24
2
(0
.4
);
pe
ric
ar
di
tis
,
0;
pl
eu
ris
y,
0;
py
el
on
ep
hr
iti
s,
0;
si
nu
si
tis
67
N
R
N
R
N
R
Po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
re
ac
tio
ns
(%
),
2/
24
2
(1
)3
42
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
282
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T1
10
m
g/
kg
of
IF
X
W
ee
k
54
60
/1
22
(4
9.
2)
;
fu
ng
al
de
rm
at
iti
s,
3/
12
2
(2
.5
);
pn
eu
m
on
ia
,
4/
12
2
(3
.3
);
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
IF
X
10
m
g
0;
he
rp
es
zo
st
er
,
04
9
n
=
12
2
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:3
2/
59
(5
4.
2%
);
al
li
nf
ec
tio
ns
no
ba
se
lin
e
IM
M
:
28
/6
3
(4
4.
4%
)3
42
43
/1
22
(3
5.
2)
49
Se
rio
us
in
fe
ct
io
ns
,
8/
12
2
(6
.6
);
ba
ct
er
ia
l
in
fe
ct
io
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,
3/
12
2
(2
.5
);
TB
,
1
(0
.8
);
ab
sc
es
s,
2/
12
2
(1
.6
);
ph
ar
yn
gi
tis
,
1/
12
2
(0
.8
);
ga
st
ro
en
te
rit
is
,
1/
12
2
(0
.8
);
ea
ra
ch
e,
0;
fe
ve
r,
1/
12
2
(0
.8
);
va
gi
ni
tis
,
0;
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
1/
12
2
(0
.8
);
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n,
1/
12
2
(0
.8
);
pa
nc
re
at
iti
s,
0;
pl
eu
ris
y,
1/
12
2
(0
.8
);
si
nu
si
tis
,
04
9
n
=
12
2
se
rio
us
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
6/
59
(1
0.
2%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
2/
63
(3
.2
%
)3
42
N
R
N
R
N
R
15
/1
22
(1
2.
3)
;
po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
re
ac
tio
ns
,
2/
12
1
(1
.7
)4
9
n
=
12
2:
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:8
/4
03
(2
.0
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:8
/3
67
(2
.2
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:8
/5
9
(1
3.
6%
);3
42
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:7
/6
3
(1
1.
1%
);
n
=
12
2:
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/3
67
(0
.0
%
);
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
40
3
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/5
9
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/6
3
(0
.0
%
)
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
283
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T1
IF
X
co
m
b
W
ee
k
54
n
=
24
3.
A
ll
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
64
/1
25
(5
1.
2%
);
al
l
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
49
/1
18
(4
1.
5%
);
A
C
T2
w
ee
k
30
n
=
24
1
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:
30
/1
02
(2
9.
4%
);
al
l
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
37
/1
39
(2
6.
6%
)3
42
Li
ch
te
ns
te
in
et
al
.3
42
n
=
24
3
se
rio
us
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
9/
12
5
(7
.2
%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
2/
11
8
(1
.7
%
);
A
C
T2
w
ee
k
30
n
=
24
1
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
10
2
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
13
9
(0
.0
%
)3
42
N
R
N
R
N
R
n
=
24
3:
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:
15
/7
90
(1
.9
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
16
/7
67
(2
.1
%
);
pa
tie
nt
s
n
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
14
/1
25
(1
1.
2%
);
pa
tie
nt
s
n
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
13
/1
18
(1
1.
0%
)
n
=
24
3:
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
79
0
(0
.0
%
);
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
76
7
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
12
5
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
11
8
(0
.0
%
)3
42
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
284
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T2
PB
O
W
ee
k
30
29
/1
23
(2
3.
6)
;
fu
ng
al
de
rm
at
iti
s,
0;
IF
X
pn
eu
m
on
ia
,
0;
IF
X
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
0;
he
rp
es
zo
st
er
,
1/
12
3
(0
.8
);
IF
X
54
9
15
/1
23
(1
2.
2)
49
1/
12
3
(0
.8
);
ba
ct
er
ia
l
in
fe
ct
io
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,
0T
B,
0;
ab
sc
es
s,
1/
12
3
(0
.8
);
ph
ar
yn
gi
tis
,0
;
ga
st
ro
en
te
rit
is
,P
BO
0;
ea
ra
ch
e,
0;
fe
ve
r,
0;
va
gi
ni
tis
,0
;
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
0;
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n,
0;
pa
nc
re
at
iti
s,
0;
pl
eu
ris
y,
0;
si
nu
si
tis
,0
49
N
R
N
R
N
R
D
ef
in
ed
as
fo
r
A
C
T1
:
10
/1
23
(8
.1
)
po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
04
9
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
285
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T2
5
m
g/
kg
of
IF
X
W
ee
k
30
18
/1
21
(1
4.
9)
;
fu
ng
al
de
rm
at
iti
s,
0;
pn
eu
m
on
ia
,
0;
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
1/
12
1
(0
.8
);
he
rp
es
zo
st
er
,
2/
12
1
(0
.8
)4
9
n
=
12
1
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:
17
/5
2
(3
2.
7%
);
al
l
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
16
/6
9
(2
3.
2%
)3
42
2/
12
1
(1
.7
);
ba
ct
er
ia
l
in
fe
ct
io
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,
0;
TB
,
0;
ab
sc
es
s,
0;
ph
ar
yn
gi
tis
,
0;
ga
st
ro
en
te
rit
is
,
1/
12
1
(0
.8
);
ea
ra
ch
e,
1/
12
1
(0
.8
);
fe
ve
r,
1/
12
1(
0.
8)
;
va
gi
ni
tis
,
0;
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
0;
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n
=
0;
pa
nc
re
at
iti
s,
0;
pl
eu
ris
y,
0;
sin
us
iti
s,
04
9
n
=
12
1
se
rio
us
in
fe
ct
io
ns
34
2
ba
se
lin
e
IM
M
:1
/5
2
(1
.9
%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:1
/6
9
(1
.4
%
)
14
/1
21
(1
1.
6)
po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
04
9
n
=
12
1;
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:4
/2
42
(1
.7
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
12
/3
16
(3
.8
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:3
/5
2
(5
.8
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:1
1/
69
(1
5.
9%
).
n
=
12
1;
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/2
42
(0
.0
%
);
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/3
16
(0
.0
%
);
pa
tie
nt
s
n
w
ith
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/5
2
(0
.0
%
);
pa
tie
nt
s
n
w
ith
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/6
9
(0
.0
%
)
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
286
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T2
10
m
g/
kg
of
IF
X
W
ee
k
30
17
/1
20
(1
4.
2)
;f
un
ga
l
de
rm
at
iti
s,
10
m
g/
kg
1
(0
.8
);
pn
eu
m
on
ia
,
10
m
g/
kg
2/
12
0
(1
.7
);
va
ric
el
la
-z
os
te
r
vi
ru
s
in
fe
ct
io
n,
0;
he
rp
es
zo
st
er
,1
/1
20
(0
.8
)49
Ru
tg
ee
rt
s
et
al
.4
9
3/
12
0
(2
.5
);
ba
ct
er
ia
l
in
fe
ct
io
n,
0;
up
pe
r
RT
I,
0;
pn
eu
m
on
ia
,0
;
TB
,0
;a
bs
ce
ss
,1
/1
20
(0
.8
);
ph
ar
yn
gi
tis
,0
;
ga
st
ro
en
te
rit
is
,0
;
ea
ra
ch
e,
0;
fe
ve
r,
0;
va
gi
ni
tis
,1
/1
20
(0
.8
);
ap
pe
nd
ic
iti
s,
0;
co
lit
is
,
0;
su
rg
ic
al
w
ou
nd
in
fe
ct
io
n,
1/
12
0
(0
.8
);
pa
nc
re
at
iti
s,
0;
pl
eu
ris
y,
0;
si
nu
si
tis
,
04
9
N
R
N
R
Ru
tg
ee
rt
s
et
al
.4
9
14
/1
20
(1
1.
7)
;
po
ss
ib
le
de
la
ye
d
hy
pe
rs
en
si
tiv
ity
1/
12
0
(0
.8
)3
42
N
R
A
C
T2
A
ll
tr
ea
te
d
pa
tie
nt
s,
sa
fe
ty
at
w
ee
k
30
,
n
=
12
1
W
ee
k
30
5
m
g/
kg
of
IF
X
W
IT
H
im
m
un
om
od
ul
at
or
s,
17
/5
2
(3
2.
7)
;5
m
g/
kg
of
IF
X
W
IT
H
O
U
T
im
m
un
om
od
ul
at
or
s,
16
/6
9
(2
3.
2)
34
2
n
=
12
0.
A
ll
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:1
3/
50
(2
6.
0%
);
al
li
nf
ec
tio
ns
no
ba
se
lin
e
IM
M
:2
1/
70
(3
0.
0%
)3
42
N
R
5
m
g/
kg
of
IF
X
W
IT
H
im
m
un
om
od
ul
at
or
s,
1/
52
(1
.9
)3
42
n
=
12
0
se
rio
us
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
1/
50
(2
.0
%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
2/
70
(2
.9
%
)3
42
N
R
N
R
N
R
5
m
g/
kg
of
IF
X
W
IT
H
im
m
un
om
od
ul
at
or
s,
3/
52
(5
.8
);
5
m
g/
kg
of
IF
X
W
IT
H
O
U
T
im
m
un
om
od
ul
at
or
s,
11
/6
9
(1
5.
9)
;
se
rio
us
in
fu
si
on
re
ac
tio
ns
.
5
m
g/
kg
of
IF
X
W
IT
H
im
m
un
om
od
ul
at
or
s,
0/
52
(0
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
.
5
m
g/
kg
of
IF
X
W
IT
H
O
U
T
im
m
un
om
od
ul
at
or
s,
0/
69
(0
);3
42
n
=
12
0:
34
2
in
fu
si
on
s
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
287
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:6
/2
24
(2
.7
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
15
/3
18
(4
.7
%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:5
/5
0
(1
0.
0%
);
pa
tie
nt
s
n
w
ith
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:9
/7
0
(1
2.
9%
);
n
=
12
0:
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/2
24
(0
.0
%
);
in
fu
si
on
s
n
w
ith
se
rio
us
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
31
8
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
50
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/7
0
(0
.0
%
)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
288
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
A
C
T2
IF
X
co
m
bi
ne
d
gr
ou
p
W
ee
k
30
A
C
T1
w
ee
k
54
n
=
24
3
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:
64
/1
25
(5
1.
2%
);
al
li
nf
ec
tio
ns
no
ba
se
lin
e
IM
M
:
49
/1
18
(4
1.
5%
);
A
C
T2
w
ee
k
30
n
=
24
1
al
li
nf
ec
tio
ns
ba
se
lin
e
IM
M
:
30
/1
02
(2
9.
4%
);
al
li
nf
ec
tio
ns
no
ba
se
lin
e
IM
M
:
37
/1
39
(2
6.
6%
)3
42
N
R
A
C
T1
w
ee
k
54
n
=
24
3
se
rio
us
in
fe
ct
io
ns
ba
se
lin
e
IM
M
:
9/
12
5
(7
.2
%
);
se
rio
us
in
fe
ct
io
ns
no
ba
se
lin
e
IM
M
:
2/
11
8
(1
.7
%
);
A
C
T2
w
ee
k
30
n
=
24
1
se
rio
us
in
fu
sio
n
re
ac
tio
ns
ba
se
lin
e
IM
M
:0
/1
02
(0
.0
%
);
se
rio
us
in
fu
sio
n
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:0
/1
39
(0
.0
%
)34
2
N
R
N
R
N
R
n
=
24
1:
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
ba
se
lin
e
IM
M
:
10
/4
66
(2
.2
%
);
in
fu
si
on
s
n
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
27
/6
34
(4
.3
%
);
n
pa
tie
nt
s
an
y
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
8/
10
2
(7
.8
2%
);
n
pa
tie
nt
s
an
y
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
20
/1
39
(1
4.
4%
);
n
=
24
1:
n
in
fu
si
on
s
w
ith
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
27
/6
34
(4
.3
%
);
n
in
fu
si
on
s
w
ith
se
rio
us
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
46
6
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
ba
se
lin
e
IM
M
:
0/
10
2
(0
.0
%
);
se
rio
us
in
fu
si
on
re
ac
tio
ns
no
ba
se
lin
e
IM
M
:
0/
13
9
(0
.0
%
)3
42
N
R
A
C
T1
,
A
C
T2
ex
te
ns
io
n
st
ud
ie
s
IF
X
co
m
bi
ne
d
gr
ou
p
n
=
23
0
N
R
N
um
be
r
in
fe
ct
io
ns
,
99
pe
r
10
0
PY
s5
5
N
um
be
r
in
fe
ct
io
ns
re
qu
iri
ng
an
tim
ic
ro
bi
al
tr
ea
tm
en
t,
41
pe
r
10
0
PY
s5
5
Pa
tie
nt
s
(4
.3
%
)
ha
d
se
rio
us
in
fe
ct
io
n.
N
um
be
r
se
rio
us
in
fe
ct
io
ns
3.
4
pe
r
10
0
PY
s.
D
ur
in
g
ex
te
ns
io
n
st
ud
ie
s,
no
re
po
rt
s
of
TB
or
ot
he
r
op
po
rt
un
is
tic
in
fe
ct
io
ns
55
N
R
N
R
N
R
N
R
N
R
EO
W
,
ev
er
y
ot
he
r
w
ee
k;
EW
,
ev
er
y
w
ee
k;
IM
M
,
im
m
un
om
od
ul
at
or
;
RT
I,
re
sp
ira
to
ry
tr
ac
t
in
fe
ct
io
n;
s.
c.
su
bc
ut
an
eo
us
.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
289
S
a
fe
ty
:
in
fe
ct
io
n
s,
se
ri
o
u
s
in
fe
ct
io
n
s,
in
fe
ct
io
n
s
re
q
u
ir
in
g
tr
e
a
tm
e
n
t,
re
a
ct
iv
a
ti
o
n
o
f
tu
b
e
rc
u
lo
si
s
o
r
h
e
p
a
ti
ti
s,
in
je
ct
io
n
si
te
re
a
ct
io
n
s,
in
fu
si
o
n
re
a
ct
io
n
s,
se
ri
o
u
s
a
ll
e
rg
ic
re
a
ct
io
n
s
(p
a
e
d
ia
tr
ic
p
o
p
u
la
ti
o
n
tr
ia
l)
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
In
fe
ct
io
n
s
In
fe
ct
io
n
s
re
q
u
ir
in
g
tr
ea
tm
en
t
Se
ri
o
u
s
in
fe
ct
io
n
s
R
ea
ct
iv
at
io
n
o
f
TB
R
ea
ct
iv
at
io
n
o
f
h
ep
at
it
is
B
In
je
ct
io
n
si
te
re
ac
ti
o
n
s
(r
el
ev
an
t
to
A
D
A
an
d
G
O
L)
In
fu
si
o
n
re
ac
ti
o
n
s
(r
el
ev
an
t
to
IF
X
)
Se
ri
o
u
s
al
le
rg
ic
re
ac
ti
o
n
s
(e
.g
.
an
ap
h
yl
ax
is
)
H
ya
m
s
5
m
g
of
IF
X
q8
w
W
ee
k
8
13
/2
2
(5
9.
1%
)5
2
N
R
N
R
N
R
N
R
N
R
4/
22
(1
8.
2%
)5
2
N
R
H
ya
m
s
5
m
g
of
IF
X
q1
2w
W
ee
k
8
14
/2
3
(6
0.
9%
)5
2
N
R
N
R
N
R
N
R
N
R
3/
23
(1
3.
0%
)5
2
N
R
H
ya
m
s
A
ll
pa
tie
nt
s
to
w
ee
k
8
(n
=
60
)
W
ee
k
8
31
/6
0
(5
1.
7%
)5
2
N
R
N
R
N
R
N
R
N
R
8/
60
(1
3.
3%
)5
2
N
R
q8
w
,
ev
er
y
8
w
ee
ks
;
q1
2w
,
ev
er
y
12
w
ee
ks
.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
290
S
a
fe
ty
:
h
e
a
rt
fa
il
u
re
,
m
a
li
g
n
a
n
ci
e
s,
h
e
p
a
to
b
il
ia
ry
e
v
e
n
ts
,
a
u
to
im
m
u
n
e
p
ro
ce
ss
e
s,
n
e
u
ro
lo
g
ic
a
l
e
v
e
n
ts
,
h
a
e
m
a
to
lo
g
ic
a
l
re
a
ct
io
n
s
(a
d
u
lt
p
o
p
u
la
ti
o
n
tr
ia
ls
)
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
U
LT
RA
1
PB
O
W
ee
k
8
0/
22
3
(0
%
)4
4
2/
22
3
(0
.9
%
)
–
ba
sa
l
ce
ll
ca
rc
in
om
a,
1;
br
ea
st
ca
nc
er
,
14
4
N
R
D
em
ye
lin
at
in
g
di
se
as
e,
0/
22
3
(0
%
)4
4
D
em
ye
lin
at
in
g
di
se
as
e,
0/
22
3
(0
%
)
N
R
Su
bm
is
si
on
M
ed
D
RA
Sy
st
em
O
rg
an
C
la
ss
an
d
Pr
ef
er
re
d
Te
rm
:
an
y
A
E,
21
8/
22
3
(8
3.
8%
);
co
lit
is
ul
ce
ra
tiv
e,
21
/2
23
(9
.4
%
)
U
LT
RA
1
16
0
m
g/
80
m
g
of
A
D
A
W
ee
k
8
0/
13
0
(0
%
)
0/
13
0
(0
%
)4
4
N
R
Lu
pu
s-
lik
e
sy
nd
ro
m
e,
0/
13
0
(0
%
)4
4
D
em
ye
lin
at
in
g
di
se
as
e,
0/
13
0
(0
%
)4
4
N
R
Su
bm
is
si
on
M
ed
D
RA
Sy
st
em
O
rg
an
C
la
ss
an
d
Pr
ef
er
re
d
Te
rm
:
an
y
A
E,
21
3/
22
3
(8
2.
9%
);
co
lit
is
ul
ce
ra
tiv
e,
13
/2
23
(5
.8
%
)
U
LT
RA
2
PB
O
W
ee
k
52
0/
26
0
(0
%
)4
5
0/
26
0
(0
%
)4
5
N
R
Lu
pu
s-
lik
e
sy
nd
ro
m
e,
0/
26
0
(0
%
)4
5
D
em
ye
lin
at
in
g
di
se
as
e,
0/
26
0
(0
%
)4
5
0/
26
0
(0
%
)4
5
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
291
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
U
LT
RA
2
16
0
m
g
of
A
D
A
at
w
ee
k
0,
80
m
g
at
w
ee
k
2
an
d
th
en
40
m
g
EO
W
be
gi
nn
in
g
at
w
ee
k
4
W
ee
k
52
1/
25
7
(0
.4
%
)4
5
M
al
ig
na
nc
ie
s:
2/
25
7
(0
.8
%
)4
5
N
R
Lu
pu
s-
lik
e
sy
nd
ro
m
e,
1/
25
7
(0
.4
%
)4
5
D
em
ye
lin
at
in
g
di
se
as
e,
0/
25
7
(0
%
)4
5
5/
25
7
(1
.9
%
)4
5
Su
bm
is
si
on
M
ed
D
RA
Sy
st
em
O
rg
an
C
la
ss
an
d
Pr
ef
er
re
d
Te
rm
:a
ny
A
E,
21
3/
25
7
(8
2.
9%
);
an
ae
m
ia
,
10
/2
57
(3
.9
%
);
iro
n
de
fic
ie
nc
y
an
ae
m
ia
,
7/
25
7
(2
.7
%
);
co
lit
is
ul
ce
ra
tiv
e,
58
/2
57
(2
2.
6%
);
ab
do
m
in
al
pa
in
,2
0/
25
7
(7
.8
%
);
na
us
ea
,1
5/
25
7
(5
.8
%
);
fa
tig
ue
,1
6/
25
7
(6
.2
%
);
py
re
xi
a,
11
/2
57
(4
.3
%
);
ga
st
ro
en
te
rit
is
,9
/2
57
(3
.5
%
);
na
so
ph
ar
yn
gi
tis
,
45
/2
57
(1
7.
5%
);
ph
ar
yn
gi
tis
,9
/2
57
(3
.5
%
);
U
RT
I,
11
/2
57
(4
.3
%
);
ar
th
ra
lg
ia
,
20
/2
57
(7
.8
%
);
he
ad
ac
he
,2
2/
25
7
(8
.6
%
);
or
op
ha
ry
ng
ea
l
pa
in
,1
5/
25
7
(5
.8
%
)
U
LT
RA
3
40
m
g
of
A
D
A
EO
W
or
EW
W
ee
k
52
1/
57
7
(0
.2
%
)
ev
en
ts
,
1
(e
ve
nt
s
pe
r
10
0
PY
,
0.
2)
3/
57
7
(0
.5
%
)
ev
en
ts
,
3
(e
ve
nt
s
pe
r
10
0
PY
,
0.
7)
N
R
D
em
ye
lin
at
in
g
di
se
as
e:
1/
55
7
(0
.2
%
);
1
ev
en
t
(e
ve
nt
s
pe
r
10
0
PY
,
0.
2)
N
R
11
/5
77
(2
.0
%
)
ev
en
ts
,
13
(e
ve
nt
s
pe
r
10
0
PY
,
3.
0)
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
292
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
U
LT
RA
3
40
m
g
of
A
D
A
EO
W
or
EW
W
ee
k
52
Su
bm
is
si
on
n
=
10
10
;
PY
s,
23
38
;
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
4
(0
.2
)
Su
bm
is
si
on
PY
s,
23
38
;
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
ex
cl
ud
in
g
ly
m
ph
om
a,
23
(1
.0
);
ly
m
ph
om
a,
3
(0
.1
)
Su
bm
is
si
on
n
=
10
10
;
PY
s,
23
38
;
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
12
(0
.5
)
Su
bm
is
si
on
n
=
10
10
;P
Y
s,
23
38
;e
ve
nt
s
(e
ve
nt
s/
10
0
PY
s)
:
de
m
ye
lin
at
in
g
di
se
as
e,
3
(0
.1
)
N
R
N
R
Su
bm
is
si
on
n
=
10
10
;
PY
s,
23
38
;
ev
en
ts
(e
ve
nt
s/
10
0
PY
s)
:
U
C
w
or
se
ni
ng
,
58
8
(2
5.
2)
;
fla
re
,
58
8
(2
5.
2)
Su
zu
ki
PB
O
W
ee
k
8
N
R
W
ee
k
8:
0/
96
(0
%
)4
6
W
ee
k
8:
1/
96
(1
.0
%
)4
6
N
R
N
R
W
ee
k
8:
1/
96
(1
.0
%
)4
6
U
C
w
or
se
ni
ng
/f
la
re
:
W
ee
k
8:
8/
96
(8
.3
%
)4
6
Su
zu
ki
PB
O
W
ee
k
52
N
R
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
0
(e
ve
nt
s/
10
0
PY
s,
0)
46
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
3
(e
ve
nt
s/
10
0
PY
s,
6.
7)
46
N
R
N
R
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,
4
(e
ve
nt
s/
10
0
PY
s,
8.
9)
46
W
ee
k
52
(n
=
96
,
PY
s,
44
.8
):
ev
en
ts
,1
5
(e
ve
nt
s/
10
0
PY
s,
33
.5
)4
6
Su
zu
ki
16
0
m
g/
80
m
g
of
A
D
A
on
ly
W
ee
k
8
N
R
1/
90
(1
.1
%
)4
6
1/
90
(1
.1
%
)4
6
N
R
N
R
1/
90
(1
.1
%
)4
6
U
C
w
or
se
ni
ng
/f
la
re
:
w
ee
k
8:
2/
90
(2
.2
%
)4
6
Su
zu
ki
80
m
g/
40
m
g
of
A
D
A
or
16
0
m
g/
80
m
g
of
A
D
A
to
w
ee
k
8
th
en
40
m
g
of
A
D
A
EO
W
W
ee
k
52
N
R
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,2
(e
ve
nt
s/
10
0
PY
s,
2.
0)
A
D
A
W
ee
k
8
re
sp
on
de
rs
pe
rf
ul
l
M
ay
o
sc
or
e
(n
=
82
,P
Y
s,
68
.7
):
1
(e
ve
nt
s/
10
0
PY
s,
1.
5)
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,5
(e
ve
nt
s/
10
0
PY
s,
5.
1)
A
D
A
W
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,P
Y
s,
68
.7
):
3
(e
ve
nt
s/
10
0
PY
s,
4.
4)
N
R
N
R
W
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,6
(e
ve
nt
s/
10
0
PY
s,
6.
1)
A
D
A
W
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,P
Y
s,
68
.7
):
4
(e
ve
nt
s/
10
0
PY
s,
5.
8)
U
C
w
or
se
ni
ng
/fl
ar
e:
w
ee
k
52
(n
=
17
7,
PY
s,
98
.2
):
ev
en
ts
,1
8
(e
ve
nt
s/
10
0
PY
s,
18
.3
)A
D
A
W
ee
k
8
re
sp
on
de
rs
pe
r
fu
ll
M
ay
o
sc
or
e
(n
=
82
,
PY
s,
68
.7
):
7
(e
ve
nt
s/
10
0
PY
s,
10
.2
)
PU
RS
U
IT
-S
C
Ph
as
e
III
PB
O
W
ee
k
6
N
R
N
R
N
R
N
R
N
R
N
R
Pr
op
or
tio
n
of
pa
tie
nt
s
re
po
rt
in
g
A
Es
th
ro
ug
h
w
ee
k
6,
38
.2
47
PU
RS
U
IT
-S
C
Ph
as
e
III
20
0
m
l/
10
0
m
g
of
G
O
L
Ph
as
e
III
W
ee
k
6
N
R
N
R
N
R
N
R
N
R
N
R
Pr
op
or
tio
n
of
pa
tie
nt
s
re
po
rt
in
g
A
Es
th
ro
ug
h
w
ee
k
6,
37
.5
47
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
293
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
PU
RS
U
IT
-M
PB
O
W
ee
k
54
N
R
N
eo
pl
as
m
be
ni
gn
=
m
al
ig
na
nt
an
d
un
sp
ec
ifi
ed
.P
BO
,1
(0
.6
).
Br
ea
st
ca
nc
er
w
as
re
po
rt
ed
in
a
pa
tie
nt
w
ho
ha
d
re
ce
iv
ed
on
ly
PB
O
du
rin
g
in
du
ct
io
n
an
d
m
ai
nt
en
an
ce
48
N
R
N
R
N
R
N
R
N
R
PU
RS
U
IT
-M
50
m
g
of
G
O
L
W
ee
k
54
N
R
50
m
g
of
G
O
L,
4
(2
.6
)4
8
N
R
N
R
N
R
N
R
N
R
PU
RS
U
IT
-M
10
0
m
g
of
G
O
L
W
ee
k
54
N
R
10
0
m
g
of
G
O
L,
4
(2
.6
).4
8
Th
re
e
m
al
ig
na
nc
ie
s
w
er
e
re
po
rt
ed
th
ro
ug
h
w
ee
k
54
in
pa
tie
nt
s
re
ce
iv
in
g
10
0
m
g
of
G
O
L
m
ai
nt
en
an
ce
;
tw
o
of
th
es
e
(r
ec
ta
lc
an
ce
r
an
d
th
yr
oi
d
ca
nc
er
)
pr
es
en
te
d
w
ith
sy
m
pt
om
s
w
hi
le
th
e
pa
tie
nt
s
w
er
e
re
ce
iv
in
g
SC
PB
O
in
du
ct
io
n
an
d
on
e
(lu
ng
ad
en
oc
ar
ci
no
m
a)
oc
cu
rr
ed
in
a
pa
tie
nt
w
ith
a
40
-y
ea
r
sm
ok
in
g
hi
st
or
y
w
ho
re
ce
iv
ed
20
0
m
g/
10
0
m
g
G
O
L
s.
c.
in
du
ct
io
n
th
er
ap
y
N
R
N
R
N
R
0
N
R
U
C
-
SU
C
C
ES
S
A
ZA
W
ee
k
8
N
R
N
R
13
/7
9
(1
6%
)5
1
N
R
N
R
N
R
N
R
U
C
-
SU
C
C
ES
S
IF
X
W
ee
k
8
N
R
N
R
3/
78
(4
%
)5
1
N
R
N
R
N
R
N
R
U
C
-
SU
C
C
ES
S
IF
X
/A
ZA
W
ee
k
8
N
R
N
R
5/
80
(6
%
)5
1
N
R
N
R
N
R
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
A
C
T1
PB
O
W
ee
k
54
N
R
O
ne
(b
as
al
ce
ll
ca
rc
in
om
a)
on
e
co
lo
ni
c
dy
sp
la
si
a
th
ro
ug
h
w
ee
k
54
in
RE
SU
LT
S-
U
C
67
N
R
N
R
N
R
N
R
A
Es
of
pa
rt
ic
ul
ar
in
te
re
st
(%
):
fu
ng
al
de
rm
at
iti
s,
8/
24
4
(3
);
pn
eu
m
on
ia
,
0;
va
ric
el
la
zo
st
er
vi
ru
s
in
fe
ct
io
n,
1/
24
4
(0
.4
);
he
rp
es
zo
st
er
,
1/
24
4
(0
.4
)6
7
A
C
T1
5
m
g/
kg
of
IF
X
i.v
.
W
ee
k
54
N
R
n
=
2.
O
ne
pa
tie
nt
w
ith
pr
os
ta
tic
ad
en
oc
ar
ci
no
m
a
w
ith
2-
ye
ar
hi
st
or
y
of
el
ev
at
ed
PS
A
co
nc
en
tr
at
io
n.
O
ne
pa
tie
nt
w
ith
co
lo
ni
c
dy
sp
la
si
a.
Tw
o
(p
ro
st
at
e
ad
en
oc
ar
ci
no
m
a,
re
ct
al
ad
en
oc
ar
ci
no
m
a)
th
ro
ug
h
54
w
ee
ks
in
RE
SU
LT
S-
U
C
,
on
e
ne
w
ca
nc
er
(s
qu
am
ou
s
ce
ll
sk
in
ca
rc
in
om
a)
de
ve
lo
pe
d
in
5
m
g/
kg
of
IF
X
gr
ou
p
pa
tie
nt
,
pl
us
on
e
co
lo
ni
c
dy
sp
la
si
a6
7
N
R
0
O
ne
pa
tie
nt
w
ith
op
tic
ne
ur
iti
s6
7
N
R
A
Es
of
pa
rt
ic
ul
ar
in
te
re
st
(%
):
fu
ng
al
de
rm
at
iti
s,
pn
eu
m
on
ia
,
va
ric
el
la
zo
st
er
vi
ru
s
in
fe
ct
io
n
=
he
rp
es
zo
st
er
67
A
C
T2
PB
O
W
ee
k
30
N
R
n
=
1.
Ba
sa
l-c
el
l
ca
rc
in
om
a4
9
N
R
0
0
N
R
A
t
w
ee
k
30
pr
op
or
tio
n
w
ith
po
si
tiv
e
te
st
s
fo
r
an
tib
od
ie
s
to
IF
X
w
ho
ha
d
in
fu
si
on
re
ac
tio
n
50
.0
(6
/1
2)
49
A
C
T2
IF
X
W
ee
k
30
N
R
n
=
1.
Re
ct
al
ad
en
oc
ar
ci
no
m
a4
9
N
R
n
=
1.
O
ne
pa
tie
nt
w
ith
lu
pu
s-
lik
e
re
ac
tio
n
(c
on
si
de
re
d
SA
E)
49
n
=
1.
O
ne
pa
tie
nt
w
ith
op
tic
ne
ur
iti
s4
9
N
R
N
R
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
295
Tr
ia
l
n
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
A
C
T2
IF
X
W
ee
k
30
N
R
0
N
R
0
n
=
1.
O
ne
pa
tie
nt
w
ith
m
ul
tif
oc
al
m
ot
or
ne
ur
op
at
hy
49
N
R
N
R
A
C
T1
,
A
C
T2
ex
te
ns
io
n
st
ud
ie
s
IF
X
al
l
N
R
M
al
ig
na
nc
y
1.
01
pe
r
10
0
PY
s.
Fi
ve
m
al
ig
na
nc
ie
s
re
po
rt
ed
du
rin
g
ex
te
ns
io
n
st
ud
ie
s
fo
r
IF
X
-t
re
at
ed
pa
tie
nt
s.
19
-y
ea
r-
ol
d
pa
tie
nt
w
ith
ad
en
oc
ar
ci
no
m
a
of
lu
ng
di
ag
no
se
d
(r
ec
ei
vi
ng
5
m
g/
kg
of
IF
X
)
1
m
on
th
af
te
r
E1
28
in
fu
si
on
.
Pa
tie
nt
w
as
no
n-
sm
ok
er
an
d
di
ed
ap
pr
ox
im
at
el
y
18
m
on
th
s
af
te
r
co
m
pl
et
in
g
ex
te
ns
io
n
st
ud
y.
O
ne
pa
tie
nt
ea
ch
de
ve
lo
pe
d
br
ea
st
ca
nc
er
an
d
pr
os
ta
te
ca
nc
er
,
bo
th
re
ce
iv
in
g
5
m
g/
kg
of
IF
X
.
Br
ea
st
ca
nc
er
di
ag
no
se
d
af
te
r
w
ee
k
E7
2
in
fu
si
on
N
R
N
R
N
o
ca
se
s
of
op
tic
ne
ur
iti
s
or
m
ul
tif
oc
al
m
ot
ir
ne
ur
op
at
hy
w
er
e
re
po
rt
ed
du
rin
g
ex
te
ns
io
n
st
ud
ie
s5
5
N
R
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
296
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
in
33
-y
ea
r-
ol
d
pa
tie
nt
w
ith
no
fa
m
ily
hi
st
or
y
of
br
ea
st
ca
nc
er
.
IF
X
di
sc
on
tin
ue
d
an
d
pa
tie
nt
tr
ea
te
d.
Pr
os
ta
te
ca
nc
er
di
ag
no
se
d
ap
pr
ox
im
at
el
y
2
w
ee
ks
af
te
r
E7
2
in
fu
si
on
in
64
-y
ea
r-
ol
d
pa
tie
nt
w
ith
pr
e-
ex
is
tin
g
pr
os
ta
tit
is
(e
le
va
te
d
PS
A
le
ve
ls
)
at
w
ee
k
E3
2.
IF
X
di
sc
on
tin
ue
d
an
d
pa
tie
nt
tr
ea
te
d.
Tw
o
pa
tie
nt
s,
ea
ch
on
10
m
g/
kg
of
IF
X
,
de
ve
lo
pe
d
a
sk
in
ne
op
la
sm
.
N
ei
th
er
re
su
lte
d
in
di
sc
on
tin
ua
tio
n
of
tr
ea
tm
en
t.
O
ne
pa
tie
nt
w
ith
ex
te
ns
iv
e
di
se
as
e
an
d
10
-y
ea
r
U
C
hi
st
or
y
at
m
ai
n
st
ud
y
ba
se
lin
e
re
ce
iv
ed
5
m
g/
kg
of
IF
X
an
d
de
m
on
st
ra
te
d
co
lo
ni
c
dy
sp
la
si
a
du
rin
g
ex
te
ns
io
n
st
ud
ie
s5
5
EO
W
,
ev
er
y
ot
he
r
w
ee
k;
EW
,
ev
er
y
w
ee
k;
U
RT
I,
up
pe
r
re
sp
ira
to
ry
tr
ac
t
in
fe
ct
io
n.
DOI: 10.3310/hta20390 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 39
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Archer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
297
S
a
fe
ty
:
h
e
a
rt
fa
il
u
re
,
m
a
li
g
n
a
n
ci
e
s,
h
e
p
a
to
b
il
ia
ry
e
v
e
n
ts
,
a
u
to
im
m
u
n
e
p
ro
ce
ss
e
s,
n
e
u
ro
lo
g
ic
a
l
e
v
e
n
ts
,
h
a
e
m
a
to
lo
g
ic
a
l
re
a
ct
io
n
s
(p
a
e
d
ia
tr
ic
p
o
p
u
la
ti
o
n
tr
ia
l)
Tr
ia
ln
am
e
Tr
ea
tm
en
t
ar
m
Ti
m
e
p
o
in
t
H
ea
rt
fa
ilu
re
M
al
ig
n
an
ci
es
an
d
ly
m
p
h
o
p
ro
lif
er
at
iv
e
d
is
o
rd
er
s
H
ep
at
o
b
ili
ar
y
ev
en
ts
/l
iv
er
en
zy
m
e
ch
an
g
es
A
u
to
im
m
u
n
e
p
ro
ce
ss
es
(e
.g
.
lu
p
u
s-
lik
e
sy
n
d
ro
m
e)
N
eu
ro
lo
g
ic
al
ev
en
ts
H
ae
m
at
o
lo
g
ic
al
re
ac
ti
o
n
s
O
th
er
H
ya
m
s
IF
X
q8
w
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
H
ya
m
s
IF
X
q1
2w
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
q8
w
,
ev
er
y
8
w
ee
ks
;
q1
2w
,
ev
er
y
12
w
ee
ks
.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
298
Appendix 6 Quality-of-life tables
Quality-of-life outcomes
Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ULTRA1 PBO Reinisch et al.344
Change from baseline at week 4: IBDQ overall, 146 SF-36 mental
and physical component summary, 43344
Change from baseline value at week 8: IBDQ overall, 152 SF-36
mental and physical component summary, 44
Reinisch et al.61
IBDQ mean response (SD) at week 8 (n= 130): 75 (57.7)
ULTRA1 ADA 160/80mg Reinisch et al.344
Change from baseline at week 4: IBDQ overall, 149 SF-36 mental
and physical component summary, 45; p-value vs. PBO, < 0.05344
Change from baseline value at week 8: IBDQ overall, 153 SF-36
mental and physical component summary, 46
Reinisch et al.61
IBDQ mean response (SD) at week 8 (n= 130): 70 (53.8); p-value vs.
PBO, 0.532
ULTRA2 PBO Sandborn et al.339
IBDQ (domain NR)
Value at week 8: 20 (36), value at week 32: 20 (41), value at
week 52: 19 (41)
Sandborn et al.339
Increase in IBDQ ≥ 16 points from baseline: value at week 8:
112/246 (45.5%), value at week 32: 54/246 (22.0%), value at
week 52: 40/246 (16.3%), value at week 8, 32 and 52: 30/246
(12.2%)
ULTRA2 ADA 160/80mg Sandborn et al.339
IBDQ (domain NR) value at week 8: 29 (36); p-value vs. PBO < 0.05,
value at week 32: 28 (41); p-value vs. PBO < 0.05, value at
week 52: 27 (42); p-value vs. PBO < 0.05
Sandborn et al.339
Increase in IBDQ ≥ 16 points from baseline: value at week 8:
144/248 (58.1%); p-value vs. PBO, p< 0.05, value at week 32:
86/248 (34.7%); p-value vs. PBO, p< 0.05, value at week 52:
65/248 (26.2%); p-value vs. PBO, p< 0.05, value at week 8, 32 and
52: 58/248 (23.4%); p-value vs. PBO, p< 0.05
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ULTRA3 Sandborn et al.339
Value at week 12: IBDQ overall, 178.2 (34.60); SF-36 physical,
NASF-36 mental, N/A339
Value at week 48: IBDQ overall, 177.2 (34.94); SF-36 physical, 49.6
(8.24); SF-36 mental, 46.1 (10.77)339
Value at week 108: IBDQ overall, 176.3 (37.15); SF-36 physical,
49.4 (8.13); SF-36 mental, 46.0 (11.00)
PURSUIT-SC Phase II PBO Sandborn et al.47
Phase II PBO change from baseline in IBDQ overall, n= 41, mean
(SD) 14.8 (37.16), median (IQR) 14.0 (–2.0 to 34.0)
Read from source graph:
Randomised in Phase II, 13
Randomised while Phase II data analysed, 12.5
Randomised in Phase III, 12.5
PURSUIT-SC Phase II GOL 100/50mg
(regimen discontinued
after Phase II)
Sandborn et al.47
Phase II 100mg/50mg of GOL change from baseline in IBDQ overall,
n=40, mean (SD) 26.2 (39.71), median (IQR) 24.5 (–5.5 to 55.0)
p= 0.287)
PURSUIT-SC Phase II GOL 200/
100mg all randomised
Sandborn et al.47
Phase II 200mg/100mg of GOL change from baseline in IBDQ
overall, n= 40, mean (SD) 24.9 (36.89), median (IQR) 16.0
(–2.5 to 49.5) (p= 0.318)
Read from source graph:
Randomised in Phase II, 14
Randomised while Phase II data analysed, 25
Randomised in Phase III, 27
PURSUIT-SC Phase II GOL 400/
200mg all randomised
Sandborn et al.47
Phase II 400mg/200mg of GOL change from baseline in IBDQ,
n= 40, mean (SD) 31.6 (26.21), median (IQR) 33.0 (9.0–54.0)
(p= 0.021)
Read from source graph:
Randomised in Phase II, 32
Randomised while Phase II data analysed,30
Randomised in Phase III, 25
PURSUIT-SC Phase III PBO Sandborn et al.47
Phase III change from baseline IBDQ PBO, n= 251, mean (SD) 14.8
(31.25), median (IQR)= 11.0 (–3.0 to 29.0)
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
PURSUIT-SC Phase III GOL 200/
100mg phase III
Sandborn et al.47
Phase III change from baseline 200mg/100mg of GOL, n=252/253,
mean (SD) 27.0 (33.72), median (IQR) 22.5 (0.5–48.5) (p< 0.0001)
PURSUIT-SC Phase III GOL 400/
200mg phase III
Sandborn et al.47
Phase III change from baseline IBDQ 400mg/200mg of GOL,
n= 255/257, mean (SD) 26.9 (34.28), median (IQR) 21.0 (0.0–50.0)
(p< 0.0001)
PURSUIT-SC Feagan et al.345
Compared with PBO, significantly greater improvements experienced
in combined GOL-treated group in IBDQ (27.2 vs. 14.6; p<0.001),
SF-36 physical component summary (4.14 vs. 2.46; p<0.01) and
mental component summary (4.89 vs. 1.60; p<0.001) at week 6.
Mean improvements in IBDQ (27.4 and 27.0), physical component
summary (4.51 and 3.78) and mental component summary
(4.69 and 5.10) comparable for 200mg/100mg of GOL and
400mg/200mg of GOL groups. Distributions of IBDQ score changed
from mean of 129.4 (SD 33.9) at baseline to 156.5 (SD 39.8) at
week 6 in GOL-treated patients, with 45.2% patients achieving
IBDQ remission vs. PBO group mean of 144.2 (SD 37.1) with 28.1%
achieving IBDQ remission (p<0.001 vs. combined GOL group)
Feagan et al.345
In cumulative percentage curve vs. PBO, greater proportions of
patients in each GOL group achieved ‘any improvement’ to ‘clinically
meaningful improvement’ in IBDQ (51.1% vs. 35.2%; p<0.001),
SF-36 physical component summary (41.0% vs. 31.6; p= 0.01) and
mental component summary (42.7% vs. 28.5%; p<0.001) at week 6
PURSUIT-SC and
PURSUIT-M
Sandborn et al.340
GOL-treated patients achieving clinical remission at week 6
displayed greater mean improvement in SF-36 physical component
summary, mental component summary, EQ-5D and IBDQ than those
not achieving remission [physical component summary 8.0 vs. 2.9
(p< 0.001), mental component summary 10.7 vs. 2.6 (p< 0.001),
EQ-5D 21.4 vs. 7.2 (p< 0.001) and IBDQ 54.7 vs. 17.7 (p< 0.001)]
Sandborn et al.340
Patients in clinical remission more likely to achieve normalised SF-36
physical component summary, normalised mental component
summary and IBDQ remission than those not achieving clinical
remission [physical component summary 53.6% vs. 25.3%
(p< 0.001), mental component summary 63.6% vs. 31.6%
(p< 0.001), IBDQ 85.5% vs. 32.2% (p< 0.001)]. Furthermore,
GOL-treated patients achieving clinical remission during induction
and maintained clinical remission at week 54 in maintenance were
also more likely to achieve normalised physical component
summary, mental component summary and IBDQ remission than
those not [physical component summary 73.5% vs. 22.7%
(p< 0.001), mental component summary 63.3% vs. 28.4%
(p< 0.001), IBDQ remission 89.8% vs. 22.7 (p< 0.001)]
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
UC-SUCCESS AZA Panaccione et al.51
Change from baseline at week 8: IBQD overall, n= 50: 37.84;
p-value between IFX, 0.539 and IFX/AZA, 0.070. Change from
baseline at week 8: SF-36 physical function, n= 58: 3.45; p-value
between IFX, 0.422 and IFX/AZA, 0.044
Change from baseline at week 16: IBQD overall, n= 53: 32.51;
p-value between IFX, 0.482 and IFX/AZA, < 0.001. Change from
baseline at week 16: SF-36 physical function, n= 54: 4.13; p-value
between IFX, 0.522 and IFX/AZA, 0.052
UC-SUCCESS IFX Panaccione et al.51
Change from baseline at week 8: IBQD, n= 53: 33.42; p-value
between IFX/AZA, 0.003. Change from baseline at week 8: SF-36
physical function, n= 63: 3.24; p-value between IFX/AZA, 0.010
Change from baseline at week 16: IBQD, n= 58: 38.55; p-value
between IFX/AZA, 0.004. Change from baseline at week 16: SF-36
physical function, n= 59: 4.10; p-value between IFX/AZA, 0.022
UC-SUCCESS IFX/AZA Panaccione et al.51
Change from baseline at week 8: IBQD, n= 53: 49.83. Change from
baseline at week 8: SF-36 physical function, n= 59: SF-36 vitality,
16.6 (22.0); 6.42
Change from baseline at week 16: IBQD, n= 57: 57.70. Value at
week 16: SF-36 physical function, n= 59: SF-36 vitality, 16.6 (22.0);
7.70
Probert PBO Probert et al.50
Change from baseline at week 6: IBQD (domain NR), 25 (28)
Change from baseline at week 6: European quality of life
(domain NR) 4 (16)
Probert IFX Probert et al.50
Change from baseline at week 6: IBQD (domain NR), 36 (49);
p-value vs. PBO, 0.22
Change from baseline at week 6: European quality of life
(domain NR) 7 (17); p-value vs. PBO, 0. 3
ACT1 PBO Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 4.5 (6.8) SF-36 mental component summary, 3.1 (9.7)
Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 2.9 (6.0) SF-36 mental component summary, 3.1 (9.7)
ACT1 PBO Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 20.70
Week 30, 17.83
Week 54, 12.33
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ACT1 5mg/kg of IFX Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 6.8 (7.8); p-value vs. PBO < 0.05; SF-36 mental
component summary, 5.6 (10.2); p-value vs. PBO < 0.05
Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 6.8 (7.4); p-value vs. PBO < 0.05; SF-36 mental
component summary, 6.1 (10.8); p-value vs. PBO < 0.05
ACT1 5mg/kg of IFX Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 41.72
Week 30, 33.31
Week 54, 32.38
ACT1 10mg/kg of IFX Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 34.71
Week 30, 35.01
Week 54, 31.42
ACT1 10mg/kg of IFX Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 5.6 (7.8); SF-36 mental component summary, 6.6 (12.0);
p-value vs. PBO < 0.05
Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 6.2 (7.9); p-value vs. PBO < 0.05; SF-36 mental
component summary, 6.2 (10.7); p-value vs. PBO < 0.05
ACT1 IFX combined Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 6.2 (7.8); p-value vs. PBO < 0.05; SF-36 mental
component summary, 6.1 (11.1); p-value vs. PBO < 0.05
Feagan et al.346
Change from baseline at week 8: SF-36 physical component
summary, 6.5 (7.7); p-value vs. PBO < 0.05; SF-36 mental
component summary, 6.2 (10.7); p-value vs. PBO < 0.05
ACT1 IBDQ: responders who
were not in remission
(n= 150)
Reinisch et al.348
Change from baseline at week 8 IBDQ (domain NR), 47 (p< 0.001
vs. non-responders)
ACT1 IBDQ: responders who
were in remission
(n= 206)
Reinisch et al.348
Change from baseline at week 8 IBDQ (domain NR), 65
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ACT1 Patients who had not
discontinued CSs at
week 30 (n= 21)
Reinisch et al.348
Change from baseline at week 30: IBDQ 55.2 (58.0), SF-36 physical
component summary 5.9 (7.4), SF-36 mental component summary
11.4 (9.6)
ACT1 Patients who had
discontinued CSs at
week 30 (n= 70)
Reinisch et al.348
Change from baseline at week 30: IBDQ (domain NR), 64.7 (65.5),
SF-36 physical component summary 9.8 (10.4), SF-36 mental
component summary 11.0 (9.2)
ACT2 PBO Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 19.81
Week 30, 17.87
ACT2 IFX 5mg/kg Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 38.65
Week 30, 31.64
ACT2 IFX 10mg/kg Metz et al.347
Mean IBDQ scores (read from source graph):
Week 8, 35.75
Week 30, 35.99
ACT1 and ACT2
combined
IBDQ: non-responders
(n= 137)
Reinisch et al.348
Mean change from baseline IBDQ (no SD for all), 12
Reinisch et al.348
Significantly greater proportions of patients in responder and
remission subgroups achieved at least a 16-point increase
(87% and 96%, respectively) or a 32-point increase (68% and
87%, respectively) in total IBDQ score vs. patients classed as
non-responders (39% and 26% respectively; p< 0.001 for all
comparisons)
ACT1 and ACT2
combined
PBO Feagan et al.346
Change from baseline at week 8, n= 244: IBDQ bowel, 7.9 (9.7);
IBDQ emotional, 6.2 (10.6); IBDQ systemic, 3.0 (4.8); IBDQ social,
3.8 (6.0); SF-36 physical functioning, 6.0 (17.3); SF-36 role-physical,
22.4 (39.7); SF-36 bodily pain, 13.1 (24.7); SF-36 general health,
5.6 (15.8); SF-36 vitality, 11.5 (20.7); SF-36 social functioning, 15.8
(24.8); SF-36 role-emotional, 12.4 (47.6); SF-36 mental health, 5.0
(18.4); SF-36 physical component summary, 3.7 (6.5); SF-36 mental
component summary, 3.0 (9.6)
Feagan et al.346
Percentage of patients who achieved clinically meaningful
improvement at value at week 8: IBDQ change ≥ 16, 49.6%; IBDQ
change ≥ 32, 32.6%; SF-36 physical component summary change
≥ 3, 40.6%; SF-36 mental component summary change ≥ 3,
32.4%; SF-36 physical component summary change ≥ 5, 34.0%;
SF-36 mental component summary change ≥ 5, 29.2%
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ACT1 and ACT2
combined
IFX 5mg/kg Feagan et al.346
Change from baseline week to 8 n= 242: IBDQ bowel, 14.5 (11.7);
p-value vs. PBO < 0.05; IBDQ emotional, 12.7 (12.6); p-value vs.
PBO < 0.05; IBDQ systemic, 5.7 (5.9); p-value vs. PBO < 0.05; IBDQ
social, 7.4 (8.0); p-value vs. PBO < 0.05; SF-36 physical functioning,
12.8 (19.3); p-value vs. PBO < 0.05; SF-36 role-physical, 29.6 (41.0);
SF-36 bodily pain, 20.2 (22.5); p-value vs. PBO < 0.05; SF-36 general
health, 10.0 (16.9); p-value vs. PBO < 0.05; SF-36 vitality, 16.6
(22.0); p-value vs. PBO < 0.05; SF-36 social functioning, 21.2 (24.8);
p-value vs. PBO < 0.05; SF-36 role-emotional, 15.5 (46.1);
SF-36 mental health, 10.6 (17.5); p-value vs. PBO < 0.05;
SF-36 physical component summary, 6.8 (7.6); p-value vs. PBO
< 0.05; SF-36 mental component summary, 5.9 (10.5); p-value vs.
PBO < 0.05
Feagan et al.346
Percentage of patients who achieved clinically meaningful
improvement at value at week 8: IBDQ change ≥ 16, 69.7%;
p-value vs. PBO < 0.05; IBDQ change ≥ 32, 56.8%; p-value vs. PBO
< 0.05; SF-36 physical component summary change ≥ 3, 62.0%;
p-value vs. PBO < 0.05; SF-36 mental component summary change
≥ 3, 52.1%; p-value vs. PBO < 0.05; SF-36 physical component
summary change ≥ 5, 48.8%; p-value vs. PBO < 0.05; SF-36 mental
component summary change ≥ 5, 40.9%; p-value vs. PBO < 0.05
ACT1 and ACT2
combined
IFX combined Feagan et al.346
Change from baseline week to 8 n= 484: IBDQ bowel, 13.7 (11.8);
p-value vs. PBO < 0.05; IBDQ emotional, 12.0 (12.6); p-value vs.
PBO < 0.05; IBDQ systemic, 5.4 (5.9); p-value vs. PBO < 0.05; IBDQ
social, 6.8 (7.5); p-value vs. PBO < 0.05; SF-36 physical functioning,
11.0 (18.9); p-value vs. PBO < 0.05; SF-36 role-physical, 31.1 (42.5);
p-value vs. PBO < 0.05; SF-36 bodily pain, 20.0 (23.4); p-value vs.
PBO < 0.05; SF-36 general health, 10.4 (18.1); p-value vs. PBO
< 0.05; SF-36 vitality, 18.3 (22.3); p-value vs. PBO < 0.05; SF-36
social functioning, 21.0 (25.9); p-value vs. PBO < 0.05; SF-36
role-emotional, 18.2 (45.4) SF-36 mental health, 10.5 (18.2);
p-value vs. PBO < 0.05; SF-36 physical component summary, 6.4
(7.7); p-value vs. PBO < 0.05; SF-36 mental component summary,
6.1 (10.9); p-value vs. PBO < 0.05
Feagan et al.346
Percentage of patients who achieved clinically meaningful
improvement at value at week 8: IBDQ change ≥ 16, 68.7%;
p-value vs. PBO < 0.05; IBDQ change ≥ 32, 54.7%; p-value vs. PBO
< 0.05; SF-36 physical component summary change ≥ 3, 59.1%;
p-value vs. PBO < 0.05; SF-36 mental component summary change
≥ 3, 49.0%; p-value vs. PBO < 0.05; SF-36 physical component
summary change ≥ 5, 50.0%; p-value vs. PBO < 0.05; SF-36 mental
component summary change ≥ 5, 43.0%; p-value vs. PBO < 0.05
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
ACT1 and ACT2
combined
IFX combined Reinisch et al.348
Mean change in PCS and MCS and individual SF-36 scale scores
from baseline to week 30 by response status (read from source
graph):
Physical component summary: non-responders (n= 137), 40.00;
responders who were not in remission (n= 150), 44.78; remission
(n= 206), 49.77
Physical functioning: non-responders (n= 137), 44.18; responders
who were not in remission (n= 150), 48.54; remission (n= 206),
51.66
Role-physical: non-responders (n= 137), 39.24; responders who
were not in remission (n= 150), 44.85; remission (n= 206), 50.76
Bodily pain: non-responders (n= 137), 42.07; responders who were
not in remission (n= 150), 47.05; remission (n= 206), 52.35
General health: non-responders (n= 137), 36.19; responders who
were not in remission (n= 150), 40.24; remission (n= 206), 45.54
Vitality: non-responders (n= 137), 41.20; responders who were not
in remission (n= 150), 47.11; remission (n= 206), 51.48
Social functioning: non-responders (n=137), 40.61; responders who
were not in remission (n=150), 48.39; remission (n=206), 52.13
Role-emotional: non-responders (n=137), 44.06; responders who
were not in remission (n=150), 48.42; remission (n=206), 51.58
Mental health: non-responders (n=137), 45.02; responders who
were not in remission (n=150), 48.76; remission (n=206), 50.95
Mental component summary: non-responders (n=137), 44.12;
responders who were not in remission (n=150), 49.1; remission
(n=206), 51.6
ACT1 and ACT2
combined
PBO/IFX combined Metz et al.347
Mean baseline and change at week 8 scores per question for each
IBDQ dimension (read from source graph):
Bowel: baseline, 3.33; week 8, 4.48
Emotional: baseline, 3.62; week 8, 4.44
Systemic: baseline, 2.89; week 8, 3.83
Social: baseline, 3.41; week 8, 4.57
Mean baseline and change at week 8 in norm-based SF-36 scale
scores (read from source graph):
Physical functioning: baseline, 42.78; week 8, 45.97
Role-physical: baseline, 33.89; week 8, 41.23
Bodily pain: baseline, 39.03; week 8, 45.10
General health: baseline, 34.28; week 8, 37.16
Vitality: baseline, 36.88; week 8, 42.30
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Study name Treatment group
HRQoL instrument and domain, time point, mean (SD)
[median] values, n/N (%) reporting improvement
Social functioning: baseline, 34.68; week 8, 41.07
Role-emotional: baseline, 41.42; week 8, 45.26
Mental health: baseline, 41.14; week 8, 44.34
Mean baseline and change at week 8 scores per question for each
IBDQ dimension (read from source graph):
Bowel: baseline, 3.34; week 8, 5.12
Emotional: baseline, 3.80; week 8, 5.00
Systemic: baseline, 3.00; week 8, 4.22
Social: baseline, 3.74; week 8, 5.47
Mean baseline and change at week 8 in norm-based SF-36 scale
scores (read from graph):
Physical functioning: baseline, 44.07; week 8, 49.49
Role-physical: baseline, 35.81; week 8, 45.07
Bodily pain: baseline, 39.68; week 8, 48.30
General health: baseline, 35.89; week 8, 40.68
Vitality: baseline, 37.84; week 8, 46.14
Social functioning: baseline, 36.93; week 8, 46.82
Role-emotional: baseline, 42.39; week 8, 48.14
Mental health: baseline, 42.11; week 8, 47.85
CS, corticosteroid; IQR, interquartile range; N/A, not applicable; NR, not reported.
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Appendix 7 Network meta-analysis tables
Induction phase
Treatments Treatment 1 Treatment 2
1 2
No
response Response Remission Total
No
response Response Remission Total
Base-case data
ULTRA 1 PBO ADA 72 46 12 130 59 47 24 130
ULTRA 2
(anti-TNF-α-naive)
PBO ADA 89 40 16 145 61 57 32 150
PURSUIT-SC Phases
II+ III
PBO GOL 218 79 23 320 162 104 58 324
ACT1 PBO IFX 76 27 18 121 37 37 47 121
ACT2 PBO IFX 87 29 7 123 43 37 41 121
Sensitivity analysis 1
ULTRA 1 PBO ADA 72 46 12 130 59 47 24 130
ULTRA 2 (ITT) PBO ADA 161 62 23 246 123 84 41 248
PURSUIT-SC Phases
II+ III
PBO GOL 218 79 23 320 162 104 58 324
ACT1 PBO IFX 76 27 18 121 37 37 47 121
ACT2 PBO IFX 87 29 7 123 43 37 41 121
Sensitivity analysis 2
ULTRA 1 PBO ADA 72 46 12 130 59 47 24 130
ULTRA 2
(anti-TNF-α-naive)
PBO ADA 89 40 16 145 61 57 32 150
PURSUIT-SC Phases
II+ III
PBO GOL 218 79 23 320 162 104 58 324
ACT1 PBO IFX 76 27 18 121 37 37 47 121
ACT2 PBO IFX 87 29 7 123 43 37 41 121
Suzuki et al. PBO ADA 62 23 11 96 45 36 9 90
Sensitivity analysis 3
ULTRA 1 PBO ADA 72 46 12 130 59 47 24 130
ULTRA 2 (ITT) PBO ADA 161 62 23 246 123 84 41 248
PURSUIT-SC Phases
II+ III
PBO GOL 218 79 23 320 162 104 58 324
ACT1 PBO IFX 76 27 18 121 37 37 47 121
ACT2 PBO IFX 87 29 7 123 43 37 41 121
Suzuki et al. PBO ADA 62 23 11 96 45 36 9 90
Further maintenance NMA data removed owing to commercial-in-confidence status. Commercial-in-confidence
information has been removed.
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Appendix 8 Network meta-analysis figures
Results when using conventional reference prior for the
between study standard deviation
vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.39 (– 1.18 to 0.39)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 1.53 to 0.66)
– 0.91 (– 1.71 to – 0.13)
– 0.09 (– 1.41 to 1.25)
– 0.52 (– 1.64 to 0.56)
– 0.43 (– 1.79 to 0.87)
– 2 – 1 0 1 2
FIGURE 93 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the induction
phase [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.02 (– 1.96 to 1.98)
– 0.33 (– 2.39 to 1.64)
– 0.43 (– 2.54 to 1.45)
– 0.24 (– 1.68 to 1.25)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.42 (– 3.23 to 2.36)
– 0.31 (– 3.14 to 2.48)
– 0.23 (– 2.70 to 2.26)
– 0.10 (– 2.10 to 1.89)
0.08 (– 2.26 to 2.56)
0.19 (– 2.24 to 2.71)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 94 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 8–32 weeks for patients starting in response [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.17 (– 1.85 to 2.23)
– 0.62 (– 2.70 to 1.41)
– 0.61 (– 2.65 to 1.44)
– 0.11 (– 1.64 to 1.35)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.78 (– 3.70 to 2.21)
– 0.79 (– 3.70 to 2.18)
– 0.28 (– 2.80 to 2.20)
0.00 (– 2.04 to 2.04)
0.51 (– 1.99 to 3.00)
0.50 (– 2.04 to 2.92)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 95 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 8–32 weeks for patients starting in remission [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.32 (– 2.29 to 2.85)
– 0.15 (– 2.74 to 2.33)
0.23 (– 2.36 to 2.75)
– 0.35 (– 2.85 to 2.30)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.10 (– 3.70 to 3.58)
– 0.47 (– 4.13 to 3.07)
– 0.68 (– 4.14 to 2.94)
0.36 (– 2.24 to 2.94)
– 0.22 (– 3.72 to 3.52)
– 0.58 (– 4.18 to 3.02)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 96 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 32–52 weeks for patients starting in response [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 1.01 (– 3.59 to 1.51)
0.03 (– 2.48 to 2.56)
– 0.17 (– 2.72 to 2.36)
– 0.23 (– 2.83 to 2.31)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.85 (– 2.72 to 4.39)
1.05 (– 2.52 to 4.61)
0.79 (– 2.79 to 4.45)
– 0.19 (– 2.78 to 2.29)
– 0.26 (– 3.89 to 3.30)
– 0.06 (– 3.65 to 3.54)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 97 Base case: comparative effect of anti-TNF-α treatment on clinical response/remission in the maintenance
phase at 32–52 weeks for patients starting in remission [SD∼U(0,2)].
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vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.36 (– 0.72 to 0.03)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 1.09 to 0.10)
– 0.92 (– 1.36 to – 0.48)
– 0.13 (– 0.86 to 0.54)
– 0.55 (– 1.14 to – 0.01)
– 0.42 (– 1.15 to 0.32)
– 2 – 1 0 1 2
FIGURE 98 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.24 (– 1.35 to  0.79)
– 0.33 (– 1.79 to 1.12)
– 0.42 (– 1.88 to 1.02)
– 0.25 (– 1.35 to 0.83)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.17 (– 1.91 to 1.70)
– 0.09 (– 1.82 to 1.74)
– 0.01 (– 1.54 to 1.49)
– 0.08 (– 1.53 to 1.41)
0.08 (– 1.73 to 1.92)
0.17 (– 1.64 to 1.95)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 99 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.04 (– 1.15 to 1.21)
– 0.61 (– 2.14 to 0.96)
– 0.60 (– 2.21 to 0.92)
– 0.12 (– 1.25 to 1.05)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.65 (–2.68 to 1.30)
– 0.65 (– 2.58 to 1.37)
– 0.15 (– 1.75 to 1.54)
0.00 (– 1.55 to 1.54)
0.50 (– 1.36 to 2.39)
0.49 (– 1.39 to 2.43)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 100 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.08 (– 1.52 to 1.66)
– 0.16 (– 2.34 to 2.08)
0.22 (– 1.96 to 2.51)
– 0.33 (– 2.56 to 1.89)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.13 (– 2.55 to 2.96)
– 0.24 (– 2.94 to 2.55)
– 0.42 (– 3.15 to 2.27)
0.38 (– 1.73 to 2.55)
– 0.17 (– 3.30 to 2.90)
– 0.54 (– 3.83 to 2.58)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 101 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.93 (– 2.45 to 0.62)
0.01 (– 2.07 to 2.07)
– 0.20 (– 2.29 to 1.84)
– 0.26 (– 2.34 to 1.90)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.74 (– 1.95 to 3.30)
0.95 (– 1.71 to 3.55)
0.69 (– 1.99 to 3.32)
– 0.22 (– 2.32 to 1.88)
– 0.28 (– 3.23 to 2.81)
– 0.06 (– 3.03 to 2.96)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 102 Sensitivity analysis 1: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼U(0,2)].
vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.32 (– 0.64 to 0.02)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 1.02 to 0.05)
– 0.92 (– 1.31 to – 0.53)
– 0.16 (– 0.79 to 0.46)
– 0.60 (– 1.12 to – 0.09)
– 0.43 (– 1.08 to 0.22)
– 2 – 1 0 1 2
FIGURE 103 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.32 (– 1.31 to 0.58)
– 0.31 (– 1.65 to 1.07)
– 0.42 (– 1.69 to 0.93)
– 0.25 (– 1.12 to 0.77)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.10 (– 1.67 to 1.58)
0.00 (– 1.59 to 1.77)
0.07 (– 1.17 to 1.56)
– 0.10 (– 1.46 to 1.20)
0.05 (– 1.52 to 1.77)
0.17 (– 1.39 to 1.87)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 104 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
0.06 (– 1.26 to 1.43)
– 0.52 (– 2.40 to 1.33)
– 0.57 (– 2.48 to 1.39)
– 0.42 (– 1.82 to 0.91)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.62 (– 3.00 to 1.67)
– 0.57 (– 2.91 to 1.67)
– 0.49 (– 2.46 to 1.40)
– 0.05 (– 1.99 to 1.84)
0.09 (– 2.20 to 2.44)
0.16 (– 2.30 to 2.48)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 105 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.09 (– 1.59 to 1.34)
– 0.15 (– 2.10 to 1.89)
0.22 (– 1.81 to 2.25)
– 0.36 (– 2.47 to 1.71)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.30 (– 2.13 to 2.87)
– 0.05 (– 2.43 to 2.51)
– 0.26 (– 2.82 to 2.28)
0.35 (– 1.73 to 2.35)
– 0.23 (– 3.10 to 2.66)
– 0.57 (– 3.46 to 2.31)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 106 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.85 (– 2.29 to  0.65)
0.03 (– 1.98 to 2.03)
– 0.17 (– 2.15 to 1.94)
– 0.24 (– 2.35 to 1.84)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.68 (– 1.78 to 3.27)
0.88 (– 1.64 to 3.38)
0.61 (– 1.96 to 3.13)
– 0.20 (– 2.19 to 1.87)
– 0.28 (– 3.15 to 2.60)
– 0.07 (– 3.00 to 2.87)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 107 Sensitivity analysis 2: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼U(0,2)].
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vs. PBO
ADA
GOL
IFX
vs. ADA
GOL
vs. GOL
IFX
IFX
– 0.35 (– 1.02 to 0.32)
Treatment comparison (probit scale) Effect (95% CrI)
– 0.49 (– 1.32 to 0.54)
– 0.91 (– 1.57 to – 0.21)
– 0.14 (– 1.28 to 1.12)
– 0.56 (– 1.48 to 0.43)
– 0.42 (– 1.71 to 0.78)
– 2 – 1 0 1 2
FIGURE 108 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
induction phase [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.21 (– 2.08 to 1.68)
– 0.32 (– 2.28 to 1.55)
– 0.43 (– 2.34 to 1.56)
– 0.23 (– 1.64 to 1.16)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.21 (– 2.95 to 2.57)
– 0.11 (– 2.77 to 2.61)
– 0.02 (– 2.35 to 2.32)
– 0.11 (– 2.03 to 1.81)
0.09 (– 2.30 to 2.50)
0.18 (– 2.20 to 2.57)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 109 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in response [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.05 (– 2.14 to 1.97)
– 0.61 (– 2.72 to 1.40)
– 0.61 (– 2.62 to 1.42)
– 0.13 (– 1.63 to 1.40)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
– 0.54 (– 3.46 to 2.29)
– 0.55 (– 3.44 to 2.41)
– 0.07 (– 2.64 to 2.56)
0.01 (– 2.07 to 2.16)
0.49 (– 2.04 to 3.10)
0.48 (– 2.06 to 2.97)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 110 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 8–32 weeks for patients starting in remission [SD∼U(0,2)].
vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.04 (– 2.59 to 2.45)
– 0.15 (– 2.70 to 2.36)
0.22 (– 2.32 to 2.85)
– 0.34 (– 3.00 to 2.25)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.27 (– 3.24 to 3.85)
– 0.11 (– 3.66 to 3.41)
– 0.29 (– 3.93 to 3.32)
0.38 (– 2.12 to 2.92)
– 0.18 (– 3.87 to 3.48)
– 0.57 (– 4.28 to 3.16)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 111 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in response [SD∼U(0,2)].
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vs. PBO
ADA
50 mg of GOL
100 mg of GOL
IFX
– 0.87 (– 3.45 to 1.64)
0.02 (– 2.56 to 2.62)
– 0.18 (– 2.64 to 2.38)
– 0.21 (– 2.70 to 2.44)
vs. ADA
100 mg of GOL
50 mg of GOL
vs. 100 mg of GOL
IFX
100 mg of GOL
vs. 50 mg of GOL
IFX
IFX
0.69 (– 2.83 to 4.39)
0.89 (– 2.78 to 4.59)
0.67 (– 2.90 to 4.35)
– 0.19 (– 2.74 to 2.31)
– 0.22 (– 3.81 to 3.37)
– 0.05 (– 3.53 to 3.56)
Treatment comparison (probit scale) Effect (95% CrI)
– 2 – 1 0 1 2
FIGURE 112 Sensitivity analysis 3: comparative effect of anti-TNF-α treatment on clinical response/remission in the
maintenance phase at 32–52 weeks for patients starting in remission [SD∼U(0,2)].
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Appendix 9 Searches for cost-effectiveness
studies
Database: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations (via Ovid).
Searched: 1946 to January 2014.
Search strategy
1. Colitis, Ulcerative/
2. ulcerative colitis.tw.
3. colitis ulcerosa.tw.
4. uc.tw.
5. colitis ulcerative.tw.
6. Colitis/
7. colitis.tw.
8. colitides.tw.
9. Inflammatory Bowel Diseases/
10. inflammatory bowel disease$.tw.
11. ibd.tw.
12. (col* and ulcer*).tw.
13. colitis gravis.tw.
14. proctocolitis.tw.
15. or/1-14
16. adalimumab.af.
17. humira.af.
18. d 2e7.af.
19. d2e7.af.
20. 331731-18-1.rn.
21. infliximab.af.
22. remicade.af.
23. 170277-31-3.rn.
24. ta650.af.
25. ta 650.af.
26. inx.af.
27. remsima.af.
28. inflectra.af.
29. ct p13.af.
30. ctp13.af.
31. golimumab.af.
32. simponi.af.
33. cnto148.af.
34. cnto 148.af.
35. 476181-74-5.rn.
36. tnf inhibitor$.tw.
37. anti tnf.tw.
38. antitnf.tw.
39. tnf antagonist$.tw.
40. tnf-alpha blocker$.tw.
41. antitumo?r necrosis factor.tw.
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42. Biosimilar Pharmaceuticals/
43. (biosimilar$ or biologic$).tw.
44. or/16-43
45. 15 and 44
Terms 1–14 are terms for the condition (ulcerative colitis) which are then combined using OR in term 15.
Terms 16–43 are terms for the interventions (infliximab, adalimumab and golimumab) which are then
combined using OR in term 44. Terms 15 and 44 are then combined using AND to find studies on the
condition and interventions in term 45.
To retrieve economic evaluations specially designed highly sensitive search filter were combined with term 45.
Economics filter below.
Economic filter
1. exp “costs and cost analysis”/
2. economics/
3. exp economics, hospital/
4. exp economics, medical/
5. economics, nursing/
6. exp models, economic/
7. economics, pharmaceutical/
8. exp “fees and charges”/
9. exp budgets/
10. budget$.tw.
11. ec.fs.
12. cost$.ti.
13. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
14. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
15. (price$ or pricing$).tw.
16. (financial or finance or finances or financed).tw.
17. (fee or fees).tw.
18. (value adj2 (money or monetary)).tw.
19. quality-adjusted life years/
20. (qaly or qalys).af.
21. (quality adjusted life year or quality adjusted life years).af.
22. or/1-22
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Appendix 10 European Quality of Life-5
Dimensions search
Database: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations (via Ovid).
Searched: 1946 to January 2014.
Search strategy
1. Colitis, Ulcerative/
2. ulcerative colitis.tw.
3. colitis ulcerosa.tw.
4. uc.tw.
5. colitis ulcerative.tw.
6. Colitis/
7. colitis.tw.
8. colitides.tw.
9. Inflammatory Bowel Diseases/
10. inflammatory bowel disease$.tw.
11. ibd.tw.
12. (col* and ulcer*).tw.
13. colitis gravis.tw.
14. proctocolitis.tw.
15. or/1-14
16. (euroqol or euro qol or eq5d or eq 5d).tw.
17. 15 and 16
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